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Summary 
 
Obesity-associated metabolic disorders are amongst the most prevalent causes of 
death worldwide. Understanding how obesity leads to the development of the 
Metabolic Syndrome (MetS) and cardiovascular disease (CVD) will enable the 
development of novel therapies that dissociate obesity from its cardiometabolic 
complications.  
 
Our laboratory views the functional capacity of white adipose tissue (WAT), the organ 
designed for safe lipid storage, as a key factor in the development of MetS and CVD. 
At a genetically-defined stage of the aberrant WAT expansion that occurs during 
obesity, adipocytes undergo a functional failure, resulting in an impaired control of 
serum free fatty acid (FFA) concentration. In such setting, FFAs and their metabolic 
derivatives accumulate in other organs, where they cause lipotoxicity, leading to the 
development of insulin resistance and CVD. We therefore aim to understand the 
pathophysiological mechanisms that induce adipocyte dysfunction. 
 
The past two decades of research have established the immune system as an 
important regulator of WAT function. The number of adipose tissue macrophages 
(ATMs), the most abundant immune cell type in WAT, increases during obesity, 
resulting in WAT inflammation. Multiple genetic and pharmacological intervention 
studies of murine models of obesity have assigned a causal link between ATM pro-
inflammatory activation and WAT dysfunction. However, while the propagation of 
inflammation in ATMs during obesity has been extensively studied, factors triggering 
ATM inflammatory activation are less clear. 
 
Recently, our lab has observed lipid accumulation in the ATMs isolated from obese 
mice. Lipid-laden ATMs were pro-inflammatory, leading us to hypothesise that 
aberrant lipid build-up in macrophages triggers WAT inflammation during 
obesity. This thesis expands on the initial findings from our lab and describes two 
novel mechanisms that potentially contribute to lipid-induced inflammatory activation 
of ATMs. 
 
  iv 
In chapter 3, the role of de novo phosphatidylcholine (PC) synthesis pathway 
during lipotoxicity in macrophages is addressed. The first part of the chapter 
demonstrates that lipotoxic environment increased de novo PC synthesis rate in bone 
marrow-derived macrophages (BMDMs) and ATMs, and that loss of rate-limiting 
enzyme in de novo PC synthesis pathway, CTP:phosphocholine 
cytidylyltransferase  (CCT) diminished saturated FFA-induced inflammation in 
BMDMs. In the second part, I show that macrophage-specific CCT deletion did not 
impact on the development of WAT inflammation or systemic insulin resistance, but 
had a minor benefitial effect on hepatic gene transcription during obesity. 
 
Chapter 4 develops on recent observations of interactions between sympathetic 
nerves and macrophages in WAT. In the first part of the chapter, I demonstrate that 
stimulating 2-adrenergic receptor (2AR), the main receptor for sympathetic 
neurotransmitter norepinephrine in macrophages, enhanced intracellular triglyceride 
storage by up-regulating diacylglycerol O-acyltransferase 1 (Dgat1) gene expression 
in BMDMs. The second part of the chapter shows that macrophage-specific 2AR 
deletion did not modulate systemic glucose and lipid metabolism during obesity, but 
mice lacking 2ARs in macrophages demonstrated augmented hepatic glucose 
production on a chow diet. Furthermore, systemic 2AR blockade or macrophage-
specific 2AR deletion in mice did not affect the thermogenic response to cold 
exposure. 
 
Chapter 5 includes the characterisation of 2AR stimulation-induced changes to the 
global cellular proteome of BMDMs, and a subsequent validation of the role of 
candidate transcription factors in regulating 2AR agonism-induced gene expression 
in BMDMs. 
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1 Introduction 
1.1 Adipose tissue inflammation and the development of insulin 
resistance 
1.1.1 Obesity and Metabolic Syndrome 
Obesity has reached epidemic proportions worldwide, with around 670 million people 
having a body-mass index (BMI) over 30 kg/m2 and clinically defined as being obese1. 
Obesity is widely associated with the range of metabolic dysfunctions, including insulin 
resistance, high blood pressure and dyslipidaemia, which are collectively termed the 
Metabolic Syndrome (MetS)2,3. Individuals with MetS exhibit a substantially greater risk 
of developing type-2 diabetes and cardiovascular disease (CVD) compared to the 
general population4. Both type-2 diabetes and CVD are amongst the highest causes 
of mortality in the world, with 8.76 million of deaths per year attributed to ischaemic 
heart disease (#1 cause of death globally), 6.24 million – to stroke (#2 cause) and 1.59 
million – to type-2 diabetes (#6 cause)5. Furthermore, treating patients with mentioned 
diseases represent a substantial financial burden on health care systems worldwide5. 
 
Current weight loss interventions, such as diet, exercise and pharmaceuticals, as well 
as therapeutic strategies targeting MetS have all had limited success6. While bariatric 
surgery can dramatically reduce the body weight and improve metabolic status of the 
patient, it is generally expensive and there are numerous risks and complications 
involved, such as bowel obstruction, gallstones, ulcers and subsequent malnutrition7. 
Therefore, deeper understanding of pathophysiological mechanisms driving MetS is 
required for the development of novel treatments. 
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1.1.2 Obesity is caused by positive energy balance 
The obesity epidemic is caused by increased food intake and a more sedentary 
lifestyle observed in modern humans8. These two factors can be viewed as increased 
energy input and decreased energy output, resulting in a positive energy balance. Like 
all living organisms, animals store excess energy as chemical bonds in the form of 
carbohydrates and fats. Positive energy balance in mammals predominantly manifests 
in the form of fatty acids, which are physiologically stored as calorie-dense triglycerides 
(TGs) in white adipose tissue (WAT)9. 
 
The ability to store energy as lipids allowed animals to survive through prolonged 
periods of food scarcity and thus was evolutionarily conserved10. However, low food 
abundance is no longer a threat to modern humans living in developed countries, 
rendering such evolutionary adaptation obsolete and damaging from the health and 
environmental points of view. The feeding behaviour and energy expenditure of 
humans is still governed by genetic mechanisms shaped through millions of years of 
evolution10. The ‘thrifty gene’ hypothesis11 thus states that genes which enabled 
individuals to efficiently collect and process food to deposit fat during periods of food 
abundance in order to provide energy during periods of food shortage are now acting 
as the main drivers of obesity in the current environment. While high degree of 
heritability (approximately 60-80%) of BMI estimated by monozygotic twin studies 
supports this hypothesis12,13, it is still being questioned by the scientific community, 
with main counterargument being the fact that the majority of the population remains 
lean despite the overabundance of food14,15. Indeed, it has been suggested that over 
the course of evolution, humans have been under pressure to remain lean in the 
obesogenic environments in order to decrease the risk of predation. Individuals storing 
more fat may be less manoeuvrable and slower to evade predators and hence higher 
fat storage increases predation mortality16-18. 
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Amongst all brain regions involved in regulating energy balance in vertebrates, 
hypothalamus has a central role19. It consists of multiple nuclei of neurons that infer 
the energy status of the animal by directly sensing circulating nutrients and by 
integrating signals from peripheral hormones. The fine balance of orexigenic and 
anorectic stimuli in hypothalamus lead to the stimulation of foraging behaviour in a 
fasted state19. Most genes linked to an increased BMI by large-scale genome-wide 
association studies (GWAS) are thus thought to play a direct role in energy balance 
sensing in hypothalamus20,21. 
 
1.1.3 Distribution of adipose tissues in humans and mice 
Two functionally and morphologically distinct types of adipose tissue exist in most 
mammals – white and brown. WAT can be further divided into two main distinctive 
types according to their anatomical location – subcutaneous (scWAT) and visceral 
(vWAT)22. scWAT is located between skin and muscle layers, and is primarily found in 
the abdomen and gluteofemoral region in humans22 (Figure 1-1 B). vWAT surrounds 
and cushions inner organs in the abdominal cavity and consists of omental, 
mesenteric, retroperitoneal, gonadal (gWAT, attached to the uterus and ovaries in 
females and epididymis and testis in men) and epicardial depots in humans22 (Figure 
1-1 B). Mice have two main scWAT depots – anterior (located in the head and neck 
region) and flank (located in the upper leg region), and four vWAT depots – mesenteric, 
retroperitoneal, perirenal and gonadal (epididymal or eWAT in male mice)22 (Figure 
1-1 A). Epididymal WAT depots are substantially larger in mice than in humans. 
 
Two main depots of brown adipose tissue (BAT) exist – interscapular and mediastinal 
in mice23, and supraclavicular and subscapular in humans24 (Figure 1-1 A,B).  
 
The most commonly studied representative adipose tissue depots in mice are inguinal 
(flank) scWAT, gWAT and interscapular BAT (Figure 1-1 A). They are also the only 
adipose tissue depots investigated in this thesis. 
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Figure 1-1. Distribution of white and brown adipose tissue depots in mice and 
humans. 
Anatomical location of indicated WAT and BAT depots in (A) mice and (B) humans. In 
(A), depots indicated as BAT, scWAT and eWAT were analysed as representative 
depots for each type of adipose tissue in this thesis. Figure provided by Dr. Vanessa 
Pellegrinelli and Dr. Vivian Peirce. 
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1.1.4 Functions of WAT 
WAT is a connective tissue with the adipocyte being its parenchymal cell25. The 
primary functions of adipocytes are postprandial energy storage as TGs in lipid 
droplets and the release of this energy as free fatty acids (FFAs) via the process of 
lipolysis in a fasted state. Both of these processes are tightly regulated by multiple local 
and peripheral signals, including hormones, cytokines, neurotransmitters and lipid 
mediators, all converging on the adipocyte25. 
 
1.1.4.1 Postprandial lipid clearance role of WAT 
Meal ingestion leads to an increased serum glucose and lipid concentration. 
Postprandial circulating lipids are predominantly TGs and cholesterol esters packaged 
into chylomicrons by intestinal epithelial cells, and very low- and low-density 
lipoproteins (vLDL and LDL) released by hepatocytes following chylomicron delivery 
to the liver26. Pancreatic beta cells directly respond to increased serum glucose by 
secreting insulin into the circulation, which signals to multiple tissues to promote 
glucose disposal. While the majority of glucose is taken up by muscle and liver to form 
glycogen in an insulin-dependent manner27, WAT responds to insulin by secreting 
lipoprotein lipase (LPL). LPL is anchored to the extracellular side of the plasma 
membrane, where it digests chylomicrons and vLDL and liberates FFAs28. Insulin 
simultaneously promotes FFA uptake and esterification in adipocytes, therefore 
reducing postprandial lipid load28 (Figure 1-2). Furthermore, adipocytes also contribute 
to the normalisation of postprandial glucose concentration by taking up glucose via 
insulin-regulated glucose transporter GLUT4 and converting it to FFAs through the 
process of de novo lipogenesis (DNL)28 (Figure 1-2). Overall, WAT plays a major role 
in the resolution of a postprandial state. 
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Figure 1-2. Energy storage and lipolysis functions of WAT. 
The top part of the figure illustrates the processes occurring in WAT in a postprandial 
state, while the bottom part – in the fasted state of the animal. Figure provided by Dr. 
Guillaume Bidault. 
 
1.1.4.2 Basal and on-demand systemic energy supply role of WAT 
WAT maintains a consistent FFA supply to other organs by basal lipolysis, which is 
greatly supressed by insulin in a postprandial state29 (Figure 1-2). During states when 
the energy requirement of tissues cannot be maintained solely by circulating glucose 
and basal lipolysis, the hypothalamus signals to WAT via sympathetic nervous system 
(SNS) to promote on-demand lipolysis29. The SNS can deliver the signal directly to 
WAT in a form of norepinephrine (NE) released locally from bundles of sympathetic 
nerves, or indirectly by promoting the release of epinephrine into circulation by 
chromaffin cells of the adrenal medulla. Both NE and epinephrine act on -adrenergic 
receptors on adipocytes, initiating an intracellular signalling cascade that rapidly 
culminates in TG hydrolysis and FFA release29. 
 
1.1.4.3 Role of WAT in circadian nutrient metabolism 
All animals exhibit a circadian pattern of feeding, sleeping and other biological 
activities30. Diurnal animals, such as humans, are active during the light phase of the 
day and sleep during the dark phase, while nocturnal animals behave in the opposite 
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manner. The majority of foraging and food consumption occurs during the active phase 
for any given species30. This temporal imbalance causes WAT to predominantly store 
lipids during the active phase, and release them into circulation during the resting 
phase31. Most other tissues have also adapted to this paradigm by utilising glucose as 
a fuel when it is readily available in the active phase, and then switching to fatty acid 
oxidation (FAO) when glucose availability is reduced in the resting phase31. WAT 
therefore was instrumental for efficient animal adaptation to circadian rhythmicity. 
 
1.1.4.4 Energy storage and insulating roles of WAT 
Environments with high degree of seasonal temperature variation typically only provide 
adequate food supply during the warm period of the year. Consequently, most 
mammals living in such environments display a circannual pattern of food intake, with 
a vast majority of calories ingested during summer. This period of hyperphagia in 
mammals is also signified by a massive expansion of WAT, leading to the development 
of muscle insulin resistance and increased circulating insulin levels32. Such dynamic 
WAT expansion allows mammals to enter a state of hibernation in winter, when food 
availability is sparse and TGs stored in adipocytes become the sole source of energy 
until spring32. Increased scWAT content also serve an insulating function that 
conserves energy required for thermogenesis32. WAT therefore allowed animals to 
inhabit continental climate areas without the need of circannual migration. 
 
1.1.4.5 Endocrine role of WAT 
Besides its aforementioned primary functions, WAT is also an endocrine organ, 
secreting specific hormones termed adipokines into circulation33. Leptin was the first 
adipokine to be discovered in 199434, and since then it has been prescribed a plethora 
of roles, including suppression of appetite35,36 and activation of the SNS output to 
adipose tissues in hypothalamus37,38, promotion of FAO in muscle39 and inhibition of 
bone formation40. Mouse and human homozygous carriers of inactivating mutations in 
leptin gene (ob/ob mouse strain) are hyperphagic and become obese early in life34,41, 
which can be reversed by supplementation with exogenous leptin36,42. Adiponectin is 
another abundant circulating adipokine mediating peripheral insulin sensitivity43.  
Adiponectin-deficient mice are more insulin resistant despite having the same fat mass 
as controls44. Besides leptin and adiponectin, multiple other adipokines with important 
roles in metabolic homeostasis and pathophysiology have been identified33, which are 
beyond the scope of this thesis. 
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1.1.5 Functions of BAT 
Like white adipocytes, brown adipocytes in BAT contain TG-rich lipid droplets. 
However, they have substantially more mitochondrial mass than white adipocytes and 
express uncoupling protein 1 (UCP1)45. In most cells, oxidation of energy substrates 
culminates in the mitochondrial electron transport chain, which utilises the bond-
dissociation energy to transport the protons from mitochondrial matrix to 
intermembrane space, creating a proton gradient and energy potential across the inner 
mitochondrial membrane. Adenosine triphosphate (ATP) synthase and UCP1 are both 
localised on the inner mitochondrial membrane and allow the protons to leak back to 
the mitochondrial matrix45. ATP synthase couples this dissipation of energy potential 
to the production of ATP, which serves as an energy donor to fuel most cellular 
reactions. UCP1 does not couple the proton leak to a chemical reaction, therefore 
membrane potential energy is dissipated as heat45. BAT utilises fatty acids stored in 
lipid droplets, as well circulating glucose and FFAs for UCP1-dependent heat 
production, which warms blood circulating through BAT and is then dispersed through 
the rest of the body45. In order to facilitate high rates of FAO for fuel production, brown 
adipocytes contain substantially smaller lipid droplets than white adipocytes, which 
allows lipolysis to occur more rapidly due to increased lipid droplet surface area to 
volume ratio23. 
 
Ability to produce heat by activating BAT allows mammals to live in the environments 
below their thermoneutral temperature (the temperature in which the heat produced by 
basal metabolic reactions is sufficient to maintain core body temperature of the animal) 
without the need of constant shivering. Cold environmental temperature of the animal 
is mainly sensed by peripheral sensory neurons that signal to the hypothalamus, which 
then rapidly increases SNS outflow to BAT45. NE released from sympathetic nerves 
acts on -adrenergic receptors on brown adipocytes, initiating lipolysis, FAO and 
UCP1-dependent heat production45. Prolonged cold exposure also results in BAT 
expansion and the recruitment of brown adipocytes in scWAT, a process often referred 
to as scWAT browning or beiging45.  
 
Recent reports describing functional BAT in adult humans sparked an interest in BAT 
activation as a potential therapy for weight loss46 and improved systemic glucose 
homeostasis47. Genetic and pharmacological mouse models of increased BAT 
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activation and scWAT browning are leaner when fed obesogenic diets due to the 
increased oxidation of fatty acids that would otherwise accumulate in WAT46. However, 
current mechanistic knowledge of BAT activation and scWAT browning in mice and 
humans is still premature for the development of successful weight loss therapeutics 
that would not have detrimental off-target effects. As both endogenous (epinephrine 
and NE) and pharmacological -adrenergic receptor agonists elicit systemic effects 
beyond thermogenesis, including increased heart rate and blood pressure, the main 
challenge in the development of successful weight loss therapies is to selectively 
increase -adrenergic signalling in BAT without directly affecting other tissues48. 
 
1.1.6 Adipose tissue expandability hypothesis 
Postprandial WAT expansion is typically counteracted by lipolysis-mediated WAT 
contraction in the fasted state. Due to the frequent variability in feeding and fasting 
periods (as discussed in 1.1.2 and 1.1.4), WAT evolved the capacity to expand greatly 
beyond its regular size, being able to buffer serum lipid concentrations postpradially 
even after prolonged periods of hyperphagia49. As a result, all other animal tissues 
have evolved in a small, WAT-buffered range of serum lipid concentration, and were 
under no constraints to develop adaptations to elevated levels of extracellular lipids 
present for prolonged periods of time49. 
 
The majority of obese individuals with MetS were initially lean with normally functioning 
WAT. Similarly, the WAT of genetically obese ob/ob mice at young ages, or of Wild-
type (WT) mice before the administration of obesogenic diets, is able to appropriately 
take up and release FFAs. Obesogenic environments leads to hyperphagia in mice 
and humans, which results in a continuous WAT expansion without prolonged fasting 
periods. However, a genetically-defined limit to a WAT expansion50 occurs when 
adipocytes become desensitised to a postprandial increase in circulating insulin, 
leading to impairments in FFA uptake and suppression of basal lipolysis51. Other 
metabolic organs, such as liver, muscle and kidney, are then subjected to chronically 
elevated circulating FFA concentrations and start to accumulate lipids51. Aberrant 
ectopic lipid accumulation causes lipid-induced toxicity (lipotoxicity), leading to 
impaired tissue function, particularly the inability to respond to insulin appropriately51. 
Initially, systemic insulin resistance is compensated for by the expansion of pancreatic 
beta cell mass and their elevated insulin production52. However, exhaustive insulin 
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production leads to apoptosis of beta cells, resulting in the loss of blood glucose level 
control and the development of type-2 diabetes52. Elevated serum lipid concentrations 
also promote the development of arterial plaques, thus directly contributing to the 
development of atherosclerosis53. 
 
The adipose tissue expandability hypothesis is supported by human and animal 
models of both increased and decreased WAT expansion capacity. Approximately 20-
30% of obese human population do not exhibit symptoms of MetS, attributed to their 
improved WAT function54. Similarly, ob/ob mice overexpressing the globular domain of 
adiponectin demonstrate elevated WAT mass, but decreased ectopic lipid 
accumulation and improved systemic insulin sensitivity compared to ob/ob controls55. 
Conversely, specific genetic mutations cause lipodystrophy in humans, characterised 
by decreased or complete ablation of WAT mass and severe systemic insulin 
resistance56. Recapitulating such mutations in mice also impairs WAT expansion and 
leads to ectopic lipid deposition and the development of insulin resistance57. Currently, 
there is a lack of in-depth mechanistic understanding of how maximal WAT expansion 
capacity is regulated.  
 
1.1.7 Adipose tissue inflammation 
Expansion and contraction of most tissues, including WAT, requires modification of 
extracellular environment. As the size of the adipocytes taking up FFAs increases, the 
extracellular matrix (ECM) needs to be degraded to accommodate enlarged cells58. 
Furthermore, appropriate tissue expansion requires coordinated increase in 
vascularisation in order to maintain sufficient tissue oxygenation and nutrient supply. 
Formation and degradation of ECM and vascularisation processes are tightly regulated 
by the immune system within a tissue58. Coincident with its dynamic remodelling, WAT 
is enriched in immune cells that adopt a regulatory (anti-inflammatory) and tissue 
remodelling profile in metabolically healthy animals58. However, in obesity WAT 
becomes infiltrated with pro-inflammatory immune cells and exhibits low-grade sterile 
inflammation59,60, as observed in other pathogen-free inflammatory diseases, such as 
rheumatoid arthritis or atherosclerosis61. 
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While a part of the scientific community regards the sterile inflammation merely as a 
symptom of impaired WAT function62, the overwhelming evidence from animal studies 
indicates a causative role for the immune system in the development of insulin 
resistance and MetS61. Multiple mouse models where cells of the innate or adaptive 
immune system had been genetically targeted demonstrated altered metabolic profile 
during obesity63. However, the evolutionary role of the immune system in the 
maintenance of healthy WAT function and during aberrant expansion remains 
unclear61. This thesis will focus on macrophages, the most abundant immune cell of 
adipose tissue, and will discuss their role in initiating and propagating WAT 
inflammation and insulin resistance. 
 
 
1.2 Macrophages and the development of adipose tissue 
inflammation 
1.2.1 Macrophage biology 
1.2.1.1 Homeostatic roles of tissue macrophages 
The macrophage is a type of leukocyte (white blood cell) of the innate immune system, 
highly specialised in phagocytosis (a process of cell engulfing a solid particle) of dying 
cells, microbes, foreign substances and cellular debris64. Macrophages continually 
monitor their environment by intra-tissue movement and macropinocytosis (non-
selective uptake of water-soluble extracellular material), identify local environmental 
changes via a multitude of cell surface and intracellular receptors and respond to such 
changes by direct phagocytosis or initiation of an immune response64. Millions of cells 
at the end of their lifespan are eliminated every day from a healthy organism in a way 
that does not trigger damage but is instead part of a homeostatic clearance programme 
that involves engulfment by macrophages65. Sensing and phagocytosis of apoptotic 
cells thus maintains macrophages in the anti-inflammatory state65. However, 
recognition of environmental changes that do not typically occur in healthy tissue, such 
as the presence of bacterial components or elevated concentrations of intracellular 
metabolites in the extracellular milieu (indicating non-apoptotic, uncontrolled cell 
death), triggers macrophage inflammatory activation, which will be discussed in more 
detail further. 
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Besides the aforementioned functions, macrophages have acquired roles specific to 
the tissues they reside in. For example, Kupffer cells (liver-resident macrophages) 
perform erythrophagocytosis (engulfment of red blood cells at the end of their lifespan) 
and process and release iron into circulation, ensuring systemic iron homeostasis66. 
Alveolar macrophages (located in the lung) degrade pulmonary surfactant released by 
type 2 alveolar cells, maintaining adequate surfactant levels67. Loss of this degradation 
process leads to the development of pulmonary alveolar proteinosis, a disease 
characterised by abnormal surfactant accumulation, interfering with the ability of the 
lung to exchange oxygen and carbon dioxide from the blood67. Microglia (brain 
macrophages) are instrumental in modifying neuronal synaptic transmission and 
plasticity required for learning68 and memory formation69. Overall, most tissues rely on 
resident macrophages to maintain their appropriate function. 
 
1.2.1.2 Macrophage development 
In the past, monocytes and macrophages were viewed as part of the continuum 
forming mononuclear phagocyte system70. According to this system, macrophages are 
fully differentiated cells that have lost proliferative potential and are constantly 
replenished by circulating monocytes produced by bone marrow-derived myeloid 
progenitors. However, recent lineage tracing71-75 and parabiosis76-79 experiments have 
found that most tissue macrophages, including Langerhans cells (epidermal 
macrophages), microglia, alveolar macrophages and Kupffer cells are renewed 
independently of circulating precursors in adult mice. Multiple fate-mapping studies 
have now established that most tissue macrophages are seeded during foetal 
development from precursors located in the extra-embryonic yolk sac72,80, or from 
foetal liver macrophages without passing through a monocyte intermediate81. 
 
A model of macrophage development strictly linking tissue-resident macrophage 
identity to embryonic origin has shortcomings as well. Depending on the study, Kupffer 
cells, splenic red pulp macrophages and peritoneal macrophages display a degree of 
engraftment of circulating monocytes during adulthood82,83, indicating that embryonic 
precursors may not be the only source of resident macrophages. Furthermore, 
circulating monocytes that contribute to tissue macrophage populations are capable of 
acquiring nearly identical phenotypes to their counterparts of embryonic origin84-86. 
Finally, bone marrow-derived precursors can rapidly repopulate tissues after the 
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ablation of resident macrophages by irradiating mice87. These observations catalysed 
the proposition of ‘niche’ hypothesis88, which suggests that each tissue has a limited 
number of available macrophage niches that are tightly regulated by chemotactic and 
growth factors produced by parenchymal cells. Once all niches are occupied by foetal 
macrophages capable of self-maintenance, circulating monocyte can only differentiate 
into a tissue macrophage when a niche is vacated. During tissue expansion or injury, 
the number of niches increase substantially, and are populated by the most competitive 
progenitors – either locally proliferating macrophages of embryonic origin, circulating 
monocytes, or both88. This model is supported by experiments demonstrating 
macrophage plasticity – the ability to rapidly acquire a phenotype specific to the 
resident tissue, despite having a different tissue of origin86. Overall, the local tissue 
environment, rather than the cellular origin, is the major determinant of a macrophage 
phenotype. 
 
Immune cells within tissues are predominantly identified by their surface protein marker 
expression. Most tissue macrophages of embryonic origin are classified by their high 
expression of adhesion receptor EMR1 (F4/80) and intermediate expression of integrin 
alpha M (CD11b) (F4/80hi, Cd11bint)89. Most macrophages differentiated from 
circulating monocytes are F4/80int-hi, Cd11bhi 89.  
 
1.2.1.3 Macrophage polarisation 
Innate immune cells, including macrophages, form the first line of defence against 
invading pathogens. While the variety of existing pathogens is virtually endless, 
different classes of pathogens express shared features characteristic of that class, 
called pathogen-associated molecular patterns (PAMPs)90. Similarly, every type of 
pathogen-free tissue damage has a distinctive molecular signature called a damage-
associated molecular pattern (DAMP). Macrophages recognise PAMPs and DAMPs 
by pattern recognition receptors (PRRs) and initiate an appropriate immune 
response90. While multiple membrane-bound and cytosolic PRRs exist, only toll-like 
receptors (TLRs) and Nod-like receptors (NLRs) will be discussed here due to their 
importance in the development of WAT inflammation.  
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Humans and mice have ten and twelve different TLRs, respectively. All TLRs localise 
on the plasma membrane, with the exception of TLRs 3, 7 and 9, which are found in 
the endosomes90. TLRs recognise a multitude of PAMPs, including the sensing of 
various bacterial components by TLRs 1, 2, 4, 5, and 11 and viral nucleic acids by 
TLRs 3, 7, 8, and 990. Binding of a PAMP to a TLR initiates an intracellular signalling 
cascade, culminating in the activation of nuclear factor-kappa B (NF-B) or interferon 
regulatory factor (IRF) transcription factors that mediate the expression of genes 
encoding inflammatory cytokines, such as tumour necrosis factor alpha (TNF) and 
interleukin-6 (IL-6)90. TLR stimulation also results in a dramatic change in macrophage 
phenotype, characterised by altered cell shape, motility, protein expression, 
membrane lipid composition and intracellular metabolism90. These changes are further 
modulated by released inflammatory cytokines signalling back to cytokine receptors 
on macrophages in an autocrine manner, or by various molecules released from 
neighbouring immune and non-immune cells signalling to macrophages in a paracrine 
manner90. Once integrated, all signalling inputs polarise macrophages to a specific 
phenotype. Classical macrophage activation, or acquisition of M1 polarisation (or 
inflammatory activation, as will be often referred to in this thesis), occurs in response 
to stimulation with bacterial antigens, such as lipopolysaccharide (LPS), which 
activates macrophages via the TLR4 receptor91. M1-polarised macrophages specialise 
at engulfing and eliminating bacteria by respiratory burst, which involves membrane-
localised production of reactive oxygen species (ROS), directed to oxidise bacterial 
membranes and proteins91. 
 
Besides direct initiation of inflammatory cytokine release, TLR stimulation also leads 
to the production of a subset of cytoplasmic NLRs, namely NLRP1, NLRP3 and 
NLRC4, and their assembly into oligomeric structures called inflammasomes90. Upon 
their activation, inflammasomes trigger a caspase-1-mediated inflammatory cascade, 
culminating in the maturation and release of the cytokines interleukin-1 (IL-1) and 
interleukin-18 (IL-18)90. IL-1 is a potent mediator of both local and systemic pro-
inflammatory responses, and is responsible for the febrile response (fever) to an 
infection by acting on temperature-sensing hypothalamic neurons92. Prolonged 
inflammasome activation ultimately leads to pyroptosis, a form of programmed cell 
death distinct from apoptosis, involving cell swelling, bursting and release of DAMPS, 
such as ATP and deoxyribonucleic acid (DNA) into extracellular space, thus further 
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propagating the immune response93. Inflammasomes are activated by a variety of 
PAMPs and DAMPs, including ATP, viruses, bacterial toxins, cholesterol crystals and 
low intracellular potassium concentrations94.  
 
Once the pathogen is eliminated and tissue damage is contained, inflammation has to 
be resolved in order prevent any further unnecessary damage to host cells. The 
second phase of the response to TLR signalling is the re-polarisation of macrophages 
to a resolution, or M2b state91. Resolution phase macrophages are characterised by 
the production of vast amounts of anti-inflammatory cytokines, such as interleukin-10 
(IL-10) and interleukin-1 receptor antagonist (IL-1RA), that potently diminish local 
inflammatory response, allowing a tissue to return to its normal state91. 
 
Not all invading pathogens cause pro-inflammatory immune responses. Certain types 
of microorganisms (including helminths, saprophytic mycobacteria and lactobacilli) 
have often been present in tissues throughout mammalian evolution. In many cases, 
it was more energy-efficient for the host to allow these microorganisms to parasitise a 
negligible amount of nutrients than to expend energy eliminating them95. Therefore, 
presence of parasites in a tissue invokes an immunomudulatory response, which leads 
to secretion of multiple anti-inflammatory molecules, including cytokines interleukin-4 
(IL-4) and interleukin-13 (IL-13) that polarise macrophages to M2a state96. M2a, or 
alternatively activated macrophages contribute to encapsulation and containment of 
parasites96. Coincidentally, macrophages present in a healthy, pathogen-free tissue 
are also M2a-polarised, and such polarisation state is known to be important for their 
tissue-remodelling activity91.  
 
The high incidence of sterile inflammatory disorders, such as allergies, arthritis and 
type-1 diabetes in modern society lead to the postulation of ‘the hygiene hypothesis’97, 
which states that increased sterility of modern environments is responsible for the 
emergence of the pathogen-free inflammatory diseases. It is supported by the fact that 
individuals raised in a farm-like environment, characterised by a frequent presence of 
animal- and soil-borne pathogens were less susceptible to developing allergies than 
individuals raised in cities98. A formulation of ‘the hygiene hypothesis’ called ‘Old 
Friends hypothesis’ reasons that tissue parasites are important for appropriate function 
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of the immune system in mammals95,99. A continuous presence of tissue parasites 
throughout mammalian evolution have produced a symbiotic relationship, in which 
parasites utilise nutrients from the host, and the host relies on parasites for immune 
system development99. Such hypotheses have led to the development of helminthic 
therapies, involving a deliberate infestation of individuals with a helminth or their egg 
in order to treat sterile inflammatory disorders, such as Crohn’s disease or 
inflammatory bowel disease (IBD)100-102. Helminth infection has also been successful 
in alleviating the symptoms of MetS in mice, as will be discussed further in this thesis 
(1.2.2.4). 
 
1.2.1.4 The role of cell metabolism in macrophage polarisation 
As already illustrated by the evolutionary choice of mammals to contain, rather than 
eliminate parasites, inflammation is an energetically costly process. Consequently, the 
intrinsic metabolism of immune cells has to be fine-tuned for nutrient conservation. 
Until recently, the metabolic reprogramming of macrophages and other immune cells 
upon activation was thought to be merely a consequence of their polarisation, 
occurring in order to sustain their energy requirements103. However, recent research 
has extensively shown that macrophage polarisation can be altered by modulating their 
intrinsic metabolism. 
 
Most cells can adapt to hypoxia (low environmental oxygen levels) by engaging in 
anaerobic metabolism104. Under normoxic conditions, most cells utilise the monomers 
of all macronutrients, including glucose, amino acids and fatty acids to fuel the 
mitochondrial tricarboxylic acid (TCA) cycle for the production of ATP by oxidative 
phosphorylation (OxPhos)105. OxPhos cannot be performed in hypoxia, therefore cells 
switch to anaerobic glycolysis to generate ATP and convert pyruvate to lactate instead 
of oxidising it in mitochondria104. Anaerobic glycolysis produces 2 ATP molecules per 
glucose molecule, which is only about 5% of its energy potential achievable by OxPhos 
(38 ATP molecules)105. However, the rate of ATP production by anaerobic glycolysis 
is approximately 100 times greater than by OxPhos105. 
 
In specific cases, such as high intensity exercise, cells utilise glycolysis for ATP 
synthesis under conditions of normoxia in order to accelerate the rate of ATP 
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production106. Cancer cells also switch their metabolism to anaerobic glycolysis due to 
their defective mitochondria in a process called Warburg effect107,108. The Warburg 
effect rapidly occurs in classically activated macrophages, which dramatically increase 
glucose uptake to fuel both the glycolysis pathway for ATP production, and the pentose 
phosphate pathway to generate reductive potential in the form of reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) required for the respiratory burst103. Rather 
than exhibiting mitochondrial dysfunction, M1 macrophages repurpose their 
mitochondria for the production of ROS, which augments macrophage bactericidal 
activity109 and acts as an intracellular signal to further propagate inflammatory gene 
expression110. Competitively inhibiting glycolysis using the metabolically inert pathway 
intermediate 2-deoxyglucose (2-DG) or by scavenging mitochondrial ROS using 
antioxidants prevents the acquisition of a pro-inflammatory phenotype in 
macrophages103,110,111. 
 
Anaerobic glycolysis during M1 polarisation is not sustainable due to excessive ROS-
induced damage to intracellular proteins and lipids, and macrophages either revert 
back to ATP generation by OxPhos during the acquisition of the resolution 
phenotype112-114 or undergo cell death115. OxPhos is also a predominant form of ATP 
generation in M2a-polarised tissue macrophages112. Blocking OxPhos by 
mitochondrial respiratory chain inhibitors prevents the polarisation of macrophages to 
a M2a state in response to IL-4 and exacerbates their pro-inflammatory phenotype 
upon classical activation116. While the oxidation of glucose, amino acids and fatty acids 
has been described to fuel OxPhos in M2 macrophages113,117, fatty acid oxidation 
(FAO) is thought to play a key role in M2 polarisation116 and will be discussed further 
in this thesis (1.3.1.4). 
 
1.2.2 The role of macrophages in adipose tissue inflammation 
1.2.2.1 The development and roles of adipose tissue macrophages 
As for their counterparts in other tissues, adipose tissue macrophages (ATMs) have 
been shown to develop from bone marrow-independent progenitors without a 
monocyte intermediate in frogs and mice118,119. ATMs exhibit a typical tissue 
macrophage behaviour, including efferocytosis of adipocytes and remodelling of the 
ECM120. Even though ATMs display a substantially different gene expression profile to 
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other tissue macrophages121, only a few specialised functions for ATMs have been 
proposed, and will be discussed further in this thesis. 
 
Regulation of adipocyte insulin sensitivity by ATMs. Similar to the relationship 
between other tissue macrophages and their parenchymal cells, ATMs can influence 
the behaviour of adipocytes through paracrine signalling. Secretion of different pro-
inflammatory cytokines, such as TNF and IL-1 by ATMs are known to reduce the 
responsiveness of adipocytes to insulin122-127. Furthermore, TNF can also inhibit 
adipocyte differentiation from precursor cells128-130. Therefore, release of inflammatory 
cytokines from ATMs has to be tightly controlled in order to maintain appropriate WAT 
function. Elevated secretion of inflammatory mediators within WAT predominantly 
occurs because of two non-exclusive reasons – expansion of the ATM population or 
an altered balance of M1 and M2 macrophages within the ATM population120. Both of 
these processes have been observed in WAT during obesity and will be discussed 
further. 
 
It is not fully clear why ATMs have evolved the ability to regulate adipocyte 
responsiveness to insulin. One hypothesis is that during acute infection, nutrients are 
diverted away from the metabolic organs (such as WAT and muscle) towards immune 
cells that require substantial amounts of energy to fight invading pathogens (as 
discussed in 1.2.1.4)131,132. In support of such hypothesis, genetic mouse models with 
hyper-inflammatory and over-proliferative myeloid cells exhibit fat loss due to 
excessive glucose uptake by myeloid cells133. Furthermore, some acute and chronic 
inflammatory diseases in humans, including chronic obstructive pulmonary disease 
and sepsis, are associated with cachexia134. 
 
Regulation of WAT lipolysis by ATMs. Upon the induction of on-demand lipolysis by 
fasting or in response to pharmacological activation of adipocyte -adrenergic 
receptors, ATMs have been shown to accumulate lipid droplets135,136. ATMs have 
therefore been suggested to buffer lipids released from adipose tissues137,138, and such 
a hypothesis has been supported by a study showing that pharmacological depletion 
of ATMs increases the rate of FFA release from WAT135. However, it is still unclear 
whether ATMs directly reduce the rate of lipolysis by taking up FFAs immediately after 
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release, and/or indirectly by secreting factors that inhibit adipocyte lipolysis. 
Furthermore, the physiological significance of such inhibitory mechanism has not yet 
been discussed or demonstrated. As -adrenergic receptor-dependent lipolysis is 
known to occur in short bursts (approximately 9 pulses of FFA release per hour)139, a 
speculative role for lipid accumulation in ATMs could be the reduction of serum FFA 
oscillations by lipid uptake during the burst release phase, and lipid release to 
circulation in-between bursts. 
 
1.2.2.2 ATM recruitment to WAT 
ATM recruitment during WAT lipolysis. Prolonged fasting and pharmacologically-
induced lipolysis has both been shown to promote135,140 or have no effect136 on ATM 
accumulation in WAT. Lipolysis-induced expansion of the ATM population is 
dependent on the recruitment of bone marrow monocytes by the release of monocyte 
chemotactic protein 1 (MCP1 or CCL2) from WAT135. Intact adipocyte lipolytic 
machinery is also crucial for this process, as ATM recruitment does not occur in fasted 
mice lacking adipose triglyceride lipase (ATGL)135,140, an enzyme catalysing the initial 
step in TG hydrolysis. However, the physiological importance of ATM recruitment 
during fasting is unclear, as mice deficient in CCL2 receptor (CCR2) do not exhibit 
differences in blood glucose or FFAs compared to WT controls141. Browning of scWAT 
upon cold exposure has also been associated with and dependent on monocyte 
recruitment to scWAT and will be discussed further in this thesis (1.4.2). 
 
ATM recruitment during WAT expansion. WAT expansion during obesity leads to a 
dramatic increase of the ATM population, with macrophages representing 
approximately 50% of total cells in hypertrophic WAT59. This increase is attributed 
mainly to infiltration of circulating monocytes142, but the proliferation of local ATMs has 
also been demonstrated143-147. Several chemokines have been implicated in monocyte 
chemotaxis to adipose tissues, of which the most well studied is the CCL2, acting via 
CCR2141,148,149. Utilising an Fabp4 promoter to overexpress Ccl2 transgenically 
specifically in adipose tissues causes macrophage recruitment and the development 
of the MetS in mice fed a standard chow diet148. Conversely, disrupting CCL2 signalling 
by genetic deletion150 or pharmacological antagonism of CCR2151 prevents monocyte 
infiltration to WAT during obesity and reduces the symptoms of MetS in mice. 
RANTES-CCR5152, CXCL5-CXCR2153 and CX3CL1-CX3CR1154 chemokine-receptor 
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pairs have also been similarly shown to contribute to the progression of WAT 
inflammation and insulin resistance. Overall, animal studies indicate that preventing 
monocyte infiltration to WAT during obesity prevents the development of WAT 
inflammation and MetS. 
 
While increased ATM proliferation precedes monocyte infiltration during WAT 
expansion, the pathological role of this increase in the number of ATMs is unclear. 
Some reports suggest that CCR2 and an inflammatory cytokine osteopontin directly 
increase ATM proliferation rate during obesity, leading to WAT inflammation and 
insulin resistance145,147. Other studies argue for an anti-inflammatory role for the 
expansion of the local ATM population, mediated by IL-4 signalling146,155. Further 
studies focusing on WAT expansion during early stages of obesity are thus required to 
understand the metabolic effects of ATM proliferation. 
 
Despite numerous studies investigating the metabolic consequences of disturbed ATM 
recruitment to WAT, the physiological trigger for this process during the onset of 
obesity is less clear. It is evident that the occurrence of a specific set of events induce 
an immune response in WAT that precedes ATM proliferation and monocyte 
infiltration156,157. However, the exact nature of these events and their chronological 
occurrence leading to WAT dysfunction is not yet understood. Deciphering the 
mechanisms initiating inflammation in WAT during obesity is crucial for understanding 
the physiological importance of WAT inflammation and might hold a key for MetS 
therapy. 
 
1.2.2.3 Inflammatory activation of ATMs during obesity 
The vast majority of ATMs localise directly next to dying adipocytes during obesity, 
forming crown-like structures (CLS)158. Multiple ATMs are required to efficiently 
process a single dying adipocyte due to their substantial differences in size. 
Macrophages in CLS collectively form an acidic extracellular compartment surrounding 
the adipocyte by secreting intact lysosomes (cellular organelles containing digestive 
enzymes)159. Adipocyte TGs are digested extracellularly by lysosomal acid lipase 
(LAL), and liberated FFAs are taken up and esterified by CLS macrophages, which 
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become lipid-laden, resembling foam cells found in advanced atherosclerotic 
plaques159,160.  
 
Based on the vast abundance of CLS in dysfunctional WAT during obesity, adipocyte 
death has been suggested to be the initiator of inflammation and monocyte 
recruitment161. Indeed, a model of artificially induced adipocyte apoptosis by targeted 
activation of caspase-8 results in monocyte infiltration and CLS formation162. However, 
mouse models in which adipocyte survival is genetically modulated do not uniformly 
exhibit alterations in WAT inflammatory profile163. Furthermore, caspase-8-induced 
adipocyte death results in a robust increase in M2, but not M1 ATM population size162, 
suggesting that there are factors regulating inflammatory activation of ATMs beyond 
adipocyte death. 
 
PRRs and their downstream intracellular signalling cascades in macrophages 
unquestionably plays a role in ATM inflammatory activation during obesity. Both whole 
body and macrophage-specific genetic ablation of either TLR4164,165, NLRP3166,167 or 
TLR4 adaptor protein MYD88168,169 protected mice from developing MetS during 
obesity. Similarly, genetically inhibiting enzymes that transduce inflammatory signals 
to transcription factors, such as p38 mitogen-activated protein kinase (p38 MAPK)170 
and c-Jun N-terminal kinases 1,2 (JNK1,2)171 prevents obesity-induced WAT 
inflammation and systemic insulin resistance. Finally, a multitude of transcription 
factors mediating macrophage polarisation and inflammatory cytokine gene 
transcription, including peroxisome proliferator-activated receptor gamma (PPAR)172 
and kruppel-like factor 4 (KLF4)173 have been reported to play a role in the 
development of WAT dysfunction and insulin resistance131,132.  
 
The list of genetically validated molecular mechanisms acting in ATMs to perpetrate 
inflammation during obesity exceeds the volume of this thesis. Instead, here I will 
predominantly focus on the factors that initiate inflammatory ATM activation. As 
obesity-related adipocyte dysfunction leads to a lipid spillover in other tissues, the 
major trigger for WAT inflammation is thought to be aberrant lipid accumulation in 
ATMs. How lipids and their metabolism affect the phenotype of macrophages will be 
discussed in 1.3. 
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1.2.2.4 Therapies targeting WAT inflammation to alleviate insulin resistance 
during obesity 
Since the discovery of obesity-induced WAT inflammation, anti-inflammatory 
interventions were proposed as therapies to alleviate insulin resistance and improve 
systemic metabolism in obese individuals. One potential advantage in utilising existing 
anti-inflammatory drugs to treat MetS is the knowledge of their clinical effects in 
humans, acquired from the treatment of sterile inflammatory disorders, such as 
rheumatoid arthritis. Amlexanox, a clinically approved drug to treat asthma and allergic 
rhinitis, has been shown to effectively reduce body weight and insulin resistance in 
obese mice by inhibiting kinases TRAF family member-associated NF-B activator 
(TANK) binding kinase 1 (TBK1) and IB kinase  (IKK) that are involved in 
inflammatory signal transduction174. Furthermore, amlexanox improved insulin 
sensitivity and hepatic steatosis in a subset of patients with type-2 diabetes, which had 
been characterised by increased WAT inflammatory gene expression compared to 
non-responders prior to the drug treatment175. The results of amlexanox clinical trial 
suggests that small-molecule anti-inflammatory drugs could be used to treat MetS in 
humans exhibiting particularly high degree of WAT inflammation. Treatment of obese 
non-diabetic patients with another small-molecule inhibitor salsalate, which targets the 
same arm of inflammatory signalling pathway, namely blocks NF-B activation by 
IKK, resulted in a reduced fasting blood glucose and increased adiponectin levels, 
thus indicating improved WAT function176-179.  
 
Monoclonal anti-TNF antibodies (such as adalimumab or infliximab) and recombinant 
IL-1 receptor antagonists (such as anakinra) have shown mixed results in the 
improvement of insulin sensitivity in humans. Studies that investigated the side effects 
of TNF antagonists in patients with rheumatoid arthritis found that prolonged 
treatment reduced basal insulin and glucose levels, indicating an enhanced insulin 
sensitivity180. On the other hand, clinical trials designed to address the efficacy of TNF 
and IL1- antibody-based antagonists and IL-1 receptor blockers on insulin sensitivity 
in patients with type-2 diabetes showed little to no significant effects181-184. However, 
some clinical trials targeting inflammatory cytokines in insulin resistant individuals 
suffered from lack of statistical power, and larger scale trials are currently ongoing185. 
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As an alternative to targeting pro-inflammatory macrophage pathways, therapies 
enhancing M2 polarisation of ATMs were successful in alleviating MetS symptoms in 
murine models of obesity. Helminth infection, leading to increased alternatively 
activated WAT macrophage population enhanced glucose tolerance in obese 
mice186,187. Furthermore, soil-transmitted helminth-infected humans had lower fasting 
plasma insulin levels compared to uninfected controls, suggesting an improved insulin 
sensitivity188,189. Finally, delivery of liposome-bound IL-10 into macrophages in vivo 
reduced WAT inflammation, serum lipid concentration and hepatic steatosis in obese 
mice190. Overall, while the interventions promoting ATM M2 polarisation have shown 
promising results in the insulin-resistant mice, future studies in humans will need to be 
conducted to verify their translatability. 
 
In accordance with our knowledge regarding the link between WAT inflammation and 
insulin resistance, the vast majority of anti-inflammatory therapies against MetS were 
designed to limit the existing inflammatory reaction without removing its 
pathophysiological trigger. As multiple macrophage inflammatory signalling cascades 
have been implicated in the development of WAT inflammation, selectively blocking 
only one of them might not be sufficient to alleviate the inflammatory response. 
Therefore, a deeper understanding of the mechanisms leading to ATM inflammatory 
activation might enable the design of pharmaceuticals specifically blocking the 
inflammatory initiation phase, which would consequently reduce the activity of all 
downstream inflammatory pathways and be potentially more effective in treating MetS 
in humans. 
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1.3 The role of lipids in regulating macrophage function 
1.3.1 The role of FFAs and sterols in regulating macrophage function 
1.3.1.1 Cellular fluxes and metabolism of free fatty acids and sterols  
In addition to their previously discussed energy storage function, FFAs also serve a 
major role as building material for membranes. Cholesterol and its metabolic 
derivatives are a part of a sterol family of lipids that cannot be burned for energetic 
purposes, and their predominant function is membrane synthesis26. Cellular 
membranes are some of the most basic features of life. Plasma membrane polarity 
and hydrophobicity enable cellular identity by preventing the concentration-mediated 
diffusion of multiple different molecules into and out of a cell. Appropriate cell function 
thus requires the maintenance of cell membrane integrity, which is ensured by a tight 
regulation of membrane synthesis, degradation and remodelling. As FFAs and 
cholesterol are essential for membrane formation, their import, synthesis, export, 
storage and breakdown are under strict control by multiple intracellular and 
extracellular cues26. Unsurprisingly, FFAs and cholesterol themselves have acquired 
a multitude of signalling roles during evolution, regulating metabolic and other aspects 
of cell function. In this section, an overview of all major metabolic pathways involving 
FFAs will be provided. This should enable the reader to place the specific lipid 
metabolism routes that will be discussed subsequently into a global map of cellular 
lipid metabolism. 
 
Figure 1-3 summarises the intracellular routes of FFAs and cholesterol in 
macrophages. Circulating FFAs are bound to serum albumin or present as TGs in 
lipoprotein particles. Once hydrolysed by LPL, FFAs enter cells via fatty acid 
translocase CD36 or fatty acid transport proteins (FATP). Prior to participating in most 
metabolic pathways, FFAs have to be activated by forming a high-energy thioester 
bond with a cofactor coenzyme A (CoA), which is catalysed by a family of long-chain 
fatty acyl-CoA synthetase (ACSL) enzymes26. There are 5 different ACSL isoforms in 
mammals, and each one of them is thought to direct FFA to specific metabolic fates191. 
Furthermore, FATP proteins ligate CoA to FFA upon its entry to a cell. Hydrolysis of 
fatty acyl-CoA (FA-CoA) thioester bond provides energy for fatty acid esterification and 
remodelling processes26. Ultimately, FA-CoAs can be oxidised in mitochondria to yield 
acetyl-CoA (that can subsequently enter the TCA cycle) or esterified to a glycerol 
backbone to form diacylglycerol (DAG), which is a precursor for phospholipid and TG 
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synthesis26. Alternatively, they can be esterified to a sterol moiety to form cholesterol 
esters or to an amino acid serine to enter ceramide synthesis pathway26.  
 
 
Figure 1-3. A simplified overview of cellular fatty acid and sterol metabolism. 
PL, phospholipid; FC, free cholesterol; CER, ceramide; FA, fatty acid. Green 
arrows/boxes indicate pathways and processes that have been shown to be beneficial, 
and red arrows/boxes – pathways and molecules that are detrimental in the ATMs 
during obesity. 
 
Sterols reach cells as fatty-acyl esters in LDL particles, which are internalised and 
directed to lysosomes, where LAL liberates free cholesterol that can then be used for 
membrane synthesis in its free form, or after re-esterification to a fatty acid26. 
 
Most cells, including macrophages, can synthesise fatty acids and cholesterol de novo 
from the end product of glycolysis pathway, acetyl-CoA26. Acetyl-CoA can be 
carboxylated to form malonyl-CoA, which is then used as a substrate for fatty acid 
synthase (FASN), a multimeric enzyme that produces a saturated fatty acid with an 
acyl chain of 16 carbons (palmitate) from 8 malonyl-CoA molecules after multiple 
rounds of elongation reactions26. Similarly, sterols are generated from acetyl-CoA 
through multiple enzymatic steps, which are catalysed by proteins of mevalonate 
pathway26. 
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There are approximately 50 known fatty acids in nature, out of which around 30 can 
be found in mice and humans. As the end product of DNL is palmitate, the remaining 
fatty acids are formed by subsequent palmitate remodelling or acquired from dietary 
sources26. The main sources of DNL-derived FFAs in mammals are liver and WAT, but 
most cells have the capacity to synthesise specific FFAs based on their needs26. Two 
predominant modifications can be applied to a fatty acyl chains – elongation and 
desaturation. The former process adds two extra carbons to the fatty acid, making it 
longer and more hydrophobic, while the latter introduces a double bond at a specific 
location within the fatty acyl chain, creating a kink in the molecule. Longer and more 
saturated fatty acids decrease membrane fluidity, therefore an appropriate balance of 
fatty acyl chain length and unsaturation needs to be maintained to ensure correct 
membrane function26. When not referred to by their common names, a numeric 
description of fatty acids will be used in this thesis, where a fatty acid with a chain 
length of x carbons, y double bonds and the position of the first double bond being z 
carbons from the methyl end of the acyl chain will be called Cx:ynz.  
 
While the overall fatty acid remodelling pathway map is complex, the synthesis of the 
most abundant fatty acids is catalysed by only several enzymes in mammals. 
Palmitatoyl-CoA can be elongated to C18:0 (stearate) by members of Elongation of 
very long chain fatty acids (ELOVL) enzyme family, out of which the main isoform in 
liver, WAT and macrophages is ELOVL6 (Figure 1-4)192. Palmitatoyl-CoA and stearoyl-
CoA can be desaturated to form monounsaturated fatty acids (MUFAs) C16:1n9 
(palmitoleate) and C18:1n9 (oleate) respectively by stearoyl-CoA desaturases (SCDs) 
(Figure 1-4)193. The main SCD isoform in liver and WAT is SCD1, while macrophages 
demonstrate both SCD1 and SCD2 activities193. The only source of C18:2n6 (linoleic 
acid) and C18:3n3 (-linolenic acid) is diet, as they cannot be derived from palmitate 
in humans and mice26. The CoA esters of these essential fatty acids are substrates of 
different ELOVL and fatty acid desaturase (FADS) enzymes, which catalyse the 
formation of multiple polyunsaturated fatty acids (PUFAs) through several elongation 
and desaturation steps (Figure 1-4). C18:2n6, C20:4n6 (arachidonic acid), C20:5n3 
(eicosapentaenoic acid or EPA) and C22:6n3 (docosahexaenoic acid or DHA) are the 
most abundant PUFAs in the phospholipids of most cells, including macrophages26. 
 
Fatty acids are also present in a cell in their free, unesterified form, bound to members 
of fatty acid-binding protein (FABP) family. FABPs and sterol-binding proteins 
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solubilise FFAs and free sterols, therefore allowing them to diffuse through cytoplasm 
and nucleus194. FFAs and sterols act as ligands for transcription factors of nuclear 
receptor family, regulating the transcription of genes involved in lipid metabolism and 
other related cellular processes26. 
 
 
 
Figure 1-4. Mammalian fatty acid remodelling pathways. 
Cellular palmitate can be derived from both DNL and diet, while the only source of 
linoleic and -linolenic acids is diet. The final step of 22:5n6 and 22:6n3 biosynthesis 
involves the hydrolysis of 2 carbons from the acyl chain by peroxisomal -oxidation. 
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1.3.1.2 The role of fatty acid, sterol and DAG signalling in regulating 
macrophage function 
Pro-inflammatory signalling of palmitate. A major structural component of the LPS 
molecule is lipid A, consisting of two phosphorylated glycosamine molecules linked 
with six fatty acyl chains195. As the fatty acyl components of LPS are saturated and 
between 10 and 16 carbons long, endogenous palmitate is hypothesised to be a ligand 
for TLR4 due to its structural resemblance to the hydrophobic moiety of lipid A196,197. 
Indeed, multiple studies have demonstrated TLR-dependent inflammatory activation 
of macrophages by palmitate, characterised by activation of JNK and p38 MAPK 
signalling pathways and induction of NF-B-dependent gene transcription164,198-201. 
Furthermore, TLR4-knockout mice are protected against developing insulin resistance 
following acute intravenous infusion of lipids or after prolonged feeding with high-fat 
diet164. Deletion of the Tlr4 gene in hematopoietic cells also improves WAT 
inflammation and insulin sensitivity in obese mice202. However, some studies argue 
against the ability of palmitate to stimulate TLR4, suggesting that an endotoxin 
contamination present in bovine serum albumin, which is used for solubilisation of 
palmitate in cell culture studies, is responsible for the activation of the TLR4 pathway 
upon palmitate treatment203. Others have proposed that an endogenous circulating 
protein fetuin-A is an essential component of TLR4 signalling complex, and is required 
for palmitate-mediated TLR4 activation204. Overall, while the precise mechanism is not 
yet clear, the majority of the field agrees with the pro-inflammatory properties of 
palmitate. 
 
Intracellular DAG signalling. Diacylglycerol is a metabolic intermediate in 
phospholipid and TG synthesis pathways (Figure 1-3). It is also produced in response 
to specific extracellular signalling cues and act as second messenger within a cell, 
mainly involved in binding and activating protein kinase C (PKC)205. Once active, PKC 
promotes differentiation and M1 polarisation in macrophages206,207, and is also known 
to supress insulin signalling in metabolically relevant tissues, such as liver and 
muscle208. Dyslipidaemia observed during obesity leads to DAG accumulation within 
hepatocytes and myocytes (muscle cells), which is hypothesised to drive the 
development of insulin resistance208. Genetic deletion of enzymes involved in DAG 
biosynthesis leads to improved metabolic profile in obese mice208. While it has not 
been directly addressed, DAG accumulation and subsequent PKC activation is also 
thought to be involved in ATM inflammatory activation during obesity209. 
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Anti-inflammatory signalling of unsaturated FFAs. Supplementing diets with 
unsaturated fatty acid-containing lipids has been long known to improve systemic 
nutrient metabolism in mice and humans210. MUFAs and PUFAs demonstrate anti-
inflammatory effects through the activation of cell surface and nuclear receptors. G 
protein-coupled receptor 120 (GPR120) is hypothesised to be the cell surface sensor 
of unsaturated fatty acids211. MUFAs and PUFAs, but not SFAs can bind to GPR120 
with varying affinities and stimulate the activation of its downstream pathway212. 
GPR120 genetic deletion does not affect WAT inflammation and insulin resistance in 
obese mice212. However, while dietary supplementation with PUFAs improves 
systemic insulin sensitivity during obesity, their beneficial effect is lost in whole body 
and hematopoietic cell-specific Gpr120 knockout mice212. Furthermore, other study 
has found that loss of GPR120 function leads to increased body mass in mice fed an 
obesogenic diet by increasing food intake213. In line with such finding, a deleterious 
mutation of GPR120 gene, leading to reduced receptor signalling activity, has been 
linked to increased BMI in humans213. Other cell surface FFA receptors, such as 
GPR40 and GPR43 have also been implicated in macrophage immunomodulation214. 
However, their agonists are short chain fatty acids derived from gut bacterial 
metabolism, which will not be covered in this thesis. 
 
Activation of nuclear receptors by FFAs. FFA and sterol sensing in the nucleus is 
critical for shaping the phenotype of macrophages. Transcription factors of PPAR 
family are activated by unsaturated fatty acids and regulate cellular FFA uptake, 
storage and oxidation.215 Macrophages deficient in their most abundant PPAR isoform 
PPAR are incapable of polarising to M2a state, and macrophage-specific PPAR 
knockout mice are more susceptible to developing insulin resistance during obesity172. 
Oxysterols, modified forms of cholesterol, are endogenous ligands of liver X receptor 
 and  (LXR and LXR) transcription factors, which reduce cellular cholesterol levels 
by regulating the expression of enzymes involved in cholesterol uptake and efflux, such 
as LDL receptor (LDLR), ATP-binding cassette transporter 1 (ABCA1) and ATP-
binding cassette sub-family G member 1 (ABCG1)216. In macrophages, LXRs have 
been shown to induce Elovl5, Fads2 and Scd2 gene transcription, leading to elevated 
intracellular production of unsaturated fatty acids217,218. Enhancing macrophage LXR 
activity by genetically removing either nuclear receptor co-repressor 1 (NCoR)218 or 
FABP4 (aP2)219 results in increased production of unsaturated fatty acids, thus 
improving the inflammatory and metabolic profile of obese mice. PUFAs promote the 
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resolution of inflammation in macrophages by uncoupling NF-B binding to DNA from 
its transcriptional activity via an unknown mechanism218,220. 
 
Until recently, PPARs and LXRs have been thought to be the predominant transcription 
factors linking fatty acid metabolism and inflammation in macrophages. However, a 
time-course analysis of FFAs in macrophages following their inflammatory activation 
have revealed that the levels of unsaturated FFAs are reduced during the initial, pro-
inflammatory phase after TLR stimulation, but are restored to the original state during 
the resolution phase220. Such reinduction of unsaturated FFA biosynthesis is mediated 
by a transcription factor sterol regulatory element-binding protein 1 (SREBP1), and it 
has been shown to mediate the resolution of inflammation in cultured macrophages 
and mice by catalysing the production of anti-inflammatory MUFAs and PUFAs220. How 
SREBP1 is activated during macrophage inflammatory activation remains to be 
investigated. 
 
1.3.1.3 The role of membrane saturation in regulating macrophage function 
Cell shape, motility and membrane-bound protein function depends on the fatty acid 
composition of cellular membranes26. Cells have therefore evolved numerous 
mechanisms to sense changes in membrane fluidity and normalise it, if necessary26. 
As most of intracellular lipid synthesis and remodelling occurs in the endoplasmic 
reticulum (ER), it is also where lipid-sensing proteins predominantly localise, including 
the inactive forms of SREBP transcriptions factors26. Inactive SREBPs are present in 
an ER-bound protein complex that perceives the membrane lipid composition221. The 
SREBP2 complex is a cellular cholesterol sensor, and when the membrane cholesterol 
levels drop, SREBP2 is proteolytically cleaved and transported into the nucleus, where 
it drives the transcription of genes encoding mevalonate pathway enzymes221. 
SREBP1 is also regulated by post-translational cleavage, which is inhibited by high ER 
PUFA levels192. Other factors that activate SREBP1 will be discussed further in this 
thesis (1.3.3.5). 
 
One of the main functions of the ER is folding and post-translational modification of 
newly synthesised proteins. Cells contain the machinery to sense the states when the 
demand for protein synthesis exceeds the capacity of the ER enzymes to facilitate 
protein folding222. In these conditions of ER overload, cells have been termed to exhibit 
ER stress. ER stress invokes an adaptive unfolded protein response (UPR), which is 
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conserved from worms to mammals and lead to the expansion of ER and biosynthesis 
of multiple chaperone proteins that facilitate protein folding222. Interestingly, altered ER 
membrane lipid composition also leads to ER stress and UPR activation independently 
of cellular proteostasis223-225.  
 
Obesity has been shown to promote ER stress in multiple cell types, including 
hepatocytes226, pancreatic  cells227, adipocytes228,229, hypothalamic neurons230 and 
ATMs231. In many cases, obesity-related ER stress is thought to be a consequence of 
altered systemic lipid metabolism, associated with increased accumulation of 
intracellular lipids. The precise cellular mechanism linking lipid accumulation and ER 
stress is not fully understood, but the elevated saturation of ER membranes has been 
suggested to be involved224,225. Indeed, treating cells with high concentrations of 
palmitate leads to a profound ER stress response due to increased ER membrane 
saturation232. Consequently, numerous studies have utilised prolonged incubations 
with palmitate to model obesity-mediated ER stress in cell culture232. Such a modelling 
system has been proven to be successful in many cases, as genetic models that exhibit 
reduced ER stress in response to palmitate in vitro often have a diminished ER stress 
response during obesity in vivo.  However, it is not yet clear whether saturated fatty 
acids are responsible for ER stress development during obesity.  
 
Animal genetic models uniformly favour a causal role of macrophage ER stress for the 
development of inflammation and insulin resistance during obesity231,233,234. The 
expression of proteins co-ordinating cellular ER stress response, namely C/EBP 
homologous protein (CHOP) transcription factor, which promotes apoptosis, and 
inositol-requiring enzyme 1α (IRE1), which catalyses the splicing-mediated activation 
of X-box binding protein 1 (XBP1)-encoding mRNA, are increased in ATMs during 
obesity231. Systemic CHOP deficiency prevents the development of insulin resistance 
in response to an obesogenic diet by maintaining ATMs in an M2 polarisation state234. 
Macrophage-specific IRE1 deletion leads to an improved metabolic profile by 
increasing systemic energy expenditure, thus attenuating weight gain during high-fat 
feeding231. Pharmacologically targeting macrophage IRE1 also decreases 
inflammation in atherosclerotic plaques, resulting in alleviated atherosclerosis235. 
While palmitate is known to induce ER stress in cultured macrophages233, the 
mechanisms that promote the ER stress response in ATMs or plaque macrophages 
are not clear. 
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1.3.1.4 The role of FAO in regulating macrophage function 
Contrary to anaerobic glycolysis, which can generate ATP at a very high rate and low 
efficiency, FAO is characterised by a low rate, but high efficiency of ATP synthesis105. 
Due to their reduced and anhydrous state, fatty acids are the most efficient energy 
source in the body, capable of producing 9 kilocalories (kcal) of energy per gram, 
compared to 4 kcal/g for carbohydrates105. Therefore, from a systemic point of view, it 
is more beneficial for a multicellular organism to restrict anaerobic glycolysis to cells 
with high energy expenditure, while having cells with low energy demand be 
preferentially fuelled by FAO. Such biological adaptation is also reflected in 
macrophage biology, where M1-polarised macrophages utilise glucose to maintain 
their high bioenergetic needs, and M2 macrophages that do not require fast rates of 
ATP production operate on FAO236. Interestingly, during the initial phase of the 
acquisition of M2 polarisation, macrophages exhibit an increased glycolytic flux that is 
diminished when the polarisation is accomplished103,237. Blocking glycolysis in 
macrophages during exposure to M2-polarising agents prevents the development of 
M2 polarisation238. Therefore, current literature suggests that regardless of the 
inflammatory nature of the trigger, the initial period of macrophage activation, 
characterised by energy-demanding processes (such as chromatin remodelling and 
gene transcription, protein expression and membrane remodelling), is fuelled by 
energy derived from glycolysis116,117.  
 
Recently published findings have suggested that FAO is not only a consequence of a 
change in the cellular phenotype in M2-polarised macrophages, but also plays a causal 
role in the acquisition of M2 polarisation238. A mechanism has been proposed, where 
exogenous and endogenous fatty acids in macrophages are initially stored as TGs in 
lipid droplets before being hydrolysed in the lysosomes by LAL and shuttled to the 
mitochondria for -oxidation238. Inhibiting this process by genetically deleting LAL, or 
pharmacologically inhibiting carnitine palmitoyltransferase I (CPT1), a mitochondrial 
FFA transporter (catalysing the initial step in FFA import, namely esterification of a fatty 
acid to carnitine), blocks FAO and prevents the development of M2 macrophages238. 
However, these findings have recently been challenged by a genetic deletion of CPT2 
(catalysing the hydrolysis of fatty acyl-carnitine within mitochondria) in macrophages, 
which results in impaired FAO but does not affect the acquisition of M2 polarisation239. 
Overall, it is now thought that FAO in M2 macrophages is a consequence, rather than 
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a cause of a change in the phenotype, and that pharmacological CPT1 inhibitor 
etomoxir blocks M2 polarisation via a yet unknown off-target effect239. 
 
Similarly to how excess FFAs can be systemically eliminated via oxidation in BAT 
during obesity, increasing the FAO capacity of a cell has been shown to be protective 
during lipotoxicity by decreasing the intracellular lipid load. Overexpression of myocyte 
CPT1 isoform (Cpt1b) in skeletal muscle alleviates insulin resistance in high-fat diet-
fed rats by reducing intramuscular TG and DAG accumulation240. Liver-specific 
overexpression of hepatic CPT1 isoform (Cpt1a) also improved the metabolic profile 
of obese mice, potentially due to a decreased hepatic DAG and ceramide 
concentrations241. Similarly, enhancing FAO by Cpt1a overexpression in macrophages 
in vitro reduces palmitate-induced inflammation242, while genetic deletion of Cpt1a in 
macrophages exacerbates saturated FFA-mediated ER stress and inflammatory 
activation243. However, FAO does not appear to be important in ATMs during obesity, 
as the loss of CPT2 and resulting loss of FAO in macrophages does not potentiate the 
development WAT inflammation or insulin resistance during high-fat feeding of mice244.  
 
1.3.2 The role of lipid droplets in regulating macrophage function 
1.3.2.1 Formation and function of intracellular lipid droplets  
Due to their hydrophobicity, TGs and cholesterol esters spontaneously group together 
and form droplets when present in an aqueous phase245. Similarly, most cells exist as 
emulsions, containing lipid droplets mainly consisting of TGs and cholesterol esters 
dispersed in the aqueous cytoplasm245. However, intracellular lipid droplets are 
membrane-enveloped organelles that do not arise spontaneously. Instead, their 
formation, stability and function is under strict control by intracellular signalling 
mechanisms245. Such regulation enables a wide variety of lipid droplet properties to be 
observed within the same animal. For example, white adipocytes in mammals each 
contain a single large lipid droplet, while brown adipocytes have multiple small lipid 
droplets. As obesity is a disorder related to excessive and abnormal TG storage, 
accumulation of lipid droplets in multiple cell types have been described to play a role 
in the development of MetS246. 
 
In eukaryotes, lipid droplets are formed de novo in the ER, where TG and cholesterol-
synthesising enzymes predominantly localise245 (Figure 1-5). De novo TG biosynthesis 
in most cells is performed via a Kennedy pathway, involving the esterification of two 
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fatty acyl-CoAs to glycerolphosphate and the hydrolysis of the phosphate group from 
the glycerol moiety to form DAGs245. DAGs can then be used for phospholipid (as will 
be described further) or TG biosynthesis. The final step of TG biosynthesis, the 
esterification of a fatty acyl-CoA to DAG, is catalysed by the diacylglycerol 
acyltransferase (DGAT) enzymes DGAT1 and DGAT2 (Figure 1-5)245. While both 
DGATs catalyse the same reaction, they share no sequence similarity and thus 
evolved independently from each other. Consequently, they exhibit different structures, 
subcellular localisations, substrate preferences, tissue and cellular distribution and 
physiological roles245.  
 
 
 
Figure 1-5. A step-wise simplified model of lipid droplet formation. 
Figure taken from Wilfling et al247. 
 
 
DGAT1 is found exclusively in the ER, where it can esterify fatty acyl-CoAs to a number 
of substrates, including DAG, monoacylglycerol, retinol, long-chain alcohols248 and 
cholesterol249, although TG synthesis appears to be its predominant function250. 
DGAT1 plays an important role in esterifying excess extracellular lipids and has been 
suggested to reduce lipotoxicity-induced ER stress250,251. TGs and cholesterol esters 
are relatively inert molecules. Therefore, when ER is faced with a lipid overload, one 
of the physiological responses is to direct the excess lipids for ‘safe’ storage within the 
lipid droplets252. Enzymes involved in TG biosynthesis are under XBP1 transcriptional 
control in the liver and are up-regulated in response to ER-stress mediated activation 
of IRE1253. Furthermore, cells deficient in DGAT1 undergo apoptosis after a 
prolonged incubation with oleate, which is otherwise well-tolerated in WT cells251. 
Physiologically, Dgat1 knockout mice are viable and have functional WAT254. 
Interestingly, these mice are resistant to high-fat diet-induced obesity and insulin 
resistance254, and also exhibit a longer lifespan on a chow diet than WT controls255. 
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Such a beneficial metabolic profile is mainly attributed to DGAT1 deficiency in the 
enterocytes (intestinal epithelial cells), which leads to an impaired postprandial lipid 
absorption256,257. Paradoxically, Dgat1 overexpression in muscle258 or heart259 also 
improves insulin sensitivity in obese animals by reducing tissue DAG levels. 
Furthermore, overexpressing Dgat1 in WAT260 or liver261 increases the respective 
tissue weight by promoting lipid storage. However, such DGAT1-dependent WAT 
expansion or liver steatosis is dissociated from any metabolic impairments related to 
ectopic lipid accumulation observed during obesity260,261. Overall, Dgat1 
overexpression models demonstrate that appropriate intracellular lipid storage has no 
adverse metabolic effects, and thus provide elegant support for both the adipose tissue 
expandability and lipotoxicity hypotheses. 
 
DGAT2 is thought to synthesise TGs predominantly from fatty acid substrates derived 
from DNL262-265. In contrast to DGAT1, DGAT2 is localised to both the ER and lipid 
droplets. Furthermore, while lipid droplets generated by DGAT1 are relatively small 
and of constant size, DGAT2-containing lipid droplets demonstrate further growth after 
budding off the ER266. Therefore, small lipid droplets are generally thought to be 
synthesised by DGAT1, and large lipid droplets – by DGAT2266. Dgat2 knockout mice 
die shortly after birth due to a defect in skin barrier function267. These mice also exhibit 
lipopenia (lack of circulating lipids), indicating that DGAT2 is the main TG-synthesising 
enzyme in mammals267. 
 
1.3.2.2 The role of lipid droplets in regulating macrophage function 
Lipid droplets in macrophages have been predominantly studied in the context of 
bacterial and parasitic infections or pathophysiological disorders, such as 
atherosclerosis268,269. Lipid droplet formation in macrophages in response to a bacterial 
infection is thought to be dependent on TLR signalling269. Lipid droplet-containing 
macrophages found in atherosclerotic plaques are termed foam cells and are derived 
from the uptake of oxidised LDL particles. Interestingly, individuals carrying 
polymorphisms attenuating TLR4 signalling have reduced risk of developing 
atherosclerosis, while being more susceptible to bacterial infections270. Based on these 
observations, recent reports have established a link between macrophage 
inflammatory activation and lipid droplet formation269. 
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Prolonged stimulation with LPS has been shown to promote TG-containing lipid droplet 
formation in macrophages in the absence of exogenous lipids271-274. Furthermore, 
macrophages activated with LPS accumulated approximately 3-fold more TGs or 
cholesterol esters when incubated with TG-containing particles or LDL, respectively271. 
LPS has also been described to reduce the rate of lipolysis, thus leading to TG 
retention in lipid-laden macrophages274. So far, the mechanisms mediating increased 
TG accumulation during macrophage inflammatory activation have been 
predominantly based on the molecular characterisation of lipid-laden and M1-polarised 
macrophages203,271,272,274-276. LPS has been observed to induce the expression of 
DGAT2 and other enzymes of the Kennedy pathway, ACSL1, multiple FABP proteins 
and lipid droplet-coating adipose differentiation-related protein (ADRP)272,274,276. 
Therefore, it is thought that LPS promotes fatty acid storage by increasing the 
expression of genes related to fatty acid uptake, TG synthesis and lipid droplet 
formation and decreasing lipolytic and FAO gene transcription238,272. However, a recent 
report has suggested that LPS-induced lipid accumulation in macrophages is driven 
entirely by the increased rate of culture medium acidification, occurring due to elevated 
lactate production by highly glycolytic inflammatory macrophages273. Indeed, simply 
manipulating the extracellular pH of macrophages is sufficient to induce lipid 
accumulation273. Interestingly, macrophages have been shown to create an acidic 
extracellular compartment to digest aggregated lipoproteins in atherosclerotic 
plaques277, or dying adipocytes in WAT159. However, the mechanisms of pH-mediated 
intracellular lipid storage are unclear.  
 
One of the main functions of lipid droplets in macrophages is the storage of 
inflammatory lipid mediator precursors268. During their inflammatory activation, 
macrophages produce fatty acid-derived eicosanoids that, depending on their type, 
either propagate or alleviate local inflammation278. Enzymes that generate 
eicosanoids, including lipoxygenases (LO) and cyclooxygenases (COX), have been 
shown to localise on lipid droplet membranes in macrophages268,279. Macrophage 
inflammatory activation promotes the release of precursor fatty acids from the lipid 
droplets, including arachidonic acid, EPA and DHA, that are then used for the synthesis 
of a multitude of eicosanoids, including leukotrienes, prostaglandins and resolvins278. 
Increased lipid droplet formation is thus thought to enhance the capacity for eicosanoid 
formation in macrophages. Indeed, significant correlations between lipid droplet 
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formation and enhanced generation of both LO- and COX-derived eicosanoids have 
been observed279-282. 
 
Similar to atherosclerotic foam cells, ATMs isolated from obese mice exhibit increased 
intracellular lipid droplet content283. Obesity has also been linked to an increased 
lysosomal biogenesis in the ATMs160,284,285. As ATMs digest dying adipocytes, a logical 
assumption is that macrophage lipid accumulation stems from FFAs released from 
extracellular TG hydrolysis. Indeed, sequestering of lipids released from digested 
adipocytes, thus buffering the release of hydrolysed FFAs into the circulation, is one 
of the proposed roles of ATM lipid droplets137,138. As already discussed in 1.2.2.1, such 
a buffering mechanism might not be restricted to the FFAs released from dying 
adipocytes, but also to FFAs liberated during on-demand lipolysis. In line with this, 
depleting macrophages from the obese adipose tissues increases the rate of FFA 
release into the circulation, while inhibiting lysosomal lipolysis of the intracellular lipid 
droplets in the ATMs reduces WAT lipolysis in obese animals284. However, the fatty 
acid composition of TGs found in ATMs is distinct to the fatty acid composition of 
adipocytes in the WAT isolated from ob/ob mice283. In particular, ATM lipid droplets 
exhibit an enrichment of MUFAs and PUFAs relative to adipocytes283, suggesting that 
ATMs do not simply store the contents of a dead adipocyte, but rather selectively buffer 
the release of unsaturated fatty acids into the circulation. The physiological role of such 
selective storage of FFAs in the ATMs remains to be investigated. 
 
While lipid droplet accumulation in macrophages is normally associated with 
pathophysiological states, it can be considered as an adaptive and protective cellular 
response against lipid-induced toxicity and inflammation. It is also important to 
emphasise that lipid droplets represent only the ‘visible’ spectrum of intracellular lipids, 
namely TGs and cholesterol esters, which are relatively biologically inert. In contrast, 
DAGs286, ceramides287 and saturated FFAs are invisible to lipid dyes but display potent 
intracellular reactivity. The relative importance between these two types of lipids in 
macrophages is emphasised by a genetic model of Dgat1 overexpression209. Dgat1-
overexpressing macrophages are protected against palmitate-induced inflammation, 
despite exhibiting increased TG accumulation in response to FFA treatment209. 
Interestingly, increased DGAT1 activity also reduces the inflammatory activation of 
macrophages in response to LPS stimulation209. Importantly, myeloid cell-specific 
overexpression of Dgat1 reduces WAT inflammation and improves the metabolic 
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profile in mice after prolonged high-fat feeding209. Furthermore, DGAT1 deficiency in 
myeloid cells leads to an increased systemic inflammation in a mouse model of 
atherosclerosis288. However, lack of DGAT1 activity does not impact saturated fatty 
acid-induced ER stress233 or oxidised LDL-induced inflammation288 in macrophages. 
Finally, while pharmacological PPAR agonists have been shown to promote Dgat1 
expression in cultured macrophages209, the physiological factors regulating Dgat1 
transcription in macrophages in vivo have not yet been described.   
 
1.3.2.3 The role of lipid droplets during hypoxia and anaerobic metabolism  
Hypoxia has been long known to promote lipid droplet accumulation in multiple cell 
types289-291. Cancer cells exhibiting high rates of anaerobic glycolysis also have 
increased lipid droplet content292. Multiple mechanisms contribute to hypoxia-induced 
lipid droplet formation, including increased DNL293,294, elevated exogenous fatty acid 
uptake295-297 and decreased FAO298. While different cells rely on separate mechanisms 
to coordinate TG accumulation during hypoxia, hypoxia-inducible factor (HIF) proteins 
appear to be necessary for lipid droplet formation in a low oxygen environment or in 
cancer cells297. 
 
The HIF family of transcription factors contain 6 members, among which the most 
studied proteins are HIF1 and HIF2, encoded by Hif1a and Epas1 genes, 
respectively299. Under normoxia, HIFs are continuously degraded by ubiquitin-
dependent targeting for proteosomal degradation299. Hypoxia stabilises HIFs in the 
nucleus, leading to the transcription of genes related to glycolytic metabolism (Glut1), 
angiogenesis (vascular endothelial growth factor A, Vegfa) and lipid metabolism (Adrp, 
Cd36)299. HIF1 activity is also important for the induction of Warburg effect and the 
survival of multiple cancer cells300. Similarly, the switch to anaerobic glycolysis in LPS-
activated macrophages and subsequent inflammatory gene expression is mediated by 
HIF1111,114,301. 
 
The functional roles of lipid droplets during hypoxia, in cancer cells and LPS-activated 
macrophages are speculative. Firstly, it has been suggested that lipid droplets ensure 
ER homeostasis during the conditions of cellular stress. The synthesis of the most 
abundant unsaturated fatty acid oleate within the cell by SCD enzymes requires 
oxygen as an electron acceptor26. In hypoxia, the metabolic flux through SCD1 is 
supressed, leading to increased exogenous MUFA uptake295. The storage of MUFAs 
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in lipid droplets during hypoxia might provide a stable cellular source of MUFAs, when 
their de novo synthesis capacity is limited, thus alleviating the pressure of lipogenesis 
and lipid remodelling from the ER.  
 
Secondly, lipid droplets have been ascribed an antioxidant role302. Reprogramming of 
cellular metabolism during hypoxia, in cancer cells or in LPS-treated macrophages is 
associated with an increased production of ROS110,303,304. ROS-induced lipid 
peroxidation is detrimental for cell survival. Consequently, cells have evolved multiple 
mechanisms to prevent the formation of lipid peroxides. For example, glutathione 
peroxidases (GPX) are a family of enzymes that catalyse the glutathione-mediated 
reduction of oxidised lipids back to their native state305. Recently, GPX4 activity has 
been shown to be essential for cancer cell survival by allowing the membrane integrity 
and functionality to be maintained during the metabolic state with a high rate of ROS 
production306,307. As lipid droplets are hydrophobic, they protect unsaturated fatty acids 
from ROS, which are mainly hydrophilic and propagate through the aqueous cytosol. 
It has been reported that during physiological states of hypoxia in Drosophila brain, 
glial cells relocate unsaturated fatty acids from their membranes to the lipid droplets in 
order to avoid lipid peroxidation302. Such adaptive processes allow successful neuron 
development, and preventing glial lipid droplet formation by Dgat1 knockdown impairs 
brain development in Drosophila302. 
 
1.3.3 The role of phospholipids in regulating macrophage function 
1.3.3.1 Cellular pathways of phospholipid biosynthesis 
Figure 1-6 illustrates the simplified intracellular pathways of phospholipid synthesis. 
The biosynthesis of aqueous precursors for phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) occurs in cytosol and nucleus26. DAGs are 
synthesised de novo from glycerol and FFAs in the ER26. The addition of choline and 
ethanolamine headgroups onto DAGs (to synthesise PC and PE, respectively) is 
catalysed in the ER, or directly on the membranes of cellular organelles, such as the 
nucleus, mitochondria or lipid droplet26. PC can then be further modified by a 
headgroup exchange between choline and serine to form phosphatidylserine (PS) in 
the ER, or by switching the DAG moiety to a ceramide to form sphingomyelin (SM) in 
the Golgi apparatus26. PE can also be modified into PS or tri-methylated to form PC in 
the ER. De novo cardiolipin (CL) synthesis occurs in mitochondria, where PS can also 
be decarboxylated to form PE26. Finally, phosphatidylinositol (PI) is synthesised in the 
  40 
ER and further modified by phosphorylation in the Golgi apparatus to form 
phosphoinositides, which play an important effector role in G protein-coupled receptor 
(GPCR) signalling26. 
 
 
 
Figure 1-6. Simplified map of cellular phospholipid biosynthesis pathways. 
 
 
Phospholipids can be degraded by phospholipases that cleave the headgroup together 
with the phosphate moiety to form DAGs, or without removing the phosphate to 
produce phosphatidic acid (PA)26. Furthermore, circulating lipoproteins contain intact 
phospholipids that can also be taken up or removed from a cell via lipoprotein 
internalisation or secretion26. Finally, PC can be removed from the liver into the bile, 
where it acts as a surfactant to aid the digestion of lipids26.  
 
1.3.3.2 Cellular PC and PE biosynthesis pathways 
PC and PE constitute the vast majority of intracellular phospholipids26. Their de novo 
biosynthesis proceeds mainly via the Kennedy pathway, which is summarised in Figure 
1-7. Firstly, phospholipid polar-group precursors ethanolamine and choline are 
phosphorylated by ethanolamine and choline kinases, respectively26. 
Phophoethanolamine and phosphocholine are then attached to a cytidine phosphate 
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by CTP:phosphoethanolamine and CTP:phosphocholine citidyltransferases (ECT and 
CCT, respectively)26. The final step of PE and PC formation is catalysed by DAG:CDP-
ethanolamine and –choline phosphotransferases, which replace the cytidine 
phosphate with DAG moiety26.  
 
PE can also be converted to PC in three subsequent methylation reactions catalysed 
by phosphatidylethanolamine N-methyltransferase (PEMT)26. This reaction is 
particularly relevant in the liver, where it produces approximately 30% of overall PC 
content308. However, as PEMT activity is thought to not be functionally relevant in 
macrophages309, the biological importance of PE to PC conversion will not be 
discussed here. 
 
The enzymes of the Kennedy pathway can significantly overlap in their substrate 
usage. For example, several choline kinase isoforms have been reported to 
phosphorylate ethanolamine and specific phosphotransferases can catalyse the 
formation of both PC and PE from their respective precursors310-312. Conversely, ECT 
and CCT are highly specific for phosphoethanolamine and phosphocholine, 
respectively313. Furthermore, the reactions catalysed by ECT and CCT have been 
shown to be rate-limiting, as most cells contain high levels of their respective 
substrates and almost no products314-316. Consequently, the enzymatic activities of 
both ECT and CCT are highly regulated, as will be discussed in 1.3.3.3. However, 
some reports have suggested that the cellular availability of ethanolamine, choline or 
DAG can limit de novo PE and PC synthesis rate317,318. Macrophages also exhibit 
functional regulation of the choline transporter and increase their rate of choline uptake 
when the demand for PC biosynthesis is high319. Therefore, it is not yet clear whether 
the regulation of choline transport or CCT enzymatic activity physiologically modulates 
the rate of PC biosynthesis in macrophages. However, it is likely that both processes 
play a role in ensuring cellular PC homeostasis, and their relative importance is 
context-dependent. Due to the observed regulation of CCT in ATMs, as will become 
evident in the results section of this thesis, here I will only discuss the role of CCT in 
regulating cellular PC levels. 
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Figure 1-7. Kennedy pathway of de novo PC and PE biosynthesis. 
Figure taken from Pulido et al320. 
 
 
Finally, most phospholipids synthesised de novo can be subsequently remodelled via 
Lands cycle26. It involves the hydrolysis of a single fatty acyl moiety from membrane 
phospholipids to form lysophospholipids (phospholipids with a single fatty acyl chain) 
and an esterification of different fatty acyl-CoAs to the newly formed 
lysophospholipids26. Acyl-CoA:lysophosphatidylcholine acyltransferases (LPCATs) 
represent a family of enzymes that catalyse the esterification of fatty acyl-CoAs to 
lysoPCs. While the de novo PC synthesis pathway is required to generate the bulk of 
membrane PCs, the activity of LPCATs is thought to be important for ensuring the 
diversity of cellular PC species321,322. There are 4 LPCAT enzymes in mammals, with 
each of them having a different preference towards esterifying specific acyl-CoAs323. 
The best-characterised LPCAT enzyme in macrophages is LPCAT3, which is 
responsible for the incorporation of PUFAs into lysoPCs324. Lpcat3-deficient 
macrophages exhibit enhanced pro-inflammatory response to LPS due to decreased 
esterification of arachidonic acid into membranes, resulting in increased intracellular 
levels of free arachidonic acid324. Macrophages lacking LPCAT3 enzyme thus produce 
higher levels of arachidonic acid-derived prostanglandins in repose to LPS, leading to 
augmented inflammatory activation324. 
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1.3.3.3 Regulation and importance of CCT for cell function 
PC is the most abundant phospholipid species, corresponding to approximately 50% 
of total cellular phospholipids in a typical mammalian cell313. Similarly, PC is the major 
phospholipid in all mammalian cellular organelles, particularly in the ER, where it can 
make up nearly 60% of all phospholipids313. Due to its high biological importance, PC 
synthesis is strictly controlled by transcriptional and post-translational regulation of 
CCT325. 
 
Two CCT-encoding genes are present in mammalian genome, namely Pcyt1a and 
Pcyt1b326. Pcyt1a encodes the CCT isoform CCT, while Pcyt1b mRNA is alternatively 
spliced to produce CCT2 and CCT3 isoforms in mice, and CCT1 and CCT2 in 
humans327,328. CCT is ubiquitously expressed, and both CCT enzymes are 
predominantly found in the brain and gonads329. In most peripheral tissues, including 
macrophages, CCT is approximately 10 times more abundant than CCT, making it 
responsible for nearly all cellular CCT catalytic activity329. The importance of CCT is 
emphasised by the Pcyt1a global knockout mouse, which exhibits embryonic lethality 
as early as 3.5 days post coitum due to a failure of progression from a morula to a 
blastocyst, where a high rate of PC synthesis is required to fuel the membrane 
formation of the rapidly dividing embryo330. In contrast, systemic deletion of the CCT2 
splice variant is well-tolerated, with female sterility resulting from gonadal failure being 
the only observed phenotype, likely occurring due to a high expression of CCT2 in 
gonads331. Interestingly, humans homozygous for inactivating mutations in the coding 
region of Pcyt1a have recently been reported332-335. In some cases, biallelic loss of a 
functional Pcyt1a gene resulted in congenital lipodystrophy and fatty liver disease335, 
while other deleterious mutations caused spondylometaphyseal dysplasia with cone-
rod dystrophy, characterised by short stature, altered bone structure and visual 
impairment, caused by cone-rod loss332-334. At present, it is not yet clear how humans 
lacking CCT activity can develop and survive until adulthood, and why the mutations 
in Pcyt1a coding sequence manifest in the aforementioned, and not other tissue 
dysfunctions. 
 
CCT activity is primarily regulated post-translationally336. The main mechanism 
leading to an increased rate of CCT activity is the translocation of the soluble inactive 
form to membranes, where it becomes activated337-340. Such membrane binding-
  44 
dependent activation requires an amphipathic helix domain of CCT, which senses 
hydrophobic properties of the membrane and mediates the docking of the 
enzyme341,342. Conditions that promote CCT membrane binding include low 
membrane PC343,344 or high membrane FFA337 and DAG345 levels. Upon binding, the 
curvature stress stored in membranes is sufficient to induce a profound conformation 
change in CCT, thus promoting its enzymatic activity346,347. 
 
CCT is also regulated by phosphorylation and proteosomal degradation. The C-
terminal domain of the enzyme contains 16 serine phosphorylation sites348-350. 
However, mutating all residues to alanine does not affect CCT membrane binding349. 
Interestingly, phosphorylation of serine 315 by extracellular signal-regulated kinases 1 
and 2 (ERK1/2) can inhibit CCT activity in lung epithelial cells351, while 
phosphorylation of CCT in macrophages, occurring predominantly due to 
phosphatase inhibition, increases its activation352. In quiescent B cells, CCT is 
continuously synthesised and targeted for proteosomal degradation353. Upon 
stimulation with LPS, proteosomal CCT degradation is inhibited, leading to an 
increased rate of PC biosynthesis required for the clonal expansion of B cells353. In an 
alveolar epithelial cell line, TNF stimulation promotes CCT ubiquitination and 
subsequent proteosomal degradation354.  
 
Pcyt1a gene exhibits a complex transcriptional regulation, with multiple transcription 
factors regulating its expression. Perhaps the best-studied physiological control of 
Pcyt1a gene expression is the cell cycle. During the synthesis or S phase of the cell 
cycle, when DNA replication occurs, transcription factor specificity protein 1 (Sp1) 
increases Pcyt1a gene transcription, which is performed in order to ensure sufficient 
capacity for PC synthesis during the subsequent division phase of cell cycle355-357. 
Deprivation of choline results in decreased PC levels and a cell cycle arrest at G1 
phase, which is a preparatory step for the S phase, in multiple cell lines356,358,359. In the 
murine macrophage cell line BAC1.2F5, the cell cycle can be arrested at G1 phase by 
removing macrophage colony stimulating factor-1 (CSF-1) from the culture medium360. 
Readdition of CSF-1 has been shown to engage the cell cycle and increase Pcyt1a 
mRNA by 4-fold361. However, the increase in mRNA expression was not caused by an 
increased rate of transcription, but by a decreased rate of mRNA degradation in 
macrophages361. 
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Multiple studies have reported SREBP1-dependent positive regulation of Pcyt1a 
transcription362-365. However, a subsequent study has suggested that SREBP1 
increases CCT activity indirectly by promoting de novo fatty acid biosynthesis, thus 
elevating the substrate supply for PC biosynthesis366. Similarly, loading cultured cells 
with fatty acids has been previously shown to increase PC biosynthesis337,367. As 
increased intracellular DAG levels can also activate CCT345, at present it is not clear 
if it is the fatty acids themselves, or their DAG metabolic derivatives that mediate 
increased CCT activity. 
 
Finally, an ER-stress mediated increase in XBP1 activity has been shown to promote 
ER expansion, driven by increased PC biosynthesis353,368,369. Overexpressing spliced 
Xbp1 in fibroblasts also leads to elevated CCT activity369. Interestingly, active XBP1 
did not change Pcyt1a mRNA levels, but enhanced the rate of CCT protein translation 
via an unknown mechanism369. 
 
1.3.3.4 The role of PC biosynthesis in regulating macrophage function 
While PC is the most abundant phospholipid in monocytes, these cells also contain 
high cellular levels of free cholesterol370. During the process of monocyte to 
macrophage differentiation, cellular cholesterol levels exhibit a 3-fold decrease and PC 
abundance increases by nearly 2-fold370. This dramatic change is cellular lipid 
composition is driven by an activation of SREBP1 transcriptional activity, leading to an 
elevated FASN, SCD1, ELOVL6, FADS1 and FADS2 enzyme-encoding gene 
expression370. In contrast, SREBP2 target gene expression and free cholesterol levels 
are decreased in mature macrophages compared to monocytes370. Increased DNL and 
fatty acid remodelling in differentiating monocytes is coupled to up-regulated PC and 
PE synthesis370. However, the mRNA levels of enzymes involved in PC and PE 
formation do not change during macrophage differentiation, indicating a post-
transcriptional regulation of CCT and ECT activity370. Finally, inhibiting FASN or 
SREBP1 reduces the rate of PC and PE production and drastically impairs 
macrophage differentiation370.  
 
The requirement of high membrane PC levels for macrophage function is explained by 
macrophage morphology. During their differentiation from monocytes, macrophages 
increase in size nearly 3-fold370. Furthermore, they expand their ER and Golgi 
apparatus370, both of which contain high PC levels313. Finally, macrophages contain 
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numerous philopodia and exhibit dynamic changes in their membranes, particularly 
during phagocytosis371. The biophysical properties of PC allow for membrane kinks to 
occur, which are associated with the initial step of phagocytosis372. 
 
Surprisingly, the macrophage-specific Pcyt1a knockout mouse has normal levels of 
peritoneal macrophages309,373. Furthermore, Pcyt1a-deficient peritoneal macrophages 
exhibit similar appearance, migration and phagocytosis capacity as WT cells, 
indicating intact macrophage differentiation373. Similarly, loss of Pcyt1a in 
hepatocytes374 or lung epithelial cells375 does not affect their development. The 
residual CCT catalytic activity in CCT-null cells is thought to occur due to 
compensatory up-regulation of CCT2 isoform309,374, which could provide a sufficient 
rate of PC synthesis to allow unimpaired cellular differentiation. Alternatively, 
circulating lipoproteins can also supply substantial amounts of PC to primary cells and 
tissues376. While macrophages lacking Pcyt1a gene exhibit normal function in the basal 
state, they fail to mount an appropriate response to specific challenges, as summarised 
below. 
 
PC metabolism in macrophages has been studied most comprehensively with regards 
to cholesterol uptake and cholesterol-induced ER stress. In advanced atherosclerosis, 
plaque rupture and thrombotic vascular occlusion is thought to occur, at least in part, 
due to the death of lipid-laden macrophages within the plaque377. As these foam cells 
are known to accumulate large amounts of free cholesterol378-381, and as excess 
intracellular free cholesterol leads to macrophage cell death382,383, adaptive 
mechanisms that protect macrophages from cholesterol-induced death are of high 
therapeutic interest.  
 
Loading cultured macrophages with acetylated LDL to model plaque foam cell 
formation is relatively well-tolerated, as excess intracellular cholesterol is esterified in 
the ER to form cholesterol esters that are safely stored in lipid droplets384. Inhibiting 
the enzyme that catalyses cholesterol esterification, acyl-CoA:cholesterol 
acyltransferase 1 (ACAT1), promotes free cholesterol retention in the ER382,383. 
Elevated free cholesterol levels result in a rapid ER expansion, which requires an 
increased rate of PC synthesis385. Such compensatory PC synthesis is not 
accompanied by increased Pcyt1a transcription, but by post-translation activation of 
the CCT enzyme352,386. PC levels in plaque-residing foam cells also positively 
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correlate with the severity of atherosclerosis386,387. In response to loading with 
acetylated LDL in the presence of ACAT1 inhibitor, CCT-null peritoneal macrophages 
exhibited a profound cell death, likely due to their inability to provide sufficient PC for 
ER expansion309. Surprisingly, despite the generation of a macrophage-specific Pcyt1a 
knockout mouse and the observed failure of macrophages to adapt to free cholesterol 
loading in vitro being published nearly two decades ago309, no follow-up studies 
regarding the susceptibility of this mouse model to atherosclerosis have been 
published yet. 
 
In LPS-activated macrophages, synthesised cytokines need to be exported outside the 
cell predominantly via Golgi apparatus388. The formation of secretory vesicles in Golgi 
requires phospholipid synthesis388. After a prolonged stimulation with LPS, Pcyt1a-
deficient macrophages exhibit reduced PC and elevated DAG levels, consistent with 
their inability to provide adequate amounts of CTP:phosphocholine for DAG:CDP–
choline phosphotransferase373. Consequently, cytokines that rely on the Golgi for 
secretion, such as TNF and IL-6, accumulate intracellularly in CCT-null 
macrophages during LPS challenge, while IL-1 release, which is Golgi-independent, 
is unimpaired373. Furthermore, macrophage-specific Pcyt1a knockout mice exhibit 
increased mortality due to impaired cytokine release during bacterial infection of the 
lung373. Defects in cytokine secretion in Pcyt1a-deficient macrophages can be restored 
by providing exogenous lyso-PC and elevating DAG levels alone does not inhibit the 
release of TNF, indicating that PC formation is the limiting factor for cytokine release 
in CCT-null cells373. 
 
1.3.3.5 The role of membrane phospholipid and cholesterol composition in 
regulating cellular function 
Besides the aforementioned cases where high rates of phospholipid (including PC) 
synthesis are required to enable intrinsic and adaptive cellular processes, a change in 
membrane PC content alone does not necessarily lead to functional membrane 
alterations. Instead, membrane fluidity and permeability are predominantly influenced 
by the relative ratio of different phospholipid and sterol species26. As each phospholipid 
species elicits a divergent effect on the physical properties of membranes, the 
interactions between all phospholipids and sterols determines the overall cellular 
membrane fluidity and integrity26. However, considering the relative effect of each 
structural lipid on membrane fluidity and integrity requires complex mathematical 
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modelling. Furthermore, even state-of-the-art lipidomic tools can only detect a subset 
of cellular phospholipids and sterols, preventing visualisation of the full complexity of 
membrane lipid biology389. Therefore, most studies investigating membrane lipid 
composition predominantly focus on the interactions between a few major membrane 
lipid species389. In this section, only the relationships between membrane PC and PE, 
cholesterol and total phospholipid will be considered. 
 
PC and PE substantially differ in their structure due to their headgroup size26. PCs 
contain a large polar choline moiety and form cylindrical structures, while PEs acquire 
a conical shape due to their small ethanolamine headgroup26 (Figure 1-8). Because of 
their different shape, PC and PE are asymmetrically distributed in the plasma 
membrane – PC is predominantly found in the outer leaflet, whereas PE is localised in 
the inner leaflet313. Such asymmetry enables the curvature, while maintaining 
membrane integrity (Figure 1-8).  
 
 
 
 
Figure 1-8. Simplified visualisation of PC and PE structures and their distribution 
within plasma membrane bilayer. 
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Appropriate PC:PE molar ratio (approximately 3 in most mammalian cells) needs to be 
maintained to ensure the integrity and function of cellular membranes. Perhaps the 
most elegant illustration of the importance of PC:PE ratio is the expansion of the lipid 
droplet. As lipid droplets have monolayer membranes, elevated PC:PE ratio is required 
to allow for the curvature of the membranes, particularly those of small lipid droplets, 
where surface area to volume ratio is relatively high246. During lipid droplet expansion, 
CCT has been shown to localise onto lipid droplet membranes to directly supply the 
substrates for PC synthesis367. Genetic deletion of Pcyt1a homologue in Drosophila 
cells or Pcyt1a in mouse macrophages induces a failure to provide adequate PC levels 
during the growth lipid droplets and lowers the PC:PE ratio of lipid droplet 
membranes367. Lower membrane PC:PE ratio leads to the coalescence of many small 
lipid droplets to a few large ones, as an attempt to minimise the membrane tension by 
reducing droplet surface area to volume ratio367. 
 
Abnormally low hepatic PC:PE ratios have been associated with liver dysfunction376. It 
has been estimated that PC comprises 60-80% of the membrane phospholipids of TG-
rich lipoproteins, including vLDL secreted by the liver26. The initial step of vLDL 
synthesis in the hepatocytes involves the lipidation of carrier protein apoliprotein B 
(apoB) in the ER, resulting in the formation of nascent vLDL particle390,391. Insufficient 
PC levels during apoB lipidation lead to low PC:PE ratio in nascent vLDL, which leads 
to its proteosomal degradation392,393. The physiological importance of this process is 
reflected by dietary choline deficiency, which promotes the development of hepatic 
steatosis in rodents394-396 and humans397,398 due to reduced vLDL secretion. Similarly, 
circulating TG concentrations in fasted hepatocyte-specific Pemt or Pcyt1a knockout 
mice are approximately 50% lower than in WT animals374,399. 
 
Another manifestation of low PC:PE ratio is the loss of hepatic plasma membrane 
integrity400. Pemt knockout animals fed choline-deficient diet are devoid of any PC 
synthesis and rapidly develop non-alcoholic steatohepatitis (NASH) and liver failure, 
which is attributed to increased plasma membrane permeability and subsequent liver 
damage400. NASH patients also exhibit a lower hepatic PC:PE ratio than healthy 
controls400. 
 
Low membrane PC:PE ratio leads to SREBP1 activation in worms and mammals401. 
While SREBPs are typically activated by the lipid-binding chaperone SREBP-cleavage 
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activating protein (SCAP), which transports SREBPs to Golgi for proteolytic cleavage 
in response to low ER levels of cholesterol or PUFAs221, PC:PE ratio-dependent 
SREBP activation does not require SCAP401,402. Instead, low PC:PE ratio mediates the 
relocalisation of SREBP-cleaving proteases from the Golgi to the ER via a retrograde 
protein transport mechanism401,402. Consistent with the cellular observations, liver-
specific Pcyt1a knockout mice exhibit increased hepatic SREBP1 processing and 
SREBP1 target gene expression401. Therefore, another potential mechanism linking 
low PC:PE ratio and liver steatosis is SREBP1 activation and a subsequent increase 
in DNL. 
 
Interestingly, abnormally high hepatic PC:PE ratio has also been linked to the 
development of liver steatosis in mice226,403. While increased SREBP1 target gene 
expression is a known causal feature of hepatic steatosis, a recent study has shown 
that the expression of genes related to phospholipid metabolism is also altered in the 
livers of ob/ob animals226. Mainly, ob/ob mice have increased hepatic Pcyt1a and 
Pemt, but reduced Pcyt2 expression, encoding PE-synthesising ECT enzyme226. 
These gene expression changes functionally lead to an elevated PC:PE ratio of hepatic 
ER membranes, resulting in a disrupted function of sarco/endoplasmic reticulum 
Ca2+ATPase (SERCA)226, which transports calcium from the cytosol into the ER. 
Diminished SERCA activity induces a profound ER-stress response, causing hepatic 
lipid accumulation and insulin resistance in ob/ob mice226. Normalising hepatic PC:PE 
ratio by liver-specific deletion of Pemt alleviates hepatic steatosis and improves the 
metabolic profile of ob/ob animals226. 
 
DAGs produced from the degradation of phospholipids by phospholipases can be 
subsequently utilised for TG biosynthesis (Figure 1-9). Strikingly, approximately 65% 
of the hepatic TG pool has been estimated to be derived from PC in a lean mouse404. 
Half of the PC-derived TG pool reaches the liver in the form of high-density lipoprotein 
(HDL) particles404 that carry the excess peripheral cholesterol to be excreted via the 
reverse cholesterol transport pathway.  
 
Glycine N-methyltransferase (GNMT) is an enzyme that negatively regulates the 
synthesis of S-adenosylmethionine (SAM), which is a methyl donor utilised in PE to 
PC conversation by PEMT (Figure 1-9). While disrupting hepatic PEMT activity by 
genetic deletion of methionine adenosyltransferase 1A (MAT1A), which catalyses SAM 
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formation, leads to hepatic steatosis due to impaired vLDL release405, enhanced PEMT 
activity caused by Gnmt gene knockout also promotes liver steatosis403. Increased PC 
formation in Gnmt-deficient mice causes elevated hepatic TG levels by promoting the 
metabolic flux through PC to DAG to TG conversion pathway403 (Figure 1-9). 
 
 
 
Figure 1-9. Simplified relationship between hepatic PC and TG levels. 
GNMT negatively regulates SAM levels by catalysing the synthesis of N-methylglycine 
(sarcosine, Sar) from glycine (Gly) and converting SAM to S-adenosylhomocysteine 
(SAH). Figure adapted from Kim et al406. 
 
 
Cholesterol is an important regulator of membrane fluidity, as its hydrophobic 
properties and relatively small size allows it to integrate in the gaps between 
membrane phospholipids407. While still debated by some researchers, cellular plasma 
membranes are thought to contain areas with high cholesterol:phospholipid ratios407. 
These areas, termed lipid rafts, have increased structural order due to a reduced 
membrane fluidity. A highly ordered environment is required for the appropriate activity 
of multiple plasma membrane proteins, including TLR4408 and proto-oncogene 
tyrosine-protein kinase Src (c-Src)409, an up-stream activator of JNK signalling. 
  52 
Saturated fatty acids have been reported to promote insulin resistance by altering the 
distribution of membrane lipid rafts409. Treating cells with palmitate stabilises c-Src 
within lipid rafts, leading to hyperactivation of JNK signalling and subsequent insulin 
resistance409. Unsaturated fatty acids exert an opposite effect by preventing c-Src 
membrane repartitioning409. Importantly, adipose tissues isolated from high-fat diet-
induced obese mice exhibit c-Src stabilisation within lipid rafts, activation of JNK 
pathway and diminished insulin signalling409. In macrophages, fatty acids derived from 
endogenous fatty acid synthesis have been shown to selectively incorporate into lipid 
rafts408. LPS- or palmitate-mediated inflammatory activation of macrophages increases 
FASN protein expression and the rate of de novo fatty acid synthesis, which is 
important for the stabilisation of TLR4 within lipid rafts408. Consequently, macrophages 
deficient in the FASN-encoding gene Fasn have diminished inflammatory activation 
following stimulation with LPS or palmitate408. Importantly, macrophage-specific Fasn 
knockout mice exhibit reduced WAT inflammation and improved systemic insulin 
resistance after prolonged high-fat feeding408. Treating FASN-deficient macrophages 
with cholesterol, but not exogenous palmitate, restores plasma membrane lipid rafts 
and rescues defective TLR4 signalling408. How macrophages discriminate endogenous 
DNL-derived fatty acids from the exogenous fatty acids taken up from the extracellular 
space remains to be investigated. 
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1.4 Interactions between macrophages and the SNS 
1.4.1 Overview of the link between nervous and immune system 
The SNS is one of the main regulators of systemic lipid metabolism. Due to its ability 
of rapidly promoting WAT lipolysis, BAT FAO and UCP1-dependent energy dissipation, 
multiple therapies that activate SNS or mimic SNS action in tissues have been 
proposed to treat obesity47. While the majority of research regarding this topic is 
focused on understanding the neuronal networks in the brain that regulate sympathetic 
tone in adipose tissues, or mapping the adrenergic signalling pathways in the 
adipocytes that link SNS activity with its functional outcomes, ATMs have also been 
reported to play a role in regulating SNS output to WAT and BAT410. Therefore, in this 
section of the chapter I will summarise the literature describing the function of 
macrophages in regulating WAT SNS tone, and also the role of the SNS in regulating 
macrophage function in multiple tissues.  
 
The initial observations of sympathetic neurotransmitters modulating the activation of 
innate immune cells were made more than 100 years ago411. Since then, all major 
immune organs, including spleen, lymph nodes and bone marrow have been 
demonstrated to have sympathetic innervation412. SNS activity in immune organs has 
been shown to regulate nearly all aspects of immune cell function, including the 
mobilisation of bone marrow cells into the circulation, leukocyte recruitment and 
adhesion, cytokine release and bacterial killing413. As the interactions between nervous 
and immune systems constitute a separate field of neuroimmunology, the summary of 
which would vastly exceed the capacity of this thesis, here I will focus my discussion 
on the findings related to the relationship between sympathetic nerves and 
macrophages. 
 
1.4.2 Regulation of tissue sympathetic tone by macrophages 
1.4.2.1 Secretion of NE by tissue macrophages 
Immune cells were first reported to produce catecholamines more than two decades 
ago414. Pharmacological inhibition of tyrosine hydroxylase (TH), a rate-limiting enzyme 
in the biosynthesis of dopamine and NE, was shown to reduce catecholamine levels 
in lymphocyte extracts, suggesting an endogenous nature of catecholamine production 
in immune cells414. Subsequently, macrophages were demonstrated to express the 
mRNA encoding TH and dopamine -hydroxylase (DBH)415,416, an enzyme converting 
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dopamine to NE. Furthermore, the transcript levels of NE-synthesising enzymes and 
NE secretion into the medium were increased in cultured macrophages in response to 
LPS stimulation. Importantly, the inhibitory effects of 2-adrenergic receptor (2AR) 
blockade on lung inflammation in response to lung injury persisted even when 
sympathetic nerve endings or T cells were ablated from the periphery416, suggesting 
that macrophages were releasing NE in order to potentiate lung damage-induced 
inflammation. A more recent report ascribed a pathogenic role to NE released from 
macrophages during experimental autoimmune encephalitis (EAE), the rodent model 
of multiple sclerosis417. Genetic deletion of a gene encoding the transcription factor 
NR4A1 was shown to enhance the expression of Th in macrophages, resulting in 
accelerated infiltration of leukocytes into the central nervous system and disease 
exacerbation417. 
 
A major shift in the field of metabolism occurred several years ago, when M2 ATMs 
were observed to produce NE during cold exposure in mice418. Strikingly, macrophage-
specific genetic deletion of the IL-4 receptor, or systemic pharmacological ablation of 
macrophages rendered mice cold-intolerant due to their inability to activate non-
shivering thermogenesis on demand418. Subsequent studies utilising different mouse 
models confirmed the role of M2-polarised ATMs in the direct regulation of scWAT 
browning, but not BAT activation via local NE production419. Cold exposure was shown 
to promote monocyte recruitment to scWAT in a CCR2-dependent manner419,420 and 
to induce ATM M2 polarisation by engaging their IL-4 receptor419. Genetically 
modifying the ATM phenotype was sufficient to affect scWAT browning during obesity, 
leading to an altered energy balance observed in multiple studies231,421,422. 
 
However, the studies regarding endogenous NE production by ATMs were recently 
challenged by multiple laboratories, which could not detect the expression of TH or 
measure detectable NE production in M2-polarised macrophages in vitro or in ATMs 
in vivo423-425. Furthermore, hematopoietic deletion of the Th gene was demonstrated 
to have no effect on adipose tissue function or energy balance on a chow or HFD423. 
However, due to the multiple independent observations of altered energy balance in 
macrophage-targeted genetic models, the role of macrophages in regulating WAT SNS 
tone was not dismissed, but rather deemed necessary of further investigation423. 
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1.4.2.2 Regulation of sympathetic nerve function by tissue macrophages 
Perhaps the main reason that fuelled the hypothesis of ATMs regulating WAT browning 
by NE production was that at the time, scWAT was thought to be poorly innervated, 
with only 2-15 % of adipocytes being in contact with sympathetic fibres426,427. However, 
state-of-the-art techniques have established that scWAT has a great abundance of 
SNS neurons, with nearly every adipocyte having a direct access to a nerve axon38,428. 
Based on these findings, macrophages are more likely to modulate tissue SNS tone 
by interacting with NE-producing nerves, rather than synthesising NE endogenously. 
 
Microglia are known to mediate nerve development in the brain429. Peripheral 
macrophages have also been implicated in injury-mediated peripheral nerve repair in 
different organisms430-432. Multiple macrophage-derived neurotrophic factors have 
been shown to guide the axons of regenerating nerves433,434. Microglia and brain 
inflammation have also been suggested to play a role in the development of 
neurodegenerative disorders, such as Parkinson’s435 and Alzheimer’s436 diseases, 
indicating both beneficial and detrimental functions of macrophages in regulating nerve 
function. 
 
Recent studies have shown that tissue macrophage-nerve interactions are required for 
an appropriate intestinal function. Macrophages present in the intestinal muscle were 
shown to regulate peristaltic activity of the colon by secreting bone morphogenic 
protein 2  (BMP2), which directly stimulated enteric neurons and altered the pattern of 
smooth muscle contractions437. In turn, enteric neurons released CSF1 that was 
required for local macrophage development437. Furthermore, sympathetic nerves 
located in small intestinal muscle were demonstrated to be activated upon gut bacterial 
infection438. NE released from activated SNS neurons acted on 2-adrenergic 
receptors (2ARs) of macrophages residing in intestinal muscle and polarised them to 
an M2 phenotype, which was suggested to mediate the resolution of intestinal 
inflammation438. 
 
Direct interactions between sympathetic nerves and macrophages in adipose tissues 
have also been recently observed by multiple groups. CX3CR1-positive macrophages 
in BAT were shown to regulate the branching of SNS neurons in developing BAT by 
expressing a signalling molecule plexin-A4425. Genetic deletion of a transcriptional 
regulator MECP2 in macrophages resulted in elevated plexin-A4 expression, which 
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acted on a neuronal semaphorin-6A receptor, leading to increased SNS nerve 
repulsion and impaired BAT innervation425. CX3CR1-positive cell-specific Mecp2 gene 
knockout mice displayed spontaneous obesity during adulthood, which was attributed 
to their impaired BAT function425. Macrophages localised directly next to sympathetic 
nerves in eWAT and scWAT were also demonstrated in two independent studies424,439, 
which reported the ability of macrophages to take up and catabolise NE released from 
SNS neurons, as will be summarised in 1.4.2.3. Finally, while not visually 
demonstrating the presence of macrophage-nerve interactions in WAT, other studies 
showed the capacity of ATMs to directly respond to NE stimulation and will be 
presented in 1.4.3. 
 
1.4.2.3 NE degradation by macrophages 
Like most endogenous receptor agonists, the signalling of monoamines is limited by 
their reuptake and degradation440. In brain, the synaptic concentrations of monoamines 
are regulated by the activity of monoamine transporters (MATs), which catalyse the 
reuptake of monoamines to the pre-synaptic neuron440. Serotonin, dopamine and NE 
have their own respective classes of MATs, out of which norepinephrine transporter 
(NET, also known as solute carrier family 6 member 2 (SLC6A2)) mediates the 
internalisation of NE441. Once taken up, NE is degraded in three sequential enzymatic 
steps as illustrated in Figure 1-10. NE is initially oxidised by monoamine oxidase 
(MAO) and methylated by catechol-O-methyltransferase (COMT), before being 
converted to metabolically inert products vanillylmandelic acid and 3-methoxy-4-
hydoxyphenylglycol that are excreted in urine440. MAO also catalyses the oxidation of 
serotonin and dopamine, thus mediating their degradation440. 
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Figure 1-10. Norepinephrine degradation pathway. 
Figure taken from Mikael Häggström442. 
 
 
The monoamine theory of depression postulates that the underlying 
pathophysiological basis of depression is reduced brain monoamine levels443. Based 
on this theory, the inhibitors of MAO were successfully developed into clinical anti-
depressants444. Furthermore, clinical and recreational drugs that affect concentration, 
activity, mood and pleasure mainly target monoamine uptake (Prozac, Ritalin, 
Adderall, amphetamine and its metabolic derivatives, and cocaine) and degradation 
(moclobemide)445. Finally, polymorphisms in the Maoa gene (encoding the MAOA 
isoform), that result in decreased MAOA enzymatic activity, have been linked to 
aggression, anti-social behaviour and mood disorders446-448. Overall, cellular 
neurotransmitter uptake and degradation plays a key role in regulating monoamine 
signalling in brain. 
 
Interestingly, SLC6A2 has been found to be expressed in periphery. NE signalling to 
osteoblasts is known to decrease bone mass. Genetic deletion of Slc6a2 has been 
reported to increase NE availability in bone, leading to reduced bone formation449. 
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Similarly, pharmacological blockade of SLC6A2 induced bone loss in WT mice449. 
Peritoneal macrophages also exhibited the ability to rapidly take up and degrade NE 
in vitro450. Surprisingly, the NE uptake into peritoneal macrophages was independent 
of SLC6A2, as it could not be inhibited pharmacologically with cocaine450. Even though 
these findings have been made over three decades ago, the molecular mechanisms 
mediating NE uptake into peritoneal macrophages and the physiological importance of 
this process are still unknown.   
 
Recently, ATMs have been reported to reduce SNS tone in WAT by taking up and 
degrading NE424,439. A group investigating molecular mechanisms driving aging-related 
impairment in WAT lipolysis discovered that ATMs isolated from aged mice expressed 
high levels of MAOA, COMT and aldehyde dehydrogenase and reductase enzymes 
and were limiting NE signalling to the adipocyte -adrenergic receptors439. The 
development of monoamine degradation programme in ATMs during aging was 
mediated by the NLRP3 inflammasome-dependent up-regulation of a transcription 
factor growth differentiation factor-3 (GDF3)439. Dysfunctional fasting- or exogenous 
NE-induced lipolysis in WAT explants from aged animals could be restored by genetic 
Nlrp3 gene deletion, or pharmacological MAOA inhibition439. An independent study 
found that scWAT contained a distinct group of ATMs that directly associated with 
sympathetic nerves424. This ATM population, termed sympathetic-associated 
macrophages (SAMs), expressed SLC6A2 and MAOA proteins and showed a capacity 
to take up and metabolise NE ex vivo424. Furthermore, SAMs became highly pro-
inflammatory during obesity424. Importantly, Slc6a2 knockout in hematopoietic cells 
increased BAT activation and scWAT browning in response to cold exposure, and 
resulted in a reduced rate of body weight gain during high-fat feeding of mice, 
suggesting that SAM-dependent NE catabolism is a physiologically relevant 
process424. The environmental factors that promote the SAM phenotype in 
macrophages remain to be investigated451. Overall, recent studies have established 
the specialised role of adipose tissue-resident macrophages in limiting NE signalling 
to adipocytes, thus opening a novel research area with a potential to develop novel 
anti-obesity therapies. 
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1.4.3 -adrenergic receptor signalling in macrophages 
1.4.3.1 The roles of adrenergic receptors in regulating macrophage function 
All catecholamines signal through membrane-bound GPCRs. NE and epinephrine 
specifically target a subset of GPCRs called adrenergic receptors, which can be further 
subdivided to 1, 2, 1, 2 and 3-adrenergic receptors. Each adrenergic receptor 
has specific signalling properties due to their discrete G protein coupling. In general, 
1-adrenergic receptors are coupled to Gq proteins, which upon activation promote 
membrane phospholipase C activity, leading to increased intracellular second 
messenger DAG and inositol triphosphate concentrations that subsequently activate 
PKC452. -adrenergic receptors are mainly coupled to Gs proteins, which generate the 
second messenger cAMP upon activation, and their signalling will be discussed in 
1.4.3.3. 2ARs are coupled to Gi proteins that inhibit the production of cAMP, thus 
antagonising the activity of -adrenergic receptors453. 
 
Most mammalian cells have a distinct adrenergic receptor expression profile, and the 
cellular response to NE or adrenaline is mediated by the integrated signalling from all 
cell surface adrenergic receptors454. For example, adipocytes mainly express 2 and 
3 adrenergic receptors455. Therefore, the production of a key effector molecule cAMP 
that regulates the intracellular lipolytic activity is decided by the relative balance of 
activatory 3-adrenergic receptor stimulation, and inhibitory 2-adrenergic receptor 
stimulation455. 
 
All tissue macrophages predominantly express 2AR (encoded by Adrb2), and 2AR 
is the best-characterised adrenergic receptor in the immune system456. Infections lead 
to high circulating concentrations of TNF, IL-1 and IL-6, all of which stimulate 
hypothalamic neurons and increase SNS tone in relevant target tissues, including 
lymphoid organs and sites of inflammation456. NE released in inflamed tissues act on 
2ARs, which rapidly supresses the immune response by increasing intracellular 
cAMP levels in the immune cells, including macrophages. Such a negative feedback 
circuit ensures an appropriate resolution of inflammation and restoration of immune 
system homeostasis after pathogen clearance. Numerous reports over the past three 
decades have documented an anti-inflammatory role of 2AR stimulation in 
macrophages456. Pharmacological 2AR inhibition during systemic LPS challenge has 
been reported to dramatically decrease animal survival rate due to an exacerbated 
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septic shock457. Furthermore, conditioning humans in the conditions of extreme cold 
has been reported to profoundly reduce the systemic levels of inflammatory mediators 
in response to intravenous administration of LPS, which has been attributed to 
increased circulating NE and epinephrine concentrations in conditioned individuals458. 
ATMs have been suggested to be maintained in an M2 polarisation state due to SNS 
activity in WAT that acts via ATM 2ARs459. Surgical denervation of WAT dramatically 
reduces tissue NE content and leads to increased WAT inflammation in chow-fed 
mice459. Conversely, elevating SNS activity in WAT by systemic leptin administration 
results in increased WAT NE concentration and reduced inflammation460. Finally, 
stimulating or antagonising macrophage 2ARs (which counteract 2AR activity) has 
been shown to promote or inhibit the secretion of pro-inflammatory cytokines, 
respectively461,462.  
 
Interestingly, while there is an overwhelming evidence for an anti-inflammatory role of 
2ARs in macrophages, a few reports have described the potentiating effect of 2AR 
activation in macrophage inflammatory activation. Stimulating LPS-macrophages with 
2AR agonist has been demonstrated to elevate IL-6 and IL-1 production in an ERK 
and p38 signalling-dependent manner463. Furthermore, acute exposure to a particulate 
matter-containing air (an experimental model of air pollution) is known to cause 
cardiovascular thrombosis, which is mediated by IL-6 released from alveolar 
macrophages464,465. Particulate matter inhalation has been shown to promote the 
systemic release of catecholamines that engage 2ARs on lung macrophages and 
stimulate IL-6 secretion in a mitochondrial ROS-dependent manner465. Macrophage-
specific genetic loss, or pharmacological 2AR inhibition in mice confers protection 
against particulate matter-induced IL-6 release and development of arterial 
thrombosis465.   
 
The reason for such discrepant findings on the modulation of inflammatory response 
in macrophages by 2AR agonism is unclear. It has been suggested that the outcome 
of 2AR signalling in macrophages can be context-dependent456. Therefore, the choice 
of inflammatory stimulus, macrophage subtype, culturing conditions and incubation 
periods might all affect the observed outcome of 2AR activation456. As the overall 
physiological role of the SNS is to ‘adapt’ the target tissue to the environmental 
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conditions and the intrinsic state of the animal, it could explain why some studies report 
a pro-inflammatory, and others an immunomodulatory role of 2AR in macrophages. 
 
-adrenergic signalling has been also demonstrated to stimulate immune cell 
mobilisation from the bone marrow and to guide circulating macrophage progenitors to 
the relevant tissues. The levels of circulating hematopoietic stem cells (HSCs), which 
give rise to all myeloid cells, exhibit circadian oscillations in mice and humans466,467. 
Such circadian fluctuations of HSC mobilisation from the bone marrow are regulated 
by NE secreted from the bone marrow SNS nerves that acts on the 3ARs of the bone 
marrow stromal cells466. Chronic environmental stress leads to increased circulatory 
HSC levels via the same mechanism468. NE released from the SNS nerve terminals in 
tissues can also act as chemoattractant for circulating monocytes. Stimulation of 2AR 
on monocytes and macrophages promotes their chemotaxis in vitro469. Furthermore, 
2AR stimulation has been shown to induce CCR2 expression in macrophages470. 
2AR-deficient macrophages fail to migrate to the heart following acute injury470,471, 
and mice carrying a myeloid cell-specific Adrb2 deletion display 100% mortality 
following myocardial infarction, compared to approximately 20% mortality observed in 
WT mice471. Finally, 1AR- and 2AR-deficient bone marrow exhibits reduced 
engraftment of the colon compared to WT bone-marrow following transplantation into 
irradiated WT mice, leading to impaired intestinal barrier integrity and an altered gut 
microbiome472. Overall, despite several conflicting reports in the literature, 
macrophage 2AR activation has been ascribed anti-inflammatory and 
chemoattractive roles by multiple studies. 
 
1.4.3.2 Murine genetic models of 2AR deficiency 
Besides already mentioned myeloid cell-specific knockout models, 2AR deficiency 
has also been investigated in other tissues. A whole-body Adrb2 knockout mouse 
exhibits normal development and has normal resting heart rate and blood pressure473. 
However, they become hypertensive during exercise and demonstrate an elevated 
hypertensive response to epinephrine compared with WT mice473. Interestingly, 2AR-
deficient animals can still exercise normally and actually have a greater total exercise 
capacity than WT controls, which could be attributed to their lower respiratory 
exchange ratio during exercise, indicating increased FAO473. In support of this, Adrb2 
knockouts have lower fat mass on chow diet than WT mice473. Subsequent study have 
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showed that 2AR-deficient animals have elevated retinal TNF levels, leading to the 
development of a diabetic retinopathy474. Furthermore, Adrb2 knockout mice display 
hyperinsulinaemia in the fasted state475. This observation is contrary to the potentiating 
effect of 2AR signalling on insulin secretion in pancreatic  cells476. A separate 
investigation has found that 2AR-deficient mice exhibit marked glucose intolerance 
due to defective insulin secretion476. Aging-induced impairments in glucose-stimulated 
insulin secretion have also been linked with reduced 2AR levels in pancreatic islets, 
and genetic overexpression of Adrb2 in the  cells of aged mice prevents the 
development of  aging-related glucose intolerance476. 
 
2AR signalling in osteoblasts (bone-forming cell) is essential for appropriate bone 
formation. Leptin has been shown to regulate bone formation by centrally modulating 
SNS tone in bones40,477. Stimulation of the β2AR in osteoblasts by NE inhibits 
osteoblast proliferation and promotes bone resorption478. Consequently, 
pharmacological or genetic inhibition of 2AR signalling leads to an increase in bone 
mass40,477. Conversely, systemic administration of β2AR agonists decreases bone 
formation, increases bone resorption, and results in an overall bone loss40,477,479. 
 
Hepatocyte 2AR signalling regulates liver nutrient metabolism. Liver-specific Adrb2 
overexpression elevates hepatic levels of gluconeogenic enzymes and decreases liver 
glycogen content480. Similarly, systemic administration of 2AR pharmacological 
agonists leads to a reduction, while 2AR blockers promote an increase in hepatic 
glycogen levels in mice and humans480,481. 2AR agonists also increase hepatic lipid 
accumulation in mice through a mechanism that is independent of WAT lipolysis482. 
Furthermore, hepatic 2AR expression and liver steatosis are increased in aged 
mice482. The age-related increase in hepatic TG accumulation observed in WT mice is 
attenuated in 2AR knockout animals, leading to improved glucose tolerance 
compared to controls483. 
 
Overall, the variety of phenotypes observed in different genetic models of tissue-
specific 2AR deficiency indicates that 2AR signalling has unique tissue and cell type-
dependent functions. This variety is perhaps expected, given the multitude of 
regulatory roles that SNS has in nearly every mammalian tissue484. Importantly, such 
observations suggest that cell-specific Adrb2 knockout models should be preferentially 
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utilised to investigate the importance of 2AR signalling in a specific cell type, in order 
to avoid the confounding effects of the loss of 2ARs in other tissues. 
 
1.4.3.3 -adrenergic receptor signalling pathway 
Figure 1-11 depicts the canonical response to Gs-coupled receptor agonism in a 
simplified manner. In response to agonist stimulation, Gs-coupled GCPRs release the 
 domain of the G protein, which then binds to adenylyl cyclase (AC) and increases its 
catalytic activity, leading to an elevated intracellular cyclic adenosine monophosphate 
(cAMP) concentration485. cAMP acts as a second messenger by modulating the activity 
of multiple down-stream effector enzymes, including protein kinase A (PKA). Once 
activated, PKA translocates into the nucleus, where it phosphorylates cAMP-
responsive element-binding protein (CREB) and promotes CREB-dependent gene 
transcription485.  
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Figure 1-11. Canonical Gas-coupled receptor signalling pathway. 
Upon GPCR activation, cAMP produced by AC binds to the regulatory subunits (R) of 
PKA, liberating the catalytic subunits and allowing their translocation into the nucleus. 
Figure taken from Altarejos and Montminy485.  
 
 
PKA also phosphorylates other proteins in a cell type-dependent manner486. For 
example, adipocytes express high levels of a lipid droplet-binding protein perilipin-1487. 
In a basal state, perilipin-1 coats the surface of a lipid droplet, thus preventing the 
intracellular TG lipases from accessing stored TGs487. However, in response to 
adipocyte -adrenergic stimulation, active PKA phosphorylates perilipin-1, leading to 
its altered conformation that allows ATGL- and HSL-mediated lipolysis to occur487. HSL 
is also directly phosphorylated by PKA, which increases its lipolytic activity488.  
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Specific GPCRs, including 2AR, also exhibit non-canonical intracellular signalling. 
After a prolonged stimulation or in response to high extracellular agonist 
concentrations, GPCRs are phosphorylated by GPCR kinases (GRKs)489. 
Phosphorylation by GRKs recruits arrestin proteins, which bind to GPCRs and promote 
their internalisation by clathrin-dependent endocytosis, thus limiting the surface 
availability and signalling of the receptor489. Upon internalisation, the GPCR-arrestin 
complex is either recycled and returned to the plasma membrane, or targeted to 
lysosomes for degradation489. Interestingly, internalised GPCR-arrestin complex has 
been reported to signal from endosomes, leading to the activation of multiple 
downstream signalling molecules, including ERK489.  
 
 
 
Figure 1-12. GPCR internalisation and -arrestin-dependent signalling. 
Figure taken from Ritter and Hall489. 
 
 
1.4.3.4 The roles of cAMP and CREB in regulating macrophage function 
The CREB family of transcription factors include CREB, cAMP response element 
modulator (CREM) and activating transcription factor 1 (ATF1)485. Several protein 
kinases, including PKA, PKC and calmodulin kinases, can phosphorylate CREB at its 
transcription activating site, serine-133485. Once phosphorylated, CREB binds to its 
coactivators CREB-binding protein (CBP) or p300 and initiate the transcription of its 
target genes485. 
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CREB has been ascribed an anti-inflammatory role in macrophages. The resolution 
phase of inflammation in macrophages is predominantly controlled by cAMP490,491. 
Inhibiting cAMP production converts resolution phase macrophages back to an M1 
phenotype, whereas enhancing intracellular cAMP levels in M1 macrophages induces 
the resolution phenotype prematurely during bacterial infection490. Similarly to CREB, 
the optimal activity of the M1 polarisation-driving transcription factor NF-B requires its 
interaction with CBP/p300492. As both phosphorylated CREB and NF-B subunit RelA 
binds to the same region of CBP/p300, it has been proposed that NF-κB activity is 
inhibited by activated CREB through competition for limiting amounts of 
CBP/p300493,494. The relative physiological contribution of such a transcriptional-
competition mechanism to the overall anti-inflammatory role of CREB has not yet been 
investigated. 
 
The gene encoding the main cytokine mediating the resolution of inflammation, Il10, is 
under the transcriptional control of CREB495. During inflammation, TLR stimulation 
leads to the activation of ERK and p38 kinases, which phosphorylate and activate 
mitogen and stress activated protein kinases (MSK) 1 and 2496. MSKs then 
phosphorylate CREB to promote IL-10 production, thus limiting macrophage 
inflammatory activation496. Interestingly, recent studies have found that CREB Ser133 
phosphorylation is required, but not sufficient for Il10 transcription497,498. The 
transcriptional induction of a subset of CREB target genes, including Il10, is also 
dependent on the binding of CREB-regulated transcription coactivators (CRTCs) to the 
CREB-CBP/p300 protein complex485. In the basal state, CRTCs are phosphorylated 
by salt-inducible kinases (SIKs), leading to their sequestering in the cytoplasm485. 
When intracellular cAMP levels are increased, PKA catalyses inhibitory 
phosphorylation of SIKs, resulting in a decreased CRTC phosphorylation. 
Dephosphorylated CRTC then translocates into the nucleus and binds to CREB485. 
Gas-coupled GPCRs have been shown to drive the formation of resolution phase 
macrophages by PKA-SIK-CRTC pathway-dependent IL-10 secretion and autocrine 
signalling498. Furthermore, pharmacologically inhibiting SIKs during TLR stimulation 
also promotes the M2b macrophage polarisation497. 
  
CREB and cAMP have an anti-inflammatory role in ATMs during obesity. Compared 
to genotype controls, macrophage-specific Creb1 knockout (encoding the major CREB 
isoform in macrophages) mice exhibit augmented WAT inflammation, glucose 
  67 
intolerance and insulin resistance after prolonged high-fat feeding499. Furthermore, 
elevated WAT SNS tone leads to cAMP-dependent inhibition of SIKs in ATMs460. Like 
CRTCs, histone deacetylase 4 (HDAC4) is sequestered in the cytoplasm due to its 
inhibitory phosphorylation by SIKs. Therefore, cAMP-mediated inhibition of SIKs 
promotes HDAC4 nuclear translocation, which modifies the chromatin structure to 
enable the resolution phase transcriptional programme in macrophages460. 
Macrophage-specific Hdac4 knockout mice exhibit increased body weight, fat mass, 
WAT inflammation and insulin resistance after high-fat feeding, compared to genotype 
controls460. Finally, genetic variants in HDAC4 gene have been associated with obesity 
in humans, suggesting that cAMP signalling in ATMs might regulate energy balance in 
humans460.  
 
1.4.3.5 The role of -arrestins in regulating macrophage function 
Compared to Gas-mediated cAMP signalling, the role of -arrestin signalling in 
macrophages is less clear. Macrophages express -arrestins 1 and 2, both of which 
have been reported to interact with 2AR in other cell types500,501. Upon their 
internalisation, both -arrestins have been reported to directly bind and prevent the 
activation of NF-B502,503. However, other studies have showed that -arrestins 
positively regulate NF-B activity504,505. -arrestin 1 has also been found to interact 
with CREB and enhance its transcriptional activity506. In cultured macrophages, -
arrestin 2 has been reported to inhibit LPS-induced cytokine production507,508. Finally, 
knockdown of β-arrestins 1 and 2 drastically decreases macrophage chemotaxis in 
vitro509. Furthermore, 2AR-mediated CCR2 expression in macrophages is dependent 
on -arrestin 2 signalling in vivo470. 
 
-arrestin signalling is metabolically beneficial during obesity. Mice deficient in -
arrestin 1 gain more weight and develop exacerbated WAT inflammation and insulin 
resistance than controls on high-fat diet510,511. Conversely, transgenic overexpression 
of β-arrestin-1 reduces diet-induced obesity and improves glucose tolerance and 
systemic insulin sensitivity510. Similarly, hepatic -arrestin 2 expression is greatly 
reduced in obese animals, and systemic -arrestin 2 deficiency leads to a worsened 
metabolic phenotype after prolonged high-fat feeding512. Hepatocyte-specific Arrb2 
deletion (encoding -arrestin 2) greatly increases liver GPCR signalling, resulting in 
diminished insulin sensitivity and impaired systemic glucose metabolism513. Liver-
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specific overexpression of Arrb2 reduces hepatic GPCR signalling and protects mice 
against the metabolic complications during obesity513. 
 
At present, it is not clear whether -arrestins play an anti-inflammatory role in ATMs 
during obesity. It has been shown that GPR120 exerts its anti-inflammatory effects 
through -arrestin 2-mediated suppression of an inflammatory signalling cascade 
downstream of TLRs212. However, no studies have investigated the metabolic profiles 
of mice with macrophage-specific -arrestin 1 or 2 deficiencies. 
 
1.4.4 The associations of human ADRB2 gene polymorphisms with 
obesity and metabolic complications 
ADRB2 gene has been sequenced in multiple human populations and more than 80 
different polymorphisms have been identified514. Two nonsynonymous single 
nucleotide polymorphisms (SNPs) resulting in amino acid changes in the 16 position 
(arginine to glycine, Arg16Gly) and the 27 position (glutamic acid to glutamine, 
Glu27Gln) are common with observed minor allele frequencies of 40-50%514. In vitro 
characterisation of ADRB2 mutants demonstrated that the Gly16 variant increased the 
agonist-stimulated internalisation of 2AR, whereas Gln27 isoform did not show any 
effects on receptor expression or signalling515,516. A third nonsynonymous SNP 
encoding an amino acid change in the 164 position (threonine to isoleucine, Thr164Ile) 
occurs with a minor allele frequency of 1-3%514. The Ile164 isoform is approximately 
four times less responsive to agonist-induced stimulation than the Thr164 isoform in 
vitro517. These three ADRB2 polymorphisms have been associated with multiple 
disorders, including asthma, hypertension, obesity and type-2 diabetes514. 
Furthermore, ADRB2 SNP carriers display altered pharmacokinetics to 2AR 
therapeutic agonists514. Here, only the major findings related to the metabolic effects 
of ADRB2 variants will be summarised. 
 
Association studies of the Arg16Gly SNP with obesity and type-2 diabetes have 
reported conflicting results. The Arg16 variant has been linked to a minor increase in 
the risk of type-2 diabetes development in two different populations518,519. Furthermore, 
the Arg16 variant has also been found to correlate with BMI in several investigations520-
522.  In contrast, other studies have reported a significant association between the 
Gly16 variant and insulin resistance523,524. Among individuals with 
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hypertriglyceridaemia, individuals homozygous for the Arg16 variant had higher 
circulating total cholesterol and LDL-cholesterol levels525. 
 
Similarly to Arg16Gly, the studies investigating the association of the Gln27Glu variant 
with metabolic outcomes have reported positive522,526, negative527,528 or no 
association518,519,529 with type-2 diabetes in different populations. In the presence of 
the Arg16 variant, Gln27 variant-carriers show an increased risk of obesity, while other 
studies have showed either a positive530-532 or no association533 of the Glu27 variant 
with BMI. 
 
The largest study on ADRB2 polymorphisms to date (64,000 individuals) reported no 
associations with either of the ADRB2 SNPs with type-2 diabetes534. In this study, out 
of 3 variants only the Thr164Ile was linked to an increased risk of obesity534. 
Furthermore, no large population GWAS studies have yet associated SNPs in the 
ADRB2 gene with obesity or type-2 diabetes. It is therefore possible that the published 
significant associations between ADRB2 variants and metabolic disorders stem from 
a small number of individuals in the study groups, and the significant effects disappear 
in large cohorts of individuals. 
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1.5 Central hypothesis and aims of thesis 
The research strategy of our laboratory has been largely shaped by ‘adipose tissue 
expandability’ hypothesis (1.1.6), stating that when the adipose tissue reaches its limit 
of expansion, lipids fail to be stored in adipocytes and start to accumulate in other cell 
types. Such aberrant ectopic lipid accumulation promotes lipotoxicity, which is the 
driving cause of obesity-related cardiometabolic complications.  
 
Within adipose tissue itself, in a lean healthy state, the lipid flux into and within ATMs 
is tightly regulated by extracellular signalling cues, and lipid availability is controlled by 
appropriately-functioning adipocytes. In obesity, adipocyte dysfunction causes 
aberrant lipid accumulation in ATMs. Furthermore, obesity dysregulates extracellular 
signals that control ATM intracellular lipid metabolism, leading to a shift from 
biologically inert (TGs, CEs) to biologically active (PCs, DAGs, ceramides, sterols) lipid 
species within ATMs.  
 
Central hypothesis: qualitative repartitioning of intracellular lipid species 
triggers the pro-inflammatory activation of ATMs, leading to the development of 
systemic insulin resistance.  
 
The proposed central hypothesis will be investigated in 3 aims, each of them 
representing a separate results chapter of this thesis: 
 
First, multiple studies presented in the introduction illustrate the importance of 
intracellular lipid metabolism and membrane lipid composition for an appropriate cell 
function. While altered PC:PE ratio has been observed in multiple tissues during 
obesity, no reports regarding fatty acid- or obesity-induced alterations in macrophage 
PC:PE ratio currently exist. Therefore, in the first results chapter of this thesis (Chapter 
3), I will aim to characterise the effects of obesity on ATM PC and PE metabolism, and 
explore the mechanistic link between the cellular PC:PE ratio and macrophage 
inflammatory activation by saturated fatty acids. 
 
Secondly, the effect of sympathetic nerve activity on ATMs is poorly understood. 
Importantly, the direct metabolic consequences of the loss of NE sensing by ATMs 
have not yet been described, as all the previous reports investigating the role of SNS 
in the regulation of WAT inflammation have manipulated the overall SNS output to 
  71 
WAT, and have thus targeted all of the cell types present in the tissue. Furthermore, 
the molecular mechanisms mediating lipid accumulation in ATMs during fasting are 
unclear. Therefore, in the second results chapter (Chapter 4) I will aim to characterise 
the effects of NE stimulation on macrophage lipid partitioning and saturated fatty acid-
induced inflammation, and to understand the role of NE signalling in ATMs in the 
regulation of WAT inflammation and systemic metabolism. 
 
In the third results chapter (Chapter 5), I will aim to describe the intracellular signalling 
and transcriptional mechanisms underlying the phenotypic changes in macrophage 
nutrient metabolism occurring in response to 2AR stimulation. 
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2 Materials and methods 
2.1 Materials 
Details of compounds used in animal and cell experiments are summarised in Table 
2-1.  
 
Compound name Source Catalogue number 
E. coli lipopolysaccharide (LPS) Sigma L4391 
Interleukin-4 (IL-4) Peprotech 214-14 
(±)-Norepinephrine (+)- bitartrate salt  Sigma A0937 
Fenoterol hydrobromide Sigma F1016 
ICI-118,511 Tocris 0821 
HG-9-91-01 BioVision B1849 
2-deoxyglucose Sigma D8375 
Chetomin Sigma C9623 
A922500 Cayman 10012708 
Bafilomycin A1 Sigma B1793 
Orlistat Sigma O4139 
Human insulin (Actrapid) Novo Nordisk ADE138C (Obtained 
from a pharmacy) 
Glucose (20% solution) CIMR n/a 
Fentanyl Martindale Pharma PL 00156/0038 
Midazolam (Hypnovel) Roche PL00031/0126 
Acepromazine Novartis GTIN5037694004606 
Methyl-[3H]- choline chloride Perkin Elmer NET109250UC 
D-[3-3H]- glucose Perkin Elmer NET331A250UC 
[1-14C]- palmitic acid Perkin Elmer NEC075H050UC 
[1-14C]- oleic acid Perkin Elmer NEC317050UC 
[1,2-14C]- acetic acid, sodium salt Perkin Elmer NEC553250UC 
[1-13C]- oleic acid CIL CLM-149 
Palmitic acid Cayman 1000627 
Oleic acid Cayman 90260 
L-Carnitine hydrochloride Sigma C0283 
Oligomycin A Sigma 75351 
FCCP Sigma C2920 
Rotenone Sigma R8875 
Antimycin A1 Sigma A8674 
Etomoxir Sigma E1905 
Table 2-1. Compounds and their sources. 
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2.2 In vivo methods 
2.2.1 Animal care 
Unless otherwise indicated, mice were housed 3-5 per-cage in a temperature-
controlled room (21C) with a 12 h light/dark cycle, with ‘lights on’ corresponding to 6 
am. Animals had ad-libitum access to food and water. All animal protocols were 
conducted in accordance with the UK Home Office and Cambridge University ethical 
guidelines.  
 
2.2.2 Animal diets 
Nutritional composition of diets are summarised in Table 2-2. A standard chow diet 
was administered to animals from weaning. For HFD studies, a specified HFD was 
administered to the animals ad-libitum from 8 weeks of age for the indicated period of 
time. 
 
Diet name Diet ID Manufacturer Carbohydrate  Protein  Lipid 
Standard chow DS-105 Safe diets 64.3 22.4 13.3 
HFD 45% D12451 Research diets 35.0 20.0 45.0 
HFD 60% D12492 Research diets 20.0 20.0 60.0 
Table 2-2. Nutritional composition of animal diets.  
Nutrient values correspond to the percentage of the total energy content of the diet. 
 
2.2.3 Animal models 
Animal age, gender, diet, housing temperature, and genetic background is described 
in legend, where applicable. 
 
WT mice used for generation of bone marrow-derived macrophages and temperature, 
diet and compound administration studies were male on a C57Bl/6J genetic 
background (bought from Charles River, UK). 
 
For all macrophage-specific gene deletion studies, animals were crossed to a mouse 
model expressing Cre recombinase from bacteriophage P1 under LysM promoter 
(LysM-Cre). This model was generated by replacing a single allele of Lyz2 gene with 
the coding sequence of Cre recombinase as described535 and was gifted to us on a 
mixed C57Bl/6J, 129/Sv genetic background by Dr. Suzanne Jackowski. LysM-Cre line 
was backcrossed to a C57Bl6/J genetic background using Marker-Assisted 
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Accelerated Backcrossing (MAX-BAX, Charles River, UK) technology until SNP 
genotyping confirmed >99% background purity. 
 
Macrophage-specific Pcyt1a knockout mouse was generated by crossing a mouse 
model containing loxP sequences surrounding Pcyt1a alleles (Pcyt1afl/fl) to the LysM-
Cre mouse. Pcyt1afl/fl mouse was generated by Prof. Ira Tabas and Dr. Susan 
Jackowski as described309, and was gifted to us on a mixed C57Bl/6J, 129/Sv genetic 
background by Dr. Suzanne Jackowski. Pcyt1afl/fl line was backcrossed to a pure 
C57Bl6/J genetic background as described for LysM-Cre line above. 
 
Macrophage-specific Adrb2 knockout mouse was generated by crossing a mouse 
model containing loxP sequences surrounding Adrb2 alleles (Adrb2fl/fl) to the LysM-
Cre mouse. Adrb2fl/fl mouse was generated by Prof. Florent Elefteriou and Prof. Gerard 
Karsenty as described536, and was gifted to us by Prof. Gerard Karsenty on a pure 
C57Bl/6J genetic background. 
 
Femur and tibia bones from macrophage-specific Hif1a301 and Hif2a537 knockout mice 
(LysM-Cre Hif1a exon2fl/fl and LysM-Cre Hif2a exon2fl/fl, respectively) and littermate 
floxed controls were gifted to us by Prof. Randall Johnson on a pure C57Bl/6J genetic 
background. 
 
All experimental macrophage-specific knockout mice were produced by crossing 
LysM+/+ with LysM+/Cre animals on a floxed/floxed background, yielding a 1:1 Mendelian 
ratio of control (floxed/floxed LysM+/+) to knockout (floxed/floxed LysM+/Cre) offspring. 
 
2.2.4 Blood sampling 
All blood samples were taken from tail vein of unrestrained animals directly into glass 
capillary tubes. At the end of each study, terminal blood samples were collected into 
blood collection tubes (0103, Vetlab) by cardiac puncture immediately after sacrifice. 
Blood samples were kept on ice before centrifuging at >10,000 g for 5 min. Serum was 
then collected and stored at -80C for subsequent analyses. 
 
2.2.5 Cold exposure 
For 72 h of cold exposure, animals in their home cages were placed in the temperature-
controlled room set at 5C (50% relative humidity). Weighing and blood sampling of 
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cold-exposed mice was performed in the same room. For 24 h of cold exposure, mice 
were placed in a temperature-controlled cabinet set at 10 C (50% relative humidity) 
and culled immediately after leaving the cabinet. 
 
2.2.6 Indirect calorimetry 
Energy expenditure (EE) and respiratory quotient (RQ) were calculated from data 
gathered from single-housed mice fed ad-libitum by a custom-made monitoring system 
(Creative Scientific UK). The monitoring system calculated oxygen and carbon dioxide 
concentrations at 18-minute intervals, with flow rates set to 400 ml/min. EE was 
calculated from oxygen consumption and carbon dioxide production measured over a 
48 h period using modified Weir equation538 (EE J/min = 15.818 x VO2 (ml/min) + 5.176 
x VCO2 (ml/min)). EE was compared between genotypes using analysis of covariance 
(ANCOVA) with body weight as a covariate. 
 
2.2.7 Food intake and faecal excretion analyses 
Daily food intake and faecal excretion were assessed by single-housing mice in cages 
containing liners and manually weighing food pellets and crumbs (food intake), and 
faeces (excretion). 
 
2.2.8 Glucose tolerance tests 
Mice were fasted for 16 h from 4 pm to 8 am. Mice were single-housed at least 1 h 
prior to being injected intraperitoneally with 1 mg/kg glucose. Blood samples for 
glucose measurement were taken at 0, 10, 20, 30, 60, 90 and 120 min after the 
injection. 
 
2.2.9 Insulin tolerance tests 
Mice were fasted for 6 h from 8 am to 2 pm. Mice we single-housed at least 1 h prior 
to being injected intraperitoneally with 0.75 IU/kg of human insulin. Insulin dose of 1 
IU/kg was used for HFD-fed mice.  Blood samples for glucose measurement were 
taken at 0, 10, 20, 30, 60, 90 and 120 min after the injection. 
 
2.2.10 Lipid tolerance tests 
Mice were fasted for 16 h from 4 pm to 8 am. Mice we single-housed at least one hour 
prior to being administered with 200 l of olive oil by oral gavage. Blood samples for 
glucose measurement were taken at 0, 1, 2, 4 and 8 h after injection. 
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2.2.11 Compound injection studies 
In order to block 2-adrenergic receptor signalling, mice were injected intraperitoneally 
with 500 g of ICI-118,551 for the period indicated in legend. 
 
2.2.12 Hyperinsulinaemic-euglycaemic clamps 
All clamp studies were performed by Dr. Sam Virtue and Dr. Anne Mcgavigan. Mice 
were fasted for 16 h from 4 pm to 8 am. Animals were anaesthetised by 
subcutaneously injecting 11 ml/kg of the following combination of drugs: fentanyl 
(0.03125 mg/ml), midazolam (0.625 mg/ml) and acepromazine (0.625 mg/ml). Once 
unconscious, mice were placed on temperature controlled heating pads (Harvard 
Apparatus) and their core body temperature was maintained at 37°C. Catheters were 
placed in the tail veins connected to two separate syringe pumps. Mice underwent a 
basal infusion period with 231 kBq/ml [3-3H]-glucose, 3 mg/ml sodium citrate in 0.9% 
NaCl solution, infused at 100 l/h for 90 min. A bolus of 30 l of hyperinsulinaemic 
infusate (basal infusate + 0.11 mU/ml human insulin) was then administered to initiate 
hyperinsulinaemia, and the hyperinsulinaemic infusate continued to be administered 
at 100 l/h for at least 90 min. Immediately after initiation of hyperinsulinaemia, 12.5% 
glucose, 3 mg/ml sodium citrate in 0.9% NaCl solution was infused at a variable rate 
in order to clamp glucose at the basal level. Blood glucose was measured every 5 min 
for 90 min and glucose infusion rate (GIR) was adjusted until mice had stable blood 
glucose values that were +/- 0.5 mM of their initial values. Serum samples were 
collected for the determination of specific activity at the end of basal and 
hyperinsulinaemic states.  
 
Radioactivity in serum was measured by mixing 10 l of serum sample with 90 l PBS, 
before adding 100 l 20% trichloroacetic acid to precipitate proteins. Samples were 
then centrifuged at 16,000 g for 10 min, and 160 l of the supernatant was transferred 
to a clean tube and air-dried at 95 C. Dried samples were resuspended in 100 l of 
water, 90 l of the sample was transferred to 4 ml of scintillation liquid (SG-BXX-24, 
Lab Logic) and subjected to liquid scintillation counting (LSC). 
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Steady state clamp GIR was considered to be the average of GIRs at 70, 80 and 90 
min following insulin infusion. Steady state kinetic parameters were calculated as 
follows: 
 
 Glucose specific activity (dpm/mol) = plasma specific activity (dpm/ml) / 
glucose concentration (mM). 
 
 Glucose turnover (Rd, mol/min) = rate of radiolabelled glucose infusion / 
glucose specific activity. 
 
 
 GIR was calculated based on the rate of 12.5% glucose solution infusion and 
expressed as mol/ml. 
 
 
 Hepatic glucose production (HGP, mol/ml) in a basal state was equal to Rd, in 
hyperinsulinaemic state it was equal to Rd – GIR. 
 
 
2.2.13 Macrophage-to-liver PC transport assay 
BMDMs were plated in 6-well plates and cellular PC was labelled by incubating cells 
in the presence of 0.074 MBq/ml methyl-[3H]- choline chloride in the medium for 24 h. 
Cells were then washed, detached using ice-cold Dulbecco’s phosphate buffered 
saline (PBS, D8537, Sigma) containing 1 mM EDTA and manually counted. Cells were 
centrifuged at 500 g, 4°C for 5 min and re-suspended in PBS at the concentration of 
106 cells/200 µl. Specific activity of cells was determined by lysing 105 cells in 100 µl 
of PBS containing 1% TritonTM X-100 (X100, Sigma), adding the lysates to scintillation 
vials containing 5 ml of Hionic-Fluor scintillation liquid (6013319, Perkin-Elmer) and 
subjecting them to LSC. 
 
106 BMDMs containing approximately 2x106 dpm were injected into each mouse, and 
blood samples were collected at 3, 6 and 24 h. Serum HDL fraction was isolated by 
using LDL and vLDL precipitation buffer according to manufacturer’s instructions 
(ab105138, Abcam). Radioactivity was determined in total and in HDL lipid and 
aqueous fractions of serum by lipid extraction as described in 2.5.7. 24 h later, mice 
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were sacrificed and liver, brain, brown adipose tissue and spleen were collected. 
Dounce homogeniser was used to homogenise approximately 100 mg of each tissue 
directly in the scintillation vials containing 5 ml of Hionic-Fluor scintillation liquid. 
Radioactivity in each tissue was measured by LSC and all counts were expressed as 
percentage values of the amount (dpm) injected. 
 
2.2.14 Serum biochemistry 
Blood glucose was measured using an AlphaTRAK 2 (Zoetis) glucose meter and strips. 
All serum biochemistry analysis was performed in Keith Burling’s Core Biochemical 
Assay Laboratory using the following commercially available kits: TG (Siemens 
Healthcare), cholesterol and HDL (Dade-Behring), free choline (Abcam), FFA 
(1138175001, Roche), ALT and AST (Siemens Healthcare) were measured 
enzymatically. LDL concentration was calculated using the Friedwald formula ([LDL] = 
[Cholesterol] – [HDL] – [TG]/2.2). Insulin was measured using electrochemical 
luminescence immunoassay (K152BZC, MesoScale Discovery). 
 
2.3 Ex vivo methods 
2.3.1 Isolation of peritoneal macrophages 
Immediately after sacrifice, 5 ml of PBS containing 0.5 mM EDTA was injected into 
palpitate peritoneal cavity. As much liquid as possible was recovered, and the 
procedure was repeated two more times with fresh PBS containing 0.5 mM EDTA. 
Pooled lavages were centrifuged at 400 g, 4 for 5 min and pellets were frozen for 
subsequent analysis. 
 
2.3.2 Isolation of alveolar macrophages 
Immediately after sacrifice, 800 µl of PBS containing 0.5 mM EDTA was injected into 
lungs. As much liquid as possible was recovered, and the procedure was repeated two 
more times with fresh PBS containing 0.5 mM EDTA. Suspension was centrifuged at 
400 g, 4 for 5 min and pellets were frozen for subsequent analysis. 
 
2.3.3 Adipose tissue fractionation 
Adipose tissues were removed after sacrifice, chopped thoroughly and re-suspended 
in 10 ml digestion solution containing 7 ml Hanks’ Balanced Salt Solution (HBSS, 
H9269, Sigma), 0.23 g bovine serum albumin (BSA, A9418, Sigma), and 20 mg 
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collagenase type II (C6885, Sigma), filtered through 0.22 μm membrane. The digestion 
was performed at 37°C for 20 min, with shaking at 100 rpm. The digestion mixture was 
then passed through a 100 µm cell strainer (352360, Falcon) into a fresh tube and 
incubated at room temperature for 10 min, allowing the adipocyte fraction to layer on 
the surface. Adipocyte fraction was collected by pipetting and frozen for subsequent 
analysis. The remaining solution was centrifuged at 400 g, 4° for 5 min and pellet was 
re-suspended in 1 ml of pre-cooled (at 4°C) selection buffer (2 mM EDTA, 0.5% bovine 
serum albumin in PBS). Total cell number was determined by manual counting. Cell 
suspension was centrifuged at 400 g, 4 for 5 min and pellet was re-suspended in 90 
l of selection buffer and 10 l of CD11b micro-beads (130049601, Miltenyi Biotec) per 
107 cells. Cell suspension was mixed and incubated for 15 min at 4°C. Cells were then 
washed by adding 3 ml of selection buffer and centrifuged at 400 g, 4° for 5 min. Pellet 
was re-suspended in 500 l of selection buffer and loaded onto a MACS LS column 
(130-042-401, Miltenyi Biotec) placed in the magnetic field of a MACS separator 
(Miltenyi Biotec) and flow-through was collected in a fresh tube. The column was then 
washed thrice with 3 ml of selection buffer. The total effluent contained unlabelled cells 
and corresponded to the adipose tissue stromal vascular fraction (SVF). The LS 
column was then removed from the MACS separator and placed in a fresh collection 
tube. The labelled cells were eluted using 5 ml of selection buffer and corresponded to 
adipose tissue macrophage (ATM) fraction. Both SVF and ATM fractions were 
centrifuged at 400 g, 4° for 5 min and pellets were frozen and stored at -80°C for 
subsequent analysis. 
 
2.3.4 Isolation of Kupffer cells 
The composition of solutions used in the procedure of Kupffer cell isolation are 
summarised in Table 2-3. All solutions were made in-house one day before the 
experiment and their pH was adjusted to 7.4 before sterile-filtering. 
 
Immediately after sacrifice, the liver was perfused through the portal vein with SC-1 at 
37°C for 5 min at a flow rate of 7.5 ml/min. Subsequently, the liver was perfused with 
sterile-filtered SC-2 containing 0.5 mg/ml Pronase E (107433, Merck Millipore) for 5 
min at a flow rate of 7.5 mL/min, and then with sterile-filtered SC-2 containing 0.25 
mg/ml Collagenase P (COLLP-RO, Sigma). After the final perfusion, liver was excised 
and placed in a glass beaker with 120 ml of sterile-filtered SC2 containing 0.4 mg/ml 
Pronase E, 0.4 mg/ml Collagenase P and 2 mg/ml DNAse I (10104159001, Sigma). 
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Liver was dissected into small pieces with scissors before sealing the beaker with tin 
foil and incubating the suspension at 37°C for 20 min. During the first 10 min of 
incubation, a single drop of 1 M NaOH was added every 2 min. During the last 10 min 
of incubation, a single drop of 1 M NaOH was added every 5 min. Suspension was 
then divided evenly between 3 50 ml Flacon tubes and they were complemented with 
SC-2 until full. All tubes were centrifuged at 25 g, room temperature for 3 min and 
pellets were discarded. Supernatants were centrifuged again at 25 g, room 
temperature for 3 min and pellets were discarded. Supernatants were then centrifuged 
at 350 g, room temperature for 10 min, resulting pellets were re-suspended in 50 ml of 
PBS and centrifuged at 350 g, room temperature for 10 min. Kupffer cells from pellets 
were isolated by magnetic CD11b micro-beads as described in 2.3.3. 
 
Chemical name SC-1 SC-2 
NaCl 8000 8000 
KCl 400 400 
NaH2PO4 75.5 75.5 
Na2HPO4 120.5 120.5 
NaHCO3 350 350 
CaCl2 . 2 H2O - 560 
HEPES 2380 2380 
EGTA 190 - 
D-(+)-Glucose 900 - 
Phenol red 6 6 
Table 2-3. Composition of solutions used in the procedure of Kupffer cell 
isolation. Concentrations for all chemicals are indicated in mg/l. 
 
2.4 In vitro methods 
2.4.1 Culture and differentiation of bone-marrow derived macrophages 
Femur and tibia bones from WT mice were isolated and cleaned, and 10 ml of Roswell 
Park Memorial Institute Medium (RPMI)-1640 (Sigma) was flushed through each bone 
using a syringe. Bone marrow cells were counted manually, pelleted by centrifugation, 
and re-suspended in RPMI-1640 with 20-30% L929 conditioned medium, 10% heat-
inactivated FBS (Gibco, Thermo Fisher Scientific) and 100 U/ml penicillin- 
streptomycin (Thermo Fisher Scientific) (macrophage differentiation medium). To 
differentiate into macrophages, cells were seeded in 10 cm non-culture treated plates 
(Falcon) at a density of 5x106 cells per plate per 10 ml of macrophage differentiation 
medium and cultured for 7 days at 37oC in 5% CO2. On day 5 of differentiation, medium 
was removed and 10 ml of fresh macrophage differentiation medium was added to 
each plate. On day 7 of differentiation, macrophages were detached using ice-cold 
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PBS containing 1 mM EDTA, counted manually, centrifuged at 500 g, room 
temperature for 5 min and re-suspended in macrophage differentiation medium at the 
concentration of 5x105 cells/ml. Immediately after, cells were plated for experiments at 
the following densities: 100 l of cell suspension per well of 96-well plate, 500 l/well 
of 24-well plate, 1 ml/well of 12-well plate, 2 ml/well of 6-well plate and 10 ml per 10 
cm plate. Cells were incubated for at least 24 h after plating before conducting 
experiments.  
 
To make L929 conditioned medium, L929 cells (CCL-1, ATCC) were seeded in DMEM 
supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin-streptomycin and 2 
mM L-glutamine (Sigma) at a density of 500,000 cells per 50 ml of medium per T175 
tissue culture flask. Medium was harvested after 1 week of culture, and then 50 mL of 
fresh DMEM supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin-
streptomycin and 2 mM L-glutamine was added onto cells and harvested 1 week later. 
Batches obtained after the first and second weeks of culture were mixed at a 1:1 ratio, 
aliquoted and stored at -20C.  
 
Detection of Mycoplasma in cell cultures was not performed. 
 
2.4.2 Cell stimulations 
All BMDM stimulations were performed in macrophage differentiation medium for 
periods indicated in legend. To polarise BMDMs to M1 or M2 state, they were treated 
for 24 h with 100 ng/ml LPS, or 10 M IL-4 respectively. In co-stimulation experiments, 
adrenergic receptor agonists were added 5 min before stimulating macrophages with 
LPS or IL-4. In all inhibitor and antagonist studies, inhibitors/antagonists were added 
30-60 min prior to stimulation.  
 
All fatty acid treatments were done using FFAs conjugated to BSA (fatty acid and 
endotoxin free, A8806, Sigma). The conjugation was performed by preparing a sterile-
filtered 1% BSA solution in macrophage differentiation medium. Both 1% BSA medium 
and concentrated fatty acid solution (100 mM of fatty acid in ethanol) were heated at 
60°C before adding fatty acid solution dropwise into 1% BSA medium in order to make 
a medium containing 1 mM fatty acid and 1% BSA. This medium was then sonicated 
until it became completely clear and used for stimulations on the same day without 
sterile filtering. FFA-free BSA solution was used as a control. 
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2.4.3 Stable isotope and radioisotope labelling 
For radiolabelling experiments, radioisotope tracers were dissolved in macrophage 
differentiation medium at the following concentrations: 0.074 MBq/ml for methyl-[3H] 
choline chloride, 0.006 MBq/ml for [1-14C]-palmitic and oleic acids and 0.148 MBq/ml 
for [1-14C] acetic acid. BMDMs were plated at the standard densities in 24-well plates 
for choline incorporation, fatty acid oxidation, lipid uptake and lipolysis assays and in 
6-well plates for lipid analysis by thin-layer chromatography.  
 
Radioactivity in total cells was determined by lysing cells in 100 µl of PBS containing 
1% TritonTM X-100, adding the lysate to scintillation vial containing 5 ml of Hionic-Fluor 
scintillation liquid and subjecting it to LSC. Radioactivity in culture medium was 
determined by adding 100 µl of cell culture supernatant to scintillation vial containing 
5 ml of Hionic-Fluor scintillation liquid and subjecting it to LSC. Radioactivity in cellular 
lipids was analysed as described in 2.5.7. 
 
For stable isotope labelling experiments, BMDMs were treated with BSA-[1-13C] oleic 
acid conjugate as described in 2.4.2 and cellular lipids were analysed as described in 
2.5. 
 
2.4.4 Fatty acid oxidation assay 
FAO assay was adapted from a published protocol539. BMDMs were treated as 
described in the legend before washing them with PBS and incubating in the presence 
of FAO medium (DMEM containing 12.5 mM HEPES, 1 mM L-carnitine, 0.3% BSA and 
100 M palmitate or 100 M oleate, radiolabelled as described in 2.4.3). 0 h NE and 
etomoxir treatments were performed after the medium change. Plates were then 
immediately sealed with parafilm M and placed at 37 C for 3 h.  
 
Meanwhile, CO2 traps were prepared by adding 200 l of concentrated HCl into the 
1.5 ml Eppendorf tubes containing paper discs, wetted with 20 l of 1 M NaOH, in the 
inner side of their lids. Once the FAO reaction finished, 400 l of medium from BMDMs 
were transferred into the CO2 traps, lids were immediately closed and tubes were 
incubated for 1 h at room temperature, allowing CO2 to escape the medium and react 
with NaOH in the paper disc. Paper discs were then transferred to scintillation vials 
containing 5 ml of Hionic-Fluor scintillation liquid and subjected to LSC. FAO rate was 
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expressed as fold change by dividing the specific activity of the paper discs from 
treated cells to that of untreated controls. 
 
2.4.5 Confocal microscopy 
Before plating BMDMs, sterile glass coverslips were added into each well of culture 
plates. After culturing, medium was aspirated, cells were washed once with PBS and 
fixed with 4% formalin solution for 10 min. Fixed cells were washed twice with PBS for 
20 min and simultaneously stained with BODIPY 493/503 for neutral lipids (D3922, 
Thermofisher Scientific) and Hoechst 33342 (B2261, Sigma) for nuclei at the 
concentrations recommended by manufacturer, followed by three 20 min washes with 
PBS. Coverslips with stained cells were mounted on microscopy slides using 
Fluoromount (F4680, Sigma) and imaged using Zeiss LSM 510 Meta Confocal 
microscope (Carl Zeiss). Excitation/emission spectra were 497/505 nm for BODIPY 
and 392/440 nm for Hoechst 33342. 
 
2.4.6 Flow cytometry 
On day 7 of differentiation, BMDMs were detached as described in 2.4.1 and 106 cells 
were centrifuged at 400 g, 4 C for 5 min and resuspended in 200 l of staining buffer 
(PBS, 1mM EDTA, 3% heat-inactivated FBS) in 5 ml round-bottom tubes (352054, 
Falcon) and maintained on ice during subsequent manipulations. For the quantification 
of cell death, detached BMDMs were pooled with the tissue culture supernatants 
containing floating dead cells. 106 Cells were stained with LIVE/DEAD dye (L10119, 
Invitrogen) according to the manufacturer’s instructions and centrifuged at 400 g, 4 C 
for 5 min.  Cells were resuspended in 200 l of staining buffer and non-specific 
antibody binding was blocked with 5 μg/ml of anti-CD16/32 (Clone 93, Biolegend) for 
20 min. BMDMs were then centrifuged at 400 g, 4 C for 5 min, resuspended in 200 l 
of staining buffer and stained with the following antibodies: anti-CD11b (M1/70, BD 
biosciences), anti-F4/80 (BM8, Biolegend), anti-CD301 (LOM-14, Biolegend), anti-
CD206 (C068C2, Biolegend) for 30 min. Cells were then washed thrice by 
resuspending in 300 l of staining buffer and centrifuging at 400 g, 4 C for 5 min. 
Finally, cells were resuspended in 300 l of staining buffer and analysed on 
LSRFortessa (BD Biosciences) flow cytometer with FACS Diva software. Data was 
analysed using TreeStar FlowJo software (Version vX0.7), by calculating median 
fluorescence intensity of each marker in the live cell population. Data acquisition and 
analysis was performed by Dr. Guillaume Bidault. 
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2.4.7 Measurement of oxygen-consumption rate and extracellular 
acidification rate 
BMDMs were plated in XF-96 cell culture plates (101085-004, Agilent) at a density of 
50,000 cells per well. On the day of experiment, cells were washed with PBS and 180 
µl of XF assay medium (modified DMEM, pH 7.4 (102365-100, Agilent), supplemented 
with 2 mM L-glutamine and 10 mM glucose) was added to each well. Plate was then 
incubated for 1 h at 37°C in the atmospheric gas environment. Real-time 
measurements of oxygen-consumption rate (OCR) and extracellular acidification rate 
(ECAR) were performed using an XF-96 Extracellular Flux Analyzer (Agilent) 
according to manufacturer’s instructions. All drugs used during the assay were diluted 
in the XF assay medium and injected automatically by the XF-96 Extracellular Flux 
Analyzer. Assays were performed by Dr. Guillaume Bidault. 
 
2.4.8 Measurement of intracellular and mitochondrial ROS production 
BMDMs were seeded at a density of 50,000 cells per well in a black 96-well plate and 
stimulated as indicated in legend. Cells were then washed with warm RPMI medium 
and incubated at 37°C with 5 μM MitoSox (mitochondrial superoxide indicator, 
M36008, Thermofisher Scientific) for 15 min. Cells were counterstained with Hoechst 
33342 for 15 min to normalise for DNA input, and a non-stained well was used to 
correct for auto-fluorescence signal from each condition. After three washes with warm 
RPMI medium, fluorescence intensity was determined using a Tecan Infinite M1000 
Pro Plate reader set to measure the excitation/emission spectra at 510/580 nm for 
MitoSox and 350/488 nm for Hoechst 33342. Assays were performed by Dr. Guillaume 
Bidault. 
 
2.5 Analytical methods 
2.5.1 Extraction and quantification of RNA 
RNA from cell samples (except adipocytes) was extracted using Rneasy Plus Mini kit 
(74106, Qiagen) following manufacturers’ instructions. 30 μl of RNAse-free water was 
used for elution. Rneasy Plus Micro kit (74004, Qiagen) was used to extract RNA from 
adipose tissue macrophage fractions, with 14 μl of RNAse-free water used for elution. 
 
RNA from tissues and adipocytes was harvested by adding 1 ml of RNA Stat-60 
reagent (Tel-Test) to approximately 100 mg of frozen tissue placed in a Lysing Matrix 
D tube (MP Biomedicals). Samples were homogenised using a FastPrep homogeniser 
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(MP Biomedicals) for 2 x 45 s at 5.5 m/s and centrifuged at 14,000 g for 5 min to pellet 
debris. The aqueous phase was transferred to a fresh tube containing 200 μl 
chloroform. Samples were mixed and centrifuged at 14,000 g, 4°C for 15 min. The 
clear upper phase containing RNA was removed and precipitated by mixing it with 500 
μl isopropanol and incubating at room temperature for 10 min. Samples were 
centrifuged at 14,000 g, 4°C for 10 min and supernatants were discarded. RNA pellets 
were then washed with 70% ethanol, air-dried and re-suspended in 100 μl of RNAse-
free water. 
 
RNA concentration and purity was determined using Nanodrop ND-1000 
spectrophotometer (Thermofisher Scientific). The absorbance was measured at 260 
nm against RNAse-free water. A single A260 unit was assumed to be equal to 40 
μg/mL of RNA. All RNA samples were stored at -80°C for subsequent processing. 
 
2.5.2 Quantitative real-time polymerase chain reaction (qRT-PCR) 
Complementary DNA (cDNA) was generated using Promega reagents in a 20 μl 
reaction as follows: 500 ng RNA was added to 1 x M-MLV reverse transcriptase master 
mix (M351A) with 2.5 mM MgCl2 (A351B), 1.25 mM dNTPs (U151B), and 5 μg/mL 
random hexamers (C118A), and denatured at 65°C for 5 min before being transferred 
directly to ice in order to prevent the reassembly of the secondary structures of RNA. 
After the addition of 1 μL of M-MLV reverse transcriptase (M170b), the reaction was 
incubated at 37°C for 1 h for cDNA synthesis and 95°C for 5 min for enzyme 
denaturation. cDNA was diluted 75-fold in RNAse-free water and stored at -20°C. 
 
qRT-PCR was performed in a 13 μL reaction with 5 μl of diluted cDNA, 6.5 μl of 2x 
TaqMan or SYBR Green reagent (Applied Biosystems), 1.3 μl of 3 mM forward and 
reverse primer mix (including 1.5 mM of probe for TaqMan reactions) and 0.2 μl of 
RNAse-free water according to the default manufacturer’s protocol (Applied 
Biosystems). Primer sequences are described in Table 2-4. Reactions were run in 
duplicate for each sample and quantified using the ABI Prism 7900 sequence detection 
system (Applied Biosystems). Duplicates were checked for reproducibility, and then 
averaged; ‘no reverse transcriptase’ controls were included to check for genomic DNA 
contamination, and ‘no template’ controls were included to check for the formation of 
primer dimers. Product specificity was determined using a dissociation curve for SYBR 
green reactions. A standard curve generated from a pool of all cDNA samples was 
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used for quantification. The expression of genes of interest was normalized using 
BestKeeper method to the geometric average of 3-4 housekeeping genes (18s, 36b4, 
Actb, and Tbp), and data was expressed as arbitrary units. 
 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) Probe (5’-3’) 
18s 
CGGCTACCACATCCAAG
GAA  
GCTGGAATTACCGCGGCT 
GAGGGCAAGTCTGGTGC
CAG 
36b4 
AGATGCAGCAGATCCGC
AT  
GTTCTTGCCCATCAGCAC
C 
 
Abca1 
TCCTCATCCTCGTCATTC
AAA 
GGACTTGGTAGGACGGAA
CCT 
 
Abcg1 
GCTGTGCGTTTTGTGCT
GTT 
TGCAGCTCCAATCAGTAG
TCCTAA 
 
Acsl1 
CAAACCAGCCCTATGAG
TGGAT 
CAGCCCGGAGCCTATGC  
Acsl4 
GACAGGCCAGTGTGAAC
GTATC 
GCCAAAGGTAAGTAGCCA
ATATATGTG 
 
Actb 
GCTCTGGCTCCTAGCAC
CAT  
GCCACCGATCCACACAGA
GT 
ATCAAGATCATTGCTCCT
CCTGAGCGC 
Adrb1 
TATCGAATCATCCGAGA
CGTACAG 
TCCCAACTCCTCCTAAACT
TTCC 
 
Adrb2 
TGGTGGTGATGGTCTTT
GTC 
GTCTTGAGGGCTTTGTGC
TC 
 
Adrb3 CCAGCCAGCCCTGTTGA 
GGACGCGCACCTTCATAG
C 
 
Adrp 
TCATCCAGAAGCTGGAG
CCA  
GCAGTCTTTCCTCCATCCT
GTC 
 
Angptl
4 
AAGATGACCCAGCTCAT
TGG 
ATCACTGTCCAGCCTCCAT
C 
 
Apoa1 
GCGGCAGAGACTATGTG
TCC 
CAGTTTTCCAGGAGATTCA
GGT 
 
Arg1 
CTCCAAGCCAAAGTCCT
TAGAG  
AGGAGCTGTCATTAGGGA
CATC 
 
Atgl 
CGCCTCTCGAAGGCTCT
CT 
TGTAGCCCTGTTTGCACAT
CTC 
 
Ccr2 
ACCTGTAAATGCCATGC
AAGT 
TGTCTTCCATTTCCTTTGA
TTTG 
 
Cd11b 
CAGACAGGAAGTAGCAG
CTCCT 
CTGGTCATGTTGATGAAG
GTGCT 
 
Cd11c 
GGCTATCAAGCATGTCA
TAACAGAAC 
CCCCTTGTTTTCTCCCATC
AG 
 
Cd206 
GCATGGGTTTTACTGCTA
CTTGATT  
CAGGAATGCTTGTTCATAT
CTGTCTT 
 
Cd36 
GCCAAGCTATTGCGACA
TGA 
TCTCAATGTCCGAGACTTT
TCA 
CACAGACGCAGCCTCCT
TTCC 
Chop 
CCACCACACCTGAAAGC
AGAA 
AGGTGAAAGGCAGGGACT
CA 
CTGGTCCACGTGCAGTC
ATGGCA 
Cidea 
GTGGACACAGAGGAGTT
CTTT 
GTCGAAGGTGACTCTGGC
TATTC 
ACAGAAATGGACACCGG
G 
  87 
Cox2 
CCCTGAAGCCGTACACA
TCA 
GTCACTGTAGAGGGCTTT
CAATTCT 
TTGAAGAACTTACAGGA
GAGAAGGAAATGGCTG 
Cpt1a 
AGGGCTGCACTCCTGGA
AG 
CACGATAAGCCAGCTGGA
GG 
 
Cpt1b 
GCGTGCCAGCCACAATT
C 
TCCATGCGGTAATATGCTT
CAT 
 
Dgat1 
AGGTTCTCTAAAAATAAC
CTTGCATT 
TCGTGGTATCCTGAATTG
GTG 
 
Dgat2 
GGCGCTACTTCCGAGAC
TAC 
TGGTCAGCAGGTTGTGTG
TC 
 
Dio2 
TGCGCTGTGTCTGGAAC
AG 
CTGGAATTGGGAGCATCT
TCA 
 
Dusp1 
GTGCCTGACAGTGCAGA
ATC 
CACTGCCCAGGTACAGGA
AG 
 
Elovl3 
AAGGTTGTTGAACTGGG
A CGA C 
GTGGTGGTACCAGTGGAC
AAA 
 
Elovl6 
TGCAGGAAAACTGGAAG
AAGTCT 
ATGCCGACCACCAAAGAT
AAA 
 
F4/80 
CAGATACAGCAATGCCA
AGCA  
GATTGTGAAGGTAGCATT
CACAAGTG 
 
Fabp4 
CACCGCAGACGACAGGA
AG 
GCACCTGCACCAGGGC 
TGAAGAGCATCATAACC
CTAGATGGCGG 
Fads1 
TGCACCCCCTCTTCTTC
GCC 
AGGCTGGGGGTCCGATGA
GG 
 
Fasn 
GCCCAGACAGAGAAGAG
GCA 
CTGACTCGGGCAACTTCC
C 
GGAGGAGGTGGTGATAG
CCGGTATGTC 
Fatp1 
CGTTTCGATGGTTATGTT
AGTGACA 
CATCACTAGCACGTCACC
TGAGA 
 
Fatp2 
GCGTGCCTCAACTACAA
CATT 
CCTCCTCCACAGCTTCTTG
T 
 
Fatp5 
AGGGTTTTTGCATTCCTG
TG 
TTGGTTCTTTCGAACCTTG
G 
 
Fbp1 
GACCCTGCCATCAATGA
GTATCT 
CCACATACCGGGCACCAT
AG 
 
Fizz1 
GGGATGACTGCTACTGG
GTG 
TCAACGAGTAAGCACAGG
CA 
 
G6pc 
CCAACCACAAGATGACG
TTCA 
ACTCTTGCTATCTTTCGAG
GAAAGA 
AAAGCCAACGTATGGATT
CCGGTGT 
Glut1 
GACCCTGCACCTCATTG
G 
GATGCTCAGATAGGACAT
CCAAG 
 
Glut4 
ACTCATTCTTGGACGGTT
CCTC 
CACCCCGAAGATGAGTGG
G 
TGGCGCCTACTCAGGGC
TAACATCA 
Gnmt 
GCTGGACGTAGCCTGTG
G 
CACGCTCATCACGCTGAA  
Got2 
TGGAGTCACAGCTGAAG
ATCTTG 
CACCTCTTGCAACCATTGC
TT 
 
Hif1a 
GCACTAGACAAAGTTCA
CCTGAGA 
CGCTATCCACATCAAAGC
AA 
 
Hif1a 
exon 2 
CGGCGAAGCAAAGAGTC
TGAAG 
GATGGTGAGCCTCATAAC
AGAAGC 
 
Hif2a 
CCAGGAGCTCAAAAGGT
GTC 
CAGGTAAGGCTCGAACGA
TG 
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Hif2a 
exon2 
ACAATGACAGCTGACAA
GGAG 
TTGTTGTAGACTCTCACTT
GCCC 
 
Hsl 
GGAGCACTACAAACGCA
ACGA 
TCGGCCACCGGTAAAGAG 
CAGGCCTCAGTGTGACC
GCCAGTT 
Il10 
CAGAGCCACATGCTCCT
AGA 
TGTCCAGCTGGTCCTTTGT
T 
 
Il1b 
TGGGCCTCAAAGGAAAG
AAT 
CAGGCTTGTGCTCTGCTT
GT 
 
Il6 
ACACATGTTCTCTGGGA
AATCGT 
AAGTGCATCATCGTTGTTC
ATACA 
 
Klf4 
CGGGAAGGGAGAAGACA
CT 
GAGTTCCTCACGCCAACG  
Lcat 
GGCTGAACTCAGTAACC
ACACA 
TTGGCTTCTAGCCGATTCC  
Lipa 
AAGGCTGCACCATAGGT
TTCA 
GGCAAGCGTCCCAATTGA  
Lpl 
TGGAGAAGCCATCCGTG
TG 
TCATGCGAGCACTTCACC
AG 
TGCAGAGAGAGGACTCG
GAGACGTGG 
Maoa 
CGGATATTCTCAGTCAC
CAATG 
ATTTGGCCAGAGCCACCT
A 
 
Mat1a 
ATCTGAGGCGCTCTGGT
GT 
CCTGCATGTACTGAACTGT
TACCT 
 
Mcp1 
AGGTCCCTGTCATGCTT
CTG  
GCTGCTGGTGATCCTCTT
GT 
 
Mgl1 
AGGTCCCTGTCATGCTT
CTG 
GCTGCTGGTGATCCTCTT
GT 
 
Msr1 
GGGAGTGTAGGCGGATC
A 
GGAGATGATAGTAGGGTG
CTCTG 
 
Nlrp3 
CCCTTGGAGACACAGGA
CTC 
GAGGCTGCAGTTGTCTAA
TTCC 
 
Nr4a1 
CTGTCCGCTCTGGTCCT
C 
AATGCGATTCTGCAGCTCT
T 
 
Pck1 
TGTGGGCGATGACATTG
C 
TGGCATTTGGATTTGTCTT
CAC 
TATCAACCCAGAAAACG
GGTTTTTTG 
Pcyt1a 
TCTGCAGGGAGCGATGA
TG 
TGTGGAGATACCTTCTGTC
CTCTGT 
TATAAGCACATCAAGGAC
GCAGGCATGTT 
Pcyt1b 
CAGTGCCAAGCACCTCA
TGA 
GGCCTATCAACTGGTGTT
CCTAA 
 
Pcyt2 
GCTGCTCCCTACGTCAC
C 
CGTCTACTGTCAGCGTGA
TGTC 
 
Pemt 
TCTGCATCCTGCTTTTGA
ACA 
TGGGCTGGCTCATCATAG
C 
 
Pgc1a 
AACCACACCCACAGGAT
CAGA 
CTCTTCGCTTTATTGCTCC
ATGA 
CAAACCCTGCCATTGTTA
AGACCGAGAA 
Pisd 
TTGCCTCTTCAGGCAGG
T 
CGCAGCAGGAACAAGGAT  
Pltp 
GCTTCTGAGGGCCACCT
AC 
TTCAGCTTCAGTGGGGAG
TT 
 
Ptdss1 
GTTAGCATTCCCCAATG
GTC 
CCAAAAACCATTCGCCATA  
Ptdss2 
CCATTTTCCAGACCTCAT
CC 
TGAGAAACAATTCGTAGAC
CACA 
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Scd1 
CTTGCGGATCTTCCTTAT
CATT 
GATCTCGGGCCCATTCG 
ACCATGGCGTTCCAGAA
TGACGTGT 
Srb1 
GCCCATCATCTGCCAAC
T 
TCCTGGGAGCCCTTTTTAC
T 
 
Srebp1
c 
GCCATGGATTGCACATTT
GA 
GGCCCGGGAAGTCACTG 
GACATGCTCCAGCTCAT
CAACAACCAAG 
Tbp 
CAAACCCAGAATTGTTCT
CCTT 
ATGTGGTCTTCCTGAATCC
CT 
 
Thbs1 
CACCTCTCCGGGTTACT
GAG 
GCAACAGGAACAGGACAC
CTA 
 
Tnf 
CATCTTCTCAAAATTCGA
GTGACAA 
TGGGAGTAGACAAGGTAC
AACCC 
CACGTCGTAGCAAACCA
CCAAGTGGA 
Ucp1 CCCGCTGGACACTGCC 
ACCTAATGGTACTGGAAG
CCTGG 
AAGTCCGCCTTCAGATC
CAAGGTGAAG 
Xbp1 
spl. 
AGCTTTTACGGGAGAAA
ACTCA 
GCCTGCACCTGCTGCG  
Xbp1 
tot. 
ACACGCTTGGGAATGGA
CAC 
CCATGGGAAGATGTTCTG
GG 
 
Ym1 
AGAAGGGAGTTTCAAAC
CTGGT 
GTCTTGCTCATGTGTGTAA
GTGA 
 
Table 2-4. Sequences of primers used in this thesis. 
FAM/TAMRA reporter and quencher detection system was used for genes with 
indicated probe sequences, and SYBR was used for the remaining genes. 
 
2.5.3 Protein extraction and quantification 
BMDMs were treated as described in legend, washed once with ice-cold PBS and 
lysed in ice-cold RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 
0.5% sodium deoxycholate, 1% NP-40, pH 7.4) containing PierceTM protease and 
phosphatase inhibitors (88668, Thermofisher Scientific). 150 µl of RIPA buffer was 
used to lyse 106 cells. Lysates were collected and centrifuged at 14,000 g, 4°C for 10 
min to remove cell debris.  
 
Protein concentration was determined by DC Protein assay (5000111, Biorad) 
according to manufacturer’s instructions. 
 
2.5.4 Western blotting 
Protein lysates were diluted in NuPAGETM LDS sample buffer (NP0007, Thermofisher 
Scientific) containing 2.5% 2-mercaptoethanol and boiled at 95°C for 5 min. 10 μg of 
protein was then separated by electrophoresis using NuPAGETM SDS-polyacrylamide 
gels (Thermofisher Scientific) and transferred to nitrocellulose membranes using the 
iBlot® Dry Blotting System (Thermofisher Scientific). Membranes were blocked for 1 h 
in 5% fat-free milk (Marvel) or 5% BSA in Tris-buffered saline containing 0.05% Tween 
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(TBST) at room temperature, and incubated overnight at 4°C with the appropriate 
primary antibody (Table 2-5). Bound primary antibodies were detected using 
peroxidase-coupled secondary anti-rabbit antibody (7074, Cell signalling) and 
enhanced chemiluminescence (WBLUF0500, Millipore). Blots were exposed digitally 
using the ChemiDoc MP System (Bio-Rad), and bands were quantified using Image 
Lab™ software (Bio-Rad). The expression of proteins was normalised to a 
housekeeping protein (β-actin), and the phosphorylation status was determined by 
normalising to a respective total protein. All protein quantification data is expressed as 
arbitrary units. 
 
Antibody (Host species) Source (Clone ID) Dilution (diluent) 
CREB (Rabbit) Cell signalling (48H2) 1:1000 (3% milk in TBST) 
P-Ser133 CREB (Rabbit) Cell signalling (87G3) 1:1000 (3% BSA in TBST) 
Β-actin (Rabbit) Abcam 1:5000 (3% milk in TBST) 
Pcyt1a (Rabbit) Abcam (EPR3940(2)) 1:2500 (3% milk in TBST) 
P-Thr183/Tyr185 JNK 
(Rabbit) 
Cell signalling (9251)  1:1000 (3% BSA in TBST) 
JNK (Rabbit) Cell signalling (9252)  1:1000 (3% milk in TBST) 
P-Thr180/Tyr182 p38 MAPK 
(Rabbit) 
Cell signalling (D3F9) 1:1000 (3% BSA in TBST) 
P38 MAPK (Rabbit) Cell signalling (9212) 1:1000 (3% milk in TBST) 
Table 2-5. Antibodies used in this thesis. 
 
2.5.5 Enzyme-linked immunosorbent assay (ELISA) 
BMDMs were treated as described in the legend and culture supernatants were 
collected. IL-1β ELISA (DY401, R&D Systems) was performed on the culture 
supernatants according to manufacturer’s instructions. 
 
2.5.6 Hepatic glycogen and glucose measurement 
Hepatic glycogen and free glucose content was determined using enzymatic glycogen 
assay kit (ab65620, Abcam) according to manufacturer’s instructions. 
 
2.5.7 Lipid extraction 
Total lipids from frozen tissue, plasma and cells were extracted using a modified Folch 
extraction method540. Glass pipettes were used throughout the procedure in order to 
avoid plastic-bound lipid contamination. 1.2 ml of HPCL-grade chloroform:methanol 
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2:1 v/v mixture was added to samples in a Lysing Matrix D tube (MP Biomedicals). 
Where applicable, appropriate amounts (calculated by approximating the average 
abundance of every fatty acid within neutral and phospholipid fraction in the sample 
and adding matching amounts of neutral and phospholipid standard) of glyceryl 
heptadecanoate (neutral lipid standard, T2151, Sigma) and 1,2-dinonadecanoyl-sn-
glycero-3-phosphocholine (phospholipid standard, 850367, Avanti Polar Lipids) were 
included in extraction mixture as internal standards. Tissue samples were 
homogenised using a FastPrep homogeniser for 2 x 45 s at 5.5 m/s, centrifuged at 
14,000 g for 5 min to pellet debris and transferred to fresh 2 ml Eppendorf tubes. Cell 
and plasma samples were homogenised by vortexing for 15 s and were not 
centrifuged. 240 μl of HPLC-grade water was added to each sample before vortexing 
for 2 min and centrifuging at 16,000 g for 10 min. 700 μl of the lower lipid fraction was 
transferred to a 7 ml glass tube. A second extraction was performed by adding 700 μl 
of fresh HPLC-grade chloroform followed by vortexing and centrifugation as above. 
900 μl of lower lipid fraction was collected and pooled with the first 700μl fraction (total 
1600μl). Collected lipid fractions were dried under nitrogen stream. Where applicable, 
dried lipid weight was determined by measuring the difference of glass vial weight 
before and after the extraction. Tissue lipid content was then determined by dividing 
the dried lipid weight by the wet weight of tissue used for extraction. Dried lipids were 
stored at -20°C for subsequent processing, or re-suspended in 100 µl chloroform, 
transferred to scintillation vials containing 5 ml of Opti-Fluor scintillation liquid 
(6013199, Perkin Elmer) and subjected to LSC.   
 
2.5.8 Total lipid fractionation to neutral and phospholipid fractions 
Lipids were fractionated into neutral and phospholipids by solid phase extraction 
(SPE). Glass pipettes were used throughout the procedure in order to avoid plastic-
bound lipid contamination. Dried lipids were re-suspended in 1 ml chloroform and 
applied to aminopropyl (NH2) solid-phase extraction columns (Bond Elut, 12113014, 
Agilent) placed in a hermetic glass SPE tank connected to a vacuum pump. The flow-
through containing neutral lipids was collected along with two subsequent washes with 
1 ml chloroform into fresh 7 ml glass vials. Phospholipids bound to the column were 
eluted with 2 ml of HPLC-grade chloroform:methanol 2:1 v/v solution into fresh 7 ml 
glass vials. Collected neutral and phospholipid fractions were dried under nitrogen 
stream and stored at -20°C for subsequent analysis. 
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2.5.9 Thin-layer chromatography 
BMDMs were treated in 6-well plates as indicated in legend and lipids were labelled 
as described in 2.4.3. Lipids from cells were extracted as described in 2.5.7 and 
solubilised in 50 µl of HPLC-grade chloroform. 20 µl of lipids were then spotted at the 
bottom of 20 cm x 20 cm thin layer chromatography (TLC) silica plates (Z292974, 
Sigma). TLC plates were placed into hermetic glass chambers containing 250 ml of 
one of the following solutions: 65:25:4 chloroform:methanol:ammonium hydroxide v/v 
for phospholipid separation, or 80:20:1 hexane:diethyl ether:acetic acid v/v for neutral 
lipid separation. Plates were allowed to develop until the solvent front was 
approximately 2 cm below the top of the plate. Plates were dried under laminar flow 
and incubated with radiographic films (47410, Fujifilm) in the dark for 1-3 days at room 
temperature. Radiographic films were developed using automated film developer and 
scanned. ImageJ software (NIH) was used to calculate the density of the bands on 
scanned radiograms. 
 
After radiogram was obtained, plates were sprayed with a total lipid dye (0.005% 
primuline (206865, Sigma) in acetone:water 4:1 v/v), then dried under laminar flow and 
imaged digitally under the UV light using the ChemiDoc MP System (Bio-Rad). 
 
In order to quantify radioactivity in a sample, the same amount (20 µl) of lipids was 
transferred to a scintillation vial containing 5 ml of Opti-Fluor scintillation liquid and 
subjected to LSC. 
 
2.5.10 Microsomal preparation 
BMDMs were treated as indicated in legend. 107 BMDMs were re-suspended in 5 ml 
of homogenising buffer (10 mM Tis-HCl, 0.25 M sucrose, 1 mM EDTA, pH 7.0) 
containing PierceTM protease and phosphatase inhibitors and homogenized in a Potter-
Elvehjam tissue grinder with PTFE pestle at 1000 rpm for 2 min on ice. The 
homogenate was transferred to 6.5 ml ultracentrifuge tubes (344088, Beckman 
Coulter) and sequentially centrifuged using 50.4 Ti rotor (347299, Beckman Coulter) 
as follows: 10 min at 700 g, 10 min at 8000 g and 10 min at 17,000 g, all at 4°C. The 
supernatant was then transferred to a fresh tube and the pellet was discarded. The 
supernatant was centrifuged at 105,000 g, 4°C for 45 min. The supernatant was then 
discarded and the pellet containing microsomes was re-suspended in 5 ml of 
centrifugation buffer (20 mM Tris-HCl, 0.4 M KCl, pH 7.4). The suspension was 
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centrifuged for at 105,000 g, 4°C for 5 min. The supernatant was discarded and the 
pellet containing microsomes was re-suspended in 50 μl of 0.1 M Tris-HCl (pH 7.4). 
Protein concentration of the microsomal preparation was quantified by DC protein 
assay (Biorad) before aliquoting and storing microsomes at -80 C. 
 
2.5.11  Gas chromatography-mass spectrometry 
2.5.11.1 Quantitative analysis of fatty acid methyl esters (FAMEs) 
In order to derive FFAs and esterified fatty acids from complex lipids into FAMEs, 750 
μl of HPLC-grade chloroform: methanol 1:1 v/v solution was added to previously dried 
lipids in 7 ml glass vials. 125 μl of 10% boron trifluoride in methanol (134821, Sigma) 
was then added into each vial. Vials were sealed and incubated in an oven at 80°C for 
90 min in order to hydrolyse fatty acid-glycerol and fatty acid-cholesterol ester bonds 
and form FAMEs. Samples were allowed to cool, and 1 ml of HPLC-grade n-Hexane 
and 500 μl of HPLC-grade water were added. Samples were briefly vortexed and 
centrifuged at 2000 g using benchtop centrifuge. The upper organic layer was 
transferred into 2 ml gas chromatography glass vials and dried under nitrogen stream. 
 
Gas chromatography-mass spectrometry was performed with Agilent 7890B gas 
chromatography system linked to Agilent 5977A mass spectrometer, using AS3000 
auto sampler. A TR-FAME column (length: 30 m, inter diameter: 0.25 mm, film size: 
0.25 μm, 260M142P, Thermofisher Scientific) was used with helium as carrier gas. 
Inlet temperature was set at 230°C. Dried FAME samples were re-suspended in HPLC-
grade n-Hexane (100 µl of solvent was used for BMDM samples and 1 ml – for tissue 
samples). 1 µl of this solution was injected for analysis. The oven programme used for 
separation is detailed in Table 2-6. If the height of any FAME peaks exceeded 108 
units, sample was re-injected with 10:1 – 100:1 split ratio. Identification of FAME peaks 
was based on retention time and made by comparison with those in external standards 
(Food industry FAME mix, 35077, Restek).  
 
Oven ramp rate (°C/min) Oven temperature (°C) Hold time (min) 
- 100 2 
25 150 0 
2.5 162 3.8 
4.5 173 5.0 
5.0 210 0 
40 230 0.5 
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Table 2-6. Oven temperature programme used for FAME separation by gas 
chromatography. Carrier gas flow was set to 1.5 ml/min. 
 
Peak integration and quantification was performed using MassHunter Workstation 
Quantitative Analysis software (version B.07.00, Agilent). Specific high-abundance 
ions from total ion chromatogram were chosen to calculate each fatty acid peak. The 
peak area values for each fatty acid were then normalised to the peak area value of 
internal standard in that sample and expressed as units/mg tissue or units/106 cells. 
When relative changes in lipids were analysed, values were expressed in molar 
percentages by dividing the area of each peak by the sum of all peak areas for a given 
sample. This analysis accounted for differences in total lipids between samples. 
 
2.5.11.2 Microsomal DGAT activity assay 
Microsomal DGAT activity assay protocol was adapted from a recent publication541. 
Eppendorf tubes containing 100 µl of DGAT reaction mixtures (50 µM of palmitoyl-CoA 
(870716P, Avanti Polar Lipids), 50 µM of oleoyl-CoA (870719P, Avanti Polar Lipids), 
333 µM sn-1,2-dioctanoylglycerol (800800O, Avanti Polar Lipids), 200 mM HEPES, 
3.2 mM MgCl2, pH 7.4) were prepared. Reactions were initiated by adding 10 µg of 
microsomes (diluted in 20 µl of water) into the reaction mixtures. ‘No acyl-CoA’ and ‘no 
microsome’ controls were included in each assay. Tubes were incubated at 30°C for 
10 min and reactions were quenched by transferring them to 2 ml glass vials containing 
1 ml of HPLC-grade chloroform: methanol 2:1 v/v solution. 280 µl of 100 mM acetic 
acid were then added to each vial. Vials were vortexed for 2 min and centrifuged at 
1,500 g, room temperature for 5 min. Lower phase containing neutral lipids was 
transferred to fresh 2 ml glass vials and samples were dried under nitrogen flow.  
 
Gas chromatography-mass spectrometry was performed using DB-5 column (Agilent), 
with helium as carrier gas. Dried lipids were re-suspended in 60 µl of HPLC-grade 
isooctane and 1 µl of solution was injected splitless for analysis. Flow rate was set to 
2 ml/min and inlet temperature was 315 C. The oven programme was as follows: initial 
oven temperature was set to 150°C, then temperature was increased at a rate of 
15°C/min until it reached 315°C, where it was maintained for an additional 18 min. 
Mass spectrometry detection was set to single ion monitoring (SIM) mode, with ions 
127.0, 327.0, 439.0 and 469.0 being monitored at a dwell time of 50 ms/ion.  
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Peak integration and quantification was performed using MassHunter Workstation 
Quantitative Analysis software (version B.07.00, Agilent). 327.0 ion was used to 
quantify the peaks, and ions 439.0 and 469.0 were used as qualifiers to identify 1,2-
dioctanoyl-3-palmitoyl-glycerol and 1,2-dioctanoyl-3-oleoyl-glycerol, respectively. ‘No 
acyl-CoA’ and ‘no microsome’ controls were used to verify the 1,2-dioctanoyl-3-
palmitoyl-glycerol and 1,2-dioctanoyl-3-oleoyl-glycerol peaks. Relative DGAT activity 
was calculated by dividing the peak area of stimulated BMDMs by the peak area of 
control BMDMs, and expressed as fold change from control.   
 
2.5.12 Sample preparation for quantitative proteomics 
BMDMs were plated in 10 cm plates and stimulated as described in legend. Protein 
was extracted and quantified as described in 2.5.3. 100 µg of protein from each sample 
was reduced, alkylated and precipitated as follows: each sample was diluted to 100 µl 
in 1 M triethylammonium bicarbonate (TEAB, 90114, Thermofisher Scientific). 
Disulphide bonds were reduced by adding 5 μl of 200 mM tris(2-
carboxyethyl)phosphine (646547, Sigma) and incubating samples at 37 °C for 1 h. 
Cysteine residues were then alkylated by adding 5 μl of 375 mM iodoacetamide 
(90034, Thermofisher Scientific) and incubating at room temperature for 30 min. 
Proteins were then precipitated by adding 500 µl of ice-cold acetone and incubating 
overnight at -20°C. Precipitated proteins were then pelleted by centrifugation at 
10,000g, 4°C for 10 min, supernatants were discarded and pellets were air-dried for 
10 min at room temperature. Samples were stored at -80°C. 
 
Pellets were solubilised in 100 µl of 100 mM HEPES buffer (pH 8.5) and digested with 
sequencing grade trypsin (V5111, Promega) with a 1:40 enzyme:protein ratio at 37°C 
for 1 h. An additional aliquot of trypsin at 1:40 concentration was added and samples 
were incubated overnight at 37 °C. Trypsin digests were centrifuged at 13,000 g for 5 
min to remove any insoluble matter and dried by vacuum centrifugation. 
 
Peptide samples were re-suspended in 100 µl of 100 mM HEPES buffer (pH 8.5). Each 
sample was then labelled with unique mass tag according to manufacturer’s 
instructions (TMT10plexTM, 90110, Thermofisher Scientific). Once labelled, samples 
were combined and dried by vacuum centrifugation. Labelled peptides were desalted 
using Sep-Pak C18 solid phase extraction cartridges according to manufacturer’s 
instructions (WAT054955, Waters). The eluate from cartridges was dried by vacuum 
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centrifugation and re-suspended in 100 µl of 20 mM HPLC-grade ammonium formate 
(pH 10.0) and 4% HPLC-grade acetonitrile v/v solution for high pH reversed-phase 
liquid chromatography. 
 
2.5.13 Quantitative proteomics by liquid chromatography-mass 
spectrometry 
Sample fractionation by high pH reverse-phase liquid chromatography and subsequent 
analysis of each eluted fraction (10 fractions in total) by mass spectrometry was 
performed in the lab of Prof. Kathryn Lilley by Dr. Houjiang Zhou. Analysis parameters 
and equipment used is described in detail in a methods section of a recent publication 
from Prof. Lilley’s group542. The full raw list of detected proteins (including the number 
and abundance of peptides detected) is deposited in the University of Cambridge data 
repository and can be accessed via the following link: 
https://doi.org/10.17863/CAM.28046 . 
 
2.6 Statistical analysis and graphical representation of data 
All data from experiments is represented as a mean, with error bars showing standard 
error of the mean and the number of replicates stated in legend. Some data is 
represented as a fold-change, and it is stated in legend to what value the data 
represented was normalised to generate the fold-change. Statistical tests used are 
also stated in legend. A student’s t-test was used to compare two groups; one-way 
analysis of variance (ANOVA) was used to compare more than 2 groups, followed by 
Bonferonni’s post-hoc test. Where more than one factor influenced the variable being 
measured, 2-way ANOVA was used to test for a significant effect of each factor as well 
as an interaction between factors. For assessment of EE or clamp GIR, ANCOVA was 
used to correct for the animal’s body weight. In these cases, significance was defined 
as p < 0.05.  
 
Statistical and pathway analysis of proteomics data was performed by a PhD student 
Aurelien Dugourd from Prof. Saez-Rodriguez group. Variance stabilisation 
normalisation (VSN) method was applied to normalise the protein expression levels 
between samples543. Differential statistical analysis was performed using LIMMA 
package544. For the prediction of biological pathways, processes and transcription 
factors, PIANO analysis545 was performed with the following ontologies: c2 canonical 
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pathways (version 6, Molecular Signatures database (v6, msigDB)), c5 biological 
processes (v6, msigDB) and transcription factor regulons (provided by Dr. Luz Garcia). 
 
In this thesis, all statistical tests were performed and graphs were generated using 
GraphPad Prism 6 software. Graphs and figures were edited for presentation using 
Adobe Illustrator CC 2015 software. 
 
2.7 Metabolizer algorithm 
The methodology of the Metabolizer algorithm used to analyse microarray data has 
been described in detail in a recent publication546. In a simplified manner, the algorithm 
uses defined Kegg pathway modules to infer the theoretical flux through metabolic 
pathways, solely based on the expression levels of genes that encode the enzymes 
constituting the pathway.  
  98 
3 The role of de novo PC synthesis during lipid-
induced inflammation in macrophages 
3.1 Introduction 
3.1.1 Preliminary data  
Our laboratory previously characterised ATMs isolated from WT and ob/ob mice at two 
metabolically distinct time points of their lifespan. At the first time point (corresponding 
to 5 weeks of age), ob/ob animals were rapidly gaining fat mass due to their 
hyperphagia, but still displayed normal glycaemia and mild hyperinsulinemia 283. 
Therefore, WAT sampled from 5-week-old ob/ob mice provided a snapshot of rapid, 
healthy WAT expansion and remodelling processes. By the second time point (16 
weeks of age), ob/ob mice had decelerated their fat mass expansion and had already 
developed WAT inflammation and dysfunction, followed by pronounced glucose 
intolerance and dyslipidaemia283. Comparative analysis of these two time points 
simultaneously could enable us to compare the behaviour of ATMs in a healthy and 
dysfunctional WAT and identify molecular mechanisms that potentially cause WAT 
inflammation and insulin resistance. 
 
One striking observation arising from transcriptomic and lipidomic analysis of ATMs 
was their specific regulation of genes related to M2 polarisation and lipid remodelling. 
When compared to age-matched WT controls, 5-week-old ob/ob ATMs had markedly 
increased mRNA levels of M2 macrophage markers and lipid metabolism genes 
Elovl6, Scd1 and Dgat1 (Figure 3-1 A,B), all of which have been described to reduce 
lipotoxic effects of exogenous saturated FFAs on macrophages 209,219. Interestingly, 
ATMs isolated from 16-week-old ob/ob mice showed an opposite phenotype, with 
down-regulation of genes encoding M2 polarisation markers and lipid metabolism 
enzymes compared to WT controls (Figure 3-1 A,B). Furthermore, the development of 
the transcriptional signature observed at 16 weeks of age co-occurred with an 
intracellular accumulation of lipids in ob/ob ATMs (Figure 3-1 C). As pharmacologically 
enhancing adipocyte storage capacity resulted in a reduction in ATM lipid accumulation 
and enhancement of M2 polarisation in ob/ob mice, this study concluded that adipocyte 
dysfunction lead to lipid accumulation within ATMs that caused their inflammatory 
activation283. While a reduction in the expression of Elovl6, Scd1 and Dgat1 in 16-
week-old ob/ob ATMs could potentially explain their inability to handle increased 
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amounts of intracellular lipids, this study did not identify any molecular mechanisms 
linking intracellular lipid accumulation to the inflammatory activation of ATMs. 
 
 
 
Figure 3-1. Phenotypic analysis of ATMs isolated from 5- and 16- week-old WT 
and ob/ob mice.  
mRNA levels of M2 polarisation markers (A) and lipid metabolism enzymes (B) in 
ATMs isolated from 5-week-old WT (n=4, white bars) and ob/ob (n=5, dark grey bars), 
and 16-week-old WT (n=6, light grey bars) and ob/ob (n=9, black bars) male mice. 
Gene expression has been measured by qPCR as described283. C. Flow cytometry 
analysis of Cd11b-positive cells from WAT stained with intracellular lipid dye Bodipy. 
*, *** p < 0.05 compared to WT using student’s t-test. All graphs are presented as 
published in Prieur et al.283. 
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Following the publication of the study by Prieur et al., lipidomic data was reanalysed to 
compare the total measured abundances of complex lipid species between ATMs 
isolated from WT and ob/ob eWAT. As the predominant phospholipid species in 
mammalian cells, including macrophages is PC370, the fact that PE was the most 
abundant measured lipid indicated incomplete detection coverage of the ATM 
phospholipidome (Figure 3-2 A). However, out of all measured lipids, the measured 
PE species were reduced and no change in the abundance of measured PC species 
was observed in the ATMs from ob/ob mice, resulting in an elevated PC to PE molar 
ratio (Figure 3-2 A).  
 
Transcriptomic data published in Prieur et al. study was also reanalysed using 
Metabolizer algorithm, which predicted the activity of cellular metabolic pathways 
based on changes of the expression of genes encoding the enzymes constituting each 
pathway. The activity of Kegg module M00090, which encompasses all the enzymes 
of de novo PC synthesis pathway (Figure 1-7), was down-regulated in 5-week-old, but 
increased in 16-week-old ATMs from ob/ob compared to age matched WT mice 
(Figure 3-2 B). Module M00092, representing the genes encoding the enzymes 
constituting de novo PE synthesis pathway (Figure 1-7) was not affected by genotype 
(Figure 3-2 C), suggesting that observed increase in PC to PE ratio in 16-week-old 
ATMs was likely driven by increased de novo PC synthesis, rather than decreased PE 
production. Importantly, as the fluidity of cellular membranes is determined by the 
relative ratios, rather than the absolute amounts of individual lipid species, an observed 
increase in PC to PE ratio was suggestive of altered membrane physical properties 
and likely to contribute to an altered phenotype of ob/ob ATMs.   
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Figure 3-2. Concentrations of lipid species and the activity of transcriptional 
modules of phospholipid biosynthesis in ATMs isolated from 5- and 16- week-
old WT and ob/ob mice. 
ATMs isolated from 5- and 16-week-old WT and ob/ob mice were subjected to 
transcriptomic and lipidomic analyses as described. A. Concentrations of measured 
complex lipid species in ATMs isolated from 16-week-old WT (n=3, black bars) and 
ob/ob (n=6, white bars) male mice, expressed as molar percentages of total measured 
lipids. B. The activity of Kegg module M00090 (PC biosynthesis), calculated based on 
transcriptional changes of genes involved in de novo PC synthesis pathway that were 
measured by microarray in ATMs isolated from 5- and 16-week-old WT and ob/ob male 
mice (n=4 /group). C. The activity of Kegg module M00092 (PE biosynthesis), 
calculated based on transcriptional changes of genes involved in de novo PE synthesis 
pathway that were measured as in (B). * p < 0.05 compared to WT using student’s t-
test. ATM isolation and omics analyses were performed as part of a published study 
managed by Dr. Xavier Prieur. Lipidomics data was re-analysed as molar percentages 
by Dr. Sam Virtue. Kegg module activity was assessed by a PhD student Cankut 
Cubuk from Prof. Joaquin Dopazo’s group. 
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Validation of the expression of genes encoding PC-synthesising enzymes by RT-qPCR 
revealed a two-fold increase in the transcript levels of rate-limiting enzyme CCT in 
16-week-old ob/ob ATMs (Figure 3-3 A), and a marked suppression of Pcyt1b 
transcription in 5-week-old ob/ob ATMs compared to WT controls (Figure 3-3 B). An 
independent experiment involving a bone-marrow transplant of WT donor bone-
marrow into irradiated WT or ob/ob host mice, showed a similar increase in Pcyt1a 
transcription in ATMs isolated from ob/ob hosts at 20 weeks of age (Figure 3-3 C).  
 
 
 
 
Figure 3-3. Expression of de novo PC biosynthesis genes in ATMs isolated from 
5-, 16- and 18-week-old WT and ob/ob mice. 
Pcyt1a (A) and Pcyt1b (B) mRNA levels (normalised to BestKeeper) in ATMs isolated 
from 5-week-old WT (n=4, black bars) and ob/ob (n=5, white bars), and 16-week-old 
WT (n=6, black bars) and ob/ob (n=9, white bars) male mice. C. Pcyt1a mRNA levels 
in ATMs isolated from 20-week-old WT (n=7, black bars) and ob/ob (n=7, white bars) 
female mice that had been irradiated at 8 weeks of age and reconstituted with bone 
marrow cells isolated from WT mice. ATMs in (A and B) were isolated as part of 
published study managed by Dr. Xavier Prieur. ATMs in (C) were isolated and analysis 
was performed by Dr. Guillaume Bidault. * p < 0.05 compared to WT using 2-way 
ANOVA with Tukey’s multiple comparisons test (A and B) or student’s t-test (C). 
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3.1.2 Research questions and aims 
Overall, the observations from the study of Prieur et al. and post hoc analyses indicated 
an inverse relationship between de novo PC synthesis and M2 polarisation, as well as 
lipid remodelling in ATMs. During healthy adipose tissue expansion, as portrayed by 
5-week-old ob/ob WAT, ATMs adopt an M2 phenotype and enhance their fatty acid 
remodelling, but reduce the rate of de novo PC biosynthesis (Error! Reference source 
not found.). However, in the dysfunctional WAT of 16-week-old ob/ob mice, ATM 
population exhibits a shift from M2 to M1 polarisation, co-occurring with increased 
intracellular lipid accumulation, down-regulation of fatty acid remodelling gene 
transcription and increase in PC:PE ratio (Error! Reference source not found.). 
Altogether, dysfunctional WAT creates a lipotoxic and inflammatory milieu, 
leading to increased PC biosynthesis in ATMs. The research questions of this 
chapter can thus be formulated as follows:  
 
1) Is an increased de novo PC biosynthesis in ATMs during obesity an adaptive 
mechanism that limits WAT inflammation? 2) Alternatively, does the increase in 
de novo PC biosynthesis in ATMs during obesity promote ER stress and WAT 
inflammation? 
 
Based on the presented literature on PC metabolism in different cell types, elevated 
de novo PC synthesis in macrophages can be speculated to either have a protective 
or a detrimental role during obesity. On the one hand, increased PC levels may enable 
ATMs to function in a lipotoxic environment by providing membrane biosynthetic 
material for lipid droplet formation and lipid partitioning towards inert FFA storage, thus 
alleviating ER from excessive lipid load and reducing ER stress and inflammation. On 
the other hand, increased de novo PC synthesis may lead to increased rate of 
saturated fatty acid incorporation to ER membranes, thus causing ER stress and pro-
inflammatory activation of ATMs233. 
 
In this chapter, I will aim to answer my proposed questions in two objectives: 
 
Objective 1. To investigate the functional impact of reduced de novo PC 
biosynthesis on macrophage function in a lipotoxic environment in vitro. 
This will be performed using BMDM as a model cell, with the initial attempt to 
understand how de novo PC biosynthesis is regulated by lipotoxic and 
  104 
inflammatory stimuli in macrophages in vitro. Subsequently, BMDMs from mice 
with macrophage-specific Pcyt1a deletion will be utilised to assess the impact of 
reduced de novo PC biosynthesis on the response of macrophages to lipotoxic 
stimuli. 
 
Objective 2. To assess the impact of reduced macrophage de novo PC 
biosynthesis on the function of metabolic tissues in lean and obese states 
in vivo. To address this, I will investigate the metabolic profile of mice lacking 
Pcyt1a gene in macrophages both in healthy, chow-fed state and after prolonged 
feeding with high-fat diet in order to induce insulin resistance and dyslipidaemia. 
Furthermore, ATMs, whole WAT and livers will be analysed for metabolic and 
inflammatory gene markers. 
 
I will ultimately combine the evidence gathered from both objectives to draw a model 
explaining the role of de novo PC biosynthesis in mediating the inflammatory activation 
of ATMs during obesity. This model will hopefully contribute to the global objective of 
providing an overall understanding of physiological processes leading to the 
development of WAT dysfunction and insulin resistance, and will complement current 
mechanisms emphasising the importance of ATM lipid metabolism for appropriate 
WAT function, particularly macrophage fatty acid synthesis408 and lipid remodelling219. 
 
 
Figure 3-4. Schematic representation of changes in ATM phenotype over time in 
ob/ob mice. 
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3.2 Results 
3.2.1 The role of Pcyt1a in palmitate-induced ER stress and inflammation 
in BMDMs 
3.2.1.1 LPS and exogenous fatty acids increased de novo PC biosynthesis in 
macrophages 
Rationale and results. The majority of choline-containing lipids are PC species, and 
the remaining minority are sphingolipids, which are synthesised from PC precursors. 
Therefore, the only way hydrophilic choline can be incorporated into hydrophobic lipid 
fraction is via de novo PC biosynthesis. Consequently, measuring the appearance of 
radiolabelled choline in lipid fraction over time is a good readout of the rate of de novo 
PC biosynthesis. Furthermore, as CCT is a rate-limiting enzyme in de novo PC 
biosynthesis pathway, this method can be considered as a proxy for the real-time 
assessment of CCT enzymatic activity in living cells. 
 
A previous study showed that de novo PC biosynthesis is required for cytokine 
secretion following LPS stimulation373. However, the rate of choline incorporation to 
PC was not affected during the initial 6 h period of LPS stimulation373. To validate this 
finding, I stimulated BMDMs with LPS and immediately tracked the incorporation of 
radiolabelled choline into total cellular lipids. Contrary to the published result373, I 
observed a nearly two-fold increase in de novo PC formation during the initial 2 h period 
following macrophage TLR4 stimulation (Figure 3-5 A). 
 
Loading cells with exogenous fatty acids has been reported to increase PC 
biosynthesis in order to generate membranes for newly formed lipid droplets367. Oleate 
has been shown to more readily lead to lipid droplet formation, compared to 
palmitate547.  Consistently, I observed an approximately 3-fold increase in de novo PC 
synthesis during the first 2 h following the exposure of BMDMs to oleate (Figure 3-5 
B). Interestingly, equimolar dose of palmitate also resulted in a smaller increase in PC 
biosynthesis despite having little to no effect on BODIPY-stained lipid droplet formation 
(Figure 3-5 B, data not shown). Furthermore, the increase in de novo PC formation 
rate in BMDMs was directly proportional to the concentration of palmitate in culture 
medium (Figure 3-5 C). As palmitate concentrations exceeding 100 M have been 
routinely used in the literature to model lipotoxicity in macrophages in vitro, I chose to 
investigate the importance of de novo PC biosynthesis for the development of ER 
stress and inflammation in response to palmitate.   
  106 
 
Figure 3-5. Incorporation of choline into lipids after BMDM stimulation with LPS 
or fatty acids. 
Specific activity of total cellular lipids of WT BMDMs treated with either 100 ng/ml LPS 
for 2 h (A), 100 M palmitate or 100 M oleate for 2 h (B) or indicated concentrations 
of palmitate for 2 h (C) in the presence of methyl-[3H] choline chloride tracer. N=4 
mice/experiment. * p < 0.05 compared to control using student’s t-test (A), 1-way 
ANOVA with Dunnett’s multiple comparisons test (B). Means in (C) are significantly 
different when tested using 1-way ANOVA with a post hoc test for left-to-right linear 
trend (significant differences are not visually indicated). All mice were of C57Bl/6J 
genetic background. 
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3.2.1.2 Pcyt1a gene deletion did not affect the differentiation of BMDMs 
Rationale and results. One previous study has utilised Pcyt1afl/fl BMDMs, where 
Pcyt1a gene was excised at the end of the differentiation by exogenously adding cell-
penetrating Cre recombinase protein367. However, so far no studies have characterised 
the differentiation capacity of BMDMs obtained from LysM-Cre Pcyt1afl/fl mice. As this 
model has been previously shown to have appropriate numbers of functional peritoneal 
macrophages373, I did not expect it to have an impaired BMDM differentiation. Indeed, 
the protein expression of macrophage surface markers F4/80, CD11b, CD206 and 
CD301 was not affected by the presence of Cre gene in the LysM locus on Pcyt1afl/fl 
background after 7 days of BMDM differentiation (Figure 3-6 A). The expression of 
macrophage surface marker genes was also similar between genotypes, with the 
exception of CD206, which was down-regulated in BMDMs from LysM-Cre Pcyt1afl/fl 
mice (Figure 3-6 B).  
 
 
Figure 3-6. Differentiation efficiency of BMDMs from LysM-Cre Pcyt1afl/fl mice.  
(A) Flow cytometry analysis of F4/80, CD11b, CD206 and CD301 macrophage surface 
marker expression in differentiated BMDMs from Pcyt1afl/fl (black bars) and Pcyt1afl/fl 
LysM-Cre (white bars) mice. (B) mRNA levels (normalised to BestKeeper) of F4/80, 
Cd11b, Cd206 in differentiated BMDMs from Pcyt1afl/fl and Pcyt1afl/fl LysM-Cre mice. 
(C) Relative yield of differentiated BMDMs from Pcyt1afl/fl LysM-Cre compared to 
Pcyt1afl/fl mice. (A) N=5 Pcyt1afl/fl and 3 Pcyt1afl/fl LysM-Cre, n=4 mice/group (B and 
C). All mice were of C57Bl/6J genetic background. * p < 0.05 compared to Pcyt1afl/fl 
using student’s t-test.  
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A typical BMDM differentiation method involves plating an even number (approximately 
5 million) of bone marrow cells in each plate and normally allows obtaining around 10 
million BMDMs per plate after 7 days of culturing. However, I noticed that bone marrow 
cells from LysM-Cre Pcyt1afl/fl produced approximately 30% less of mature BMDMs 
compared to Pcyt1afl/fl controls in three independent cultures (Figure 3-6 C, 
representative result of three cultures). 
 
Conclusion. CCTα deficiency did not affect BMDM differentiation but reduced the 
yield of mature BMDMs. 
 
3.2.1.3 Pcyt1a gene deletion reduced CCT protein levels and decreased the 
basal rate of choline, palmitate and acetate incorporation into BMDM 
lipids 
Rationale and results. Next, I investigated the CCT deletion efficiency in LysM-Cre 
Pcyt1afl/fl BMDMs. The action of Cre recombinase on Pcyt1a gene locus in 
macrophages was previously shown to be not completely penetrant, resulting in a 
mixed population of Pcyt1a-expressing (approximately 20-30% of population) and 
Pcyt1a-deficient cells (approximately 70-80% of population)373. While I did not analyse 
individual cells, I also found approximately 70% reduction in Pcyt1a mRNA levels in 
LysM-Cre Pcyt1afl/fl BMDMs compared to controls on mixed C57Bl/6J, 129/Sv genetic 
background (Figure 3-37 C, same genetic background as published previously373), and 
approximately 50% reduction on pure C57Bl/6J genetic background (Figure 3-7 A). 
CCT protein levels were reduced by approximately 70% in LysM-Cre Pcyt1afl/fl 
BMDMs on pure C57Bl/6J genetic background (Figure 3-7 B, C). The rate of choline 
incorporation to cellular lipids was reduced by approximately 50% and 30% on mixed 
C57Bl/6J, 129/Sv and pure C57Bl/6J genetic backgrounds, respectively (Figure 3-37 
B, Figure 3-7 D). The reduction of de novo PC biosynthesis in LysM-Cre Pcyt1afl/fl 
BMDMs was accompanied by a small reduction in palmitate incorporation, and 
approximately 30% decrease in acetate incorporation to cellular lipids, indicating 
reduced rate of total fatty acid synthesis on a pure C57Bl/6J genetic background 
(Figure 3-7 D).  
 
Despite observing a more potent decrease in Pcyt1a mRNA and de novo PC 
biosynthesis in LysM-Cre Pcyt1afl/fl BMDMs on mixed C57Bl/6J, 129/Sv, compared to 
a pure C57Bl/6J genetic background, I chose to perform all in vitro experiments on a 
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pure C57Bl/6J genetic background. The rationale for this decision was that most 
murine metabolic phenotyping studies involve the use of C57Bl/6J mice, having all 
experiments performed on the same background would ensure a higher reproducibility 
of our work. 
 
 
Figure 3-7. Validation of CCT deletion in BMDMs from LysM-Cre Pcyt1afl/fl mice.  
Pcyt1a mRNA (normalised to BestKeeper) (A), representative Western blots (B) and 
quantification of CCT relative to -actin protein levels (C) in differentiated BMDMs 
from Pcyt1afl/fl (black bars) and Pcyt1afl/fl LysM-Cre (white bars) mice. (D) Incorporation 
of 3H-choline, 14C-palmitate and 14C-acetate, present at tracer amounts in the medium 
for 3 h, into cellular lipids of unstimulated BMDMs from Pcyt1afl/fl and Pcyt1afl/fl LysM-
Cre mice. N=5 Pcyt1afl/fl and 3 Pcyt1afl/fl LysM-Cre (A and C), n=4 mice/group (D). All 
mice were of C57Bl/6J genetic background. * p < 0.05 compared to Pcyt1afl/fl using 
student’s t-test.  
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3.2.1.4 Pcyt1a gene deletion did not affect LPS-induced JNK phosphorylation 
in BMDMs 
Rationale. Ablation of cellular fatty acid synthesis has been previously shown to result 
in impaired JNK phosphorylation in response to LPS408. I have confirmed the published 
observation that stimulating BMDMs with LPS increased the rate of fatty acid synthesis 
(Figure 3-8 B). As LPS-induced fatty acid synthesis and de novo PC synthesis were 
reduced to a similar extent in LysM-Cre Pcyt1afl/fl BMDMs (Figure 3-8 A, B), I 
hypothesised that de novo-synthesised fatty acids are utilised by de novo PC 
biosynthesis pathway to generate PC. I therefore investigated whether Pcyt1a deletion 
resulted in impaired LPS-induced JNK phosphorylation, as reported for BMDMs 
deficient in Fasn gene408.  
 
Results. Despite having reduced rate of fatty acid synthesis, LysM-Cre Pcyt1afl/fl 
BMDMs did not show an impairment in JNK phosphorylation after acute LPS treatment 
compared to controls (Figure 3-8 C, D).  
 
Conclusion. This result indicated that TLR4-JNK signalling pathway was intact in 
LysM-Cre Pcyt1afl/fl BMDMs. 
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Figure 3-8. Induction of fatty acid synthesis and phosphorylation of JNK in 
response to LPS in BMDMs from LysM-Cre Pcyt1afl/fl mice.  
Incorporation of 3H-choline (A) and 14C-acetate (B) tracers into cellular lipids of 
Pcyt1afl/fl (black bars) and Pcyt1afl/fl LysM-Cre (white bars) BMDMs during the 
stimulation with 100 ng/ml LPS for 3 h. Representative Western blots (C) and 
quantification of phosphorylated JNK splicing form p54 relative to total p54 protein 
levels (D) in Pcyt1afl/fl and Pcyt1afl/fl LysM-Cre BMDMs stimulated with 100 ng/ml LPS 
for 30 min. N=4 mice/group. * p < 0.05 compared to Pcyt1afl/fl and # < 0.05 compared 
to unstimulated control using 2-way ANOVA with Bonferroni’s multiple comparisons 
test. All mice were of C57Bl/6J genetic background. 
  
  112 
3.2.1.5 Pcyt1a gene deletion resulted in formation of giant lipid droplets 
without affecting TG biosynthesis in oleate-treated BMDMs 
Rationale. Decreased rate of de novo PC biosynthesis has been previously reported 
to result in giant lipid droplets after loading cells with oleate.  
 
Results. I confirmed this observation in LysM-Cre Pcyt1afl/fl BMDMs exposed to oleate 
in order to induce lipid droplet formation (Figure 3-9 A). As intracellular TG storage is 
known to play a protective role during palmitate-induced lipotoxicity209, I investigated 
whether increased size of lipid droplets in BMDMs had any effect on their capacity to 
synthesise TGs. LysM-Cre Pcyt1afl/fl BMDMs incorporated the same amount of oleate 
in the TG fraction as controls, despite having substantially larger lipid droplets (Figure 
3-9 B, C). 
 
Conclusion. Any potential changes in lipotoxicity-mediated stress and inflammation 
caused by reduced PC synthesis in BMDMs are not likely to be due to altered TG 
storage capacity. 
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Figure 3-9. Formation of lipid droplets and intracellular triglycerides in response 
to oleate in BMDMs from LysM-Cre Pcyt1afl/fl mice.  
A. Representative confocal microscopy image of Pcyt1afl/fl and Pcyt1afl/fl LysM-Cre 
BMDMs stained with BODIPY (green) or Hoechst 33342 (blue) after 16 h incubation in 
the presence of 100 M oleate. Representative radiogram (B) and quantification (C) of 
TG fraction of neutral lipids separated by TLC from Pcyt1afl/fl (n=5, black bars) and 
Pcyt1afl/fl LysM-Cre (n=3, white bars) BMDMs treated with 100 M oleate for 16 h in 
the presence of 14C-oleate tracer. Mice were of mixed C57Bl/6J, 129/Sv (A) and pure 
C57Bl/6J genetic background (B, C). 
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3.2.1.6 Pcyt1a gene deletion supressed cellular stress signalling and Tnf 
gene expression in palmitate-treated BMDMs 
Rationale. Having established that reduced PC synthesis did not affect TLR4-JNK 
signalling axis and fatty acid partitioning to TGs, I next assessed the response of 
Pcyt1a-deficient macrophages to a lipotoxic insult.  
 
Results. I treated LysM-Cre Pcyt1afl/fl BMDMs with increasing concentrations (0, 200, 
400 and 600 M) of palmitate for a prolonged period of time. Both 400 and 600 M 
concentrations of palmitate were potently cytotoxic, and the amount of viable cells after 
treatment with 600 M palmitate was not sufficient for protein analysis. As expected, 
palmitate caused the activating phosphorylation of stress-responsive MAPKs JNK 
(both splicing isoforms p54 and p46) and p38 in control macrophages in a dose-
dependent manner (Figure 3-10 A-D). However, LysM-Cre Pcyt1afl/fl BMDMs showed 
a marked reduction in JNK and p38 phosphorylation following palmitate treatment 
compared to controls (Figure 3-10 A-D). Similarly, induction of Tnf gene expression by 
400 and 600 M palmitate was supressed in Pcyt1a-deficient BMDMs (Figure 3-10 E).  
 
Conclusion. Pcyt1a-deficient BMDMs exhibited diminished inflammatory activation in 
response to palmitate. 
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Figure 3-10. Inflammatory activation of BMDMs from LysM-Cre Pcyt1afl/fl mice in 
response to prolonged incubation with palmitate.  
Representative Western blots (A) and quantification of phosphorylated JNK splicing 
forms p54 and p46 and phosphorylated p38 MAPK relative to respective total protein 
levels (B-D) in Pcyt1afl/fl (black bars) and Pcyt1afl/fl LysM-Cre (white bars) BMDMs 
treated with 0, 200 or 400 M palmitate for 16 h. E. Tnf mRNA levels (normalised to 
BestKeeper) in Pcyt1afl/fl and Pcyt1afl/fl LysM-Cre BMDMs treated with 0, 200, 400 or 
600 M palmitate for 16 h. N=5 Pcyt1afl/fl and 3 Pcyt1afl/fl LysM-Cre mice. * p < 0.05 
compared to Pcyt1afl/fl using 2-way ANOVA with Bonferroni’s multiple comparisons 
test. N.d. indicates undetectable protein level, where significant differences were not 
assessed. All mice were of C57Bl/6J genetic background. 
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3.2.1.7 Pcyt1a gene deletion alleviated palmitate-induced cell death of BMDMs  
Rationale. As I have observed profound cell death of BMDMs after a prolonged 
treatment with high doses (>200 M) of palmitate, I decided to assess whether Pcyt1a 
deletion affected the cytotoxicity of palmitate in BMDMs using flow cytometry. 
 
Results. I treated LysM-Cre Pcyt1afl/fl and control BMDMs with increasing 
concentrations of palmitate overnight. As already observed in 3.2.1.6, palmitate 
caused cell death in BMDMs in a dose-dependent manner (Figure 3-11). However, cell 
death was attenuated in LysM-Cre Pcyt1afl/fl BMDMs treated with 250 M and 500 M 
palmitate, compared to control cells (Figure 3-11). 
 
Conclusion. Pcyt1a-deficient BMDMs were less susceptible to cell death in response 
to a prolonged treatment with 250 and 500 M palmitate than controls. 
 
 
Figure 3-11. Cell death of BMDMs from LysM-Cre Pcyt1afl/fl mice in response to 
prolonged incubation with palmitate. 
Flow cytometry quantification of cell death (expressed as a percentage of LIVE/DEAD 
dye-positive cells relative to total BMDM population) in Pcyt1afl/fl (black bars, n=4) and 
Pcyt1afl/fl LysM-Cre (white bars, n=4) BMDMs treated with BSA or 125, 250 or 500 M 
palmitate for 16 h. * p < 0.05 compared to Pcyt1afl/fl using 2-way ANOVA with 
Bonferroni’s multiple comparisons test. All mice were of C57Bl/6J genetic background.  
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3.2.1.8 Pcyt1a gene deletion did not affect the rate of ER stress development 
following palmitate treatment, but reduced ER stress and Tnf gene 
expression after prolonged palmitate treatment 
Rationale. Palmitate has been shown to exert some of its inflammatory effects in 
macrophages by causing ER stress548. I therefore decided to investigate whether 
diminished inflammatory and stress activation of Pcyt1a-deficient BMDMs was caused 
by a reduced rate of ER stress development.  
 
Results. I chose 250 M concentration of palmitate for this experiment, as my previous 
results indicated that it potently induces ER stress without having a major effect on cell 
viability (data not shown). I treated LysM-Cre Pcyt1afl/fl BMDMs with palmitate for 
different lengths of time (0, 1, 2, 4, 6 and 8 h) and measured the induction of Chop 
transcription and Xbp1 mRNA splicing as markers of ER stress. As expected, palmitate 
induced a transcriptional ER stress response in a time-dependent manner in control 
cells (Figure 3-12 B, C). LysM-Cre Pcyt1afl/fl BMDMs exhibited increased basal 
transcription of ER stress markers, as it has been reported previously for different cell 
types with impaired de novo PC biosynthesis223 (Figure 3-12 B, C). However, Pcyt1a-
deficient BMDMs developed ER stress in response to palmitate at the same rate as 
controls (Figure 3-12 B, C). Acute induction of Tnf transcription in response to 
palmitate, likely driven by TLR4 activation, was also similar in both genotypes, with 
LysM-Cre Pcyt1afl/fl BMDMs showing only minor reduction in Tnf message levels 4 h 
post stimulation (Figure 3-12 A). 
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Figure 3-12. Inflammatory activation and development of ER stress in BMDMs 
from LysM-Cre Pcyt1afl/fl mice in response to acute treatment with palmitate. 
mRNA levels (normalised to BestKeeper) of Tnf (A), Chop (B) and the ratio of spliced 
to total Xbp1 mRNA levels (C) in Pcyt1afl/fl (black lines, n=4) and Pcyt1afl/fl LysM-Cre 
(red lines, n=4) BMDMs treated with 250 M palmitate for 0, 2, 4, 6 and 8 h in a reverse 
time-course manner. T=0 h were treated with BSA for 8 h. * p < 0.05 compared to 
Pcyt1afl/fl using 2-way ANOVA with Bonferroni’s multiple comparisons test. All mice 
were of C57Bl/6J genetic background. 
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Interestingly, LysM-Cre Pcyt1afl/fl BMDMs showed a reduction in ER stress markers 
and Tnf mRNA compared to controls following the exposure to 250 M palmitate for a 
prolonged period of time (Figure 3-13 A-C).  
 
Conclusion. Reduced PC biosynthesis in macrophages alleviated ER stress during 
chronic, but not acute lipotoxic stress. 
 
 
 
 
Figure 3-13. Inflammatory activation and development of ER stress in BMDMs 
from LysM-Cre Pcyt1afl/fl mice in response to prolonged treatment with palmitate.  
mRNA levels (normalised to BestKeeper) of Tnf (A), Chop (B) and the ratio of spliced 
to total Xbp1 mRNA levels (C) in Pcyt1afl/fl (black bars, n=4) and Pcyt1afl/fl LysM-Cre 
(white bars, n=4) BMDMs treated with 250 M palmitate for 24 h. * p < 0.05 compared 
to Pcyt1afl/fl using 2-way ANOVA with Bonferroni’s multiple comparisons test. All mice 
were of C57Bl/6J genetic background. 
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3.2.1.9 Pcyt1a gene deletion did not affect the rate of palmitate incorporation 
to cellular PC in palmitate-treated BMDMs 
Rationale. CCT inhibition has been previously suggested to reduce the rate of 
saturated fatty acid incorporation to membrane PC, which would concomitantly slow 
down the rate of ER stress development233. I have already shown that in the 
unstimulated state, Pcyt1a-deficient BMDMs incorporated palmitate to cellular lipids at 
a lower rate than controls (Figure 3-7 D). However, cells can shuttle fatty acids to 
phospholipids through de novo biosynthesis or lipid remodelling pathways, and the 
relative contribution of each pathway might depend on the exogenous fatty acid 
concentration. Therefore, I investigated whether reduced ER stress and inflammatory 
activation following the treatment with high concentration of palmitate was due to its 
impaired incorporation to PC in LysM-Cre Pcyt1afl/fl BMDMs.  
 
Results. I treated cells with 250 M palmitate and traced its movement into PC 
fraction. However, despite having reduced basal rate of palmitate incorporation into 
cellular lipids, Pcyt1a-deficient BMDMs esterified palmitate to PC and total lipids at the 
same rate as controls (Figure 3-14 A-C). 
 
I then tested whether a prolonged treatment of LysM-Cre Pcyt1afl/fl BMDMs with fatty 
acids resulted in palmitate re-partitioning from PC fraction. As it has been reported 
previously, a larger amount of palmitate appeared in PC fraction than oleate233 (Figure 
3-15 A,B). However, neither of the fatty acids showed a difference in the total amount 
incorporated into a PC fraction after prolonged treatment between LysM-Cre Pcyt1afl/fl 
BMDMs and controls (Figure 3-15 A,B).  
 
Conclusion. This finding indicated that the rate of palmitate esterification to membrane 
phospholipids does not link reduced de novo PC biosynthesis to diminished induction 
of ER stress and inflammation during chronic treatment with palmitate. 
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Figure 3-14. Incorporation of palmitate into lipids in BMDMs from LysM-Cre 
Pcyt1afl/fl mice in response to acute treatment with palmitate.  
Representative radiogram (A) and quantification (B) of PC fraction of phospholipids 
separated by TLC from Pcyt1afl/fl (black lines) and Pcyt1afl/fl LysM-Cre (red lines) 
BMDMs treated with 250 M palmitate for 2, 4, 6 and 8 h in the presence of 14C-
palmitate tracer. (C) Specific activity of total lipids from Pcyt1afl/fl and Pcyt1afl/fl LysM-
Cre BMDMs treated as in (A and B). N=4 mice/group. All mice were of C57Bl/6J 
genetic background. 
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Figure 3-15. Incorporation of fatty acids into lipids in BMDMs from LysM-Cre 
Pcyt1afl/fl mice after prolonged incubation with palmitate and oleate. 
Representative radiogram (A) and quantification (B) of PC fraction of phospholipids 
separated by TLC from Pcyt1afl/fl (black bars, n=5) and Pcyt1afl/fl LysM-Cre (white bars, 
n=3) BMDMs treated with 100 M palmitate or 100 M oleate for 16 h in the presence 
of respective 14C-labelled tracer. All mice were of C57Bl/6J genetic background. 
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3.2.1.10 Pcyt1a gene deletion diminished the suppression of fatty acid 
remodelling gene transcription after prolonged treatment with 
palmitate 
Rationale. Elongation and desaturation of fatty acids by macrophages have been 
ascribed a protective role during LPS and palmitate-induced inflammation219,220. One 
of the major transcription factors regulating the expression of fatty acid remodelling 
genes in macrophages is SREBP1220. Interestingly, reduced cellular PC levels can 
lead to the induction of SREBP1 transcriptional activity401,402. I therefore investigated 
whether Pcyt1a-deficient BMDMs had altered regulation of SREBP1-target genes 
Elovl6, Scd1 and Fads1 that encode fatty acid elongation and desaturation enzymes.  
 
Results. As observed in ATMs isolated from 16-week-old ob/ob mice, prolonged 
treatment with palmitate down-regulated fatty acid remodelling gene expression, 
suggesting a diminished SREBP1 transcriptional activity (Figure 3-16). When 
compared to controls, LysM-Cre Pcyt1afl/fl BMDMs showed higher expression of Elovl6 
and Fads1, and no change in Scd1 mRNA levels after a prolonged treatment with 
palmitate (Figure 3-16).  
 
 
Figure 3-16. Fatty acid remodelling gene transcription in BMDMs from LysM-Cre 
Pcyt1afl/fl mice after prolonged incubation with palmitate.  
mRNA levels (normalised to BestKeeper) of Elovl6, Scd1 and Fads1 in Pcyt1afl/fl (black 
bars, n=4) and Pcyt1afl/fl LysM-Cre (white bars, n=4) BMDMs treated with 250 M 
palmitate for 24 h. * p < 0.05 compared to Pcyt1afl/fl using 2-way ANOVA with 
Bonferroni’s multiple comparisons test. All mice were of C57Bl/6J genetic background. 
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Rationale. Next, I checked whether BMDMs had a capacity to elongate and/or 
desaturate palmitate present at a high extracellular concentration. I treated cells with 
100 M of 1-13C palmitate isotope. Labelling first carbon of the molecule allowed me 
to monitor palmitate elongation and desaturation, as these processes do not modify 
the carboxyl-end of fatty acids.  
 
Results. As expected, I observed a dramatic increase in 1-13C palmitate to 
endogenous 1-12C palmitate ratio after a prolonged incubation of BMDMs with stably-
labelled palmitate, indicating its incorporation to phospholipids (Figure 3-17). 
Treatment with labelled palmitate also resulted in the formation of labelled palmitoleate 
(C16:1n7) and stearate (C18:0), respective desaturation and elongation reaction 
products of palmitate (Figure 3-17).  
 
Conclusion. These findings indicated that BMDMs are functionally capable of 
remodelling exogenous fatty acids present at lipotoxic concentrations, and also 
suggested that maintained transcription of fatty acid remodelling enzymes in Pcyt1a-
deficient BMDMs after prolonged treatment with palmitate could explain reduced ER 
stress and inflammation. 
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Figure 3-17. Remodelling of exogenous palmitate in BMDMs.  
Ratio of 1-13C to 1-12C isotopes of C16:0, C16:1n7 and C18:0 fatty acids measured by 
GC-MS in lipids of BMDMs treated with 100 M 1-13C palmitate for 16 h. N=4 mice. 
Significant differences are not indicated. All mice were of C57Bl/6J genetic 
background. 
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3.2.2 The importance of Pcyt1a in macrophages for glucose and lipid 
metabolism of lean and obese mice on mixed C57Bl/6J, 129/Sv 
genetic background 
3.2.2.1 The rationale for experimental methodology performed for in vivo 
metabolic phenotyping of LysM-Cre Pcyt1afl/fl mice 
Dietary treatments and housing conditions. LysM-Cre Pcyt1afl/fl mice have been 
previously studied in vivo373, but none of their metabolic characteristics have been 
described yet. I decided to use 45% kcal HFD (manufactured by Research Diets) to 
induce obesity and insulin resistance because it had been routinely used by our group 
to model HFD-induced obesity. HFD was administered to animals from 8 weeks of age, 
as previous results from our group suggested that mice of this age developed insulin 
resistance at a faster rate than mice fed HFD immediately after weaning at 4 weeks of 
age (data not shown). High-fat feeding continued for 8 weeks before mice were 
subjected to metabolic testing, as this period is sufficient to induce insulin resistance 
and WAT inflammation in WT animals283. Mice were individually housed a week prior 
to initial energy balance analysis in order to acclimatise them to the experimental 
conditions of metabolic cages and reduce stress response during the analysis. Mice 
remained single housed during the remaining period of metabolic testing, as re-
housing them in groups was likely to result in fighting. Finally, mice were culled for 
tissues at 20 weeks of age, having been fed HFD for 12 consecutive weeks. 
 
Glucose and insulin tolerance tests were primarily done to assess muscle glucose 
uptake and hepatic glucose production. Lipid tolerance test was a readout for 
intestinal lipid absorption rate and WAT lipid uptake. Serum biochemicals were 
measured to provide insight on liver, muscle, adipose tissue, pancreatic beta cell and 
intestinal function. Finally, gene transcription analysis of WAT fractions, whole WAT 
and livers were performed to investigate inflammation, insulin signalling and nutrient 
metabolism of each cell fraction or organ. 
 
Power analysis. I chose to study 8 mice per group, because previous work from our 
lab indicated that such sample number was sufficient to observe a significant difference 
of 20% between groups in metabolic tests with 80% confidence. In this and the 
following chapter, sample size of less than 8 animals per group in any metabolic 
studies was either due to unexpected animal loss, or a post hoc decision to exclude 
mice from analysis that were statistical outliers for multiple metabolic characteristics. 
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All metabolic analyses of chow-fed control group of Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl 
mice were performed at the same age as HFD-fed group to account for aging effects. 
However, chow and HFD groups were analysed in two separate batches. Importantly, 
as my main aim was to identify phenotypic differences between Pcyt1afl/fl and LysM-
Cre Pcyt1afl/fl mice, only genotype was used as a dependent variable in statistical 
analysis, as distinguishing the diet from batch effects would be difficult. In graphs 
containing data from both chow and HFD mice, such grouping was solely done to 
illustrate the directionality of diet-induced change of a presented parameter, and not 
for statistical comparison of chow and HFD groups.   
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3.2.2.2 Macrophage-specific Pcyt1a deletion did not affect total energy 
balance of chow-fed mice on mixed genetic background  
Rationale. I initially investigated whether deficiency of Pcyt1a in macrophages affected 
any components of energy balance of chow-fed mice.  
 
Results. Genotype had no effect on body weight, chow consumption or average 
energy expenditure at 16 weeks of age, when mice were analysed in metabolic cages 
(Figure 3-18 A,B,C). 
 
 
Figure 3-18. Food intake and energy expenditure of chow-fed Pcyt1afl/fl and 
LysM-Cre Pcyt1afl/fl mice on mixed genetic background.  
Body weight (A), food intake (B) and average energy expenditure plotted against body 
weight assessed over 48 h in Pcyt1afl/fl (black dots, n=7) and Pcyt1afl/fl LysM-Cre (red 
dots, n=8) 16-week-old male mice on mixed C57Bl/6J, 129/Sv background. Statistical 
significance was assessed by student’s t-test (A and B) or one-way ANCOVA (C).  
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3.2.2.3 Macrophage-specific Pcyt1a deletion did not affect serum metabolite 
concentrations of chow-fed mice on mixed genetic background 
Results. Chow-fed LysM-Cre Pcyt1afl/fl animals exhibited normal serum 
concentrations of insulin, FFAs, TGs, lipoprotein-bound cholesterol and choline in the 
fed state (Table 3-1). Overnight fasting elevated FFAs and reduced insulin and TGs to 
the same level in both genotypes (Table 3-1). Blood glucose levels were not affected 
by fasting or genotype on a chow diet (Table 3-1). 
 
 
Feeding state Random fed Fasted overnight 
Genotype Pcyt1afl/fl 
LysM-Cre 
Pcyt1afl/fl 
Pcyt1afl/fl 
LysM-Cre 
Pcyt1afl/fl 
Glucose (mM) 10.86 ± 0.56 10.76 ± 0.38 10.16 ± 0.77 10.61 ± 0.50 
Insulin (μg/L) 1.33 ± 0.3 1.71 ± 0.41 0.44 ± 0.08 0.46 ± 0.09 
FFA (mM) 1.12 ± 0.08 1.11 ± 0.13 1.46 ± 0.19 1.36 ± 0.13 
TG (mM) 2.24 ± 0.18 2.13 ± 0.25 1.60 ± 0.12 1.70 ± 0.23 
Total cholesterol (mM) 3.89 ± 0.37 3.56 ± 0.21 - - 
HDL cholesterol (mM) 2.30 ± 0.24 2.09 ± 0.13 - - 
LDL cholesterol (mM) 0.57 ± 0.09 0.51 ± 0.07 - - 
Total choline (μM) 45.14 ± 1.60 47.85 ± 3.33 - - 
Table 3-1. Serum biochemistry of chow-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl 
mice on mixed genetic background in a random-fed state or after overnight fast.  
Concentrations of serum biochemicals are expressed as means ± SEM. N=7 Pcyt1afl/fl, 
n=8 LysM-Cre Pcyt1afl/fl 16-20-week-old male mice on mixed C57Bl/6J, 129/Sv 
background.    
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3.2.2.4 Macrophage-specific Pcyt1a deletion did not impact glucose, insulin 
and lipid tolerance of chow-fed mice on mixed genetic background 
Results. Following exogenous administration of glucose, chow-fed LysM-Cre Pcyt1afl/fl 
mice were able to normalise serum glucose concentration at the same rate as controls 
(Figure 3-19 A,B). There were no differences in insulin-mediated serum glucose uptake 
between genotypes (Figure 3-19 C,D). Finally, both groups showed similar serum TG 
concentration curves following gavage with olive oil (Figure 3-19 E,F).  
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Figure 3-19. Glucose, insulin and lipid tolerance tests of chow-fed Pcyt1afl/fl and 
LysM-Cre Pcyt1afl/fl mice on mixed genetic background.  
Blood glucose concentration curves (A) and AUC (B) of mice injected with 1 mg/kg 
glucose at T=0 min after an overnight fast. Blood glucose concentration curves (C) and 
AUC (D) of mice injected with 0.75 IU/kg insulin at T=0 after 6 h fast. Serum TG 
concentration curves (E) and AUC (F) of mice administered with 200 l of olive oil by 
oral gavage at T=0 after overnight fast. N=7 Pcyt1afl/fl (black lines/dots) and n=8 LysM-
Cre Pcyt1afl/fl (red lines/dots)16-19-week-old male mice on mixed C57Bl/6J, 129/Sv 
background. Statistical significance was assessed by student’s t-test (B, D, F). 
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3.2.2.5 Macrophage-specific Pcyt1a deletion did not affect the weights of 
metabolic tissues of chow-fed mice on mixed genetic background 
Results. Chow-fed LysM-Cre Pcyt1afl/fl animals had similar body weight as controls at 
the end of the study (Figure 3-20 A). The expression of Pcyt1a in macrophages did not 
affect the weight of BAT, scWAT, eWAT and liver, relative to total body weight (Figure 
3-20 B-E). 
 
 
 
Figure 3-20. Tissue weights of chow-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice 
on mixed genetic background.  
Body weight (A) and weights of BAT (B), scWAT (C), eWAT (D) and liver (E), 
expressed as a percentage of body weight of Pcyt1afl/fl (n=7, black dots) and LysM-
Cre Pcyt1afl/fl (n=8, red dots) 20-week-old male mice on mixed C57Bl/6J, 129/Sv 
background culled in a random fed state. Statistical significance was assessed by 
student’s t-test. 
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3.2.2.6 Macrophage-specific Pcyt1a deletion did not affect total energy balance 
of HFD-fed mice on mixed genetic background  
Results. Animals of both genotypes had similar body weight after 8 weeks of high-fat 
feeding (Figure 3-21 A). There were no differences between HFD-fed LysM-Cre 
Pcyt1afl/fl animals and controls in food intake and energy expenditure during 48 h of 
metabolic cage analysis (Figure 3-21 B,C). 
 
 
Figure 3-21. Food intake and energy expenditure of HFD-fed Pcyt1afl/fl and LysM-
Cre Pcyt1afl/fl mice on mixed genetic background.  
Body weight (A), food intake (B) and average energy expenditure plotted against body 
weight assessed over 48 h in Pcyt1afl/fl (black dots, n=7) and Pcyt1afl/fl LysM-Cre (red 
dots, n=6) 16-week-old male mice on mixed C57Bl/6J, 129/Sv background, fed a 45% 
kcal fat diet (D12451) from 8 weeks of age. Statistical significance was assessed by 
student’s t-test (A and B) or one-way ANCOVA (C).  
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3.2.2.7 Macrophage-specific Pcyt1a deletion did not affect serum metabolite 
concentrations of HFD-fed mice on mixed genetic background 
Results. Serum concentrations of insulin, FFAs, TGs, lipoprotein-bound cholesterol 
and choline in LysM-Cre Pcyt1afl/fl animals in the fed state were equivalent to controls 
(Table 3-2). Overnight fasting elevated FFAs and reduced insulin to the same level in 
both genotypes (Table 3-2). Serum TGs and blood glucose levels were not affected by 
fasting or genotype after HFD (Table 3-2). 
 
Feeding state Random fed Fasted overnight 
Genotype Pcyt1afl/fl 
LysM-Cre 
Pcyt1afl/fl 
Pcyt1afl/fl 
LysM-Cre 
Pcyt1afl/fl 
Glucose (mM) 9.96 ± 0.64 9.87 ± 0.71 9.81 ± 0.50 9.40 ± 0.63 
Insulin (μg/L) 4.56 ± 1.70 12.99 ± 9.16 0.53 ± 0.13 0.57 ± 0.20 
FFA (mM) 0.83 ± 0.18 0.71 ± 0.07 1.05 ± 0.1 1.05 ± 0.05 
TG (mM) 1.40 ± 0.24 1.48 ± 0.28 1.50 ± 0.11 1.50 ± 0.14 
Total cholesterol (mM) 6.39 ± 0.28 6.63 ± 0.38 - - 
HDL cholesterol (mM) 3.05 ± 0.17 3.19 ± 0.12 - - 
LDL cholesterol (mM) 2.7 ± 0.19 2.77 ± 0.32 - - 
Total choline (μM) 59.94 ± 7.92 57.07 ± 2.73 - - 
Table 3-2. Serum biochemistry of HFD-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice 
on mixed genetic background in a random-fed state or after overnight fast.  
Concentrations of serum biochemicals are expressed as means ± SEM. N=7 Pcyt1afl/fl, 
n=6 LysM-Cre Pcyt1afl/fl 16-20-week-old male mice on mixed C57Bl/6J, 129/Sv 
background, fed a 45% kcal fat diet (D12451) from 8 weeks of age. 
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3.2.2.8 Macrophage-specific Pcyt1a deletion did not impact the glucose, insulin 
and lipid tolerance of HFD-fed mice on mixed genetic background 
Results. LysM-Cre Pcyt1afl/fl mice showed a similar serum glucose clearance rate as 
controls on HFD (Figure 3-22 A,B). No genotype-mediated effect on insulin-mediated 
circulating glucose uptake was observed in HFD-fed mice (Figure 3-22 C,D). Finally, 
HFD-fed LysM-Cre Pcyt1afl/fl mice had comparable serum TG concentration curves to 
controls following olive oil ingestion (Figure 3-22 E,F). 
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Figure 3-22. Glucose, insulin and lipid tolerance tests of HFD-fed Pcyt1afl/fl and 
LysM-Cre Pcyt1afl/fl mice on mixed genetic background.  
Blood glucose concentration curves (A) and AUC (B) of mice injected with 1 mg/kg 
glucose at T=0 min after an overnight fast. Blood glucose concentration curves (C) and 
AUC (D) of mice injected with 1 IU/kg insulin at T=0 after 6 h fast. Serum TG 
concentration curves (E) and AUC (F) of mice administered with 200 l of olive oil by 
oral gavage at T=0 after overnight fast. N=7 Pcyt1afl/fl (black lines/dots) and n=6 LysM-
Cre Pcyt1afl/fl (red lines/dots)16-19-week-old male mice on mixed C57Bl/6J, 129/Sv 
background, fed a 45% kcal fat diet (D12451) from 8 weeks of age. Statistical 
significance was assessed by student’s t-test (B, D, F). 
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3.2.2.9 Macrophage-specific Pcyt1a deletion had no effect on the metabolic 
tissue weights of HFD-fed mice on mixed genetic background 
Results. Genotype had no effect on body weight at the end of the study (Figure 3-23 
A). The weights of adipose tissue depots were unchanged in HFD-fed LysM-Cre 
Pcyt1afl/fl animals, when normalised to the total body weight and compared to controls 
(Figure 3-23 B-D). Liver to body weight ratio showed a high degree of variability after 
high-fat feeding, and was not different between genotypes (Figure 3-23 E). 
 
 
Figure 3-23. Tissue weights of HFD-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice 
on mixed genetic background.  
Body weight (A) and weights of BAT (B), scWAT (C), eWAT (D) and liver (E), 
expressed as a percentage of body weight of Pcyt1afl/fl (n=7, black dots) and LysM-
Cre Pcyt1afl/fl (n=6, red dots) 20-week-old male mice on mixed C57Bl/6J, 129/Sv 
background, fed a 45% kcal fat diet (D12451) from 8 weeks of age and culled in a 
random fed state. 
  
  138 
3.2.2.10 Macrophage-specific Pcyt1a deletion had no major effect on 
eWAT gene expression in chow-fed mice on mixed genetic background 
Method. At the end of study, eWATs from all mice were digested and ATMs were 
isolated using CD11b-positive purification. Gene expression in adipocytes, ATMs and 
the pool of remaining eWAT cells (CD11b-negative fraction) was compared between 
LysM-Cre Pcyt1afl/fl animals and controls.  
 
Results. As expected, presence of Cre recombinase in LysM allele reduced Pcyt1a 
expression by approximately 50% in ATMs, but not other eWAT cell types (Figure 3-24 
A). Genotype had no effect on the expression of genes encoding de novo PC 
biosynthesis enzymes CCT and PEMT, lipid metabolic enzyme LAL and lipid droplet-
associated protein ADRP in any eWAT cell fraction (Figure 3-24 A). As I have already 
observed in BMDMs, Pcyt1a gene deficiency increased ER stress-related transcription 
of Chop and decreased surface marker Cd206 gene expression in ATMs (Figure 3-24 
A,B). Besides increased Arg1 gene expression in the adipocyte and CD11b-negative 
fractions, genotype had no effect on the expression of measured immune system-
related genes (Figure 3-24 B). 
 
3.2.2.11 Macrophage-specific Pcyt1a deletion had no major effect on 
eWAT gene expression in HFD-fed mice on mixed genetic background 
Results. eWATs isolated from HFD-fed groups were analysed in the same manner as 
described in 3.2.2.10. Pcyt1a transcription was also reduced by approximately 50% in 
ATMs from LysM-Cre Pcyt1afl/fl mice compared to controls (Figure 3-25 A). eWAT 
adipocytes from LysM-Cre Pcyt1afl/fl animals exhibited elevated expression of genes 
Cd36 and Abca1, encoding enzymes involved in fatty acid transport and reverse 
cholesterol export (Figure 3-25 A). However, no other measured metabolic and 
immune system-related genes showed a genotype-mediated regulation in eWAT 
fractions on HFD (Figure 3-25 A,B). 
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Figure 3-24. Gene expression analysis of eWAT cell fractions isolated from 
chow-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice on mixed genetic background.  
mRNA levels (normalised to BestKeeper) of metabolic genes Pcyt1a, Pcyt1b, Pemt, 
Lipa, Adrp, Chop (A) and immune system genes Cd206, Cd11b, F4/80, Cd11c, Arg1, 
Mcp1, Il1b, Il6, Tnf (B) from adipocyte, Cd11b-positive and Cd11b-negative fractions 
of eWAT isolated from Pcyt1afl/fl (n=7, black bars) and LysM-Cre Pcyt1afl/fl (n=8, white 
bars) 20-week-old male mice on mixed C57Bl/6J, 129/Sv background culled in a 
random fed state. * p < 0.05 compared to Pcyt1afl/fl using student’s t-test. 
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Figure 3-25. Gene expression analysis of eWAT cell fractions isolated from HFD-
fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice on mixed genetic background.  
mRNA levels (normalised to BestKeeper) of metabolic genes Pcyt1a, Pcyt1b, Fabp4, 
Lipa, Adrp, Chop, Lpl, Cd36, Fatp1, Dgat1, Abca1, Abcg1 (A) and immune system 
genes Cd206, Cd11b, F4/80, Cd11c, Msr1, Il1b, Il6, Tnf (B) from adipocyte, Cd11b-
positive and Cd11b-negative fractions of eWAT isolated from Pcyt1afl/fl (n=7, black 
bars) and LysM-Cre Pcyt1afl/fl (n=6, white bars) 20-week-old male mice on mixed 
C57Bl/6J, 129/Sv background, fed a 45% kcal fat diet (D12451) from 8 weeks of age 
and culled in a random fed state. * p < 0.05 compared to Pcyt1afl/fl using student’s t-
test. 
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3.2.2.12 Macrophage-specific Pcyt1a deficiency resulted in a reduced 
hepatic gluconeogenic gene transcription in HFD-fed mice on mixed 
genetic background 
Rationale. To investigate genotype effects on HFD-induced hepatic insulin resistance 
and inflammation, livers isolated from HFD-fed mice were assessed for macrophage 
marker and insulin-regulated metabolic gene expression.  
 
Results. No differences were found between LysM-Cre Pcyt1afl/fl and control animals 
in hepatic mRNA levels of macrophage markers and insulin-regulated metabolic genes 
(Figure 3-26 A). However, while genotype had no effect on gluconeogenic gene 
expression in chow-fed mice, LysM-Cre Pcyt1afl/fl mice exhibited reductions in liver 
genes encoding gluconeogenic enzymes phosphoenolpyruvate carboxykinase (Pck1) 
and fructose-1,6- biphosphatase (Fbp1) after HFD compared to control mice (Figure 
3-26 A). 
 
3.2.2.13 Macrophage-specific Pcyt1a deficiency resulted in reduced 
hepatic lipid metabolism gene transcription in HFD-fed mice on mixed 
genetic background 
Rationale. Reduced transcriptional signature of gluconeogenesis in LysM-Cre 
Pcyt1afl/fl animals on HFD lead me to perform further hepatic gene expression analysis, 
focusing on lipid metabolism-related genes.  
 
Results. Out of all measured FFA metabolism genes, Dgat1 gene was reduced in 
LysM-Cre Pcyt1afl/fl animals compared to controls on HFD (Figure 3-27 A). Similarly, 
the expression of phospholipid metabolism-related genes Pcyt1a, Ptdss1 and Mat1a 
was lower in the livers of LysM-Cre Pcyt1afl/fl mice on HFD (Figure 3-27 C). Finally, I 
observed genotype-dependent alterations in the levels of genes related to lipoprotein 
metabolism both on chow and HFD. Transcripts for LPL and APOA1, the main protein 
component of HDL particle, were reduced, while gene encoding phospholipid transfer 
protein (PLTP), which catalyses the transfer of PC from circulating vLDL to HDL, was 
increased in LysM-Cre Pcyt1afl/fl animals on a chow diet (Figure 3-27 B). The levels of 
messages for angiopoietin-like 4 and lecithin-cholesterol acyltransferase (LCAT), 
enzyme mediating the formation of cholesterol esters from PC and free cholesterol, 
were lower in LysM-Cre Pcyt1afl/fl mice than in controls on HFD (Figure 3-27 B). 
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Figure 3-26. Insulin-regulated and immune system gene expression analysis of 
livers isolated from chow and HFD-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice on 
mixed genetic background.  
A. mRNA levels (normalised to BestKeeper) of immune system genes F4/80, Cd11b, 
Cd206 and insulin-regulated metabolic genes Elovl6, Scd1, Srebp1c, Fasn, Pgc1a in 
the livers isolated from Pcyt1afl/fl (n=7, dark grey bars) and LysM-Cre Pcyt1afl/fl (n=6, 
light grey bars) 20-week-old male mice on mixed C57Bl/6J, 129/Sv background, fed a 
45% kcal fat diet (D12451) from 8 weeks of age and culled in a random fed state. B. 
mRNA levels of insulin-regulated gluconeogenic genes Pck1, G6pc and Fbp1 in the 
livers isolated from Pcyt1afl/fl (n=7, black bars) and LysM-Cre Pcyt1afl/fl (n=8, white 
bars) chow-fed 20-week-old male mice on mixed C57Bl/6J, 129/Sv background, and 
of the same genotypes fed 45% kcal fat diet (D12451) from 8 weeks of age (as in A), 
culled in a random fed state. * p < 0.05 compared to Pcyt1afl/fl using student’s t-test. 
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Figure 3-27. Metabolic gene expression analysis of livers isolated from chow and 
HFD-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice on mixed genetic background.  
mRNA levels (normalised to BestKeeper) of fatty acid metabolism genes Fatp1, Fatp2, 
Fatp5, Cd36, Got2, Dgat1, Dgat2, Cpt1a (A), lipoprotein metabolism genes Apoa1, 
Lcat, Pltp, Lpl, Angptl4, Abca1, Abcg1, Srb1 (B) and phospholipid metabolism genes 
Pcyt1a, Pcyt2, Pemt, Pisd, Ptdss1, Ptdss2, Mat1a, Gnmt (C) in the livers isolated from 
chow-fed Pcyt1afl/fl (n=7, black bars), LysM-Cre Pcyt1afl/fl (n=8, white bars) and HFD-
fed Pcyt1afl/fl (n=7, dark grey bars), LysM-Cre Pcyt1afl/fl (n=6, light grey bars) 20-week-
old male mice on mixed C57Bl/6J, 129/Sv background, culled in a random fed state. 
HFD-fed group received 45% kcal fat diet (D12451) from 8 weeks of age. * p < 0.05 
compared to Pcyt1afl/fl using student’s t-test. 
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3.2.2.14 Macrophage-specific Pcyt1a deficiency had no effect on liver lipid 
and glycogen content in chow- or HFD-fed mice on mixed genetic 
background 
Results. In contrast to observed changes in hepatic gene transcription, I found no 
differences in hepatic lipid or glycogen content between LysM-Cre Pcyt1afl/fl and control 
animals on either chow or HFD (Figure 3-28 A,B). 
 
 
 
Figure 3-28. Hepatic lipid, glycogen and glucose levels in chow and HFD-fed 
Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice on mixed genetic background.  
A. Total lipid weight (as percentage of tissue weight) of the livers isolated from chow-
fed Pcyt1afl/fl (n=7, black dots), LysM-Cre Pcyt1afl/fl (n=8, red dots) and HFD-fed 
Pcyt1afl/fl (n=7, black dots), LysM-Cre Pcyt1afl/fl (n=6, red dots) 20-week-old male mice 
on mixed C57Bl/6J, 129/Sv background, culled in a random fed state. B. Glycogen and 
free glucose content of the livers isolated from HFD-fed Pcyt1afl/fl (n=7, black dots) and 
LysM-Cre Pcyt1afl/fl (n=6, red dots) 20-week-old male mice. HFD-fed group received 
45% kcal fat diet (D12451) from 8 weeks of age. 
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3.2.3 The importance of Pcyt1a in macrophages for glucose and lipid 
metabolism of lean and obese mice on a pure C57Bl/6J genetic 
background 
3.2.3.1 The rationale for the changes of experimental settings for in vivo 
metabolic phenotyping of LysM-Cre Pcyt1afl/fl mice on a pure C57Bl/6J 
genetic background 
As metabolic phenotypic of LysM-Cre Pcyt1afl/fl animals on C57Bl/6J genetic 
background was performed approximately 2 years after the results from the study on 
mixed genetic background were obtained, I decided to change a few experimental 
parameters, based on the initial results and published literature. 
 
Dietary treatments. The most significant alteration in the phenotyping protocol was a 
change from 45% to 60% kcal fat obesogenic diet. Performing an unbiased literature 
analysis on the diets used to induce obesity and insulin resistance in animal models 
with immune cell-specific genetic modifications revealed that the vast majority of 
publications used D12492 (Research Diets) 60% kcal fat diet in their experiments. I 
therefore decided to utilise the same diet type to allow higher reproducibility of my 
results, and to be able to compare my data with other published observations. 
 
As I did not observe any major effects of Pcyt1a deletion on ATM phenotype or WAT 
function on mixed genetic background, I decided to omit lipid tolerance test from the 
phenotyping protocol. Furthermore, instead of analysing each eWAT fraction 
individually, I measured gene transcription in whole eWAT. 
 
I also decided to exclude lipoprotein and choline measurements from the analysis of 
serum biochemicals, as they were not affected by genotype on mixed genetic 
background. Instead I chose to quantify circulating liver enzymes, alanine and 
aspartate aminotransferases (ALT and AST, respectively), as a proxy for HFD-induced 
liver damage. 
 
The remaining parameters remained as described in 3.2.2.1. 
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3.2.3.2 Macrophage-specific Pcyt1a deletion did not affect total energy balance 
of chow-fed mice on C57Bl/6J genetic background  
Results. Genotype had no effect on body weight at 16 weeks of age, when mice were 
analysed in metabolic cages (Figure 3-29 A). Chow consumption and average energy 
expenditure were similar between LysM-Cre Pcyt1afl/fl and control animals during 48 h 
of metabolic cage analysis (Figure 3-29 B,C). 
 
 
 
Figure 3-29. Food intake and energy expenditure of chow-fed Pcyt1afl/fl and 
LysM-Cre Pcyt1afl/fl mice on C57Bl/6J genetic background.  
Body weight (A), food intake (B) and average energy expenditure plotted against body 
weight assessed over 48 h in Pcyt1afl/fl (black dots, n=7) and Pcyt1afl/fl LysM-Cre (red 
dots, n=9) 16-week-old male mice on a pure C57Bl/6J background. Statistical 
significance was assessed by student’s t-test (A and B) or one-way ANCOVA (C).  
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3.2.3.3 Macrophage-specific Pcyt1a deletion did not affect serum metabolite 
concentrations of chow-fed mice on C57Bl/6J genetic background 
Results. Serum concentrations of insulin, TGs and liver enzymes were not different 
between LysM-Cre Pcyt1afl/fl mice and controls on chow diet (Table 3-3). Fasting 
potently supressed insulin levels in both genotypes (Table 3-3). Finally, genotype had 
no effect on the circulating levels of glucose and FFAs in either fed or fasted states 
(Table 3-3). 
 
 
Table 3-3. Serum biochemistry of chow-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl 
mice on C57Bl/6J genetic background in a random-fed state or after an overnight 
fast.  
Concentrations of serum biochemicals are expressed as means ± SEM. N=7 Pcyt1afl/fl, 
n=9 LysM-Cre Pcyt1afl/fl 16-19-week-old male mice on a pure C57Bl/6J background.   
 
  
Feeding state Random fed Fasted overnight 
Genotype Pcyt1afl/fl 
LysM-Cre 
Pcyt1afl/fl 
Pcyt1afl/fl 
LysM-Cre 
Pcyt1afl/fl 
Glucose (mM) 9.5 ± 0.44 10.47 ± 0.24 6.39 ± 0.35 5.8 ± 0.3 
Insulin (μg/L) 1.34 ± 0.22 1.37 ± 0.24 0.11 ± 0.01 0.14 ± 0.02 
FFA (mM) 1.34 ± 0.2 1.77 ± 0.12 1.06 ± 0.09 1.14 ± 0.09 
TG (mM) 2.26 ± 0.28 2.47 ± 0.17 - - 
ALT (U/L) 72.29 ± 33.62 48.56 ± 12.16 - - 
AST (U/L) 483.71 ± 301.51 339.67 ± 151.04 - - 
ALT/AST ratio 0.24 ± 0.04 0.28 ± 0.05 - - 
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3.2.3.4 Macrophage-specific Pcyt1a deletion did not impact glucose and insulin 
tolerance of chow-fed mice on C57Bl/6J genetic background 
Results. Following exogenous administration of glucose, chow-fed LysM-Cre Pcyt1afl/fl 
mice were able to normalise serum glucose concentration at the same rate as controls 
(Figure 3-30 A,B). There were no differences in insulin-mediated serum glucose uptake 
between genotypes (Figure 3-30 C,D). 
 
 
Figure 3-30. Glucose and insulin tolerance tests of chow-fed Pcyt1afl/fl and LysM-
Cre Pcyt1afl/fl mice on C57Bl/6J genetic background.  
Blood glucose concentration curves (A) and AUC (B) of mice injected with 1 mg/kg 
glucose at T=0 min after an overnight fast. Blood glucose concentration curves (C) and 
AUC (D) of mice injected with 0.75 IU/kg insulin at T=0 after 6 h fast. N=7 Pcyt1afl/fl 
(black lines/dots) and n=9 LysM-Cre Pcyt1afl/fl (red lines/dots)16-18-week-old male 
mice on a pure C57Bl/6J background. Statistical significance was assessed by 
student’s t-test (B, D). 
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3.2.3.5 Macrophage-specific Pcyt1a deletion did not affect the weights of 
metabolic tissues of chow-fed mice on C57Bl/6J genetic background 
Results. There were no genotype-dependent differences in total body weight, and 
BAT-, scWAT-, eWAT- and liver-to-body weight ratios between chow-fed LysM-Cre 
Pcyt1afl/fl and control mice in the fed state at the end of the study (Figure 3-31 A-E). 
However, there was a statistically significant outlier for the relative liver weight in the 
control group (Figure 3-31 E, 3.64% vs group average ± SEM of 5.04 ± 0.24%). As all 
the other measured parameters in the outlier mouse were within a normal range, it was 
not excluded from the analysis. 
 
 
Figure 3-31. Tissue weights of chow-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice 
on C57Bl/6J genetic background.  
Body weight (A) and weights of BAT (B), scWAT (C), eWAT (D) and liver (E), 
expressed as a percentage of body weight of Pcyt1afl/fl (n=7, black dots) and LysM-
Cre Pcyt1afl/fl (n=9, red dots) 20-week-old male mice on a pure C57Bl/6J background 
culled in a random fed state. Statistical significance was assessed by student’s t-test. 
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3.2.3.6 Macrophage-specific Pcyt1a deletion did not affect total energy balance 
of HFD-fed mice on C57Bl/6J genetic background  
Results. HFD-fed LysM-Cre Pcyt1afl/fl mice had similar body weights as controls at the 
start of metabolic cage analysis (Figure 3-29 A). No differences in food intake or 
average energy expenditure were observed between genotypes on HFD over 48 h of 
analysis (Figure 3-32 B,C). 
 
 
 
Figure 3-32. Food intake and energy expenditure of HFD-fed Pcyt1afl/fl and LysM-
Cre Pcyt1afl/fl mice on C57Bl/6J genetic background.  
Body weight (A), food intake (B) and average energy expenditure plotted against body 
weight assessed over 48 h in Pcyt1afl/fl (black dots, n=8) and Pcyt1afl/fl LysM-Cre (red 
dots, n=8) 16-week-old male mice on a pure C57Bl/6J background, fed a 60% kcal fat 
diet (D12492) from 8 weeks of age. Statistical significance was assessed by student’s 
t-test (A and B) or one-way ANCOVA (C).  
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3.2.3.7 Macrophage-specific Pcyt1a deletion had no effect on serum 
metabolite concentrations of HFD-fed mice on C57Bl/6J genetic 
background 
Results. Serum levels of glucose, insulin, FFAs, TGs and liver enzymes were not 
different in either fed or fasted states between genotypes on HFD (Table 3-4).  
 
 
Feeding state Random fed Fasted overnight 
Genotype Pcyt1afl/fl LysM-Cre Pcyt1afl/fl Pcyt1afl/fl 
LysM-Cre 
Pcyt1afl/fl 
Glucose (mM) 11.19 ± 0.24 11.6 ± 0.49 9.25 ± 0.25 8.76 ± 0.58 
Insulin (μg/L) 3.75 ± 0.72 3.45 ± 0.83 0.74 ± 0.18 0.57 ± 0.13 
FFA (mM) 1.07 ± 0.13 1.32 ± 0.04 1.62 ± 0.1 1.45 ± 0.07 
TG (mM) 1.53 ± 0.15 1.47 ± 0.05 - - 
ALT (U/L) 122.88 ± 38.07 107.71 ± 23.78 - - 
AST (U/L) 289.38 ± 86.75 455.86 ± 177.7 - - 
ALT/AST ratio 0.45 ± 0.07 0.41 ± 0.1 - - 
Table 3-4. Serum biochemistry of HFD-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice 
on C57Bl/6J genetic background in a random-fed state or after overnight fast.  
Concentrations of serum biochemicals are expressed as means ± SEM. N=8 Pcyt1afl/fl, 
n=8 LysM-Cre Pcyt1afl/fl 16-19-week-old male mice on a pure C57Bl/6J background, 
fed a 60% kcal fat diet (D12492) from 8 weeks of age. 
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3.2.3.8 Macrophage-specific Pcyt1a deletion did not impact the glucose and 
insulin tolerance of HFD-fed mice on C57Bl/6J genetic background 
Results. Both genotypes exhibited similar rates of blood glucose clearance following 
the administration of exogenous glucose (Figure 3-33 A,B). There were no differences 
in insulin-mediated serum glucose uptake between genotypes (Figure 3-33 C,D). 
 
 
Figure 3-33. Glucose and insulin tolerance tests of HFD-fed Pcyt1afl/fl and LysM-
Cre Pcyt1afl/fl mice on C57Bl/6J genetic background.  
Blood glucose concentration curves (A) and AUC (B) of mice injected with 1 mg/kg 
glucose at T=0 min after an overnight fast. Blood glucose concentration curves (C) and 
AUC (D) of mice injected with 1 IU/kg insulin at T=0 after 6 h fast. N=8 Pcyt1afl/fl (black 
lines/dots) and n=7-8 LysM-Cre Pcyt1afl/fl (red lines/dots)16-18-week-old male mice on 
a pure C57Bl/6J background, fed a 60% kcal fat diet (D12492) from 8 weeks of age. 
Statistical significance was assessed by student’s t-test (B, D). 
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3.2.3.9 Macrophage-specific Pcyt1a deletion did not affect the weights of 
metabolic tissues of HFD-fed mice on C57Bl/6J genetic background 
Results. The expression of Pcyt1a in macrophages did not affect the total body weight 
or the weight of BAT, scWAT, eWAT and liver, relative to total body weight on HFD at 
the end of the study (Figure 3-34 A-E). 
 
 
Figure 3-34. Tissue weights of HFD-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice 
on C57Bl/6J genetic background.  
Body weight (A) and weights of BAT (B), scWAT (C), eWAT (D) and liver (E), 
expressed as a percentage of body weight of Pcyt1afl/fl (n=8, black dots) and LysM-
Cre Pcyt1afl/fl (n=7, red dots) 20-week-old male mice on a pure C57Bl/6J background, 
fed a 60% kcal fat diet (D12492) from 8 weeks of age and culled in a random fed state. 
Statistical significance was assessed by student’s t-test. 
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3.2.3.10 Macrophage-specific Pcyt1a deletion had no effect on eWAT 
gene expression in chow- and HFD-fed mice on C57Bl/6J genetic 
background 
Results. No genotype-dependent differences were observed in either inflammatory or 
metabolic gene transcription in eWAT on chow or HFD (Figure 3-35 A,B). 
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3.2.3.11 Macrophage-specific Pcyt1a deficiency modestly reduced G6pc 
and Dgat1 gene transcription in HFD-fed mice on C57Bl/6J genetic 
background 
Results. The expression of hepatic inflammatory markers F4/80, Cd11b and Tnf was 
comparable between LysM-Cre Pcyt1afl/fl and controls on HFD (
 
Figure 3-36 A). Similar to the results obtained on mixed genetic background, the 
expression of gluconeogenic gene G6pc was lower in LysM-Cre Pcyt1afl/fl mice than in 
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control group on HFD, indicating a lower HGP rate (
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Figure 3-36 A). Finally, modest reduction in Dgat1 was observed in LysM-Cre Pcyt1afl/fl 
animals compared to controls on HFD (
 
Figure 3-36 B). 
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Figure 3-35. Immune system and metabolic gene expression analysis of eWATs 
isolated from chow and HFD-fed Pcyt1afl/fl and LysM-Cre Pcyt1afl/fl mice on 
C57Bl/6J genetic background.  
mRNA levels (normalised to BestKeeper) of immune system genes F4/80, Cd11b, 
Cd206, Mgl1, Cd11c, Tnf, Il1b, Il6, Mcp1 (A) and metabolic genes Glut4, Fasn, Lpl, 
Angptl4, Cd36, Pcyt1a (B) in the eWATs isolated from chow-fed Pcyt1afl/fl (n=7, black 
bars), LysM-Cre Pcyt1afl/fl (n=9, white bars) and HFD-fed Pcyt1afl/fl (n=8, dark grey 
bars), LysM-Cre Pcyt1afl/fl (n=7, light grey bars) 20-week-old male mice on a pure 
C57Bl/6J background, culled in a random fed state. HFD-fed group received 60% kcal 
fat diet (D12492) from 8 weeks of age. * p < 0.05 compared to Pcyt1afl/fl using student’s 
t-test. 
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Figure 3-36. Immune system, gluconeogenic and lipid metabolism gene 
expression analysis of livers isolated from chow and HFD-fed Pcyt1afl/fl and 
LysM-Cre Pcyt1afl/fl mice on C57Bl/6J genetic background. 
mRNA levels (normalised to BestKeeper) of immune system genes F4/80, Cd11b, Tnf, 
gluconeogenic genes Pck1, G6pc, Fbp1 (A) and lipid metabolism genes Fasn, Scd1, 
Adrp, Dgat1, Cd36, Pcyt1a, Mat1a (B) in the livers isolated from chow-fed Pcyt1afl/fl 
(n=7, black bars), LysM-Cre Pcyt1afl/fl (n=9, white bars) and HFD-fed Pcyt1afl/fl (n=8, 
dark grey bars), LysM-Cre Pcyt1afl/fl (n=7, light grey bars) 20-week-old male mice on a 
pure C57Bl/6J background, culled in a random fed state. HFD-fed group received 60% 
kcal fat diet (D12492) from 8 weeks of age. * p < 0.05 compared to Pcyt1afl/fl using 
student’s t-test. 
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3.2.4 The role of Pcyt1a in macrophages in mediating macrophage-to-liver 
PC transport 
3.2.4.1 Rationale for performing macrophage-to-liver PC transport assay using 
LysM-Cre Pcyt1afl/fl BMDMs 
Rationale. Because I observed a transcriptional signature that is suggestive of a 
modest improvement in hepatic metabolism in obese LysM-Cre Pcyt1afl/fl mice 
compared to controls without any major changes in eWAT or liver inflammation, I 
considered alternative ways that macrophages could affect hepatic metabolism.  
 
All tissue macrophages transiently accumulate high levels of cholesterol through 
phagocytosis of dead cells, which is then transported to the liver via HDL particles for 
disposal. While HDL is classically viewed as a cholesterol-carrying lipoprotein, it 
contains large amounts of phospholipid that is also internalised by the liver549. Recently 
it has been shown that HDL-bound PC delivered to the liver contribute to the hepatic 
PC and TG pools404. As PC is the main lipid species in HDL, and reverse cholesterol 
transport to a premature HDL particle increases de novo PC synthesis rate in 
macrophages550, I hypothesised that Pcyt1a-deficient macrophages might have an 
impaired PC transfer to APOA1 protein, thus decreased rate of HDL lipidation. LysM-
Cre Pcyt1afl/fl mice would consequently have a net reduction in PC delivery to the liver 
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that might result in a mild improvement in hepatic metabolism on HFD, supporting my 
data (Figure 3-27,  
Figure 3-36). This hypothesis was supported by disrupted hepatic expression of genes 
involved in lipoprotein metabolism in LysM-Cre Pcyt1afl/fl animals, namely Apoa1, 
which encodes the main protein component of HDL, and Lcat and Pltp, encoding 
enzymes responsible for PC transfer between lipoprotein particles (Figure 3-27 B).  
 
Method. In order to directly demonstrate decreased macrophage-to-liver PC transport 
in LysM-Cre Pcyt1afl/fl mice, I decided to establish a recently published assay that 
involves an intraperitoneal injection of 3H-PC-labelled macrophages into host mice and 
tracing the appearance of radiolabel in the serum and liver404.  
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3.2.4.2 Optimisation of PC radiolabelling and validation of donor BMDM 
phenotype for liver-to-macrophage PC transport assay 
Rationale and optimisation. As a uniform PC labelling between LysM-Cre Pcyt1afl/fl 
and control BMDMs was desired, I needed to take into account the difference in the 
rate of choline incorporation into the cellular PC fraction. Since de novo PC synthesis 
rate was approximately 50% lower in LysM-Cre Pcyt1afl/fl BMDMs than controls (Figure 
3-37 B), I considered increasing the specific activity of the medium used for labelling 
Pcyt1a-deficient cells by 50% to achieve the same radiolabel content in cells of both 
genotypes. Initially I validated that incorporation of labelled choline into the cells over 
24 h was directly proportional to its specific activity in the media (Figure 3-37 A). Based 
on the linear relationship between specific activity in the labelling media and radiolabel 
incorporation to cells, I decided to use a medium with the specific activity of 0.06 
MBq/ml to label controls, and of 0.12 MBq/ml to label LysM-Cre Pcyt1afl/fl BMDMs. 
Indeed, 24 h of incubation with indicated media resulted in cells of both genotypes 
having a specific activity of approximately 1 dpm/cell. 
 
Rationale. The expression of genes related to lipoprotein metabolism was analysed in 
cells that were used for macrophage-to-liver PC transport assay.  
 
Results. Pcyt1a expression was reduced by approximately 70% in LysM-Cre Pcyt1afl/fl 
BMDMs compared to controls (Figure 3-37 C). Transcript levels of Abca1 and Abcg1 
genes, which encode proteins regulating cholesterol and phospholipid efflux from cells 
to HDL particles, were similar in Pcyt1a-deficient and control macrophages (Figure 
3-37 C). Finally, the expression of genes encoding scavenger receptors that are 
involved in lipoprotein particle uptake was also influenced by genotype - LysM-Cre 
Pcyt1afl/fl BMDMs had higher levels of Cd36, but lower levels of Srb1 mRNA than 
controls (Figure 3-37 C). 
 
3.2.4.3 Pcyt1a gene deletion did not affect the rate of PC release from 
macrophages into serum  
Method. After 24 h of labelling, 2 millions of LysM-Cre Pcyt1afl/fl and control donor 
BMDMs having a specific activity of 1 dpm/cell were injected into host WT mice. Serum 
samples from host mice were then taken at 3.5, 7 and 24 h post injection. LDL and 
vLDL particles were subsequently removed from serum samples by chemical 
precipitation, and processed samples were fractionated to lipid and aqueous phases. 
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Radioactivity measured in the lipid fraction corresponded to HDL-bound PC, while 
aqueous phase contained radiolabelled free choline released from degradation of PC 
by phospholipases.  
 
 
Figure 3-37. Optimisation of PC radiolabelling, de novo PC biosynthesis and 
lipoprotein metabolism gene expression in BMDMs from donor Pcyt1afl/fl or 
LysM-Cre Pcyt1afl/fl mice.  
A. Specific activity of WT BMDMs (expressed per single cell) cultured in the presence 
of 0.05, 0.1 and 0.2 MBq/ml 3H-choline tracer for 24 h. B. Incorporation of 3H-choline 
tracer into cellular lipids of unstimulated BMDMs from Pcyt1afl/fl (black bars) and 
Pcyt1afl/fl LysM-Cre (white bars) mice over 3 h. C. mRNA levels (normalised to 
BestKeeper) of phospholipid and lipoprotein metabolism genes Pcyt1a, Abca1, Abcg1, 
Cd36, Srb1 in unstimulated BMDMs from Pcyt1afl/fl and Pcyt1afl/fl LysM-Cre mice on 
mixed C57Bl/6J, 129/Sv background. N=4 mice/group. * p < 0.05 compared to 
Pcyt1afl/fl using student’s t-test. 
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Results. Host mice injected with LysM-Cre Pcyt1afl/fl BMDMs displayed a comparable 
rate of radioactivity appearance in total serum to controls (Figure 3-38 A). Mice carrying 
LysM-Cre Pcyt1afl/fl BMDMs had slightly elevated radioactivity levels in the aqueous 
phase of the serum compared to controls at 24 h after injection (Figure 3-38 B). No 
differences in the rate of appearance of HDL-bound PC was observed between donor 
genotypes (Figure 3-38 C). 
 
 
 
Figure 3-38. Presence of 3H-choline tracer in the serum of mice after IP injection 
with 3H-PC-labelled BMDMs from donor Pcyt1afl/fl or LysM-Cre Pcyt1afl/fl mice.  
Host mice were injected with 106 BMDMs with a total specific activity of 106 dpm per 
mouse. Specific activity (expressed as percentage of injected dose) of total serum (A) 
and aqueous (B) and lipid (C) serum HDL fractions of WT 10-week-old female mice, 
3.5, 7 and 24 h after injection with 3H-PC-labelled BMDMs from donor Pcyt1afl/fl (black 
lines) and LysM-Cre Pcyt1afl/fl (red lines) 10-week-old female mice on mixed C57Bl/6J, 
129/Sv background. N=4 donor BMDM mice/group, n=8 host mice/group (BMDMs 
from a single donor were injected into two WT hosts). * p < 0.05 compared to Pcyt1afl/fl 
using 2-way ANOVA with Bonferroni’s multiple comparisons test. 
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3.2.4.4 Pcyt1a gene deletion did not affect the total PC delivery from 
macrophages into the liver 
Rationale. 24 h after injection, host mice were culled and radioactivity levels were 
measured in the liver, spleen, brain and BAT in order to assess the cumulative delivery 
of PC from macrophages during the assay.  
 
Results. No genotype-dependent differences in the radioactivity concentration or total 
tissue radioactivity levels were found in the liver, spleen or BAT between two groups 
(Figure 3-39 A,B). Host mice carrying LysM-Cre Pcyt1afl/fl BMDMs had a minor 
increase in radioactivity concentration and total radioactivity amount in the brain, 
compared to controls (Figure 3-39 A,B). 
 
 
Figure 3-39. Presence of 3H-choline tracer in the tissues of mice 24 h after IP 
injection with 3H-PC-labelled BMDMs from donor Pcyt1afl/fl or LysM-Cre Pcyt1afl/fl 
mice.  
Host mice were injected with 106 BMDMs with a total specific activity of 106 dpm per 
mouse. Liver, spleen, brain and BAT were isolated 24 h after injection, homogenised 
and specific activity (expressed as a percentage of injected dose) was quantified and 
expressed as the total tissue amount (A) or amount per g of tissue (B). N=4 donor 
Pcyt1afl/fl (black bars) and n= 4 donor LysM-Cre Pcyt1afl/fl (white bars) 10-week-old 
female mice on mixed C57Bl/6J, 129/Sv background, n=8 10-week-old female host 
mice/group (BMDMs from a single donor were injected into two WT hosts). * p < 0.05 
compared to Pcyt1afl/fl using student’s t-test. 
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3.3 Discussion 
This chapter describes how de novo PC biosynthesis in macrophages is linked to the 
development of ER stress and inflammation in response to saturated FFAs, and how 
it affects the metabolic health of a whole animal in lean and obese states. The study 
stemmed from the finding that de novo PC biosynthesis was increased in ATMs 
isolated from obese mice. The results obtained in this chapter were expected to 
expand the current view of how lipotoxicity leads to the inflammatory activation of 
ATMs during obesity. The main findings of this chapter were as follows: 
 
1) LPS and lipotoxic concentrations of palmitate increased de novo PC synthesis 
in BMDMs. 
 
2) Pcyt1a-deficient BMDMs had diminished inflammatory activation and ER 
stress after prolonged treatment with lipotoxic concentrations of palmitate. 
 
3) LysM-Cre Pcyt1afl/fl mice did not exhibit changes in WAT inflammation or 
systemic insulin sensitivity on chow or HFD, but demonstrated minor benefitial 
changes in hepatic gene expression on HFD. 
 
3.3.1 De novo PC synthesis was increased in ATMs from obese mice and 
BMDMs stimulated with LPS and palmitate  
While de novo PC synthesis in ATMs was not directly measured, I observed an 
increased Pcyt1a gene transcription and elevated PC:PE ratio in ATMs isolated from 
16-week-old ob/ob mice compared to WT controls, indicating increased de novo PC 
synthesis rate. In future, a more direct validation of this finding could be performed by 
isolating ATMs from lean and obese mice and incubating them in the presence of 
radiolabelled choline in order to assess the rate of choline incorporation into PC. 
However, a previous study linking increased PC levels to ER stress and insulin 
resistance in the liver during obesity was also conducted without directly assessing 
hepatic de novo PC synthesis rate and solely relied on gene transcription and lipidomic 
analyses226, suggesting that such parameters accurately reflect PC synthesis rate in 
vivo. 
 
Contrary to a previous published observation373, I found that LPS acutely increased de 
novo PC synthesis rate in macrophages. A difference in macrophage cell type 
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(thioglycolate-elicited peritoneal macrophages versus BMDMs) could potentially 
explain such discrepancy. Thioglycolate is known to induce inflammatory activation of 
peritoneal macrophages551, and could potentially increase basal PC synthesis rate 
even after elicitation and prolonged culturing. Observed induction of PC synthesis after 
LPS treatment might therefore be blunted in thioglycolate-elicited macrophages. 
 
In agreement with the previous study, I found that treating BMDMs with oleate 
increased de novo PC synthesis rate367. This was likely due to the oleate-induced lipid 
droplet formation and post-translational activation of CCT. Importantly, I was first to 
observe an increase in de novo PC biosynthesis rate following the stimulation of 
BMDMs with palmitate. However, the effect size of palmitate stimulation compared to 
LPS or equimolar concentration of oleate on the induction of PC synthesis was 
substantially smaller. As palmitate has been previously shown to signal via TLR4 
receptor552, but also to weakly induce lipid droplet formation, it is unclear which of the 
two mentioned processes is responsible for palmitate-mediated increase in de novo 
PC synthesis rate in BMDMs. In the future, this question could be addressed by utilising 
TLR4-knockout BMDMs, in which all direct signalling effects of palmitate should be 
lost, and any changes in de novo PC synthesis rate could be attributed to the 
intracellular metabolic processing of palmitate. Alternatively, WT BMDMs could be 
treated with palmitate in the presence of DGAT1 inhibitor in order to block lipid droplet 
formation. If the increase in de novo PC synthesis persisted in this setting, then it would 
be most likely driven by the inflammatory signalling of palmitate. 
 
3.3.2 Pcyt1a-deficient BMDMs did not exhibit impairments in 
differentiation, LPS signalling or palmitate incorporation to PC  
Unlike most studies that investigated the importance of a metabolic enzyme for 
macrophage polarisation, I did not profile the phenotype of LPS-treated macrophages, 
because it has already been partially addressed in a previous study373. As Pcyt1a-
deficient macrophages exhibited impaired Golgi-dependent secretion of inflammatory 
cytokines TNF and IL-6, their M1 phenotype after prolonged LPS stimulation would 
most likely be different due to a lack of autocrine signalling by mentioned cytokines, as 
it has been observed in LPS-stimulated TNF receptor-deficient macrophages553. While 
in our experiments I also measured Tnf gene expression as a readout for palmitate-
induced inflammation, published studies have observed that TNF secretion induced 
by LPS is around 100 times higher than by palmitate408. As macrophages from LysM-
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Cre Pcyt1afl/fl animals exhibited an approximately two-fold reduction in LPS-induced 
TNF secretion373, I think that the remaining capacity of de novo PC synthesis must 
be sufficient to release TNF from Pcyt1a-deficient macrophages in response to 
palmitate. 
 
Importantly, in agreement with a previous study, I found the differentiation of Pcyt1a-
deficient BMDMs to be intact373. It is also likely that the reduction in macrophage yield 
after differentiation is a compensatory mechanism for a reduced PC synthesis rate in 
LysM-Cre Pcyt1afl/fl BMDMs. Since disrupting PC formation by inhibiting fatty acid 
synthesis has been shown to impair BMDM differentiation370, it is unclear how Pcyt1a-
deficient macrophages can maintain the differentiation capacity of WT cells. A likely 
explanation is that remaining de novo PC synthesis rate is sufficient to provide enough 
PC for differentiating Pcyt1a-deficient BMDMs. In future, I will compare whole 
lipidomes of LysM-Cre Pcyt1afl/fl BMDMs and controls to further verify that Pcyt1a 
deficiency does not impair membrane phospholipid composition. 
 
Macrophages lacking FASN enzyme exhibit impaired LPS-induced JNK activation due 
to altered lipid composition of membrane microdomains408. Despite observing reduced 
fatty acid synthesis rate in Pcyt1a-deficient macrophages, I found their JNK 
phosphorylation to be intact after LPS stimulation. One likely explanation for this 
discrepancy is that Fasn knockout macrophages have a substantially greater reduction 
in fatty acid synthesis rate compared to Pcyt1a knockouts, therefore possess defective 
lipid rafts within plasma membranes. However, it is also possible that FASN-deficient 
macrophages do not differentiate appropriately, as described in a separate study370. 
Impaired differentiation could also explain reduced phospholipid levels in lipid rafts and 
decreased JNK phosphorylation after LPS stimulation, but surprisingly macrophage 
differentiation markers were not analysed in the study408. Another important thing to 
note is that I have not assessed the composition of lipid rafts in Pcyt1a knockout 
BMDMs. While my experiments and a published report373 indicate that TLR4 signalling 
is intact in Pcyt1a-deficient macrophages, in future, the lipid composition of membrane 
rafts can be directly measured using detergent-based isolation and LC-MS detection. 
Overall, Pcyt1a-deficient BMDMs had reduced fatty acid synthesis rate, but showed 
no impairments in JNK phosphorylation after LPS stimulation, indicating that reduced 
de novo PC biosynthesis did not affect TLR4-JNK signalling axis. 
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Contrary to a suggestion made by a recent study233, I did not find de novo PC synthesis 
to be responsible for palmitate incorporation into the PC fraction of lipids when 
macrophages were treated with high concentrations of palmitate. However, I did 
observe reduced palmitate incorporation into cellular lipids in LysM-Cre Pcyt1afl/fl 
BMDMs compared to controls in a basal state. Such discrepancy suggests a 
mechanism where de novo PC synthesis pathway in macrophages can utilise both 
endogenously and exogenously derived palmitate as a substrate in an unstimulated, 
homeostatic state. Once macrophages are exposed to atypically high palmitate 
concentrations, the Lands cycle most likely becomes responsible for rapid palmitate 
incorporation into PC fraction. The best studied LPCAT enzymes in macrophages are 
predominantly responsible for incorporating PUFAs into membrane PCs554. However, 
a potential Lands cycle enzyme mediating palmitate incorporation into membrane PCs 
in macrophages could be LPCAT1, which demonstrates a preference towards 
palmitoyl-CoA323. Cells lacking Lpcat1 exhibit augmented apoptosis in response to 
high extracellular PUFA concentrations, due to the inability to maintain appropriate 
levels of membrane saturation555. Whether Lpcat1-deficient BMDMs are protected 
against palmitate-induced ER stress and inflammation could be investigated in future. 
 
3.3.3 The relationship between cellular PC levels and FFA remodelling 
capacity and inflammation in palmitate-treated macrophages 
The most striking findings obtained in the first part of this chapter are reduced ER 
stress, cell death and inflammation and greater expression of SREBP1-regulated fatty 
acid remodelling genes in LysM-Cre Pcyt1afl/fl BMDMs compared to controls after 
prolonged incubation with palmitate. Induction of SREBP1-dependent gene 
transcription has been previously shown to have anti-inflammatory effects219,220, 
therefore it is a likely mechanism that limits palmitate-induced inflammation in Pcyt1a-
deficient macrophages. Alternatively, ER stress induced by prolonged palmitate 
treatment could indirectly cause inflammation by promoting cell death. Indeed, LysM-
Cre Pcyt1afl/fl BMDMs exhibit reduced cell death and inflammation in response to 
cytotoxic doses of palmitate. While it would be of interest to know whether palmitate-
induced ER stress is directly coupled to pro-inflammatory signalling pathways, or 
promote inflammation indirectly by causing cell death, the important fact is that 
functionally Pcyt1a-deficient macrophages have reduced inflammatory activation in 
response to palmitate. 
 
  171 
The observed decrease in SREBP1 target genes following prolonged treatment with 
palmitate is in line with current literature, which suggests that ER membrane saturation 
inhibits SREBP1 cleavage and activation556. However, LysM-Cre Pcyt1afl/fl BMDMs are 
likely to demonstrate reduced SREBP1 inhibition via an alternative mechanism, 
involving the sensing of low PC levels within the ER401,402. It has been already 
described that while their basal PC concentration is normal, Pcyt1a-deficient 
macrophages are incapable of maintaining appropriate PC levels after prolonged 
treatment with LPS, when the demand for de novo PC biosynthesis is high373 (Figure 
3-40). A likely hypothesis is that prolonged treatment with palmitate would also 
decrease PC levels in LysM-Cre Pcyt1afl/fl BMDMs compared to controls, and 
thus lead to increased SREBP1 activation and diminished ER stress, cell death 
and inflammation compared to control cells. However, three key experiments will 
be performed using Pcyt1a-deficient BMDMs and controls to further prove this 
hypothesis in future: 
 
a) Cellular PC levels after prolonged treatment with palmitate will be quantified by 
lipidomic analysis. 
b) SREBP1 activation after prolonged treatment with palmitate will be measured 
by Western blot. 
c) Palmitate remodelling and overall fatty acid desaturation in response to 
prolonged treatment with palmitate will be assessed by lipidomic analysis. 
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Figure 3-40. Reduced PC levels in Pcyt1a-deficient macrophages after prolonged 
LPS stimulation. 
Control (white) and LysM-Cre Pcyt1afl/fl (black) thioglycolate-elicited peritoneal 
macrophages were incubated with 10 ng/ml LPS or without LPS for 18 h, and total 
lipids were extracted. PC was isolated by thin layer chromatography and quantified by 
flame ionization. Values were normalized to cell numbers. Data are the mean of 
determinations from at least two individual mice of each genotype. Error bars indicate 
mean ± SEM. *, P < 0.05 using 2-way ANOVA. Graph is presented as published by 
Tian et al373. 
 
 
If the results obtained from the suggested experiments were in line with proposed 
hypothesis, it would indicate a mechanism where the capacity of a macrophage to 
maintain its PC levels in response to high saturated FFA concentrations is 
detrimental, resulting in reduced FFA remodelling activity and increased ER 
stress, cell death and inflammation (Figure 3-41). Importantly, such model would be 
in line with the phenotype of ATMs isolated from WT and ob/ob animals at 5 and 16 
weeks of age, where de novo PC synthesis is inversely related to M2 polarisation 
and FFA remodelling gene transcription (Error! Reference source not found.). 
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Figure 3-41. Schematic representation of a potential mechanism mediating 
reduced ER stress and inflammation observed in CCT-deficient BMDMs after 
prolonged treatment with palmitate. 
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3.3.4 Macrophage-specific Pcyt1a deficiency did not alter WAT 
inflammation and systemic insulin sensitivity in lean or obese 
mice 
Despite reducing ER stress and inflammatory activation in response to palmitate in 
vitro, macrophage-specific Pcyt1a deletion did not affect the inflammatory profile of 
eWAT during obesity in vivo. There are other examples in the literature in which 
genetically modified macrophages exhibit altered inflammatory profile in vitro, but 
genetic manipulation of macrophages in vivo does not affect WAT inflammation during 
obesity557,558. Owing to the complexity of pathophysiological mechanisms occurring 
during obesity, it is difficult to pinpoint a reason for such discrepancy between the 
behaviour of macrophages in the cell culture and adipose tissue. However, unaltered 
development of WAT inflammation in LysM-Cre Pcyt1afl/fl animals can be attributed to: 
 
a) Incomplete deletion of Pcyt1a gene in the ATM population by CRE 
recombinase. I observed approximately 50% reduction in Pcyt1a mRNA levels 
in ATMs isolated from in LysM-Cre Pcyt1afl/fl mice on a mixed genetic 
background. As described by a previous publication373, such reduction most 
likely indicates a presence of a mixed population, where one half of total cells 
express normal levels of Pcyt1a gene, and the other half lacks Pcyt1a transcript 
entirely. It is therefore plausible that having a functional anti-inflammatory 
mechanism in only half of the ATM population is insufficient to prevent the 
development of WAT inflammation. Pcyt1a deletion efficiency in ATMs might be 
improved by expressing CRE recombinase under a different promoter, such as 
Csf1r or Cd11b, instead of Lysm. Alternatively, LysM-Cre Pcyt1afl/fl mice could 
be further crossed to Pcyt1a+/- line330, and all in vivo experiments could be 
performed on Pcyt1a+/- background to further reduce Pcyt1a gene expression. 
 
b) Differences in eWAT inflammation induced by HFD and ob/ob genetic 
background. I observed increased Pcyt1a transcription and elevated PC:PE 
levels in ob/ob ATMs compared to WT controls at 16 weeks of age. However, 
metabolic studies in this chapter were performed using a mouse model of HFD-
induced obesity. There are multiple differences between genetically and diet-
induced obese animal models, including their daily caloric intake, nutritional 
composition of food and endogenous effects of leptin. Importantly, the majority 
of fatty acyl chains in WAT isolated from of ob/ob mouse are derived from the 
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DNL, while HFD decrease DNL in WAT and promote the storage of dietary 
FFAs. As lipids within eWAT are hypothesised to trigger ATM inflammatory 
activation, the FFA composition of adipocytes is a likely determinant of the 
development of WAT inflammation. It is therefore plausible that the rate of de 
novo PC biosynthesis in ATMs is only increased in response to DNL-derived, 
and not dietary lipids. In future, I will analyse the total lipidome of ATMs isolated 
from mice after prolonged high-fat feeding to assess if their PC:PE ratio is 
increased compared to chow-fed controls. I will also transplant the bone marrow 
of LysM-Cre Pcyt1afl/fl and control mice into ob/ob hosts to re-create the 
conditions under which elevated PC:PE ratio in ATMs was originally observed, 
in order to test whether Pcyt1a-deficient bone marrow could improve the 
metabolic profile of ob/ob animals. 
 
c) Poor in vivo translatability of findings observed in BMDMs treated with 
palmitate. Despite being frequently utilised in the literature, the treatment of 
macrophages with high concentrations of palmitate in the absence of other 
FFAs does not fully reflect pathophysiological mechanisms occurring in WAT 
during obesity. Prolonged high-fat feeding results in elongation and 
desaturation of the fatty acyl chains in WAT559, therefore ATMs are exposed to 
a mixture of FFAs that are predominantly unsaturated. It has been shown that 
even low doses of oleate can completely ablate the effects of palmitate on ER 
stress and inflammation in vitro233. Furthermore, treating macrophages with 
FFA mixture that resembles WAT fatty acyl composition does not induce ER 
stress and inflammation136. At present, it is not clear how complex FFA mixtures 
affect macrophages, but it is possible that the protective effect of reduced rate 
of PC synthesis only occurs in response to treatment with saturated FFAs. 
However, such question will not be answered until lipid-mediated ER stress and 
inflammation can be modelled in vitro in a physiological manner. 
 
3.3.5 Macrophage-specific Pcyt1a deficiency modestly improved liver 
metabolic gene transcription during obesity 
Despite not having any effect on WAT inflammation and systemic insulin sensitivity, 
Pcyt1a deletion in macrophages had a favourable outcome on liver metabolic gene 
transcription after high fat feeding on two different genetic backgrounds. There was a 
genetic background-dependent effect - LysM-Cre Pcyt1afl/fl mice on mixed genetic 
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background exhibited a more pronounced down-regulation of hepatic genes related to 
gluconeogenesis and lipid metabolism on HFD compared to the same line on C57Bl/6J 
genetic background. A stronger impact on metabolic gene transcription on mixed 
genetic background could be attributed to a higher deletion efficiency of Pcyt1a gene 
(approximately 70% reduction of Pcyt1a mRNA in BMDMs on mixed genetic 
background vs 50% reduction on C57Bl/6J background). 
 
The effect size of observed changes in hepatic gene expression between LysM-Cre 
Pcyt1afl/fl and control animals is marginal. This is a likely reason why measured 
alterations in gene expression did not translate into changes in hepatic lipid content or 
have any effect on systemic glucose metabolism. An important thing to note is that I 
have investigated a macrophage-specific knockout mouse model, thus the impact on 
the whole body metabolism was expected to be lower compared to global gene 
knockout models.  Furthermore, the deletion efficiency of Pcyt1a in ATMs was only 
around 50%, therefore the observed effect sizes likely underestimate the full biological 
importance of de novo PC biosynthesis in macrophages in regulating hepatic gene 
transcription during obesity. 
 
As gluconeogenesis and FFA uptake are generally increased in the liver during fasting, 
hepatic mRNA measurements indicate that Pcyt1a in macrophages might play a role 
after high-fat feeding in the fasted state. As summarised in the introduction, ATMs 
accumulate lipids after prolonged fasting. Perhaps such lipid accumulation, combined 
with inflammatory milieu of eWAT during HFD, is sufficient to transiently create 
pathophysiological conditions where reduced rate of de novo PC synthesis provides a 
favourable ATM inflammatory profile. Unfortunately, I did not have tissues from HFD-
fed LysM-Cre Pcyt1afl/fl mice in the fasted state to assess WAT inflammation, which I 
will perform in future. Furthermore, I will perform hyperinsulinemic-euglycemic clamp 
analysis of HFD-fed mice lacking Pcyt1a in macrophages in the fasted state to 
accurately assess hepatic glucose production. 
 
Alternatively, there might be other ways through which macrophages influence hepatic 
gene transcription during obesity. Even though lack of Pcyt1a in macrophages had no 
effect on liver inflammation after high-fat feeding on both genetic backgrounds, I cannot 
fully rule out Kupffer cells as mediators of the phenotypic differences between LysM-
Cre Pcyt1afl/fl and control mice. In future, I am planning to isolate Kupffer cells from 
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HFD-fed mice to compare their transcriptomes and lipidomes to controls from chow-
fed animals. If they show any obesity-induced changes in PC metabolism, I will isolate 
Kupffer cells from LysM-Cre Pcyt1afl/fl mice after high-fat feeding to analyse their 
inflammatory and metabolic profile. 
 
Finally, hepatic gene transcription indicated altered lipoprotein metabolism in LysM-
Cre Pcyt1afl/fl animals. While they exhibited normal total, LDL- and HDL-bound serum 
cholesterol levels, it is plausible that the size or shape of their HDL particles was 
altered, leading to impaired reverse cholesterol transport. However, the results from 
our established in vivo assay did not suggest any genotype-dependent changes in 
macrophage-to-liver PC transport via HDL. One major issue with measuring PC 
transport to the liver is PC labelling – 3H-choline, which I utilised in the assay, can be 
removed from PC by phospholipases and enter the circulation in its free form. This 
does not occur when macrophage-to-liver cholesterol transport is investigated, as mice 
and humans do not break down 14C-cholesterol but excrete it. Based on the serum 
tracer levels, 3H-choline predominantly appeared in the lipid phase at 3.5 and 7 h post 
injection, but there was no further elevation in the radioactivity concentration in lipid 
fraction from 7 to 24 h after injection, suggesting that any potential changes in serum 
or tissue tracer levels after 7 h are due to circulating free choline. Higher radioactivity 
levels in the serum and brain of mice 24 h after the injection with Pcyt1a-deficient 
BMDMs than controls could simply indicate increased free choline content of LysM-
Cre Pcyt1afl/fl macrophages. Overall, this assay could be improved by culling animals 
7 h after injection, when the 3H-choline is delivered to tissues predominantly as HDL-
bound PC. However, since I did not observe any differences in HDL-3H-PC 
appearance in serum between mice injected with LysM-Cre Pcyt1afl/fl or control 
BMDMs, it is likely that macrophage-to-liver PC transport is not responsible for 
changes in hepatic gene transcription in this model. 
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3.3.6 Conclusions 
In this chapter, I found that de novo PC synthesis was increased in ATMs isolated from 
obese mice and in BMDMs treated with saturated fatty acid palmitate. Lack of a rate-
limiting enzyme in de novo PC synthesis pathway, CCT, diminished palmitate-
induced ER stress and inflammation in BMDMs by up-regulating SREBP1-dependent 
fatty acid remodelling gene transcription. Mice lacking Pcyt1a in macrophages did not 
exhibit any changes in WAT inflammation and function in lean and obese states, but 
had a hepatic transcriptional signature indicative of mildly improved glucose and lipid 
metabolism after high-fat feeding. Further experiments are required to validate a 
proposed anti-inflammatory mechanism in Pcyt1a-deficient BMDMs in vitro, and to 
understand the relationship between de novo PC synthesis in macrophages and the 
regulation of hepatic gene transcription in vivo. 
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4 The role of 2-adrenergic receptor in the regulation of 
adipose tissue macrophage function  
4.1 Introduction 
4.1.1 Early insights leading up to the project: -adrenergic receptor 
activation in macrophages reduced their lipolysis rate 
At the start of my degree, the paradigm of nerve-immune interactions had already been 
established, but there were no reports on the communication between SNS and 
macrophages within adipose tissues. Therefore, little preliminary data was available in 
the literature when I initiated this project in the first year of my degree. 
 
My interest in macrophage 2AR was sparked from the insights obtained during the 
optimisation of a lipolysis assay in BMDMs. Lipolysis assays are routinely performed 
in our institute and involve culturing adipocytes with radiolabelled oleate overnight, 
then washing cells and incubating them in the fresh medium. The appearance of a 
radioactive tracer in the medium in an unstimulated state is a readout for basal lipolysis, 
and on-demand lipolysis is assessed by stimulating adipocytes with PKA activators 
immediately after the medium change. Surprisingly, during the initial assay 
optimization I found that forskolin, which promotes cAMP production by increasing 
adenylyl cyclase activity, suppressed the rate of oleate release from BMDMs (data not 
shown). In order to understand the mechanism for forskolin-mediated lipolysis 
suppression, I stimulated macrophages with insulin, which inhibits lipolysis in 
adipocytes, and forskolin, isoprenaline and CL-316,243, all of which promote on-
demand adipocyte lipolysis by activating PKA. Quantification of the amount of oleate 
released in 4 h showed that isoprenaline reduced the rate of lipolysis in BMDMs, while 
other stimuli did not show an effect compared to unstimulated cells  (Figure 4-1 A). I 
confirmed this finding by performing a dose-response experiment, which revealed that 
isoprenaline already suppressed FFA release in BMDMs at 10 nM (Figure 4-1 B). 
Therefore, my initial results revealed that activating -adrenergic receptors in 
macrophages reduced their lipolysis rate. 
 
  180 
 
Figure 4-1. The effect of PKA activity modulators on the lipolysis rate in BMDMs. 
Oleate release into the medium by BMDMs (pre-loaded with 250 M oleate in the 
presence of 14C-oleate tracer for 16 h) during 4 h post stimulation with (A) 100 nM 
insulin, 10 M forskolin, 100 nM isoprenaline or 10 M CL-316,243, or (B) indicated 
concentrations of isoprenaline. Lipolysis rate is expressed as specific activity of the 
medium of treated cells relative to untreated controls. N=4 mice/experiment. * p < 0.05 
compared to control using one-way ANOVA with Bonferroni’s multiple comparisons 
test.  
 
On the basis of this observation, together with the evidence that prolonged fasting 
leads to adipocyte lipolysis and lipid accumulation in ATMs135,136 and given the fact 
that a mechanistic basis for such opposing effect has not yet been addressed, I 
hypothesised that NE released from nerve endings in WAT may play a dual role by 
activating lipolysis in adipocytes and inhibiting lipid release in ATMs. Therefore, I 
decided to gather more preliminary data that could justify studying the importance of 
-adrenergic receptors in the regulation of ATM lipid metabolism. 
 
4.1.2 Acquisition of preliminary data 
4.1.2.1 2AR activation increased TG storage in BMDMs 
I initially sought to understand which isoform of -adrenergic receptors may be the 
target of isoprenaline in BMDMs. Gene expression analysis revealed that Adrb2 gene 
was transcribed, while Adrb1 and Adrb3 mRNA (encoding 1AR and 3AR, 
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respectively) could not be detected in BMDMs, suggesting that isoprenaline acted on 
2AR.  
 
In order to simulate a fasted state-like environment of ATMs, I treated BMDMs with NE 
for 10 min before placing them in the presence of 250 M 13C-oleate. The amount of 
exogenous oleate in the neutral lipid fraction of unstimulated cells was comparable 
between incubations lasting 8 and 24 h, suggesting that during initial 8 h of treatment 
BMDMs reached their limit of oleate storage within macrophage lipid droplets and did 
not further expand their TG pool (Figure 4-2). Interestingly, when macrophages were 
stimulated with NE, the amount of exogenous oleate was increased 2-fold after 8 h, 
and 3-fold after 24 h of incubation, indicating that NE enhanced TG storage capacity 
in BMDMs (Figure 4-2). Importantly, this stimulatory effect of NE was lost in the 
presence of 2AR-specific antagonist ICI-118,511, suggesting that NE modulated TG 
metabolism in BMDMs via its action on 2AR (Figure 4-2). 
 
 
Figure 4-2. The effect of 2AR stimulation on the TG storage capacity in BMDMs. 
GC-MS quantification of 13C-oleate in the neutral lipid fraction of BMDMs stimulated 
with 1 M NE (white bars) or with 1 M NE and 1 M ICI-118,511 (grey bars) for 10 
min and then treated with 250 M 13C-oleate for 8 and 24 h. Values are normalised to 
the 13C-oleate amount in the neutral lipid fraction of unstimulated cells (black bars) 
after 8 h of oleate loading. N=4 mice. * p < 0.05 compared to control at each time point 
using two-way ANOVA with Bonferroni’s multiple comparisons test. 
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4.1.2.2 Macrophage-activating stimuli down-regulated Adrb2 gene expression 
in BMDMs 
Next, I have investigated how different stimuli affected Adrb2 gene expression in 
BMDMs. 1 h NE treatment reduced Adrb2 mRNA levels in BMDMs, indicating a 
negative feedback on the receptor gene transcription upon its stimulation (Figure 4-3 
A). This finding suggested that any potential reductions in Adrb2 transcript observed 
in vivo might reflect elevated 2AR agonism at the time of sacrifice.  
 
 
Figure 4-3. Regulation of Adrb2 gene transcription by NE, LPS, IL-4 and palmitate 
in BMDMs. 
Adrb2 mRNA levels (normalised to BestKeeper) in BMDMs treated with (A) 1 M NE 
for 1 h, with (B) 100 ng/ml LPS or 10 M IL-4 for 24 h, or with (C) 250 M palmitate for 
indicated periods of time. N=4 mice/experiment. * p < 0.05 compared to 0 h using (A) 
student’s t-test or (B, C) one-way ANOVA with Bonferroni’s multiple comparisons test. 
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Prolonged treatment with LPS and IL-4 potently decreased Adrb2 transcription in 
BMDMs (Figure 4-3 B). High dose of palmitate also reduced Adrb2 transcript levels in 
a time-dependent manner (Figure 4-3 C). Overall, regardless of its inflammatory 
nature, macrophage activation suppressed Adrb2 gene transcription. 
 
4.1.2.3 Characterisation of Adrb2 gene expression in macrophages in vivo 
In order to characterise the expression of Adrb2 in different tissue macrophages, I 
isolated macrophages from lung, peritoneum, adipose tissues and liver, and included 
BMDMs for relative comparison. Compared to BMDMs, alveolar and peritoneal 
macrophages, ATMs and liver CD11b-positive cells showed higher Adrb2 mRNA 
levels (Figure 4-4 A). Furthermore, as recently reported459, Adrb2 gene expression 
was enriched in the ATM fraction within eWAT (Figure 4-4 B). 
 
 
Figure 4-4. Adrb2 gene expression in tissue macrophages and eWAT cellular 
fractions. 
Adrb2 mRNA levels (normalised to BestKeeper) in (A) macrophages isolated from 
indicated tissues and BMDMs, or in (B) adipocyte, Cd11b-negative and Cd11b-positive 
eWAT cellular fractions. All macrophages in (A) were isolated from the same mice (8-
week-old males, n=3, C57Bl/6J genetic background), with the exception of liver 
macrophages, which were isolated from separate age-, sex- and genetic background-
matched animals (n=3). eWATs in (B) were isolated from 16-week-old males of 
C57Bl6/J genetic background (n=8). Statistical differences were not assessed. 
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Next, I investigated whether 24 h of fasting could induce lipid accumulation in eWAT 
ATMs, as previously described135,136. Indeed, ATMs isolated from eWATs of fasted 
mice showed increased Adrp (also known as Plin2) mRNA levels compared to eWAT 
macrophages from fed mice, indicating increased amount of lipid droplets (Figure 4-5 
A). However, fasting did not modulate Adrb2 gene expression in ATMs (Figure 4-5 B). 
 
 
 
Figure 4-5. Adrp and Adrb2 gene expression in ATMs in fed and fasted states. 
(A) Adrp (Plin2) and (B) Adrb2 mRNA levels (normalised to BestKeeper) in eWAT 
Cd11b-positive cells isolated from mice in a fed state or after 24 h of fasting. N=3 8-
week-old C57Bl/6J males/condition. * p < 0.05 between two conditions using student’s 
t-test. 
 
WAT function depends on the time of the day, where lipid storage predominates in the 
active phase and lipolysis - in the resting phase of the day. I therefore hypothesised 
that ATMs could be subjected to regular short periods of fasting-induced lipolysis every 
day. In order to validate this, I isolated scWAT cellular fractions at three distinct times 
of day. 9 am (3 h after lights on or zeitgeber time (ZT) 3) corresponded to an early 
period of resting phase, 3 pm (ZT 9) – to a late period of resting phase and 9 pm (ZT15) 
– to an early period of active phase. Increased SNS output to scWAT promotes its 
browning, which can be used as a molecular readout for local sympathetic nerve firing. 
As Ucp1 mRNA in adipocytes is elevated upon NE stimulation560, Ucp1 gene 
expression in the adipocyte fraction can be used as a proxy for SNS activity in scWAT 
at the time of sacrifice.  
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Ucp1 and Adrb3 genes showed highest levels of expression in the adipocytes at ZT3, 
indicating an elevated SNS output to scWAT during early period of resting phase 
(Figure 4-6 B). Interestingly, mRNA levels of Adrp and Dgat1 were also increased at 
ZT3 in CD11b-positive cell fraction, suggesting that ATMs responded to enhanced 
local SNS activity by increasing their TG storage (Figure 4-6 A). Of relevance, Adrb2 
transcription in ATMs demonstrated an opposite regulation to Ucp1 gene expression 
in adipocytes (Figure 4-6), indicating an activation-induced negative feedback on 
receptor gene transcription, as observed in BMDMs after the treatment with NE (Figure 
4-3 A). Overall, Adrb2 mRNA in ATMs was regulated by feeding-fasting status of 
the animal, with the Adrb2 transcript levels in the ATM fraction inversely 
correlating with the SNS output to scWAT. 
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Figure 4-6. Time of day-dependent regulation of adrenergic and lipid metabolism 
gene transcription in ATMs and adipocytes. 
(A) Adrp, Adrb2, Maoa and Dgat1 mRNA levels (normalised to BestKeeper) in Cd11b-
positive cell fraction, and (B) Adrb3 and Ucp1 mRNA levels (normalised to 
BestKeeper) in adipocyte fraction of scWATs isolated from mice at 9 am (ZT3), 3 pm 
(ZT9) and 9 pm (ZT15). Isolations were performed in two batches, with all time points 
in a single batch acquired on the same day. N=8 (two batches of 4) 8-week-old males 
of C57Bl/6J genetic background/time-point. All presented genes are significantly 
different (p < 0.05) for time variable when assessed by one-way ANOVA with 
Bonferroni’s multiple comparisons test, with the exception of Maoa, where p=0.08. 
 
 
Chronic obesity is known to elevate peripheral SNS tone561. However, on-demand 
lipolysis in obese animals is supressed, in part due to adipocyte -adrenergic receptor 
desensitisation562. Obesity has been previously shown to down-regulate Adrb2 gene 
expression in ATMs459. In line with a published report459, I found that prolonged high-
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fat feeding increased pro-inflammatory cytokine Tnf and reduced M2 polarisation 
marker and Adrb2 gene expression in macrophages isolated from eWAT (Figure 4-7). 
While it was not clear whether decreased Adrb2 levels in ATMs during obesity are due 
to activation-induced receptor desensitisation, reduced 2AR-positive macrophage 
population or other unknown mechanisms, this finding indicated that 2AR signalling 
in ATMs was affected by high-fat diet-induced obesity. 
 
 
Figure 4-7. Expression of Adrb2 and macrophage polarisation marker genes in 
mice fed HFD for 1, 3 or 6 months. 
The expression of M2 macrophage marker (Cd206, Mgl1), M1 macrophage marker 
(Tnf) and Adrb2 genes (normalised to BestKeeper) in Cd11b-positive cell fraction of 
eWATs isolated from mice fed 45% kcal fat HFD (white bars) for 1, 3 or 6 months and 
from age-matched chow-fed controls (black bars). HFD was administered to mice from 
weaning. All mice were males of C57Bl/6J genetic background. N=4 (1 month chow), 
n=2 (1 month HFD), n=4 (3 months chow), n=5 (3 months HFD), n=2 (6 months chow), 
n=7 (6 months HFD). * p < 0.05 compared to chow-fed control at each time-point using 
two-way ANOVA with Bonferroni’s multiple comparisons test. Tissue collections, cell 
isolations and RNA purifications were performed by a PhD student Crystal Mok. 
  188 
4.1.3 Research questions and aims 
Overall, my preliminary data showed that macrophages isolated from WAT expressed 
high levels of Adrb2 gene. Together with recent studies reporting a presence of 
sympathetic nerve-associated macrophages (SAMs) in BAT425 and WAT424,439, these 
findings suggested that the activity of 2AR-positive macrophages in a close proximity 
to sympathetic nerves within adipose tissues could be directly influenced by changes 
in the local sympathetic tone, similarly to intestinal macrophages438. The regulation of 
Adrb2 expression in ATMs in a physiological and pathophysiological manner indicated 
that 2AR signalling could directly modulate ATM function in vivo. Furthermore, 
chemokine receptor property of 2AR469,470 might be important for an appropriate 
localisation of SAMs to their neighbouring nerve fibres. 
 
Despite extensive characterisation of changes in ATM lipid metabolism during obesity, 
physiological cues regulating macrophage lipid metabolism remain largely unknown. 
My preliminary results suggested that NE might regulate TG storage in ATMs in a 
physiological manner. In line with my findings, large scale gene transcription analysis 
from a recent report424 showed that SAMs located in scWAT had higher expression 
levels of genes encoding TG-synthesising enzymes Dgat1 and Dgat2 than other 
analysed macrophage populations (Figure 4-8).  
 
Finally, early experiments investigating circulating catecholamine clearance in living 
humans indicated that -adrenergic receptor stimulation is required for efficient 
catecholamine degradation563,564. 2AR in SAMs might therefore act as a sensor for 
increased local SNS tone, leading to up-regulation of NE degradation machinery 
contributing to negative regulation of sympathetic nerve firing. 
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Figure 4-8. Expression of Dgat1 and Dgat2 genes in different tissue macrophage 
populations. 
The expression of Dgat1 and Dgat2 genes in microglia (n=3), SAMs isolated from 
scWAT (SAM fibers) (n=2), SAMs isolated from superior cervical ganglia (SAM 
ganglia) (n=3), peritoneal (n=3), scWAT (n=2) and eWAT (n=2) ATMs. Macrophage 
populations were isolated and analysed as described in a recent report424. Data was 
obtained from Gene Expression Omnibus database (GSE103847). Values are 
expressed as reads per kilobase of transcript per million of mapped reads (RPKM) + 
SEM. Statistical differences were not assessed. 
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Based on the available literature and my preliminary data, the research questions of 
this chapter can be formulated as follows: 
 
1) Does NE signalling via 2ARs in macrophages alleviate the pro-inflammatory 
effects of FFAs by partitioning them towards TG storage within lipid droplets? 
2) Does 2AR signalling in macrophages affect the development of WAT 
inflammation and insulin resistance during obesity? 3) Do 2ARs in ATMs 
regulate SNS tone in WAT by mediating NE uptake and degradation? 
 
The research questions of this chapter are summarised in Figure 4-8 
 
 
Figure 4-9. Schematic representation of a dual role of norepinephrine signalling 
in adipose tissues.  
NE secreted from sympathetic nerves in adipose tissues simultaneously stimulate 
macrophage 2ARs and adipocyte 3ARs. 3AR stimulation promotes FFA release 
from adipocytes, while 2AR stimulation counteracts the inflammatory effects of FFAs 
by increasing TG storage, and enhances NE degradation in mitochondria. Pathways 
in green represent beneficial, while pathways in red – detrimental processes for WAT 
function that occur during obesity.   
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In this chapter, I will aim to address my research questions in two objectives: 
 
Objective 1. To identify and characterise the molecular mechanisms 
through which 2AR activation leads to increased TG storage in 
macrophages and to determine whether 2AR activation can protect 
macrophages from palmitate-induced ER stress and inflammation. This 
will be performed by tracing radiolabelled fatty acid fluxes within intracellular 
lipid pools of BMDMs treated with 2AR agonists.  
 
Objective 2. To assess the impact of the loss of macrophage 2AR 
signalling on the function of metabolic tissues in lean and obese states in 
vivo. To address this, I will utilise a mouse model with macrophage-specific 
Adrb2 deletion to study the metabolic effects of 2AR signalling in macrophages 
during states of elevated SNS tone in adipose tissues, namely cold exposure. I 
will also subject mice lacking 2AR in macrophages to prolonged high-fat 
feeding and assess their energy balance, glucose and lipid metabolism. Livers 
and adipose tissues from in vivo experiments will be analysed for metabolic and 
inflammatory gene expression in order to assess the importance of macrophage 
2AR signalling for tissue metabolism and inflammation during states of 
elevated SNS tone and obesity. 
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Expected impact. The data obtained from both aims would be beneficial to the field 
of metabolism in multiple ways.  
 
Firstly, unravelling a novel pathway regulating macrophage TG metabolism could 
contribute to our understanding of molecular mechanisms leading to the development 
of lipid-induced inflammation in macrophages observed during obesity and 
atherosclerosis.  
 
Secondly, my findings would follow up on recent reports regarding nerve-macrophage 
interactions in small intestine and adipose tissues by providing an insight into how 
increased firing of neighbouring sympathetic neurons affect macrophage lipid 
metabolism.  
 
Third, as human polymorphisms in the coding region of ADRB2 gene have been linked 
to increased rates of obesity, dyslipidaemia and insulin resistance514, this chapter could 
provide insight on the contribution of 2ARs in macrophages to the development of 
such metabolic traits in the ADRB2 polymorphism carriers. Finally, 2AR is one of the 
best characterised GPCR, and there are numerous pharmaceuticals that agonise or 
block this receptor with high selectivity, including novel intracellular allosteric 
antagonists565. Therefore, depending on the results obtained from Objective 2, 
macrophage-specific targeting of 2AR could be considered as a therapeutic approach 
to treat obesity, MetS or other disorders in which SNS tone is altered. 
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4.2 Results 
4.2.1 Molecular mechanisms driving increased TG accumulation in 
response to 2AR stimulation in BMDMs 
4.2.1.1 2AR agonist stimulated the transcription of CREB target genes, 
including Dgat1 in BMDMs 
Rationale. Most publications regarding the effects of macrophage 2AR agonism have 
focused either on its immunomodulatory role during LPS treatment, or investigated the 
phenotype of macrophages that had been treated with 2AR agonist for a prolonged 
period of time (24 h). Since my preliminary experiments showed that 2AR activation 
suppressed lipolysis in BMDMs within the first 4 h of stimulation, I rationalised that the 
early signalling events leading up to changes in BMDM TG metabolism would be 
important. Thus I initially sought to understand the specificity and signalling kinetics of 
2AR stimulation in BMDMs. 
 
As -adrenergic stimulation is well known to induce CREB phosphorylation and 
promote the expression of CREB target genes, I performed a time-course stimulation 
of BMDMs with the 2AR-specific agonist fenoterol in order to determine the kinetics 
of CREB-dependent gene transcription upon 2AR activation. As readouts for CREB 
transcriptional activity, I chose four CREB target genes with a known function in 
macrophages: a) Nr4a1 (encoding transcription factor Nur77, which is a negative 
regulator of inflammation in macrophages); b) Klf4 (encoding a transcription factor that 
promotes M2 polarisation in macrophages); c) Cox2 (encoding an enzyme 
cyclooxygenase-2, involved in the synthesis of prostaglandins that diminish 
macrophage inflammatory activation); d) Dusp1 (encoding an enzyme dual specificity 
protein phosphatase 1, which dephosphorylates JNK and p38 kinases, therefore 
limiting macrophage inflammatory activation).  
 
Results. All four canonical CREB target genes showed the same expression profile 
upon 2AR activation, characterised by a sharp immediate increase in mRNA levels 
that reached their peak of expression at approximately 1 h, and returned backed to 
baseline at approximately 3 h post stimulation (Figure 4-10). This finding indicated a 
rapid and transient activation of CREB-dependent gene transcription upon 2AR 
activation. 
 
Next, I utilised CREB target gene prediction tool (http://natural.salk.edu/CREB/) to 
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identify enzymes involved in TG biosynthesis containing CRE sequence in their 
promoters. Dgat1 gene was predicted to be regulated by CREB, which was also 
confirmed in a study demonstrating the up-regulation of DGAT1 protein expression 
through the recruitment of CREB-CRTC complex to Dgat1 gene promoter in skeletal 
myocytes in response to isoprenaline566. Indeed, Dgat1 mRNA levels increased 
following 2AR activation in BMDMs, peaking at 2 h and returning to baseline at 8 h 
post stimulation (Figure 4-10). 
 
Furthermore, As recent reports have assigned a major role for LAL in macrophage 
lipolysis238, I also measured Lipa gene expression in fenoterol-treated BMDMs. 
Consistent with a reduced rate of fatty acid release from lipid-laden BMDMs, 2AR 
activation progressively reduced Lipa transcript levels until 6 h post stimulation (Figure 
4-10). 
 
 
 
Figure 4-10. Regulation of CREB target gene transcription in BMDMs in response 
to β2AR stimulation by fenoterol. 
Nr4a1, Cox2, Klf4, Dusp1, Dgat1 and Lipa mRNA levels (normalised to BestKeeper) 
in BMDMs treated with 1 M fenoterol for 0, 30, 45, 60, 90, 120, 180, 240, 300, 360, 
420 or 480 min. N=4 mice. Statistical differences were not assessed.  
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4.2.1.2 NE and fenoterol activated CREB transcription specifically via 2AR 
Rationale. In order to ensure that fenoterol specifically acted on 2ARs in BMDMs, 
and that the observed outcome on gene transcription and TG metabolism was not due 
to off-target effects, I studied BMDMs from mice lacking 2AR specifically in 
macrophages.  
 
Results. Treating control BMDMs with fenoterol for 20 min potently induced the 
activatory phosphorylation of CREB and another cAMP-activated transcription factor 
ATF1 (Figure 4-11). Importantly, fenoterol had no effect on CREB and ATF1 
phosphorylation in LysM-Cre Adrb2fl/fl BMDMs, indicating its specificity to 2ARs 
(Figure 4-11). 
 
 
Figure 4-11. CREB phosphorylation in control and LysM-Cre Adrb2fl/fl BMDMs in 
response to β2AR stimulation by fenoterol.  
Representative Western blots (out of 4 mice/group) of p-Ser133 CREB and p-Ser63 
ATF1 (detected by the same antibody due to the sequence similarity surrounding 
phosphorylation sites), total CREB and -actin proteins in Adrb2fl/fl and LysM-Cre 
Adrb2fl/fl BMDMs stimulated with 1 M fenoterol for 20 min.  
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Next, I stimulated BMDMs with NE in the presence or absence of 2AR-specific 
antagonist ICI-118,511 to validate whether NE could invoke similar effects on gene 
transcription as fenoterol in a 2AR-specific manner. Indeed, treatment of NE 
mimicked the effects of fenoterol on Dgat1 and Lipa gene transcription in BMDMs, and 
the observed response to NE was completely blocked in the presence of ICI-118,511 
(Figure 4-12). 
 
 
  
Figure 4-12. Regulation of Dgat1 and Lipa gene expression in BMDMs in 
response to 2AR stimulation by NE.  
Dgat1 and Lipa mRNA levels (normalised to BestKeeper) in BMDMs treated with 1 M 
NE alone (black lines) or 1 M NE and 1 M ICI-118,511 (red lines) for 0, 1, 2, 4, 6, 
and 8 h. N=4 mice. Statistical differences were not assessed. 
 
 
Finally, I treated LysM-Cre Adrb2fl/fl and control BMDMs with fenoterol and different 
concentrations of NE and measured CREB target gene expression. While in control 
cells NE potently induced Nr4a1 and Dgat1 gene expression in a dose-dependent 
manner at 1 and 4 h, respectively, the effects of NE and fenoterol were completely 
absent in 2AR-deficient BMDMs (Figure 4-13 A,B).  
 
Conclusion. The effects of NE and fenoterol on CREB phosphorylation and gene 
transcription were specific to 2AR stimulation in BMDMs. 
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Figure 4-13. Nr4a1 and Dgat1 gene expression in LysM-Cre Adrb2fl/fl BMDMs 
stimulated with fenoterol and different doses of NE.  
(A) Nr4a1 mRNA levels (normalised to BestKeeper) after 1 h of stimulation, and (B) 
Dgat1 mRNA levels (normalised to BestKeeper) after 4 h of stimulation of Adrb2fl/fl 
(black bars) and LysM-Cre Adrb2fl/fl (white bars) BMDMs with indicated doses of NE or 
1 M fenoterol. N=4 mice/group. * p < 0.05 compared between genotypes using 2-way 
ANOVA with Bonferroni’s multiple comparisons test. 
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4.2.1.3 2AR activation rapidly supressed the release of intracellular oleate in 
BMDMs independently of TG hydrolysis, lipophagy or re-esterification 
Rationale. My preliminary experiments have already shown reduced release of 
intracellular oleate from BMDMs during initial 4 h after 2AR activation (Figure 4-1). 
However, these experiments were not informative in terms of kinetics of oleate release 
from BMDMs. In the attempt to understand how 2AR stimulation delays the kinetics 
of oleate release, I performed a frequent sampling of the medium from oleate-loaded 
BMDMs following 2AR activation.  
 
Results. As published previously567, oleate release rate from unstimulated cells 
progressively reduced over time after medium change, which is a consequence of 
increased extracellular oleate concentration, leading to its increased rate of re-uptake 
and re-esterification (Figure 4-14 A,B). 
 
 
Figure 4-14. Kinetics of oleate release from BMDMs following 2AR activation. 
Oleate release into the medium by BMDMs (pre-loaded with 250 M oleate in the 
presence of 14C-oleate tracer for 16 h) 1, 2, 3, 5 and 7 h post medium change in the 
presence (red lines) or absence (black lines) of 1 M fenoterol. Lipolysis rate is 
expressed as (A) a percentage of specific activity measured in the medium at the time 
of sampling compared to total initial specific activity (the sum of the specific activity of 
the medium at the final time-point of sampling and total cellular specific activity), or as 
(B) a rate of oleate release (calculated by dividing the difference of specific activity in 
the medium between two subsequent time-points by the difference of sampling time 
between the same time-points). N=4 mice. T=0 represents background radioactivity. * 
p < 0.05 compared to control at each time-point using two-way ANOVA with 
Bonferroni’s multiple comparisons test.  
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The suppression of oleate release from BMDMs by 2AR activation was already 
evident at 1 h following medium change and stimulation with fenoterol (Figure 4-14 A). 
However, the most prominent change in oleate release rate occurred between 1 and 
3 h after 2AR activation (Figure 4-14 B). The effects of NE on the oleate release rate 
from BMDMs were comparable to the effects of fenoterol, and they were prevented in 
the presence of 2AR-specific blocker, indicating a 2AR signalling-specific event 
(Figure 4-15 A). 
 
Rationale. In order to identify the intracellular processes that mediate the inhibitory 
effects of 2AR activation on oleate release, I utilised the following inhibitors: A922500, 
in order to inhibit DGAT1 and prevent the re-esterification of released oleate; orlistat, 
to inhibit TG lipases; bafilomycin A1, to block autophagy, thus preventing lipid droplet 
fusion with lysosomes (lipophagy).  
 
Results. As expected, inhibiting DGAT1 increased (Figure 4-15 B), while blocking 
autophagy and the action of TG lipases reduced the rate of oleate release from 
BMDMs (Figure 4-15 C,D). However, all the inhibitors still elicited an effect of 
comparable magnitude in 2AR agonist-treated BMDMs (Figure 4-15 B-D).  
 
Conclusion. The inhibitory action on oleate release by 2AR activation did not depend 
on facilitated fatty acid re-esterification, or inhibition of TG lipases or autophagy. 
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Figure 4-15. The effect of triglyceride synthesis, lipolysis and autophagy 
inhibitors on 2AR-mediated suppression of oleate release from BMDMs. 
Oleate release into the medium by BMDMs (pre-loaded with 250 M oleate in the 
presence of 14C-oleate tracer for 16 h) at indicated time-points post medium change. 
BMDMs were pre-treated with (A) 1 M ICI-118,511, (B) 1 M A922500, (C) 10 M 
orlistat and (D) 100 nM bafilomycin A1 for 30 min before medium change and treatment 
with either (A, B) 1 M NE or (C, D) 1 M fenoterol. N=4 mice/experiment. Within each 
graph, grey lines represent control cells, and black, blue and red lines – stimulation 
with 2AR agonist alone, treatment with inhibitor alone, or co-treatment with 2AR 
agonist and inhibitor, respectively. In all graphs, each treatment was significantly 
different from every other treatment at all measured time-points (except T=0, which 
represents background radioactivity) when analysed using two-way ANOVA with 
Bonferroni’s multiple comparisons test. Statistical differences are not visually 
indicated. 
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4.2.1.4 Acute 2AR activation diminished oleate oxidation in BMDMs 
Rationale. As 2AR stimulation supressed the rate of intracellular oleate release, I 
wanted to evaluate whether activating 2AR could also decrease the rate of FAO in 
BMDMs. In order to test this, I optimised an assay to assess the rate of exogenous 
FAO in BMDMs, involving incubating cells with 100 M of fatty acid containing 14C-
labelled tracer in a hermetically sealed plate in order to trap CO2 in the medium. 14CO2 
can then be extracted from the medium and quantified, corresponding to complete -
oxidation of exogenous fatty acids, which predominantly occurs in mitochondria.  
 
Results. As expected, acute treatment with etomoxir (CPT1 inhibitor) reduced the rate 
of both palmitate and oleate oxidation, and prolonged LPS stimulation diminished the 
rate of oleate oxidation in BMDMs (Figure 4-16 A,B). Interestingly, while 2AR 
stimulation by NE did not affect the rate of palmitate oxidation, it rapidly decreased the 
rate of oleate oxidation (Figure 4-16 A,B). 
 
 
Figure 4-16. The oxidation of exogenous palmitate and oleate in response to 
2AR activation in BMDMs. 
(A) 100 M palmitate and (B) 100 M oleate oxidation in WT BMDMs (n=4 mice), pre-
treated with 100 ng/ml LPS for 24 h, 1 M NE for 8, 4 or 0 h, or 100 M etomoxir for 
30 min and incubated for 3 h in a hermetic manner. Values are expressed as specific 
activity of captured 14CO2 from the medium during 3 h incubation. * p < 0.05 compared 
to control using one-way ANOVA with Bonferroni’s multiple comparisons test. 
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4.2.1.5 2AR activation increased TG storage in a predominantly DGAT1-
dependent manner 
Rationale. My initial observations also included the increase in BMDM TG storage 
capacity in response to 2AR activation (Figure 4-2). However, as such effect was 
observed following 8 and 24 h of 2AR activation, it was not clear whether it occurred 
due to the same mechanism(s) that mediated the suppression of oleate release and/or 
oxidation from BMDMs (Figure 4-14, Figure 4-15), or via an alternative process. 
 
As I have measured a substantial increase in Dgat1 mRNA after 2AR stimulation, I 
decided to assess whether this transcriptional change also translated to an increased 
DGAT enzymatic activity. For this, I adapted a recently published gas chromatography-
based assay, involving measuring fatty acyl-CoA esterification rate to sn-1,2-
dioctanoylglycerol substrate in the presence of cellular microsomes541. Due to the 
distinct elution times of the reaction products sn-1,2-dioctanoyl-3-palmitoylglycerol and 
sn-1,2-dioctanoyl-3-oleoylglycerol, I was able to simultaneously measure the 
esterification rates of palmitoyl-CoA and oleoyl-CoA substrates in a single reaction. 
Furthermore, during the assay optimisation in BMDMs, I found that both palmitoyl-CoA 
and oleoyl-CoA esterification could be completely inhibited by DGAT1-selective 
inhibitor A922500, indicating a predominant role of DGAT1 isoform in catalysing TG 
condensation in BMDMs (data not shown).  
 
Results. Previous gene expression analysis of BMDMs treated with LPS or IL-4 for 24 
h performed in our lab showed that Dgat1 mRNA levels were not modulated by the 
polarisation of macrophages towards M1 or M2 states (data not shown). Consistent 
with such findings, DGAT activity towards palmitoyl-CoA and oleoyl-CoA was 
unchanged after prolonged treatment with LPS or IL-4, compared to untreated BMDMs 
(Figure 4-17 A,B). In line with an observed increase in Dgat1 mRNA, I found a 2-fold 
increase in DGAT activity for both palmitoyl-CoA and oleoyl-CoA in BMDMs 8 h after 
2AR activation (Figure 4-17 A,B). DGAT activity for both substrates remained 
elevated even 24 h after 2AR activation, showing a 50% increase compared to 
untreated BMDMs (Figure 4-17 A,B). 
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Figure 4-17. DGAT1 activity-dependent oleate uptake in BMDMs following 2AR 
activation. 
DGAT activity in the microsomal fraction of BMDMs stimulated with 100 ng/ml LPS or 
10 M IL-4 for 24 h, or 1 M NE for 8 or 24 h, using (A) palmitoyl-CoA or (B) oleoyl-
CoA as a substrate. Esterification rate is expressed as fold change from untreated 
cells. (C) Oleate uptake by BMDMs, stimulated with 1 M fenoterol, 1 M A922500 or 
10 M orlistat, as indicated below the graph, and treated with 250 M oleate in the 
presence of 14C-oleate tracer for 16 h. Oleate uptake is expressed as a fold change in 
specific activity of stimulated cells from unstimulated controls. N=4 mice/experiment. * 
p < 0.05 compared to (A, B) control or (C) between indicated columns using one-way 
ANOVA with Bonferroni’s multiple comparisons test. In (C), the following comparisons 
were also significantly different but not visually indicated: Ctrl vs orl/ fen + orl; A922 vs 
every other column (except ctrl), fen vs A922 + orl/ fen + A922 + orl; fen + orl vs fen + 
A922/ A922 + orl/ fen + A922 + orl; fen + A922 vs fen + A922 + orl; A922 + orl vs fen 
+ A922 + orl. 
  204 
Rationale. Next, I wanted to investigate whether increased DGAT1 activity was 
mediating enhanced oleate uptake in 2AR agonist-treated BMDMs. To test this, I 
stimulated cells with fenoterol in the presence of DGAT1 inhibitor A922500. In order to 
rule out the role TG lipases as targets of 2AR action in BMDMs, I also co-treated the 
cells with 2AR agonist and orlistat.  
 
Results. As expected, blocking DGAT1 activity reduced the overall BMDM oleate 
uptake by approximately 50% (Figure 4-17 C). The remaining 50% of specific activity 
within the cell was likely due to oleate incorporation into phospholipids, as reported 
previously233. In contrast, orlistat enhanced exogenous oleate content within BMDMs 
by approximately 40%, presumably caused by an increased TG retention within 
intracellular lipid droplets (Figure 4-17 C). While fenoterol still invoked an increase in 
oleate uptake in the presence of A922500 and orlistat, the magnitude of the increase 
was greatly reduced when A922500 was present (Figure 4-17 C, 56% increase in 
fenoterol-treated cells compared to control, and 13% increase in fenoterol + A922500-
treated cells compared to A922500 alone). Orlistat also diminished the magnitude of 
the increase in oleate uptake (Figure 4-17 C, 31% fenoterol + orlistat-treated cells 
compared to orlistat alone). Co-treatment of cells with A922500 and orlistat had a 
similar effect to A922500 treatment alone (Figure 4-17 C, 13% increase in fenoterol + 
A922500 + orlistat compared to A922500 + orlistat alone).  
 
Conclusion. DGAT1 activity could account for the majority of 2AR agonism-elicited 
effects on the oleate uptake in BMDMs. 
 
Rationale. Finally, I decided to directly assess the effect of 2AR activation on BMDM 
TG storage, and whether it was mediated by increased DGAT1 activity. I stimulated 
BMDMs with fenoterol in the presence of A922500 and loaded them with radiolabelled 
palmitate and oleate.  
 
Results. 2AR activation or DGAT1 inhibition did not change the levels of intracellular 
FFAs or 1,3-DAGs in BMDMs loaded with either oleate or palmitate (total lipid staining, 
Figure 4-18, Figure 4-19). However, the radiolabelled FFA, 1,2- and 1,3-DAG species 
were increased in BMDMs following 2AR activation, suggesting an increased flux 
through lipid metabolic pathways that utilise such molecules as reaction intermediates 
(radiogram, Figure 4-18, Figure 4-19).  
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Consistent with my previous findings, I observed a profound increase in overall TG 
levels in BMDMs after 2AR activation and incubation with oleate, that could be mainly 
attributed to exogenous oleate incorporation, as indicated by increased TG 
radiolabelling (Figure 4-18). While TG amount in palmitate-treated cells was too low to 
be detected by primuline staining, the flux of 14C-palmitate to intracellular TGs showed 
a similar pattern to 14C-oleate (Figure 4-19). Fenoterol also promoted the incorporation 
of exogenous oleate and palmitate to CEs (radiogram, Figure 4-18, Figure 4-19). 
Interestingly, while the effects of 2AR agonism on palmitate incorporation to cellular 
TGs and CEs were completely blocked by A922500 (Figure 4-19), the esterification of 
exogenous oleate was still increased in fenoterol-treated cells when DGAT1 was 
inhibited (Figure 4-18).  
 
Conclusion. Overall, these findings indicated that 2AR activation potentiated 
palmitate incorporation in TGs in a DGAT1-dependent manner. However, oleate 
content in TGs was increased in both DGAT1-dependent and other unknown 
mechanism. 
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Figure 4-18. The effect of 2AR activation and DGAT1 inhibition on the flux of 
exogenous oleate through neutral lipids in BMDMs. 
Total lipid stain (image above) and autoradiogram (image below) of the TLC plate 
containing separated neutral lipids isolated from BMDMs that had been stimulated with 
1 M fenoterol or 1 M A922500 (as indicated below the graph) and then treated with 
100 M oleate containing 14C-oleate tracer for 16 h. N=4 mice. The migration of the 
neutral lipid species indicated on the left side of the images were determined using 
chemical standards. CE and 1,2-DAG bands were not observed in the total lipid stain. 
  207 
 
Figure 4-19. The effect of 2AR activation and DGAT1 inhibition on the flux of 
exogenous palmitate through neutral lipids in BMDMs. 
Total lipid stain (image above) and autoradiogram (image below) of the TLC plate 
containing separated neutral lipids isolated from BMDMs that had been stimulated with 
1 M fenoterol or 1 M A922500 (as indicated below the graph) and then treated with 
100 M palmitate containing 14C-palmitate tracer for 16 h. N=4 mice. The migration of 
the neutral lipid species indicated on the left side of the images were determined using 
chemical standards. CE and 1,2-DAG bands were not observed in the total lipid stain. 
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4.2.1.6 2AR activation decreased palmitate-induced inflammatory activation 
in BMDMs independently of ER stress or TG storage  
Rationale. As my results have shown that 2AR activation promoted DGAT1-
dependent lipid storage in BMDMs, and a similar magnitude of Dgat1 transcriptional 
increase by genetic overexpression was previously described to prevent palmitate-
induced inflammatory activation of macrophages209, I decided to test whether 2AR 
stimulation could reduce the ER stress and inflammation in BMDMs treated with 
palmitate. I stimulated cells with fenoterol in the presence of A922500 before treating 
them with palmitate.  
 
Results. As I have already observed in the previous chapter, palmitate induced Tnf 
gene expression after 4 h of incubation, and Tnf mRNA returned to its basal levels 
after 8 h of incubation (Figure 4-20 A). 2AR activation completely diminished the peak 
in Tnf transcription, but such inhibitory effect could not be prevented by blocking 
DGAT1 (Figure 4-20 A). Furthermore, fenoterol did not reduce the rate of ER stress 
development in palmitate-treated BMDMs, as the expression of ER stress markers 
Chop and spliced Xbp1 isoform was comparable in cells stimulated with 2AR agonist 
and controls in the presence of palmitate (Figure 4-20 A). Finally, while 2AR activation 
showed a modest reduction in Chop transcription, it did not affect Xbp1  mRNA splicing 
in BMDMs after a prolonged incubation with palmitate, and Chop mRNA levels could 
not be restored to the level observed in controls in the presence of A922500 (Figure 
4-20 B).  
 
Conclusion. Overall, I found that 2AR agonist diminished the early inflammatory 
activation, but not the development of ER stress in palmitate-treated BMDMs, and its 
early anti-inflammatory effect was independent of enhanced TG storage.  
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Figure 4-20. The effects of 2AR activation and DGAT1 inhibition on palmitate-
induced ER stress and inflammatory activation of BMDMs. 
(A) Tnf and Chop mRNA (normalised to BestKeeper), and the ratio of spliced to total 
Xbp1 mRNA levels in BMDMs treated with 1 M fenoterol (black lines), 100 M 
palmitate (red lines), 1 M A922500 (grey lines), palmitate + fenoterol (green lines), 
palmitate + A922500 (blue lines), palmitate + fenoterol + A922500 (yellow lines). N=4 
mice. * p < 0.05 compared between palmitate and palmitate + fenoterol at each time-
point using two-way ANOVA with Bonferroni’s multiple comparisons test. (B) Chop 
mRNA (normalised to BestKeeper) and the ratio of spliced to total Xbp1 mRNA levels 
in BMDMs treated with 1 M fenoterol, 1 M A922500 and fenoterol + A922500 (as 
indicated below the graphs) and then stimulated with 250 M palmitate for 24 h. N=4 
mice. * p < 0.05 compared between indicated treatments using two-way ANOVA with 
Bonferroni’s multiple comparisons test. 
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4.2.2 The importance of 2AR in macrophages for glucose and lipid 
metabolism on a pure C57Bl/6J genetic background 
4.2.2.1 Macrophage-specific Adrb2 deletion did not affect total energy balance 
of chow-fed mice 
Rationale. Prior to conducting any in vivo experiments designed to analyse specific 
metabolic traits, I decided to perform general metabolic phenotyping of LysM-Cre 
Adrb2fl/fl animals in order to understand how 2AR deficiency in macrophages affect 
systemic energy balance and glucose and lipid homeostasis on a chow diet or after 
prolonged high-fat feeding. 
 
As one of the initial hypotheses was that 2AR might be important for limiting SNS 
outflow to the adipose tissues by regulating NE degradation in SAMs, that could in turn 
increase energy expenditure and reduce the body weight, I measured the body weight 
of the animals from the early post-weaning period (6 weeks of age) until the initial 
metabolic cage analysis (16 weeks of age).  
 
Results. No differences in the body weight was observed throughout this period 
(Figure 4-21 A) or using metabolic cage analysis (Figure 4-21 B) between LysM-Cre 
Adrb2fl/fl and control mice. While genotype did not affect the food intake and energy 
expenditure during 48 h of measurement (Figure 4-21 C,D), some animals of both 
genotypes exhibited a profound stress response, indicated by the absence of chow 
consumption (Figure 4-21 C) and weight loss (not shown) during analysis. Average 
daily RER was similar between genotypes on a chow diet (Figure 4-21 E). 
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Figure 4-21. Body weight, food intake and energy expenditure of chow-fed 
Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice. 
(A) Weekly body weight measurements prior to the study, and (B) body weight, (C) 
food intake, (D) average energy expenditure plotted against body weight and (E) 
average RER values during light and dark parts of the day assessed over 48 h in 
Adrb2fl/fl (black lines/dots/bars, n=8) and LysM-Cre Adrb2fl/fl (red lines/dots and white 
bars, n=8) 16-week-old male mice on a pure C57Bl/6J genetic background. Statistical 
differences between genotypes were assessed using two-way ANOVA with 
Bonferroni’s multiple comparisons test (A, E) student’s t-test (B, C) or one-way 
ANCOVA (D). 
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4.2.2.2 Macrophage-specific Adrb2 deletion increased the levels of circulating 
liver enzymes in chow-fed mice  
Results. Chow-fed LysM-Cre Adrb2fl/fl animals and controls exhibited similar serum 
concentrations of glucose, insulin, FFAs and TGs in the fed state (Table 4-1). 
Unusually high measured FFA levels in both groups indicated a potential sample 
quality issue (Table 4-1). The levels of liver enzyme AST was elevated in LysM-Cre 
Adrb2fl/fl mice, with no change in the ALT to AST ratio compared to control group (Table 
4-1). Finally, genotype did not affect the insulin, glucose and FFA concentration after 
an overnight fast (Table 4-1). 
 
Table 4-1. Serum biochemistry of chow-fed Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice 
in a random-fed state or after overnight fast. 
Concentrations of serum biochemicals are expressed as means ± SEM. N=8 Adrb2fl/fl, 
n=8 LysM-Cre Adrb2fl/fl 16-19-week-old male mice on a pure C57Bl/6J genetic 
background. * p < 0.05 compared between genotypes using student’s t-test. 
  
Feeding state Random fed Fasted overnight 
Genotype Adrb2fl/fl 
LysM-Cre 
Adrb2fl/fl 
Adrb2fl/fl 
LysM-Cre 
Adrb2l/fl 
Glucose (mM) 8.63 ± 0.47 8.48 ± 0.22 6.00 ± 0.24 7.19 ± 0.58 
Insulin (μg/L) 2.33 ± 0.86 1.41 ± 0.26 0.27 ± 0.03 0.29 ± 0.06 
FFA (mM) 2.4 ± 0.24 2.94 ± 0.28 1.41 ± 0.11 1.29 ± 0.09 
TG (mM) 2.36 ± 0.24 2.94 ± 0.28 - - 
ALT (U/L) 29.5 ± 2.64 120 ± 42.25 - - 
AST (U/L) 154 ± 40.09 
473.38 ± 
123.78* 
- - 
ALT/AST ratio 0.24 ± 0.04 0.34 ± 0.11 - - 
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4.2.2.3 Macrophage-specific Adrb2 deletion improved systemic glucose 
clearance of chow-fed mice during GTT 
Results. LysM-Cre Adrb2fl/fl animals exhibited a higher rate of glucose clearance from 
the blood during the GTT compared to control mice, as indicated by lower AUC (Figure 
4-22 A,B). Furthermore, blood glucose concentration was higher in LysM-Cre Adrb2fl/fl 
mice after 6 h fast (average of 10.19 ± 0.26 in Adrb2fl/fl group vs 11.45 ± 0.41 in LysM-
Cre Adrb2fl/fl group, p=0.02). However, both genotypes had comparable areas under 
curve during the ITT (Figure 4-22 C,D). 
 
 
Figure 4-22. Glucose and insulin tolerance tests of chow-fed Adrb2fl/fl and LysM-
Cre Adrb2fl/fl mice. 
Blood glucose concentration curves (A) and AUC (B) of mice injected with 1 mg/kg 
glucose at T=0 min after an overnight fast. Blood glucose concentration curves (C) and 
AUC (D) of mice injected with 0.75 IU/kg insulin at T=0 after 6 h fast. N=8 Adrb2fl/fl 
(black lines/dots) and n=8 LysM-Cre Adrb2fl/fl (red lines/dots) 16-18-week-old male 
mice on a pure C57Bl/6J background. * p < 0.05 compared between genotypes using 
student’s t-test (B, D). 
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4.2.2.4 Macrophage-specific Adrb2 deletion tended to increase the liver weight 
of chow-fed mice 
Results. There were no genotype-dependent differences in total body weight, and 
BAT-, scWAT-, eWAT- and liver-to-body weight ratios at the end of the study (Figure 
4-23 A-E).  
 
 
Figure 4-23. Tissue weights of chow-fed Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice. 
Body weight (A) and weights of BAT (B), scWAT (C), eWAT (D) and liver (E), 
expressed as a percentage of body weight of Adrb2fl/fl (n=8, black dots) and LysM-Cre 
Adrb2fl/fl (n=8, red dots) 19-week-old male mice on a pure C57Bl/6J background culled 
in a random fed state. Statistical significance was assessed using student’s t-test. 
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4.2.2.5 Macrophage-specific Adrb2 deletion reduced the body weight gain 
during HFD in mice without affecting food intake or energy expenditure 
Results. Animals of both genotypes weighed similarly at 8 weeks of age, when the 
high-fat feeding was initiated (Figure 4-24 A). LysM-Cre Adrb2fl/fl mice gained body 
weight at a lower rate than control group and exhibited a reduced total body weight 
after 7 weeks of HFD, and during the metabolic cage analysis (Figure 4-24 A-C). 
However, no genotype-dependent differences in food intake or energy expenditure 
were observed between groups during 48 h of analysis (Figure 4-24 D,E).  
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Figure 4-24. Body weight, food intake and energy expenditure of HFD-fed 
Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice. 
Weekly body weight measurements prior to the study (dotted line indicates the switch 
from chow to HFD) expressed as (A) average body weight or as (B) percentage body 
weight increase from the start of HFD and (C) body weight, (D) food intake, (E) average 
energy expenditure plotted against body weight assessed over 48 h in Adrb2fl/fl (black 
lines/dots, n=7) and LysM-Cre Adrb2fl/fl (red lines/dots, n=7) 16-week-old male mice on 
a pure C57Bl/6J genetic background, fed a 60% kcal fat diet (D12492) from 8 weeks 
of age. * p < 0.05 compared between genotypes using two-way ANOVA with 
Bonferroni’s multiple comparisons test (A, B) student’s t-test (C, D) or one-way 
ANCOVA (E). 
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4.2.2.6 Macrophage-specific Adrb2 deletion had no effect on serum metabolite 
concentrations of HFD-fed mice 
Results. Despite their lower body weight, LysM-Cre Adrb2fl/fl mice showed similar 
levels of serum glucose, insulin, TGs and FFAs in the fed state to controls (Table 4-2). 
No differences in serum ALT levels and ALT/AST ratio were observed between two 
groups (Table 4-2). Circulating glucose, insulin and FFA levels were similar between 
genotypes after overnight fast (Table 4-2). 
 
 
Table 4-2. Serum biochemistry of HFD-fed Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice 
in a random-fed state or after overnight fast. 
Concentrations of serum biochemicals are expressed as means ± SEM. N=7 Adrb2fl/fl, 
n=7 LysM-Cre Adrb2fl/fl 16-19-week-old male mice on a pure C57Bl/6J genetic 
background, fed a 60% kcal fat diet (D12492) from 8 weeks of age. 
  
Feeding state Random fed Fasted overnight 
Genotype Adrb2fl/fl 
LysM-Cre 
Adrb2fl/fl 
Adrb2fl/fl 
LysM-Cre 
Adrb2l/fl 
Glucose (mM) 10.94 ± 0.66 10.27 ± 0.69 9.8 ± 0.44 9.3 ± 0.63 
Insulin (μg/L) 8.48 ± 1.53 9.43 ± 3.1 1.25 ± 0.16 1.06 ± 0.25 
FFA (mM) 1.05 ± 0.07 1.2 ± 0.09 0.7 ± 0.06 0.69 ± 0.08 
TG (mM) 1.06 ± 0.06 1.25 ± 0.09 - - 
ALT (U/L) 191.71 ± 21.74 109.57 ± 37.85 - - 
AST (U/L) 255 ± 20.06 227 ± 59.05 - - 
ALT/AST ratio 0.81 ± 0.14 0.49 ± 0.08 - - 
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4.2.2.7 Macrophage-specific Adrb2 deletion did not impact the glucose or 
insulin tolerance of HFD-fed mice 
Results. LysM-Cre Adrb2fl/fl mice were leaner than HFD-fed controls during GTT and 
ITT (data not shown). However, following exogenous administration of glucose, they 
normalised serum glucose concentration at the same rate as controls (Figure 4-25 
A,B). There were no differences in insulin-mediated serum glucose uptake between 
genotypes (Figure 4-25 C,D). 
 
 
Figure 4-25. Glucose and insulin tolerance tests of HFD-fed Adrb2fl/fl and LysM-
Cre Adrb2fl/fl mice. 
Blood glucose concentration curves (A) and AUC (B) of mice injected with 1 mg/kg 
glucose at T=0 min after an overnight fast. Blood glucose concentration curves (C) and 
AUC (D) of mice injected with 1 IU/kg insulin at T=0 after 6 h fast. N=7 Adrb2fl/fl (black 
lines/dots) and n=7 LysM-Cre Adrb2fl/fl (red lines/dots) 16-18-week-old male mice on a 
pure C57Bl/6J background, fed a 60% kcal fat diet (D12492) from 8 weeks of age. 
Statistical significance was assessed using student’s t-test (B, D). 
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4.2.2.8 Macrophage-specific Adrb2 deletion reduced liver weight of HFD-fed 
mice 
Results. LysM-Cre Adrb2fl/fl animals weighed approximately 8% less than controls at 
the end of the study (Figure 4-26 A). No differences in BAT-, scWAT-, and eWAT-to-
body weight ratios were observed between genotypes (Figure 4-26 B,C). LysM-Cre 
Adrb2fl/fl group had a reduced liver-to-body weight ratio compared to control mice on 
HFD (Figure 4-26 D,E). 
 
 
Figure 4-26. Tissue weights of HFD-fed Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice. 
(A) Body weight and weights of (B) BAT, (C) scWAT, eWAT (D) and liver (E), 
expressed as a percentage of body weight of Adrb2fl/fl (n=7, black dots) and LysM-Cre 
Adrb2fl/fl (n=7, red dots) 19-week-old male mice on a pure C57Bl/6J background, fed a 
60% kcal fat diet (D12492) from 8 weeks of age and culled in a random fed state. * p 
< 0.05 compared between genotypes using student’s t-test. 
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4.2.2.9 Macrophage-specific Adrb2 deletion reduced metabolic gene 
expression, but had no effect on the inflammatory gene expression in 
ATMs isolated from chow- or HFD-fed mice 
Rationale. At the end of the study, eWATs isolated from both chow- and HFD-fed 
groups were digested and ATMs were isolated using CD11b-positive purification. 
Similarly to the previous chapter, tissues from chow and HFD groups were obtained at 
different times, therefore statistical comparisons were only performed between 
genotypes, and not between diets in any following tissue analyses. However, results 
from both diets were presented alongside in the same graphs in order to visualise the 
directional change of each analysed parameter during HFD. 
 
Results. High excision rate of Adrb2 gene was observed, with ATMs isolated from 
LysM-Cre Adrb2fl/fl animals containing approximately 15% of Adrb2 mRNA compared 
to the control levels in both chow- and HFD-fed groups (Figure 4-27 A). No 
compensatory increase in Adrb1 transcription was observed in 2AR-deficient ATMs 
from chow- or HFD-fed groups (Figure 4-27 A). No differences in the expression of 
ATM inflammatory or M2 marker genes were observed between genotypes in either 
chow- or HFD-fed groups (Figure 4-27 A). Interestingly, while 2AR-deficient ATMs 
exhibited equivalent mRNA levels of metabolic genes to the control cells in chow-fed 
group, they showed lower expression of metabolic genes Cd36, Dgat1, Acsl1, Acsl4, 
Pcyt1a and Glut1 compared to controls in HFD-fed group, indicating decreased lipid 
uptake (Figure 4-27 B). Finally, the expression of gene encoding moamine oxidase A 
was unchanged in 2AR-deficient ATMs compared to controls in chow or HFD groups 
(Figure 4-27 B). 
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Figure 4-27. Gene expression analysis of eWAT ATMs isolated from chow and 
HFD-fed Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice.  
mRNA levels (normalised to BestKeeper) of (A) Adrb1, Adrb2 and immune system 
genes Tnf, Il1b, Il6, Ccr2, Cox2, Il10, Fizz1 and Mgl1, (B) metabolic genes Cd36, Adrp, 
Dgat1, Acsl1, Acsl4, Pcyt1a, Glut1, Hif1a, Chop, Thbs1, Maoa and the ratio of spliced 
to total Xbp1 mRNA levels in CD11b-positive fraction of eWAT isolated from chow-fed 
Adrb2fl/fl (n=8, black bars), LysM-Cre Adrb2fl/fl (n=8, white bars) and HFD-fed Adrb2fl/fl 
(n=7, dark grey bars), LysM-Cre Adrb2fl/fl (n=7, light grey bars) 19-week-old male mice 
on a pure C57Bl/6J genetic background, culled in a random fed state. HFD-fed group 
received 60% kcal fat diet (D12492) from 8 weeks of age. * p < 0.05 compared to 
Adrb2fl/fl using student’s t-test. 
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4.2.2.10 Macrophage-specific Adrb2 deletion had no major effect on 
scWAT and BAT gene expression in chow- or HFD-fed mice 
Results. Ucp1 mRNA levels were similar between genotypes in scWAT from chow- 
and HFD-fed groups, indicating that macrophage-specific 2AR deficiency did not 
impact the browning of WAT (Figure 4-28 A). Chow-fed LysM-Cre Adrb2fl/fl animals had 
increased Cd206, but similar Cd11b, Pgc1a and Cidea mRNA levels in scWAT 
compared to controls (Figure 4-28 A). On HFD, Adrb3, Lpl, Glut4 and Hsl scWAT 
mRNA levels were comparable between the two groups (Figure 4-28 A). Adrb2 mRNA 
in scWAT was similar in chow-fed, but was decreased in HFD-fed LysM-Cre Adrb2fl/fl 
mice, suggesting that nearly 50% of Adrb2 expression in scWAT from HFD animals is 
derived from ATMs (Figure 4-28 A). 
 
BAT from chow- and HFD-fed groups showed the same expression levels of Ucp1, 
Adrb3, Cd36, Glut4 and Hsl between genotypes (Figure 4-28 B). LysM-Cre Adrb2fl/fl 
mice had lower Atgl mRNA on a chow diet. Pgc1a, Cd206, Fatp1 and Cpt1b transcript 
levels were comparable on a HFD to controls (Figure 4-28 B). Similarly to the 
observations in scWAT, Adrb2 expression was lower in the chow-fed LysM-Cre 
Adrb2fl/fl animals compared to controls, indicating that approximately 10% of Adrb2 
transcript levels in BAT are derived from the ATMs (Figure 4-28 B).  
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Figure 4-28. Gene expression analysis of scWAT and BAT isolated from chow 
and HFD-fed Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice. 
(A) Ucp1, Pgc1a, Cidea, Maoa, Adrb2, Adrb3, Cd206, F4/80, Cd11b, Tnf, Lpl, Cd36, 
Glut4, Atgl and Hsl mRNA levels in scWAT and (B) Ucp1, Pgc1a, Adrb2, Adrb3, 
Cd206, F4/80, Cd11b, Cd36, Fatp1, Glut4, Atgl, Hsl and Cpt1b mRNA levels 
(normalised to BestKeeper) in BAT isolated from chow-fed Adrb2fl/fl (n=8, black bars), 
LysM-Cre Adrb2fl/fl (n=8, white bars) and HFD-fed Adrb2fl/fl (n=7, dark grey bars), LysM-
Cre Adrb2fl/fl (n=7, light grey bars) 19-week-old male mice on a pure C57Bl/6J genetic 
background, culled in a random fed state. HFD-fed group received 60% kcal fat diet 
(D12492) from 8 weeks of age. * p < 0.05 compared to Adrb2fl/fl using student’s t-test. 
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4.2.2.11 Macrophage-specific Adrb2 deletion increased hepatic Fasn 
mRNA in chow-fed mice, but had no major impact on hepatic gene 
expression in HFD-fed mice 
Results. Livers from chow-fed LysM-Cre Adrb2fl/fl animals expressed higher levels of 
Fasn gene, but showed no differences in the mRNA levels of other metabolic or 
immune system genes compared to controls (Figure 4-29). On a HFD, 2AR deficiency 
in macrophages did not affect the expression of metabolic or immune system genes 
(Figure 4-29). Similarly to the adipose tissues, Adrb2 mRNA was lower in LysM-Cre 
Adrb2fl/fl animals on both diets, indicating that approximately 20% and 40% of hepatic 
Adrb2 expression is derived from Kupffer cells on a chow and HFD, respectively 
(Figure 4-29). 
 
 
Figure 4-29. Gene expression analysis of livers isolated from chow and HFD-
fed Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice. 
Adrb2, F4/80, Cd206, Tnf, Srebp1c, Fasn, Scd1, Elovl6, Dgat1, Cd36 and Pepck 
mRNA levels (normalised to BestKeeper) in livers isolated from chow-fed Adrb2fl/fl 
(n=8, black bars), LysM-Cre Adrb2fl/fl (n=8, white bars) and HFD-fed Adrb2fl/fl (n=7, dark 
grey bars), LysM-Cre Adrb2fl/fl (n=7, light grey bars) 19-week-old male mice on a pure 
C57Bl/6J genetic background, culled in a random fed state. HFD-fed group received 
60% kcal fat diet (D12492) from 8 weeks of age. * p < 0.05 compared to Adrb2fl/fl using 
student’s t-test. 
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4.2.2.12 Macrophage-specific Adrb2 deletion reduced hepatic lipid 
accumulation in HFD-fed mice 
Results. As the liver weight of HFD-fed LysM-Cre Adrb2fl/fl mice was reduced 
compared to the control group, I assessed the hepatic lipid content in order to 
determine whether the observed weight reduction resulted from decreased lipid 
accumulation in the liver. Indeed, while there were no genotype-dependent differences 
in hepatic lipid content on a chow diet, livers from HFD-fed LysM-Cre Adrb2fl/fl animals 
contained less lipid, indicating a lower degree of hepatic steatosis (Figure 4-30). 
 
 
 
Figure 4-30. Hepatic lipid levels in chow and HFD-fed Adrb2fl/fl and LysM-Cre 
Adrb2fl/fl mice. 
Total lipid weight (as percentage of tissue weight) of the livers isolated from chow-fed 
Adrb2fl/fl (n=8, black dots), LysM-Cre Adrb2fl/fl (n=8, red dots) and HFD-fed Adrb2fl/fl 
(n=7, black dots), LysM-Cre Adrb2fl/fl (n=7, red dots) 19-week-old male mice on a pure 
C57Bl/6J genetic background, culled in a random fed state. HFD-fed group received 
60% kcal fat diet (D12492) from 8 weeks of age. * p < 0.05 compared between 
genotypes using student’s t-test. 
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4.2.2.13 Macrophage-specific Adrb2 deletion increased relative hepatic 
palmitate levels in chow-fed mice, but had no major impact on the 
hepatic fatty acid composition of HFD-fed mice 
Rationale. Intrigued by an increased Fasn expression in the chow-fed LysM-Cre 
Adrb2fl/fl animals compared to controls, I measured hepatic fatty acid composition of 
both chow- and HFD-fed groups. I fractionated total liver lipids into phospholipid and 
neutral lipid fractions and analysed them separately in order to identify specific 
changes in membrane remodelling or TG storage.  
 
Results. Relative palmitate levels were increased in the phospholipids of LysM-Cre 
Adrb2fl/fl animals compared to controls on a chow diet (Figure 4-31 A). Genotype had 
no effect on hepatic phospholipid fatty acid composition on a HFD (Figure 4-31 A). 
Similarly, hepatic TGs contained a higher proportion of palmitate in chow-fed LysM-
Cre Adrb2fl/fl mice, but had normal levels of other measured fatty acid species 
compared to controls (Figure 4-31 B). On a HFD, 2AR deficiency in macrophages did 
not affect hepatic TG fatty acid composition (Figure 4-31 B). 
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Figure 4-31. Hepatic fatty acid composition of chow and HFD-fed Adrb2fl/fl and 
LysM-Cre Adrb2fl/fl mice. 
Relative abundance of C16:0, C16:1n7, C18:0, C18:1n9, C18:1n7, C18:2, C18:3, 
C20:3, C20:4, C20:5, C22:6 (levels of C20:3 and C20:5 were below detection limit in 
B) fatty acids (expressed as molar percentages of each fatty acid relative to an overall 
fatty acid molar abundance in a given sample) in (A) phospholipid or (B) neutral lipid 
fraction of livers isolated from chow-fed Adrb2fl/fl (n=8, black bars), LysM-Cre Adrb2fl/fl 
(n=8, white bars) and HFD-fed Adrb2fl/fl (n=7, dark grey bars), LysM-Cre Adrb2fl/fl (n=7, 
light grey bars) 19-week-old male mice on a pure C57Bl/6J genetic background, culled 
in a random fed state. HFD-fed group received 60% kcal fat diet (D12492) from 8 
weeks of age. * p < 0.05 compared between genotypes using student’s t-test. 
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4.2.2.14 Macrophage-specific Adrb2 deletion did not affect the body 
weight, food intake or faecal excretion in mice on a chow diet, or during 
the initial 2 weeks of high-fat feeding 
Rationale. As I previously observed reduced body weight of LysM-Cre Adrb2fl/fl 
animals compared to controls after prolonged high-fat feeding without any obvious 
changes in energy expenditure or thermogenic markers in BAT and scWAT of these 
mice, I decided to assess whether 2AR deficiency in macrophages affects food intake 
or faecal excretion in chow- or HFD-fed animals. I therefore measured the body weight 
and assessed daily food intake in singly housed animals for 12 days on a chow-diet, 
before placing the same mice on a HFD and continuing the assessment for additional 
12 days. I also measured faecal excretion during the last 5 days of each 12-day period.  
 
Results. Genotype had no effect on food intake or faecal excretion on a chow-diet, 
when mice demonstrated a stable body weight (Figure 4-32 A-C). LysM-Cre Adrb2fl/fl 
animals did not exhibit differences in the body weight gain, food intake or faecal 
excretion compared to controls during the first 12 days of HFD, indicating no genotype-
dependent alterations in energy balance after a diet change (Figure 4-32 D-G). 
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Figure 4-32. Body weight, food intake and excretion of faeces of chow and HFD-
fed Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice. 
(A) Cumulative food intake, (B) daily body weight measurements and (C) cumulative 
faecal weight assessed over 12 days (faecal weight was measured during last 5 days 
of the 12-day period) on chow diet, and (D) cumulative food intake, daily body weight 
measurements expressed as (E) absolute body weight or (F) percentage body weight 
increase from the start of HFD and cumulative faecal weight assessed over 12 days 
(faecal weight was measured during last 5 days of the 12-day period) on 60% kcal fat 
diet (D12492). N=8 Adrb2fl/fl (black lines) and n=8 LysM-Cre Adrb2fl/fl (red lines) male 
mice. 12 day-long chow diet intake analysis was initiated at 14 weeks of age and was 
immediately followed by 12-day long HFD intake analysis. 
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4.2.2.15 Macrophage-specific Adrb2 deletion increased blood glucose 
levels in the fed state after 2 weeks of HFD  
Results. At the end of the food intake study, LysM-Cre Adrb2fl/fl animals and controls 
had similar body weight and BAT-, scWAT-, eWAT- and liver-to-body weight ratios 
(Figure 4-33 A, C-E). Interestingly, 2 weeks of high-fat feeding increased blood glucose 
levels in the fed state in LysM-Cre Adrb2fl/fl mice compared to controls (Figure 4-33 B, 
F). 
 
 
 
Figure 4-33. Tissue weights and blood glucose levels in Adrb2fl/fl and LysM-Cre 
Adrb2fl/fl mice after a short-term HFD. 
(A) Body weight, (B) blood glucose levels and weights of (C) BAT, (D) scWAT, (E) 
eWAT and (F) liver, expressed as a percentage of body weight of Adrb2fl/fl (n=7, black 
dots) and LysM-Cre Adrb2fl/fl (n=7, red dots) 19-week-old male mice on a pure 
C57Bl/6J background, fed a 60% kcal fat diet (D12492) from 8 weeks of age and culled 
in a random fed state. * p < 0.05 compared between genotypes using student’s t-test. 
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4.2.2.16 Macrophage-specific Adrb2 deletion reduced glucose infusion 
rate during hyperinsulinaemic-euglycaemic clamp of chow-fed mice 
Rationale. As I observed increased blood glucose levels after 6 h fast, as well as 
elevated Fasn expression and relative palmitate levels in the livers of chow-fed LysM-
Cre Adrb2fl/fl animals compared to controls, I decided to perform hyperinsulinaemic-
euglycaemic clamps on chow- and HFD-fed animals in order to measure the rate of 
hepatic glucose production (HGP), and also to formally assess the impact of 2AR 
deficiency in macrophages on systemic insulin sensitivity in mice. 
 
Results. Chow-fed LysM-Cre Adrb2fl/fl group weighed similarly to controls leading up 
to the experiment (Figure 4-34 A). LysM-Cre Adrb2fl/fl mice that successfully undergone 
clamp procedure had a comparable body weight to controls (Figure 4-34 B). No 
difference in blood glucose levels after an overnight fast was observed between 
genotypes in this group, and all analysed mice were clamped within 1 mM range of 
their basal blood glucose levels (Figure 4-34 C). Interestingly, LysM-Cre Adrb2fl/fl mice 
required lower glucose infusion rate (GIR) to maintain stable blood glucose 
concentration in hyperinsulinaemic state compared to controls (Figure 4-34 D,E). 
 
4.2.2.17 Macrophage-specific Adrb2 deletion increased insulin-mediated 
glucose disposal during hyperinsulinaemic-euglycaemic clamp of HFD-
fed mice 
Results. Unlike my previous observation, 2AR deficiency in macrophages did not 
affect the body weight of mice during high-fat feeding (Figure 4-35 A). Successfully 
clamped mice had similar body weight, blood glucose concentration after overnight 
fast and required similar GIR to maintain stable blood glucose levels during the clamp 
(Figure 4-35 B, C,D, F). Interestingly, LysM-Cre Adrb2fl/fl animals showed increased 
glucose disposal during clamp, despite exhibiting similar clamp HGP compared to 
controls (Figure 4-35 E).  
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Figure 4-34. Hyperinsulinaemic-euglycaemic clamp analysis of chow-fed 
Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice. 
(A) Weekly body weight measurements prior to the study (perfomed at 155 days of 
age), n=11 Adrb2fl/fl (black lines) and n=9 LysM-Cre Adrb2fl/fl (red lines) male mice on 
a pure C57Bl/6J background. (B) Body weights, (C) blood glucose levels and (D) 
glucose infusion rate during the clamp. Insulin was administered at T=0 min. Last 3 
blood samples were considered as a hyperinsulinaemic (‘clamped’) state and were 
used for determining the clamp rate of glucose disposal (Rd) and HGP. Only the data 
from the animals that were successfully clamped is presented (n=6 mice/genotype). 
(E) Summary of the results (Adrb2fl/fl, black bars and LysM-Cre Adrb2fl/fl, white bars) 
and (F) the correlation between body weight and GIR. * p < 0.05 compared between 
genotypes using (A) two-way ANOVA with Bonferroni’s multiple comparisons test, (B, 
E) student’s t-test or (F) one-way ANCOVA. In (F), p=0.08. Experiment and data 
analysis was performed by Dr Sam Virtue and Dr Anne Mcgavigan. 
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Figure 4-35. Hyperinsulinaemic-euglycaemic clamp analysis of HFD-fed Adrb2fl/fl 
and LysM-Cre Adrb2fl/fl mice. 
(A) Weekly body weight measurements prior to the study (perfomed at 155 days of 
age. Dotted line indicates the switch from chow to 60% kcal HFD (D12492)), n=10 
Adrb2fl/fl (black lines) and n=11 LysM-Cre Adrb2fl/fl (red lines) male mice on a pure 
C57Bl/6J background. Duration of HFD was 12 weeks. (B) Body weights, (C) blood 
glucose levels and (D) glucose infusion rate during the clamp. Insulin was administered 
at T=0 min. Last 3 blood samples were considered as a hyperinsulinaemic (‘clamped’) 
state and were used for determining the clamp rate of glucose disposal (Rd) and HGP. 
Only the data from the mice that were successfully clamped is presented (n=5 
mice/genotype). (E) Summary of the results (Adrb2fl/fl, black bars and LysM-Cre 
Adrb2fl/fl, white bars) and (F) the correlation between body weight and GIR. * p < 0.05 
compared between genotypes using two-way ANOVA with Bonferroni’s multiple 
comparisons test (A) student’s t-test (B, E) or one-way ANCOVA (F). In (F), p=0.22. 
Experiment and data analysis was performed by Dr Sam Virtue and Dr Anne 
Mcgavigan. 
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4.2.2.18 Systemic 2AR blockade reduced liver weight of mice after a 
short-term cold exposure 
Rationale. After completing the initial metabolic phenotyping experiments, I decided 
to investigate the effects of macrophage 2AR deficiency on the metabolic profile of 
mice exposed to cold, when SNS tone to adipose tissues is increased in order to 
enhance thermogenesis and to promote lipolysis to fuel increased lipid utilisation by 
UCP1-positive adipocytes.  
 
I initially decided to use ICI-118,511 to block all 2ARs in mice before placing them 
from the room temperature to 10 C. As the predominant NE receptor mediating 
lipolysis and thermogenesis in adipocytes is 3AR, I hypothesised that inhibiting 2AR 
would mostly affect macrophages and vascular smooth muscle cells. 
 
Results. Exposure of animals to 10 C for 24 h did not affect their body weight 
independently of 2AR blockade (Figure 4-36 A). Core body temperature was reduced 
in cold to the same degree in both groups (Figure 4-36 B). Interestingly, while 2AR 
blockade during cold exposure did not impact the BAT-, scWAT- and eWAT-to-body 
weight ratios, it reduced the liver-to-body weight ratio compared to controls (Figure 
4-36 C-F). 
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Figure 4-36. Body weight, core temperature and tissue weights of cold-exposed 
mice treated with 2AR blocker. 
(A) Body weight and (B) rectal temperature of 12-week-old male mice on a pure 
C57Bl/6J genetic background under the standard housing conditions (RT, both 
groups), or after an intraperitoneal bolus injection of ICI-118,511 (500 g/mouse, red 
dots) and an immediate switch to the environmental temperature of 10 C for 24 h (24h 
10C). Control mice were injected with PBS (black dots). Weights of (C) BAT, (D) 
scWAT, (E) eWAT and (F) liver, expressed as a percentage of body weight after 24 h 
at 10 C. N=5 mice/group for (B), and n=4 mice/group for (A, C-F). * p < 0.05 compared 
between genotypes using (A, B) two-way ANOVA with Bonferroni’s multiple 
comparisons test or (C-F) student’s t-test. 
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4.2.2.19 Systemic 2AR blockade increased BAT Ucp1 expression levels 
after a short-term cold exposure 
Results. Animals injected with ICI-118,511 had higher Ucp1 mRNA levels, indicating 
an increased BAT thermogenic function (Figure 4-37 A). The expression of beige 
adipocyte marker genes Ucp1 and Dio2 was similar, while Elovl3 mRNA levels were 
higher in scWAT of cold exposed mice treated with 2AR-blocker compared to controls 
(Figure 4-37 B). Treatment with ICI-118,511 did not affect Adrb2 mRNA levels in BAT 
or scWAT (Figure 4-37 A,B). 
 
 
 
Figure 4-37. Gene expression analysis of BAT and scWAT isolated from cold-
exposed mice treated with 2AR blocker. 
(A) Ucp1, Elovl3, Pgc1a, Dgat1 and Adrb2 mRNA levels (normalised to BestKeeper) 
in BAT, and (B) Ucp1, Dio2, Elovl3, Cidea and Adrb2 mRNA levels (normalised to 
BestKeeper) in scWAT of 12-week-old male mice on a pure C57Bl/6J genetic 
background, injected with PBS (n=5, black bars) or ICI-118,511 (500 g/mouse, n=5, 
white bars) and placed at 10 C for 24h. * p < 0.05 compared between genotypes using 
student’s t-test. 
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4.2.2.20 Macrophage-specific Adrb2 deletion did not affect the systemic 
response to cold exposure 
Rationale. Next, I decided to investigate how mice carrying a macrophage-specific 
Adrb2 deletion respond to a cold environment. To test this, I placed LysM-Cre Adrb2fl/fl 
and control animals at 5 C and measured their body weight, core body temperature, 
circulating glucose and FFAs before and after 6, 24 and 72 h in a cold environment.  
 
Results. LysM-Cre Adrb2fl/fl mice exhibited comparable weight loss and core body 
temperature at 5 C to controls (Figure 4-38 A,B). Cold exposure equally increased 
blood glucose concentration in both genotypes (Figure 4-38 C). While circulating FFA 
levels were higher in LysM-Cre Adrb2fl/fl animals compared to controls before cold 
exposure, atypically high serum FFA concentration indicated potential sample 
degradation, which could also explain observed decrease in serum FFA levels in both 
groups over the course of cold exposure, rather than the expected increase (Figure 
4-38 D). 
  
  238 
 
Figure 4-38. Body weight, core body temperature, circulating glucose and FFA 
levels in Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice during cold exposure. 
(A) Body weight (expressed as percentage of the body weight at T=0), (B) rectal 
temperature, (C) blood glucose and (D) serum FFA levels measured after 6, 24 and 
72 h of exposure to 5 C environmental temperature in Adrb2fl/fl (n=11, black lines) and 
LysM-Cre Adrb2fl/fl (n=8, red lines) 16-week-old male mice on a pure C57Bl/6J genetic 
background. * p < 0.05 compared between genotypes at each time-point using two-
way ANOVA with Bonferroni’s multiple comparisons test. 
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4.2.2.21 Macrophage-specific Adrb2 deletion did not affect the weight of 
metabolic tissues of mice after 72 h of cold exposure 
Results. There were no genotype-dependent differences in total body weight, and 
BAT-, scWAT-, eWAT-, and liver-to-body weight ratios after 72 h of cold exposure 
(Figure 4-39 A-E). 
 
 
Figure 4-39. Tissue weights of Adrb2fl/fl and LysM-Cre Adrb2fl/fl mice after 72 h 
of cold exposure. 
(A) Body weight and weights of (B) BAT, (C) scWAT, (D) eWAT and (E) liver, 
expressed as a percentage of body weight of Adrb2fl/fl (n=11, black dots) and LysM-
Cre Adrb2fl/fl (n=8, red dots) 16-week-old male mice on a pure C57Bl/6J genetic 
background, placed at 5 C for 72 h. Statistical differences were compared between 
genotypes using student’s t-test. 
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4.2.2.22 Macrophage-specific Adrb2 deletion did not affect scWAT gene 
expression after 72 h of cold exposure 
Results. After 72 h at 5 C, LysM-Cre Adrb2fl/fl and control animals had similar levels 
of Ucp1, Pgc1a, Cidea, Elovl3, Atgl, Hsl, Adrb1, Adrb2, Adrb3, Cd11b, F4/80 and 
Cd206 mRNA in scWAT, indicating no genotype-dependent differences in scWAT 
browning or inflammation (Figure 4-40).  
 
 
Figure 4-40. Gene expression analysis of scWAT isolated from Adrb2fl/fl and 
LysM-Cre Adrb2fl/fl mice after 72 h of cold exposure. 
Ucp1, Pgc1a, Cidea, Elovl3, Atgl, Hsl, Adrb1, Adrb2, Adrb3, Cd11b, F4/80 and Cd206 
mRNA levels (normalised to BestKeeper) in scWAT isolated from Adrb2fl/fl (n=11, black 
dots) and LysM-Cre Adrb2fl/fl (n=8, red dots) 16-week-old male mice on a pure 
C57Bl/6J genetic background, placed at 5 C for 72 h. Statistical differences were 
compared between genotypes using student’s t-test. 
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4.3 Discussion 
This chapter describes how NE signalling via 2AR regulates TG metabolism in 
macrophages, and how the loss of macrophage 2AR signalling affects the metabolic 
health of a whole animal in lean and obese states. This study was initiated after 2AR 
stimulation had been found to reduce lipolysis and promote lipid accumulation in 
BMDMs. The main findings of this chapter were as follows: 
 
1) 2AR activation enhanced TG storage in BMDMs by increasing Dgat1 transcription. 
 
2) LysM-Cre Adrb2fl/fl mice did not exhibit changes in WAT inflammation or systemic 
insulin sensitivity on a chow or HFD. 
 
3) Both systemic inhibition of 2ARs and macrophage-specific Adrb2 deletion did not 
alter the thermogenic response of mice to a cold environment challenge.  
 
4.3.1 2AR activation promoted FFA storage in BMDMs 
In this chapter, I demonstrated that 2AR stimulation rapidly supressed lipolysis and 
enhanced TG storage in BMDMs via two independent mechanisms. 
 
My lipolysis experiments have shown that the inhibitory effect on the oleate release 
from BMDMs occurs during 1-3 h post 2AR activation. Interestingly, such inhibition 
was not dependent on TG hydrolysis, oleate re-esterification to TGs or lipophagy. One 
potential reason for reduced appearance of radiolabelled oleate in the medium after 
stimulating lipid-laden BMDMs with 2AR agonist that was not tested in this chapter 
could be decreased rate of oleate oxidation, as observed independently during the 
measurement of FFA oxidation rates in response to NE stimulation. As the medium 
used in BMDM culture contain bicarbonate buffering system, CO2 produced by BMDMs 
during complete -oxidation of fatty acids will be initially trapped in the medium before 
equilibrating with atmospheric gas. Therefore, it is possible that a part of radioactivity 
released from radiolabelled oleate-laden BMDMs after the medium change does not 
correspond to liberated 14C-oleate, but rather to 14CO2 produced from the complete 
oxidation of 14C-oleate. I will test such hypothesis in the future by performing lipid 
extraction on the supernatants of the lipolysis assay of BMDMs. If the inhibitory effect 
of 2AR activation on the oleate release from BMDMs are due to decreased 14CO2 
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release, there should be equal amounts of radiolabel in the lipid phase of the 
supernatants from 2AR agonist-treated BMDMs and controls. Furthermore, I will 
investigate whether the inhibitory effect on the radiolabel appearance in the medium 
could be blocked by etomoxir. 
 
Unlike inhibition of lipolysis, increased TG storage in BMDMs occur after prolonged 
2AR activation and is predominantly mediated by up-regulated DGAT1 enzymatic 
activity. While increased TG esterification in response to 2AR agonism can be 
explained by a transcriptional activation of Dgat1 gene, it is difficult to understand the 
biological importance of such process. Previous report has ascribed an anti-
inflammatory role for DGAT1 in macrophages during treatments with LPS or 
palmitate209. However, the protective effects of DGAT1 during lipotoxicity are thought 
to be mediated by decreased intracellular concentrations of its substrate DAG258. My 
results showed that despite increased DGAT1 activity and TG synthesis, the absolute 
levels of DAG species in palmitate-treated BMDMs were not affected by 2AR 
activation or DGAT1 blockade. Consistent with such observation, anti-inflammatory 
effects of 2AR agonist in BMDMs during stimulation with palmitate were not mediated 
by increased DGAT1 activity, but likely by direct suppression of intracellular TLR 
signalling pathway, as described in other reports where 2AR stimulation inhibited NF-
B activation in LPS-treated macrophages459,568. 
 
4.3.2 Macrophage-specific Adrb2 deletion did not lead to increased WAT 
inflammation during obesity 
Current literature supports the anti-inflammatory role for macrophage 2AR in multiple 
tissues, including WAT. Gut luminal bacterial infection has been shown to rapidly 
activate gut extrinsic sympathetic innervation, leading to the activation of 2AR in the 
intestinal muscle macrophages and promoting their M2 polarisation, thus limiting the 
tissue inflammation438. Similarly, leptin-mediated increase in NE signalling in WAT has 
been suggested to reduce WAT inflammation through elevating cAMP levels in 
ATMs460. Furthermore, surgically denervating eWAT or BAT has been shown to 
increase their Tnf expression levels, supposedly due to decreased 2AR signalling in 
ATMs459. Finally, treating obese rats with 2AR agonist has attenuated inflammation 
and fibrosis in the kidneys and heart569. 
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In the light of published reports, it is surprising that I did not observe elevated WAT 
inflammation in the macrophage-specific Adrb2 knockout mice compared to controls 
after prolonged high-fat feeding. In fact, my results indicated a tendency towards a 
favourable metabolic phenotype in obese animals lacking 2ARs in macrophages, 
even when there was no difference in the total body-weight, as characterised by an 
increased rate in insulin-mediated glucose disposal compared to genotype controls in 
euglycaemic clamp experiment.  It is important to emphasise that all the previous 
publications suggesting an anti-inflammatory role for 2AR signalling in ATMs did not 
utilise a macrophage-specific Adrb2 knockout animal model, which is a best available 
tool to directly assess the importance of 2AR signalling in ATMs on the development 
of WAT inflammation. Both the activation of SNS by leptin460, or surgical denervation 
of WAT459 would directly affect the adipocytes by modulating their 3AR activation. 
Therefore, my results suggest that the anti-inflammatory properties of NE signalling in 
WAT observed in the previous studies are likely due to -adrenergic stimulation of the 
adipocytes, which subsequently affect ATMs through a paracrine signalling that 
remains to be investigated. 
 
The anti-inflammatory action of 2AR agonist observed during the palmitate treatment 
of BMDMs in vitro did not translate into elevated M1 or reduced M2 polarisation in 
2AR-deficient ATMs in vivo. Such finding further emphasise the complexity of a 
physiological system and indicate that using canonical tools to study lipotoxicity in 
macrophages in vitro is not always a good model for processes occurring in the WAT. 
In the following results chapter (Chapter 5), I will describe a more detailed 
characterisation of the phenotype of 2AR agonist-treated BMDMs, which might help 
to explain the unexpected phenotype of LysM-Cre Adrb2fl/fl mice. 
 
4.3.3 Macrophage-specific Adrb2 deletion had a minor effect on hepatic 
glucose metabolism 
Reduced body weight gain during high-fat feeding, and increased body weight loss 
following cold exposure in LysM-Cre Adrb2fl/fl animals could theoretically be explained 
by elevated SNS tone in BAT and/or scWAT. However, no changes in Ucp1 or other 
genes that reflect increased BAT activity or scWAT browning were observed between 
genotypes on a HFD, or following cold exposure. Furthermore, the resistance to 
acquire body mass during obesity could not be replicated in two different cohorts of 
LysM-Cre Adrb2fl/fl mice. Finally, no differences in the overall energy balance were 
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found on a chow diet, or during the initial period of high-fat feeding between LysM-Cre 
Adrb2fl/fl animals and controls. Based on the presented evidence, it is difficult to identify 
the potential reasons for such discrepant in vivo findings in this chapter. 
 
When compared to genotype controls, mice lacking 2AR in macrophages showed 
increased blood glucose levels in a fasted state on a chow diet and in a fed state after 
a short-term HFD; increased circulating liver enzyme AST on a chow diet; elevated 
hepatic Fasn expression and relative palmitate levels in the fed state on a chow diet. 
Furthermore, chow-fed LysM-Cre Adrb2fl/fl mice had reduced GIR during 
hyperinsulinaemic-euglycaemic clamp compared to controls, likely resulting from 
increased HGP during a clamp. In summary, macrophage-specific Adrb2 deletion 
caused elevated HGP in multiple experimental settings. Interestingly, increased SNS 
tone in the liver is known to promote HGP570,571. Furthermore, hepatic SNS signalling 
has been shown to supress ketogenesis, which utilises FFAs, including palmitate, as 
substrates572. Therefore, it is possible that the observed changes in the liver profile of 
LysM-Cre Adrb2fl/fl mice are caused by reduced NE degradation by Kupffer cells, 
leading to increased hepatic SNS tone. In future, I will investigate such hypothesis by 
measuring NE concentration in the livers of LysM-Cre Adrb2fl/fl and control animals in 
the fed and fasted states. I will also isolate Kupffer cells from mice of both genotypes 
in order to assess the expression of genes encoding monoamine degradation 
enzymes. 
 
As several in vivo findings in this chapter pointed to a role of macrophage 2AR in 
limiting SNS tone in liver, in future I will employ a more mechanistic approach to study 
the importance of macrophage 2AR for NE degradation in vivo. SLC6A2 deficiency 
in macrophages has been found to increase Ucp1 levels in BAT and scWAT after 2 h 
of cold exposure of mice compared to controls424. Therefore, I will place LysM-Cre 
Adrb2fl/fl and control animals at 4 C for 2 h in order to investigate the early SNS-
mediated signalling events leading  to increased BAT activation and scWAT browning 
in response to cold. It is possible that after 24 h of cold exposure, the physiological 
system adapts to a decreased rate of NE degradation by reducing SNS output to the 
adipose tissues. Such short-term regulatory mechanism could be physiologically 
important for the adaptation to circadian environmental temperature fluctuations, and 
my proposed experiment would provide the basis for the future studies in this area. 
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4.3.4 Conclusions 
In this chapter, I found that NE, acting via 2AR, altered BMDM lipid metabolism by 
supressing oleate release and oxidation, and enhancing TG storage. While 2AR 
activation supressed palmitate-induced inflammatory activation of BMDMs, such 
suppression was not mediated by increased TG storage capacity. Despite the 
published and observed anti-inflammatory effects of 2AR agonism in BMDMs, 
macrophage-specific Adrb2 knockout animals did not show differences in WAT 
inflammation or systemic insulin sensitivity compared to controls on a chow or HFD. 
Finally, mice lacking Adrb2 in macrophages did not exhibit any differences in their 
response to a cold environment, but had a minor increase in HGP during fasting on a 
chow diet. In future, additional experiments will need to be performed in order to 
understand the importance of macrophage 2AR in regulating SNS signalling within 
different tissues. 
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5 The regulation of gene and protein expression in 
BMDMs in response to 2AR activation 
5.1 Introduction 
The in vitro studies presented in Chapter 4 predominantly focused on the molecular 
mechanisms mediating increased TG storage in BMDMs in response to 2AR 
stimulation. However, one finding that I did not discuss in Chapter 4 was the 
transcriptional regulation of Dgat1 gene following 2AR agonism. All measured 
canonical CREB target genes had a similar pattern of expression in response to 2AR 
activation, characterised by a rapid increase in mRNA levels immediately after 
stimulation with fenoterol, a peak of expression at 1 h, and a decline to the basal mRNA 
levels at 2-3 h after 2AR activation (Figure 5-1). Interestingly, increase in Dgat1 
mRNA was delayed and only commenced at 1 h, peaked at 2-4 h, and returned to the 
baseline at 8 h post stimulation (Figure 5-1). Such finding indicated that DGAT1 and 
potentially other intracellular metabolic enzymes were under a different transcriptional 
control compared to the canonical CREB target genes in response to 2AR activation. 
 
Subsequently in this chapter, the canonical CREB target genes that showed peak 
mRNA levels at 1 h after 2AR activation will be referred as early phase genes, and 
the transcripts that exhibited delayed up-regulation post stimulation, including Dgat1 – 
as late phase genes (Figure 5-1). 
 
 
Figure 5-1. A hypothetical model of a biphasic induction of gene transcription 
following 2AR activation.  
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Furthermore, the in vitro studies of Chapter 4 focused only on 2AR agonism-elicited 
effects on BMDM fatty acid metabolism. Whether 2AR activation induces other 
changes to the intracellular BMDM nutrient metabolism is not yet known. 
 
Based on my in vitro data presented in Chapter 4, I predict 2AR stimulation in 
macrophages to elicit a range of phenotypic changes. In part, these changes will be 
mediated by altered abundance of specific proteins. Therefore, in this chapter I 
propose the following research questions: 
 
1) What is the identity of proteins induced by an acute 2AR stimulation in 
BMDMs? 2) What factors regulate the induction of these proteins in response to 
2AR activation? 
 
In this Chapter, I will aim to answer my research questions through the following 
objectives:  
Objective 1. To characterise the changes in global protein expression elicited by 
2AR agonism in BMDMs. This will be performed using large-scale proteomic 
analysis of 2AR agonist-treated BMDMs. Based on the alterations in cellular 
proteome, bioinformatics tools will be utilised to predict the changes in metabolic and 
signalling pathways, as well as transcription factors that might mediate the BMDM 
phenotype induced by 2AR activation. 
 
Objective 2. To validate the importance of predicted transcription factors in 
regulating gene transcription following 2AR stimulation in BMDMs. Based on 
the results obtained in Objective 1, I will utilise pharmacological inhibitors and genetic 
cell models to identify signalling pathways and transcription factors regulating BMDM 
gene expression and lipid metabolism in response to 2AR activation alone or during 
inflammatory activation by LPS. 
 
Expected impact. Overall, I expect that the results obtained in this chapter will help to 
explain the phenotype observed in LysM-Cre Adrb2fl/fl animals during obesity. 
Furthermore, the data from this chapter will contribute to the rapidly growing field 
investigating SNS-macrophage interactions by providing an insight into the effects of 
sympathetic nerve activation on the phenotype of neighbouring macrophages. 
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5.2 Results 
5.2.1 Acute effects of 2AR activation on BMDM proteome  
5.2.1.1 Acute 2AR activation induced profound changes in BMDM proteome 
Rationale. As my previous results indicated that fenoterol was specifically stimulating 
2AR without any off-target effects on CREB phosphorylation, I decided to utilise it for 
2AR activation in the proteomic analysis of BMDMs. Because of my primary interest 
in macrophage lipid metabolism, I used the kinetics of 2AR stimulation-induced Dgat1 
transcription to determine the appropriate time point for the proteome comparison. 
Since Dgat1 mRNA levels peaked at approximately 4 h after 2AR activation, I chose 
to perform 6 h treatment of BMDMs with fenoterol, accounting for the delay between 
gene transcription and protein expression. 
 
Results. In total, peptides corresponding to 5268 proteins were measured with a high 
degree of confidence. The coverage of proteome was incomplete, since multiple 
proteins that are known to be present in BMDMs, such as DGAT1, were not detected. 
The p value distribution analysis showed an enrichment in the abundance changes 
with a low p value (<0.05), indicating that 2AR activation for 6 h selectively modulated 
a specific set of measured proteins, and observed differences between two states were 
not due to a random distribution of protein amounts (Figure 5-2 A).  
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Figure 5-2. Visualisation of changes to BMDM proteome induced during 6 h 
following 2AR activation.  
(A) Frequency of proteins exhibiting a change in abundance at any degree of statistical 
significance and (B) the confidence and fold change in protein abundance between 
BMDMs treated with 1 M fenoterol for 6 h and untreated controls. Hyperbolic cut-off 
lines and blue colouring in (B) is for visual comparison between up- and down-
regulated proteins. Red dot corresponds to the most increased protein 
thrombospondin-1. N=3 mice. Data normalisation, analysis and visualisation was 
performed by PhD student Aurelien Dugourd from Prof. Rodriguez group.   
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Plotting the confidence of change against the magnitude of change revealed that 2AR 
activation both increased and decreased the abundance of specific proteins, with a 
small bias towards down-regulating protein expression (Figure 5-2 B). Such 
observation is not uncommon for short-term cell stimulations, where agonist-induced 
protein degradation predominates over the synthesis of new proteins. Furthermore, 
one specific protein, thrombospondin-1 (THBS1), exhibited a much greater increase 
upon 2AR activation than any other measured protein (Figure 5-2 B), and will be 
discussed further in this chapter. 
 
5.2.1.2 Acute 2AR stimulation increased the activity of intracellular metabolic 
processes and pathways in BMDMs 
Rationale. Next, all measured proteins were analysed for biological trends in an 
unbiased manner based on the p value of changes between treated and non-treated 
groups (Figure 5-2 B, y axis). Gene Ontology (GO) database was utilised to identify 
proteins that are involved in the same biological processes, and Reactome, Kegg, 
NABA, Biocarta and PID databases were used to assign differentially expressed 
proteins to biological pathways.  
 
Results. Amongst all GO biological processes that had been up-regulated by 2AR 
stimulation, cellular metabolic processes were highly represented, including 
carbohydrate, protein and lipid metabolism processes (Figure 5-3 A). Similar trend was 
observed in the list of pathways showing elevated activity after 2AR activation, with 
the expression of proteins related metabolism of proteins, lipids and glucose being 
increased (Figure 5-4 A). Interestingly, despite fenoterol having no affinity to NE-
degrading enzymes573, the most up-regulated biological pathway in 2AR agonist-
treated BMDMs was ‘neuronal system’, which includes proteins involved in the 
neurotransmitter uptake and degradation (Figure 5-4 A). Finally, there was a clear 
trend for reduced activity of biological processes and pathways related to gene 
transcription, mRNA processing and DNA replication after 2AR activation in BMDMs 
(Figure 5-3 B, Figure 5-4 B). 
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Figure 5-3. GO biological processes altered by 2AR activation in BMDMs. 
Lists of GO biological processes that were either (A) up-regulated (green bars) or (B) 
down-regulated (blue bars) in BMDMs stimulated with 1 M fenoterol for 6 h. 
Processes within each list were ranked based on the confidence of change (expressed 
as –log10 (p value)). Due to the replicate number (n=3), the lowest possible p value 
obtained from the analysis was 0.0001. In cases where multiple processes had a p 
value of 0.0001, those processes were ranked based on the number of proteins 
contributing to the activity of that specific process. Data normalisation, analysis and 
visualisation was performed by PhD student Aurelien Dugourd from Prof. Rodriguez 
group.   
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Figure 5-4. Biological pathways altered by 2AR activation in BMDMs. 
Lists of biological pathways from Reactome, Kegg, NABA, Biocarta and PID databases 
that were either (A) up-regulated (green bars) or (B) down-regulated (blue bars) in 
BMDMs stimulated with 1 M fenoterol for 6 h. Pathways within each list were ranked 
based on the confidence of change (expressed as –log10 (p value)). Due to the 
replicate number (n=3), the lowest possible p value obtained from the analysis was 
0.0001. In cases where multiple pathways had a p value of 0.0001, those pathways 
were ranked based on the number of proteins contributing to the activity of that specific 
pathway. Data normalisation, analysis and visualisation was performed by PhD student 
Aurelien Dugourd from Prof. Rodriguez group.   
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5.2.1.3 Acute 2AR stimulation increased HIF1-dependent protein expression 
Rationale. All measured proteins were then subjected for transcription factor analysis, 
which predicted the likelihood of transcription factor activity based on the p value of 
their target gene product changes between treated and non-treated groups.  
 
Results. Consistent with an increased abundance of proteins involved in lipid 
metabolism, 2AR stimulation was predicted to elevate the activity of SREBP1 and 
retinoid X receptor  (RXR), which are known regulators of cellular lipid metabolism 
(Figure 5-5). Interestingly, HIF1 showed highest predicted transcriptional activity in 
BMDMs after 2AR stimulation (Figure 5-5). In line with this finding, the most up-
regulated protein in response to 2AR activation, THBS1, is a known HIF target gene 
product574. 
 
 
Figure 5-5. Transcription factors predicted to have elevated activity after 2AR 
activation in BMDMs. 
List of transcription factors predicted to have increased activity in BMDMs stimulated 
with 1 M fenoterol for 6 h. Transcription factors  were ranked based on the confidence 
of change (expressed as –log10 (p value)). Data normalisation, analysis and 
visualisation was performed by PhD student Aurelien Dugourd from Prof. Rodriguez 
group.   
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5.2.1.4 Acute 2AR stimulation increased the expression of enzymes involved 
in catecholamine catabolism in BMDMs 
Results. SAMs have been reported to express the enzymes involved in monoamine 
degradation, which are part of the ‘neuronal system’ pathway. SAMs isolated from a 
healthy WAT were shown to express MAOA and SLC6A2424, while aging also up-
regulated the ATM genes encoding aldehyde dehydrogenase and aldo-keto reductase 
enzymes that catalyse the final step of NE breakdown439. Interestingly, treating cells 
with 2AR agonist fenoterol, which cannot be oxidised by MAOA573, resulted in a small 
increase in all detected proteins involved in NE breakdown (Figure 5-6). Elevated 
levels of the enzymes involved in monoamine oxidation in 2AR-treated BMDMs were 
also accompanied by a large increase in NLRP3 protein, which has been described to 
drive the development of monoamine degradation transcriptional programme in the 
ATMs during aging439 (Figure 5-6). 
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Figure 5-6. The effect of 2AR activation on the expression of proteins related to 
monoamine degradation in BMDMs. 
Fold change in the abundance of indicated proteins between BMDMs treated with 1 
M fenoterol for 6 h and untreated controls, as described in 5.2.1.1. N=3 mice. 
Statistical differences are not indicated. Data normalisation and analysis was 
performed by PhD student Aurelien Dugourd. 
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5.2.2 Acute effects of 2AR activation on BMDM glucose metabolism 
5.2.2.1 Acute 2AR stimulation promoted aerobic glycolysis in BMDMs 
Rationale. As glucose and lipid metabolism were amongst the top up-regulated 
pathways in the proteomic analysis of 2AR agonist-treated BMDMs, I decided to 
functionally assess BMDM nutrient utilisation in response to 2AR stimulation. 
Monocarboxylate transporter 4 (MCT4), responsible for transporting intracellular 
lactate outside of the cell, was highly up-regulated in BMDMs following fenoterol 
treatment (9.73 fold increase, adj. p value = 0.0005 compared to untreated controls). 
Based on this finding, I hypothesised that 2AR stimulation could increase lactate 
production through enhancing aerobic glycolysis in BMDMs. To test such hypothesis, 
real-time extracellular acidification rate (ECAR) was assessed after 2AR activation.  
 
Results. Indeed, an increase in ECAR was readily observed 40 min after fenoterol 
treatment, reaching the peak ECAR increase of approximately 20% compared to 
control BMDMs at 80 min after 2AR activation (Figure 5-7 A). The observed ECAR 
increase was sustained throughout the duration of the assay (up to 3 h following 
fenoterol treatment), and was completely abolished when BMDMs were treated with 2-
DG, indicating that the difference in the ECAR in response to 2AR agonism was 
driven entirely by glycolysis (Figure 5-7 A). Similar result was obtained in response to 
NE, and the increase in ECAR was diminished in 2AR-defficient BMDMs (Figure 5-7 
B).  
 
Conclusion. 2AR activation rapidly increased the rate of aerobic glycolysis in 
BMDMs.  
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Figure 5-7. Extracellular acidification rate in response to 2AR activation in 
BMDMs.  
ECAR, expressed as fold change compared to initial 4 basal measurements, in (A) WT 
BMDMs (n=4 mice, 8 technical replicates per mouse per condition) treated with 10 M 
fenoterol (grey dots represent treated cells, black dots – controls) at 21 min of the 
assay (as indicated by the dashed line in the graph), or in (B) Adrb2fl/fl (black dots) and 
LysM-Cre Adrb2fl/fl (red dots) BMDMs (n=4 mice/group, 8 technical replicates per 
mouse per condition) treated with 1 M NE at 21 min of the assay (as indicated by the 
dashed line in the graph). At the end of the assay, glycolysis was inhibited by injecting 
10 mM 2-DG (at the time indicated by the dashed line in the graphs). Experiments and 
data analysis was performed by Dr Guillaume Bidault. * p < 0.05 compared to control 
at each time-point using two-way ANOVA with Bonferroni’s multiple comparisons test. 
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5.2.2.2 Acute 2AR activation increased mitochondrial ROS in BMDMS 
Rationale. Prolonged treatment of macrophages with LPS results in enhanced aerobic 
glycolysis and decreased oxygen consumption rate (OCR), which is a consequence of 
mitochondrial repurposing from oxidative phosphorylation towards the production of 
ROS110. In order to assess whether mitochondrial function is affected in BMDMs in 
response to 2AR activation, I performed mitochondrial stress assay in BMDMs 1 h 
after NE stimulation, when ECAR was reaching its maximal increase compared to an 
unstimulated state. Mitochondrial function was assessed by measuring OCR in a basal 
state, and in response to a sequential injection of the following compounds: ATP 
synthase inhibitor oligomycin (where residual OCR represents the sum of ATP 
synthesis-independent mitochondrial proton leak and OCR from cellular processes 
other than electron transport chain), mitochondrial uncoupler FCCP (where OCR 
represents maximal mitochondrial respiratory capacity), FAO inhibitor etomoxir (where 
the difference in OCR between FCCP and etomoxir represents the rate of 
mitochondrial FAO) and electron transport chain complex I and III inhibitors rotenone 
and antimycin A (where the residual OCR represents oxygen-consuming cellular 
processes other than electron transport chain). 
 
Results. Contrary to LPS treatment, which results in increased basal ECAR and 
decreased basal OCR, no difference in basal OCR was detected in BMDMs treated 
with NE for 1 h, despite elevated basal ECAR (Figure 5-8 A, Figure 5-7 B). Surprisingly, 
maximal respiratory capacity was elevated in NE-treated BMDMs, and such increase 
was maintained after etomoxir injection, suggesting an FAO-independent effect 
(Figure 5-8 A). However, despite unimpaired mitochondrial respiration, mitochondrial 
ROS production was increased in BMDMs after acute 2AR activation (Figure 5-8 B). 
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Figure 5-8. Mitochondrial respiration and ROS production in response to 2AR 
activation in BMDMs. 
(A) OCR, expressed as pmoles of oxygen/min, measured in WT BMDMs (n=4 mice, 8 
technical replicates per mouse per conditions) pre-treated with 1 M NE (grey dots 
represent treated cells, black dots – controls) for 1 h and subjected to mitochondrial 
stress assay involving sequential injections of 1 M oligomycin, 1.5 M FCCP, 40 M 
etomoxir and 100 nM rotenone + 1 M antimycin A  at indicated time-points in the 
graph and 3 consecutive OCR measurements in between injections. (B) Mitochondrial 
ROS production in WT BMDMs (n=8 mice) treated with 1 M NE for 1 h (red dots), 
normalised to untreated controls (black dots). Experiments and data analysis was 
performed by Dr Guillaume Bidault. * p < 0.05 compared to control (A) at each time-
point using two-way ANOVA with Bonferroni’s multiple comparisons test, (B) using 
student’s t-test. 
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5.2.3 The role of glycolysis and HIF transcription factors in the regulation 
of gene transcription in BMDMs in response to 2AR activation 
5.2.3.1 Pharmacological inhibition of glycolysis prolonged the transcription of 
early phase genes, but diminished the late phase gene expression in 
BMDMs in response to 2AR activation 
Rationale. My results so far have established that 2AR activation induced a change 
in BMDM nutrient metabolism, characterised by a rapid increase in aerobic glycolysis 
and mitochondrial ROS production, increased flux of exogenous fatty acids towards 
TG storage and a decrease in oleate lipolysis and -oxidation. Similar metabolic profile 
is observed when macrophages are activated by LPS, leading to an up-regulation of 
the aerobic glycolysis rate and increased fatty acid storage within lipid droplets272. 
Aerobic glycolysis in BMDMs has been previously shown to activate transcription factor 
HIF1111, and HIF1 itself is indispensable for ensuring an appropriate glycolytic flux 
and the maintenance of ATP levels in macrophages301. Consequently, genetic deletion 
of Hif1a gene in macrophages inhibits their inflammatory activation103,301. Furthermore, 
hypoxia is known to promote exogenous FFA accumulation within lipid droplets in 
multiple cell types (as summarised in the introduction), and HIF1 was shown to be 
instrumental in such process297. HIF1 activation has also been shown to promote cell 
cycle arrest575,576, characterised by decreased DNA replication and gene transcription, 
which was also observed in BMDMs following 2AR activation (Figure 5-3 B, Figure 
5-4 B). Finally, 2AR has recently been described to be involved in hypoxia sensing, 
and 2AR stimulation has been demonstrated to stabilise HIF1577. 
 
Based on the high confidence of HIF1 transcriptional activation, as predicted by the 
proteomic analysis of fenoterol-treated BMDMs (Figure 5-5), and the cellular metabolic 
profile consistent with increased HIF1 activation, I decided to test whether HIF 
proteins were important for 2AR stimulation-induced gene expression.  
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Results. As aerobic glycolysis has been shown to mediate HIF1 activation in 
macrophages, I initially stimulated BMDMs with 2AR agonist in the presence of 2-DG. 
Interestingly, I found that inhibiting glycolysis either unchanged or enhanced the 
expression of early phase genes at 1 h after 2AR activation (Figure 5-9 A). 
Furthermore, while the mRNA levels of early phase genes returned to their basal level 
after 4 h of stimulation with fenoterol, this transcriptional decrease was supressed by 
2-DG (Figure 5-9 A). However, the expression of late phase genes, including Thbs1 
(encoding thrombospondin-1) was diminished when 2-DG was present during 2AR 
activation (Figure 5-9 B).  
 
Conclusion. Inhibiting glycolysis during 2AR stimulation prolonged the transcription 
of early phase genes, but supressed the expression of late phase genes in BMDMs. 
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Figure 5-9. The effect of glycolysis inhibitor on 2AR agonism-mediated gene 
expression in BMDMs. 
mRNA levels (normalised to BestKeeper) of (A) early phase genes Nr4a1, Klf4, Dusp1 
and Cox2, and (B) late phase genes Hif1a, Dgat1 and Thbs1 in BMDMs stimulated 
with 10 mM 2-deoxyglucose (grey lines), 1 M fenoterol (black lines) or both 
compounds together (red lines) for 0, 1 and 4 h. N=4 mice. * p < 0.05 compared 
between fenoterol and fenoterol + 2-DG at each time-point using two-way ANOVA with 
Bonferroni’s multiple comparisons test.  
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5.2.3.1 Pharmacological inhibition of HIF transcription factors prolonged the 
transcription of early phase genes, but diminished the late phase gene 
expression in BMDMs in response to 2AR activation 
Rationale. Next, I decided to use a selective inhibitor of HIF transcription factors to 
further elucidate their role in 2AR agonism-mediated transcriptional response. 
Chetomin is a compound isolated from a large-scale screen, specifically targeting HIF 
interaction with its transcriptional co-activator p300, which is required for the activity of 
both HIF1 and HIF2 transcription factors578. Importantly, chetomin does not affect 
the interaction of p300 with its other partnering transcription factors, such as 
SREBP2578.  
 
Results. When chetomin was present during 2AR stimulation, the induction of early 
phase genes was either unchanged or slightly diminished compared to controls at 1 h 
time-point, but the return of the early target gene mRNA to the basal levels was 
supressed at later time-points (Figure 5-10 A). Interestingly, while the induction of late 
phase genes Hif1a and Thbs1 was inhibited, Dgat1 transcription was enhanced by 
chetomin following 2AR activation (Figure 5-10 B).  
 
Conclusion. In summary, the results obtained using pharmacological HIF inhibitor 
chetomin were comparable to 2-DG, with the exception of Dgat1 transcriptional 
induction. 
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Figure 5-10. The effect of HIF1-p300 protein complex inhibitor chetomin on 
2AR agonism-mediated gene expression in BMDMs. 
mRNA levels (normalised to BestKeeper) of (A) early phase genes Nr4a1, Klf4, Dusp1 
and Cox2, and (B) late phase genes Hif1a, Dgat1 and Thbs1 in BMDMs stimulated 
with 1 M fenoterol in the presence (red lines) or absence (black lines) of 100 nM 
chetomin for 0, 1, 2, 4, 6 and 8 h. N=4 mice. * p < 0.05 compared between treatments 
at each time-point using two-way ANOVA with Bonferroni’s multiple comparisons test.  
  265 
5.2.3.2 Genetic deletion of HIF1 or HIF2 DNA binding domain did not affect 
the induction of gene transcription in response to 2AR activation 
Rationale. As my evidence for HIF1 activation in response to 2AR agonism has so 
far been based on the molecular observations and the use of pharmacological tools, I 
obtained BMDMs from animals that lack the exon 2 of Hif1a gene specifically in 
macrophages, encoding its DNA binding domain579.  
 
Results. Similarly to the previously published observations301, I measured 
approximately 85% deletion in the exon 2 of Hif1a gene in HIF1-KO BMDMs, while 
the levels of remaining Hif1a transcript were slightly increased (Figure 5-11 A). 
Furthermore, the basal transcription of HIF1 target gene Glut1 was diminished in 
HIF1-deficient cells (Figure 5-11 A). However, unlike what has been described 
previously301, I did not see a reduction in basal Vegfa mRNA levels in HIF1-KO 
BMDMs compared to controls (Figure 5-11 A). Importantly, I did not observe an 
impairment in the fold induction of either canonical HIF1 target genes Glut1 and Vegfa 
(Figure 5-11 A), or early and late phase genes Nur77, Dgat1 and Thbs1 in HIF1-KO 
BMDMs compared to controls in response to 2AR activation (Figure 5-11 B). 
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Figure 5-11. The importance of HIF1 DNA binding for 2AR agonism-mediated 
gene expression in BMDMs. 
mRNA levels (normalised to BestKeeper) of (A) Hif1a (measured using standard and 
exon 2-intron 2 boundary-spanning primer sets) and its target genes Glut1 and Vegfa, 
and of (B) Thbs1, Dgat1 and Nur77 in Hif1a exon2fl/fl (n=3, black lines) and LysM-Cre 
Hif1a exon2fl/fl (n=2, red lines) BMDMs stimulated with 1 M fenoterol for 0, 1, 2, 4, 6 
and 8 h. * p < 0.05 compared between genotypes at each time-point using two-way 
ANOVA with Bonferroni’s multiple comparisons test.  
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Rationale. HIF2 has also been described to be important for macrophage 
inflammatory activation537, but its role in regulating gene transcription during 
inflammation is thought to be substantially different than the role of HIF1580. As Thbs1 
gene transcription has been previously shown to be dependent on HIF2581,582, I 
decided to investigate whether HIF2 mediates the induction of gene expression in 
response to 2AR activation. In order to do so, I obtained BMDMs from the animals 
with a macrophage specific deletion of Epas1 exon 2, encoding the DNA binding 
domain of HIF2583.  
 
Results. The excision of exon 2 in HIF2-KO BMDMs was verified by an observed 
reduction in the length of PCR amplicon containing exon 2 of Epas1 gene (Figure 5-12 
A). However, the induction of early and late phase genes in response to 2AR 
activation in BMDMs was not affected by the capacity of HIF2 to bind DNA (Figure 
5-12 B). Interestingly, while there was only a minor impairment in the relative Thbs1 
transcriptional induction after 4 h of 2AR stimulation in HIF2-KO BMDMs compared 
to controls, the basal level of Thbs1 mRNA was approximately 3-fold increased, and it 
remained higher throughout the period of 2AR stimulation in HIF2-KO BMDMs 
(Figure 5-12 B).  
 
Conclusion. Neither HIF1, nor HIF2 transcriptional activity was required for 2AR 
agonism-mediated gene expression.  
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Figure 5-12. The importance of of HIF2 DNA binding for 2AR agonism-
mediated gene expression in BMDMs. 
(A) PCR amplicon of exon 2 of  Epas1 mRNA (generated using Epas1 exon 2-spanning 
primers), separated on 1.5% agarose gel and (B) mRNA levels (normalised to 
BestKeeper) of Nr4a1, Klf4, Cox2, Dgat1, Thbs1 (expressed both as a relative amount 
to the housekeeper genes and as a fold increase from unstimulated cells) and Hif1a in 
Epas1 exon2fl/fl (n=3, black lines) and LysM-Cre Epas1 exon2fl/fl (n=3, red lines) 
BMDMs stimulated with 1 M fenoterol for 0, 1, 2, 4 and 8 h. * p < 0.05 compared 
between genotypes at each time-point using two-way ANOVA with Bonferroni’s 
multiple comparisons test.  
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5.2.4 The effects of 2AR activation on the inflammatory activation of 
BMDMs 
5.2.4.1 2AR activation mimicked the anti-inflammatory effects of salt-inducible 
kinase inhibition in BMDMs 
Rationale. CREB is a known regulator of Il10 transcription in macrophages584. 2AR 
activation has been previously shown to promote Il10 transcription in macrophages, 
both in CREB-dependent585 and CREB-independent manner457. It has also been 
proposed that the transcriptional increase in Il10 gene is largely responsible for the 
anti-inflammatory effects of -adrenergic agonists in macrophages stimulated with 
LPS586.  
 
PGE2, an agonist of another Gs-linked GPCR, has been shown to elevate Il10 
transcription in LPS-treated macrophages by promoting the inhibitory phosphorylation 
of salt-inducible kinases (SIKs), leading to the formation of an active CREB-CRTC 
transcription factor complex498. Similarly, pharmacological inhibition of SIKs also 
showed a potent anti-inflammatory effect in macrophages by promoting CREB-
dependent IL-10 production in response to LPS497. 
 
I therefore attempted to reproduce the reported anti-inflammatory effects of 2AR 
agonism in LPS-treated macrophages, and compare them to the effects of SIK 
inhibition. Furthermore, I wanted to investigate whether SIK blockade could potentiate 
the transcriptional response to 2AR agonism in BMDMs. To test this, I stimulated 
BMDMs with LPS in the presence of either fenoterol or SIK inhibitor HG-9-91-01, or 
with fenoterol and HG-9-91-01 in the absence of LPS.  
 
Results. I found that LPS alone potently increased Tnf gene expression after 1 h, while 
the induction in Il10 transcription was only observed after 6 h, indicating an early pro-
inflammatory response and a delayed autocrine signalling-mediated resolution phase 
in LPS-treated cells (Figure 5-13). Interestingly, both 2AR agonism and SIK inhibition 
elicited similar reduction in early phase Tnf transcription, while increasing Il10 mRNA, 
which was likely driven by the formation of an active CREB-CRTC complex, as the 
transcription of a canonical CREB target gene Nr4a1 was also potentiated by both 
fenoterol and HG-9-91-01 in LPS-treated BMDMs (Figure 5-13). Surprisingly, while 
both immunomodulators supressed Tnf transcription, they potently enhanced the 
expression of Il1b gene, which has a CRE sequence in its promoter587 (Figure 5-13). 
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Finally, HG-9-91-01 diminished the induction of Nr4a1, but increased the expression 
of Dgat1 and Thbs1 in 2AR agonist-treated cells (Figure 5-13). LPS showed an 
opposite effect to HG-9-91-01 by enhancing Nr4a1, but supressing Dgat1 and Thbs1 
transcriptional induction after fenoterol stimulation (Figure 5-13). Interestingly, both 
2AR agonism and SIK blockade showed synergistic effects with LPS in increasing 
Hif1a gene expression (Figure 5-13).  
 
Conclusion. My results confirmed the anti-inflammatory effect of 2AR activation, 
likely mediated by an increased early phase Il10 transcription. Furthermore, they also 
showed that LPS promoted the induction of early phase genes, but diminished the 
transcription of late phase genes in 2AR-agonist-treated BMDMs, while SIK inhibition 
had the opposite effect.   
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Figure 5-13. The effects of 2AR activation and salt-inducible kinase inhibition 
on LPS-induced gene transcription in BMDMs. 
mRNA levels (normalised to BestKeeper) of inflammatory genes Tnf, Il10 and Il1b, and 
2AR-responsive genes Nr4a1, Dgat1, Thbs1 and Hif1a in BMDMs treated with 1 M 
fenoterol (black lines), 100 ng/ml LPS (red lines), LPS + fenoterol (green lines), LPS + 
100 nM HG-9-91-01 (blue lines) and fenoterol + HG-9-91-01 (grey lines) for 0, 1, 2, 4, 
and 6 h. N=4 mice. For genes Tnf, Il10 and Il1b: * p < 0.05 compared between LPS 
and LPS + fenoterol, and # p < 0.05 compared between LPS and LPS + HG-9-91-01 
at each time-point using two-way ANOVA with Bonferroni’s multiple comparisons test. 
For genes Nr4a1, Dgat1, Thbs1 and Hif1a: $ p < 0.05 compared between fenoterol 
and LPS + fenoterol, and & p <0.05 compared between fenoterol and fenoterol + HG-
9-91-01 at each time-point using two-way ANOVA with Bonferroni’s multiple 
comparisons test. 
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5.2.4.2 2AR activation enhanced inflammasome-dependent IL-1 secretion in 
BMDMs 
Rationale. Intrigued by the potentiating effects of 2AR agonism on Il1b transcription 
in LPS-treated BMDMs, I decided to evaluate whether 2AR stimulation alone could 
promote the expression of genes encoding IL-1 and NLRP3 inflammasome, which 
has recently been described to mediate the development of norepinephrine 
degradation pathway in ATMs during aging439.  
 
Results. Indeed, 2AR activation rapidly increased Il1b and Nlrp3 mRNA levels in 
BMDMs (Figure 5-14 A). Furthermore, while BMDMs treated with NE alone did not 
produce detectable IL-1 levels (data not shown), NE enhanced the release of IL-1 
in the presence of canonical inflammasome activators LPS and ATP, and this 
potentiating effect was lost in 2AR-defficient BMDMs (Figure 5-14 B). 
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Figure 5-14. IL-1 secretion in response to 2AR activation in BMDMs. 
(A) Il1b and Nlrp3 mRNA levels (normalised to BestKeeper) in WT BMDMs treated 
with 1 M fenoterol for 0, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420 or 480 min. N=4 
mice. Statistical differences were not assessed. (B) IL-1 levels (expressed in pg/ml 
of cell supernatant) in the medium of Adrb2fl/fl (n=4 mice, black bars) and LysM-Cre 
Adrb2fl/fl (n=4 mice, white bars) BMDMs treated sequentially with 1 M NE for 1h (or 
left untreated for controls), then with 100 ng/ml LPS for 2 h, and then with 5 mM ATP 
for 30 min. * p < 0.05 compared genotypes, and # p < 0.05 compared between NE-
treated and control cells using two-way ANOVA with Bonferroni’s multiple comparisons 
test. 
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5.3 Discussion 
This chapter describes how NE signalling via 2AR regulates gene and protein 
expression, and cellular glucose metabolism in macrophages. The experiments 
described in the chapter aimed to gain a better understanding of the effects of 2AR 
activation on the phenotype of macrophages. The main finding of the chapter was that 
2AR stimulation rapidly induced a hypoxic-like phenotype in BMDMs, characterised 
by aerobic glycolysis, increased lipid storage and elevated HIF-dependent gene 
transcription. Glycolysis was required for the appropriate induction of late phase gene 
transcription during 2AR activation. Furthermore, the molecular interaction between 
transcription factors HIF and p300, but not direct HIF1 or HIF2 transcriptional activity 
was mediating the transcription of late phase genes.  
 
5.3.1 2AR activation induced two phases of gene transcription in BMDMs 
Phosphorylation of CREB and the induction of CREB-dependent gene transcription in 
response to -adrenergic receptor stimulation has been described numerous times, 
and is widely accepted in cell signalling research485. However, in the current and 
previous chapters I found a novel property of 2AR-dependent CREB target gene 
induction in macrophages, characterised by two subsequent waves of gene 
transcription. It is important to emphasise that such observation would have not been 
possible without a frequent sampling during my experiments in order to obtain accurate 
gene transcription kinetics. The lack of knowledge on the kinetic properties of signalling 
is also a likely reason why such finding has not been made before in other labs, despite 
the studies on 2AR in macrophages dating back for over 2 decades456. Had I analysed 
only 1 h, 8 h or 24 h time-points following 2AR activation in BMDMs, I would have not 
found the induction of late phase genes, including Dgat1, and therefore would not have 
been able to design the proteomics study and identify the effects of 2AR stimulation 
on macrophage nutrient metabolism. 
 
Despite the observed biphasic gene expression, the underlying mechanism that 
regulate such response is not completely clear. As summarised in the introduction, 
2AR is known to act through the Gs, but also to engage -arrestin-MAPK signalling 
axis. Furthermore, as 2AR has been shown to elicit both pro- and anti-inflammatory 
effects in macrophages, it has been suggested that Gas signalling is responsible for the 
immunomodulatory, and -arrestin is driving the pro-inflammatory response in 
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macrophages456. It is therefore possible that the induction of early phase genes 
observed in this chapter is mediated by increased intracellular cAMP, leading to CREB 
phosphorylation and transcriptional activation, while the late phase gene transcription 
is dependent on -arrestin signalling. In line with such hypothesis, I have recently 
obtained preliminary data in BMDMs showing that when CREB phosphorylation starts 
to diminish at 1 h following 2AR stimulation, there is an increase in ERK 
phosphorylation (data not shown), which is a known downstream event of a -arrestin 
signalling pathway588. I am currently in the process of testing whether 
pharmacologically inhibiting -arrestin signalling or ERK enzymes would diminish the 
induction of late phase genes in response to 2AR activation in BMDMs. 
 
Another potential explanation for the biphasic gene expression is that some of the 
factors induced during the initial phase following 2AR activation in BMDMs are directly 
regulating the transcription of the second phase genes. Indeed, the product of Nr4a1 
gene, which is highly and rapidly upregulated 1 hour post 2AR stimulation, has been 
described to control the expression of a subset of metabolic genes in macrophages 
589. I will attempt to adress this in future using cycloheximide, a pharmacological 
inhibitor of protein translation. If the proposed mechanism of regulation is true, the 
induction of the second phase of genes in response to 2AR activation should be lost 
in BMDMs pretreated with cycloheximide. 
 
It is also difficult to pinpoint the exact role of HIF1 in regulating 2AR activation-
dependent gene transcription in BMDMs. The results obtained from the proteomics 
experiment and metabolic analysis of 2AR-agonist treated BMDMs overwhelmingly 
indicate the activation of HIF1-dependent gene expression. In line with this, blocking 
glycolysis, which is a known upstream event of HIF1 activation in macrophages, or 
utilising pharmacological HIF inhibitor diminished the induction of late phase genes in 
response to 2AR agonism in BMDMs. Therefore, perhaps the most unexpected result 
in this chapter was the conserved 2AR stimulation-dependent gene transcription in 
HIF1-KO BMDMs. It is important to emphasise that due to the architecture of loxP 
sites surrounding Hif1a exon 2, its excision by Cre recombinase does not result in a 
frame shift or introduce a premature stop codon in the remaining 3’ region of Hif1a 
mRNA590. It is not the case for the Epas1 floxed allele, which produces an mRNA 
containing multiple premature stop codons after Cre-mediated excision583. While it has 
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not been verified, it is possible that HIF1-KO cells may still produce a stable HIF1 
protein that lacks its DNA binding domain, but retain the capacity to bind the 
transcriptional co-activators. Indeed, a published report utilising the same Hif1a exon 
2-floxed genetic model crossed with a mouse expressing Cre recombinase in 
hepatocytes showed that despite lacking HIF1-dependent transcriptional response, 
HIF1-KO livers still contained a protein recognised by an anti-HIF1 antibody in a 
Western blot591. Another recent report has also identified a truncated form of HIF1 
protein using anti-HIF1 antibody in a Western blot of hypoxic BMDMs from Tie2-Cre 
Hif1a exon 2-floxed mice592.  
 
Based on the opposing results obtained using pharmacological HIF inhibitor and a 
genetic model lacking HIF1 DNA binding domain, it is tempting to speculate that 
HIF1 mediates the transcription of the late phase genes in response to 2AR 
activation in BMDMs independently of its DNA binding. In line with such hypothesis, 
HIF inhibitor chetomin does not target HIF1 DNA binding domain, but disrupt the 
interaction between HIF1 and its transcriptional co-activator p300578. Interestingly, 
p300 also interacts with CREB, and CREB-p300-HIF1 transcriptional complex has 
been previously shown to be present in cells and bind to Ldha gene promoter593 . 
Furthermore, late phase genes Hif1a and Thbs1 have CRE sequences in their 
promoter, suggesting that CREB, rather that HIF1 binding to DNA might be important 
for their transcriptional induction in BMDMs in response to 2AR activation. Finally, it 
is unclear what role the glycolysis plays in the regulation of late phase gene 
transcription, but it could lead to the nuclear translocation of pyruvate kinase M2 
(PKM2) isoform, similarly to what has been described in LPS- treated macrophages594. 
PKM2 is a part of glycolysis pathway, but has also been shown to translocate to the 
nucleus and facilitate the interaction between HIF1 and p300 when 
phosphorylated595. It is possible that inhibiting glycolysis in 2AR agonist-stimulated 
macrophages could disrupt the PKM2 nuclear translocation, therefore preventing 
HIF1 binding to p300. 
 
Overall, my results from this chapter suggests a mechanism, where 2AR activation 
leads to a rapid phosphorylation of CREB by PKA and the induction of CREB target 
gene transcription within 30 min of stimulation (Figure 5-15). Simultaneously, 2AR 
agonism promotes aerobic glycolysis, which mediates HIF1-dependent gene 
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transcription without the requirement of HIF1 DNA binding (Figure 5-15). Inhibiting 
glycolysis or the formation of a transcription factor complex containing HIF1 
diminishes the induction of late phase gene transcription, but prolongs the expression 
of the early phase transcripts, suggesting that CREB is retained to the promoters of 
the early phase genes when the late phase of transcription is blocked (Figure 5-15). 
Interestingly, blocking HIF1-p300 interaction also enhances Dgat1 transcription, 
indicating that glycolysis also drives CREB interaction with transcriptional co-activators 
other than HIF1. Overall, it seems that CREB or p300 availability is a limiting factor 
for the magnitude of both early and late phase gene transcription, and that glycolysis 
and potentially other intracellular signalling mechanisms redirect CREB-p300 complex 
from the early phase to the late phase gene promoters by catalysing its interaction with 
different transcriptional co-activators, such as HIF1. Similar competition mechanisms 
for p300 availability have already been observed between HIF1 and p53596, between 
SNIP1 and NF-B597, between AP-1 and CREB598, between STAT-2 and NF-B599 and 
between ER and NF-B600 transcription factors. 
 
I am currently in the process of validating the proposed mechanism in multiple steps. 
Firstly, total RNA sequencing of BMDMs treated with 2AR agonist for 1 h and 4 h is 
on-going. The results from a global transcription analysis will allow me to identify all 
early phase genes (showing an increase in mRNA levels at 1h compared to control 
before a reduction to the basal levels at 4 h post stimulation) and all late phase genes 
(showing an increase in mRNA levels at 4 h compared to control). Initially, transcription 
factor prediction analysis will be performed on all detected transcripts in order to 
confirm the role of CREB and HIF1, but also to identify novel transcription factors 
mediating gene expression in response to 2AR stimulation. Next, the promoters of all 
up-regulated genes will be checked for the presence of CRE or other common 
response elements, in order to verify the mechanism of the relocation of the 
transcription factor complex from the early to late phase gene promoters. Finally, I will 
individually immunoprecipitate CREB, p300 and HIF1 from BMDMs treated with 
2AR agonist for 30 min (corresponding to the highest rate of transcription of the early 
phase genes) and for 90 min (corresponding to the highest rate of transcription of the 
late phase genes) and assess bound chromatin for the promoter sequences of both 
early and late phase genes. If my proposed mechanism is correct, CREB-p300 
complex should be predominantly localised at the early phase gene promoters at 30 
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min, while CREB-p300-HIF1 complex would be bound to the late phase gene 
promoters at 90 min post 2AR activation. Such redirection of CREB-p300 complex 
should be disrupted in the presence of HIF1-p300 interaction inhibitor chetomin, but 
remain intact in BMDMs lacking DNA binding domain of HIF1. 
 
 
Figure 5-15. Proposed model of the induction of gene transcription by NE in 
BMDMs. 
Molecular processes on the left side of the dashed line occur between 0-60 min after 
2AR activation, while the ones on the right side – between 60 - 240 min. 
 
 
While my experiments in this chapter did not indicate the identity of the transcription 
factor mediating Dgat1 gene expression in response to 2AR activation, such regulator 
is also likely to be present in a complex with CREB-p300, as Dgat1 promoter contains 
a CRE sequence. Interestingly, p300-ChREBP transcription factor complex has 
previously been described to regulate lipogenic gene expression in hepatocytes, 
including Dgat1601,602. Furthermore, SIK2 was shown to inhibit p300-ChREBP 
transcriptional activity by phosphorylating p300, and SIK2 genetic deletion enhanced 
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hepatic lipogenic gene expression601. I observed enhanced Dgat1 expression in 
BMDMs following 2AR activation in the presence of SIK inhibitor, suggesting that 
CREB-p300-ChREBP could also be regulating lipogenic gene expression in 
macrophages. In future, I will obtain ChREBP-deficient BMDMs to verify the role of 
ChREBP in Dgat1 transcription in response to 2AR activation. 
Overall, most in vitro gene expression studies in this chapter were relatively basic and 
did not directly investigate the importance of 2AR activation in macrophages in the 
setting of lipotoxicity. However, understanding the role of glycolysis and HIF1 in 
response to 2AR stimulation is of high importance, because it indicates the 
dependence of the 2AR signalling outcome on the cellular microenvironment. 
In a healthy animal, characterised by adipose tissue normoxia and controlled blood 
glucose levels, 2AR activation in ATMs will favour the expression of early phase 
genes, predominantly encoding anti-inflammatory factors. However, obesity results in 
aberrant WAT expansion, leading to low oxygen levels in WAT and stabilisation of 
HIF1 in ATMs603. Furthermore, insulin resistance observed during obesity manifests 
in an impaired regulation of blood glucose concentration and prolonged periods of 
hyperglycaemia. In such hypoxic and hyperglycaemic adipose tissue environment, 
2AR signalling in ATMs would favour the late phase gene transcription, leading to 
diminished anti-inflammatory response. Therefore, my results in this chapter will help 
to direct the future studies on the role of sympathetic nerve-ATM interactions in obesity. 
 
Sympathetic nervous system is also known to regulate tumour microenvironment in 
multiple cancers, thus mediating the tumour growth and cancer progression604. A 
recent report has found that mice lacking Adrb2 gene in the endothelial cells are 
protected against prostate cancer progression due to reduced angiogenesis605. While 
this study reported that macrophage-specific Adrb2 deletion did not affect the prostate 
cancer development605, 2AR in tumour-associated macrophages might be important 
for the progression of other cancer types. Importantly, tumour cells have been shown 
to compete for limited nutrient amounts present in the tumour microenvironment, and 
reduced tumour glucose availability has been described to inhibit the inflammatory 
activation of tumour growth-limiting T cells606. Similarly, reduced glucose availability in 
tumour-associated macrophages would favour the induction of early phase genes in 
response to 2AR signalling, therefore enhancing the anti-inflammatory response 
linked with an accelerated tumour growth607. Overall, my results in this chapter suggest 
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an additional mechanism for increased M2 polarisation of tumour-associated 
macrophages, leading to a faster progression of cancers associated with increased 
SNS activity, that could be investigated in future. 
 
5.3.2 A potential link between mitochondrial ROS production and 
increased lipid storage in 2AR agonist-treated BMDMs 
One potential reason for increased DGAT1 activity could be the elevated production of 
mitochondrial ROS, as observed in BMDMs after 2AR stimulation. ROS are known to 
oxidise double bonds in the fatty acids, which can be prevented by storing fatty acids 
as TGs in the lipid droplets302. As observed in the previous chapter in 2AR-treated 
BMDMs, DGAT1 inhibition completely blocked the increase in palmitate esterification, 
while enhanced storage of oleate as TGs was still observed even in the absence of 
DGAT1 enzymatic activity, suggesting alternative mechanisms that could selectively 
store unsaturated fatty acids in the lipid droplets, thus protecting them from oxidation. 
In future, I will investigate the mechanism of selective esterification of fatty acids based 
on their saturation using complex FFA mixtures that represent WAT fatty acid 
composition. I will treat BMDMs with 2AR agonist in the presence of WAT FFA mixture 
and analyse cellular neutral lipids using GC-MS in order to test whether 2AR 
activation could favour the storage of unsaturated FFAs. Furthermore, I will isolate 
ATMs from mice after prolonged fasting in order to measure their neutral lipid 
composition, and compare it to the fatty acid profile of the adipocytes for the differences 
in their relative saturation. Finally, I will investigate if co-treating BMDMS with 2AR 
agonist and WAT FFA mixture in the presence of DGAT1 inhibitor leads to increased 
formation of lipid peroxides. Overall, the presence of a selective storage of unsaturated 
FFAs in the ATMs in response to 2AR activation would indicate a similar mechanism 
as already observed in the microglia resident in the hypoxic areas of the developing 
brain, where glial lipid droplets have an antioxidant function302. Such finding could also 
lead to a new project aiming to describe the molecular mechanisms involved in the 
selective fatty acid storage in macrophage lipid droplets. 
 
5.3.3 The role of macrophage 2AR in the interactions between 
macrophages and sympathetic nerves 
My proteomic analysis revealed that the most up-regulated biological process in 2AR 
agonist-treated BMDMs was ‘neuronal system’, involving the cellular response to a 
neighbouring neuron. While such finding is perhaps expected, as 2AR is directly 
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stimulated by activated sympathetic nerves, it suggests a mechanism where 
macrophages could acquire the phenotype observed in SAMs in vivo through a 
continuous 2AR stimulation by NE released from the neighbouring nerves. While such 
mechanism will need to be investigated further in future, my results in this chapter point 
in its favour. 
 
The protein showing the highest fold increase in response to 2AR activation in 
BMDMs is THBS1, which is known to promote TGF signalling, and thus mediate cell 
migration, attachment, proliferation and differentiation608. Interestingly, high levels of 
THBS1 have been found in the developing brain, where it has been shown to mediate 
synaptogenesis609,610. Circulating THBS1 concentration is increased following brain 
injury611, when elevated brain NE turnover is also observed612. THBS1-deficient mice 
have worsened neurological outcomes than controls in response to traumatic brain 
injury613. Furthermore, THBS1 is important for neuronal migration in CNS614, and has 
been shown to guide the regenerating peripheral nerve axons following injury615. 
Overall, it is possible that SAMs facilitate the sympathetic innervation of adipose 
tissues by secreting THBS1 in response to NE in a positive feedback manner. 
 
At present, it is not clear whether BMDMs are capable of taking up and degrading NE, 
despite expressing the enzymes involved in the breakdown of monoamines. According 
to a recent report, the expression of SLC6A2 is required for NE import and degradation 
in SAMs424. Furthermore, out of all analysed tissue macrophage populations, Slc6a2 
gene expression is restricted to SAMs, suggesting that they are the only macrophages 
capable of NE breakdown424. However, an earlier study has found that cultured 
peritoneal macrophages can rapidly import and degrade NE, despite lacking Slc6a2 
expression450. Cocaine, a known inhibitor of SLC6A2 activity, did not block NE uptake 
into peritoneal macrophages, indicating a presence of alternative ways for cellular NE 
import450. Interestingly, the highest rate of NE import into peritoneal macrophages was 
observed at the concentration that I found to maximally activate 2AR in BMDMs 
(approximately 10 M)450, suggesting that 2AR might be important for NE uptake into 
macrophages. 
 
Based on the detected proteins from my proteomic analysis, BMDMs predominantly 
express aldehyde dehydrogenases (mainly located in the mitochondria) over aldo-keto 
reductases (mainly cytosolic), suggesting that mitochondrial NE degradation pathway 
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plays a major role in macrophages. It is therefore possible that increased aerobic 
glycolysis and mitochondrial ROS, and decreased oleate -oxidation observed in 
response to 2AR activation in BMDMs is a mechanism used to repurpose 
mitochondria for NE breakdown in an analogous way as mitochondrial repurposing for 
ROS production is achieved during LPS treatment110. In line with such hypothesis, 
MAOA enzymatic activity has been suggested to produce ROS at higher rate than any 
other mitochondrial ROS generators616. Therefore, similar OCR despite reduced 
mitochondrial oleate oxidation in NE-treated BMDMs could be explained by increased 
oxygen consumption by MAOA. 
 
I am currently collaborating with Prof. Jeff Dalley’s lab in setting up a liquid 
chromatography-electrochemical detection-based assay to simultaneously measure 
NE and its degradation products in BMDMs and their culture medium. Such assay will 
not only allow me to measure the rate of NE uptake and degradation in BMDMs, but 
also will be informative regarding the relative contribution of the activity of aldehyde 
dehydrogenases and aldo-keto reductases for NE breakdown in macrophages. I will 
utilise this assay to assess whether genetically or pharmacologically disrupting 2AR 
signalling would decrease the rate of NE uptake or degradation in BMDMs. If 2AR 
activation was found to be important for regulating NE breakdown, I will attempt to 
identify molecular mechanisms responsible for this effect. One potential way how 2AR 
could up-regulate NE degradation is through NLRP3-dependent increase in 
monoamine breakdown enzyme gene expression. I would therefore test whether the 
potentiating effects of 2AR agonism on NE degradation are lost in the presence of 
NLRP3 inhibitor. Interestingly, MAOA is also known to be regulated post-
translationally617,618, and MAOA activity is increased upon the phosphorylation of 
mitochondrial proteins by PKA in the presence of high cAMP levels618. As PKA activity 
is increased in response to 2AR activation, it could link 2AR signalling to NE 
degradation. Finally, -adrenergic receptor activity has already been shown to be 
important for the clearance of circulating monoamines in humans563. It is therefore 
likely that NE clearance by SAMs also depends on 2AR signalling.  
 
Lastly, SAMs have been demonstrated to contain high levels of Adrb2 mRNA (Figure 
5-16), and one of the most enriched pathways in SAMs compared to other tissue 
macrophages is cAMP signalling pathway424. Interestingly, the expression of genes 
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induced in response to 2AR stimulation in BMDMs is enriched in SAMs compared to 
other analysed tissue macrophage populations424, suggesting an increased 2AR 
activation in SAMs in vivo (Figure 5-17). In future, it would be of interest to investigate 
the SAM abundance and morphology in LysM-Cre Adrb2fl/fl animals. Furthermore,  to 
check whether 2AR deficiency in SAMs leads to a decreased expression of 2AR 
stimulation-responsive genes. 
 
 
 
Figure 5-16. Adrb2 gene expression in spenic macrophages, scWAT 
macrophages, and scWAT SAMs. 
Adrb2 mRNA in macrophages from spleen, scWAT or associated to SNS fibres in 
scWAT. N=3 pools of 10 mice/group. Graph was taken from a recent publication, where 
cell isolation and analysis was also described424. 
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Figure 5-17. Expression of 2AR stimulation-responsive genes in different tissue 
macrophage populations. 
The expression of Nr4a1, Cox2, Klf4, Dusp1, Dgat1 and Thbs1 genes in microglia 
(n=3), SAMs isolated from scWAT (SAM fibers) (n=2), SAMs isolated from superior 
cervical ganglia (SAM ganglia) (n=3), peritoneal (n=3), scWAT (n=2) and eWAT (n=2) 
ATMs. Macrophage populations were isolated and analysed as described in a recent 
report424. Data was obtained from Gene Expression Omnibus database (GSE103847). 
Values are expressed as reads per kilobase of transcript per million of mapped reads 
(RPKM) + SEM. Statistical differences were not assessed. 
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As 2AR signalling outcome was shown to be dependent on cellular glycolysis and 
oxygen sensing, it is possible that 2AR activation in the ATMs present in a 
hypertrophic WAT might be substantially different than in BMDMs and likely favour the 
induction of late phase genes. Interestingly, increased circulating levels of THBS1 
protein, encoded by a late phase gene, has been found in obese patients, and its 
concentration in the serum correlated with WAT inflammation and systemic insulin 
resistance markers619. Furthermore, THBS1-deficient mice display reduced WAT 
inflammation and insulin resistance during obesity620,621. The large increase in THBS1 
protein levels in 2AR agonist-treated BMDMs suggests a mechanism linking 2AR 
signalling in ATMs and THBS1-dependent inflammation in the WAT of obese mice. In 
future, I will measure THBS1 protein levels in WATs isolated from chow- and HFD-fed 
LysM-Cre Adrb2fl/fl and control animals to investigate whether 2AR deficiency in ATMs 
could reduce WAT THBS1 expression during obesity. 
 
5.3.4 Conclusions 
Overall, I found that NE, acting via 2AR, altered BMDM nutrient metabolism by 
increasing glycolysis, supressing oleate release and oxidation, and enhancing TG 
storage. My results also revealed a biphasic induction of gene transcription in response 
to 2AR activation in BMDMs, where a second phase of gene expression was 
dependent on glycolysis and the formation of HIF1-p300 transcriptional complex. In 
future, additional experiments will need to be performed to further describe the 
intracellular signalling cascade downstream of 2AR and also to understand the 
importance of 2AR for NE catabolism in macrophages. 
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6 General discussion 
6.1 Overview 
This thesis presented two integrated projects with a common focus on the role of ATM 
lipid metabolism in mediating obesity-associated WAT inflammation. I have addressed 
two main objectives: 
 
1) I have defined the role of de novo PC synthesis during palmitate-induced 
inflammation in cultured macrophages, and during obesity-induced WAT inflammation 
in ATMs. 
 
2) I have characterised the molecular mechanisms responsible for NE signalling-
dependent increase in macrophage TG storage capacity, and defined how NE 
signalling in ATMs impact the development of WAT inflammation and insulin resistance 
during obesity. 
 
Both projects were executed with a common research strategy that involved an initial 
phase of BMDM phenotypic characterisation, and a subsequent validation of in vitro 
findings in a murine model of HFD-induced obesity and insulin resistance. 
Furthermore, both projects investigated relevant biological processes that were 
regulated pathophysiologically in murine ATMs, thus examining the causal relationship 
between the alterations in each process and the development of WAT inflammation 
during obesity. The experiments presented in Chapter 5 contained a broad descriptive 
analysis of BMDM cellular phenotype induced by adrenergic stimulation, the relevance 
of which extend beyond obesity-induced WAT inflammation, to other biological 
systems where SNS-macrophage interactions have been observed, such as gut 
bacterial infection or tumour development. 
 
Since I have already discussed the main experimental findings and future work within 
the results chapters of this thesis, in this final chapter I will more generally discuss the 
limitations of the in vitro modelling systems utilised in this thesis, and I will propose 
alternative approaches to model ATMs and SAMs in physiological and 
pathophysiological states in vitro. Furthermore, here I will express my opinion 
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regarding the potential drugability of ATM lipid metabolism and GPCR signalling in 
treating obesity-induced WAT inflammation and insulin resistance. 
 
6.2 Modelling ATMs and WAT inflammation in vitro 
6.2.1 Cell culture model of ATMs 
Like the majority of published reports that investigated macrophage genes involved in 
the development of obesity-induced WAT inflammation, I utilised BMDMs to model 
ATMs present in an obese animal. There are a few major advantages in working with 
BMDMs:  
 
 They are relatively cheap to obtain and culture. 
 One mouse yields enough BMDMs to perform virtually any experiment 
regardless of the amount of input material that is required. 
 BMDMs are not immortalised, and thus represent a more physiological model 
cell type than immortalised macrophage-like cell lines, such as RAW264.7 or 
J774.2.  
 
Peritoneal macrophages, which are also commonly utilised for the research in the area 
of adipose tissue inflammation, are considered to be another good primary 
macrophage model for in vitro work. The primary advantage of using peritoneal 
macrophages is that they differentiate in vivo and, when compared to BMDMs, are 
more similar to tissue macrophages. However, the yield of peritoneal macrophages is 
low when they are obtained from a healthy mouse. Inducing peritonitis by thioglycollate 
injection increases the yield of cells, but also skews the macrophages to M1 
polarisation622, making the experiments focusing on macrophage inflammatory 
activation difficult to interpret. 
 
The main and the most critical downside in using BMDMs and peritoneal macrophages 
as model cells is that they do not resemble ATMs in terms of their global 
transcriptome121. Therefore, the way BMDMs and peritoneal macrophages metabolise 
lipids and behave in lipid-rich environments is likely to be substantially different 
compared to ATMs. This thesis provided a few examples where the cellular response 
observed in BMDMs in vitro did not occur in ATMs in vivo. In order to obtain more 
physiological conditions in vitro, one could either work with isolated ATMs directly, or 
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attempt to induce an ATM-like phenotype in BMDMs or peritoneal macrophages. 
Having a good in vitro model of ATMs would facilitate the discovery of different 
macrophage genes contributing to the development of WAT inflammation. Only the 
gene knockout models that show a phenotype in the in vitro culture model of ATMs 
could be further studied in mice in vivo, which would reduce the number of animals 
used, the time of the researcher and the cost of the study. 
 
6.2.1.1 Culturing isolated ATMs 
There are several publications that performed in vitro studies on cultured 
ATMs160,284,623,624. A recent report has found that ATMs isolated from obese mice 
secrete more IL-6 and CXCL1, but less TNF in the medium compared to ATMs 
obtained from lean animals623. Furthermore, unlike classically activated macrophages, 
which reduce their oxidative phosphorylation rate and switch to aerobic glycolysis for 
ATP production, ATMs from obese mice exhibit an increase in both glycolysis and 
oxidative phosphorylation rates compared to ATMs isolated from lean animals120. 
These results suggest that the phenotype of ATMs during obesity does not resemble 
the phenotype of BMDMs induced by LPS or palmitate treatment in vitro, for reasons 
that are yet unknown. However, these findings might have been skewed by the cellular 
stress resulting from adipose tissue enzymatic digestion and subsequent column 
purification. 
 
At the start of my PhD, I have made several attempts to culture isolated ATMs in vitro. 
However, I noticed that macrophages isolated using antibodies conjugated to magnetic 
beads did not exhibit a ‘healthy morphology’ under microscope. Furthermore, isolated 
ATMs start detaching from cell culture plates as early as 6 h post plating, indicating 
cell death. 
 
One could argue that by using an optimised method of isolation and an optimised 
formulation of medium for subsequent culturing, ATMs could be maintained in a culture 
for a prolonged period without affecting cell viability. However, as macrophage is a 
plastic cell type, ATMs might quickly lose their native cellular identity after being placed 
in cell culture for a prolonged period, making them similar to BMDMs in terms of their 
phenotype and responsiveness to stimuli. Overall, I do not think that performing in vitro 
studies on isolated ATMs currently is, or could potentially be a viable approach for 
studying the mechanisms driving adipose tissue inflammation in vitro. While 
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comparative analyses of ATMs isolated from different genetically modified animal 
models in lean and obese states can be very informative, the methods of studying 
isolated ATMs in my opinion should be entirely analytic, such as flow cytometry and 
post-lysis RNA, protein and lipid analyses. 
 
6.2.1.2 Differentiating macrophage progenitors into ATM-like cells 
An alternative approach of studying ATM biology is to differentiate BMDMs into ATM-
like cells. A similar approach is routinely used to model osteoclasts (macrophage-like 
bone cells that mediate bone degradation) in vitro, which involves adding a cytokine 
receptor activator of nuclear factor kappa-Β ligand (RANKL) to a culture medium during 
BMDM differentiation625. Osteoclasts obtained in this manner are capable of resorbing 
bone after being plated on dentine or bone slices, thus phenotypically resembling their 
in vivo counterparts625. 
 
Several studies have modelled adipose tissue microenvironment by co-culturing 
adipocyte and macrophage cell lines626-631. However, the focus of most of these studies 
was adipocyte metabolism, thus the effect of the co-culture system on macrophages 
is poorly understood. One study has reported comparable effects between the direct 
presence of macrophages in the culture and the addition of macrophage-conditioned 
medium on the adipocyte metabolism, arguing that the majority of the intercellular 
communication effects results from the paracrine signalling629. On the other hand, 
another study has found that co-culturing adipocyte and macrophage cell lines induces 
phenotypic changes that cannot be explained by paracrine signalling alone628. 
 
A recent study has described a new protocol for obtaining ATM-like cells in vitro by 
differentiating BMDMs in the presence of WAT explants within the culture284. According 
to the study, the lipid metabolism of ATM-like cells differentiated in this manner was 
comparable to ATMs in vivo284. At the start of my PhD, I attempted to replicate this 
published protocol several times. While I found that BMDMs differentiating in WAT 
explant co-cultures contained more intracellular lipids than control BMDMs, the 
transcriptional signature of ATM-like cells was substantially different to ATMs isolated 
from WAT (data not shown, but described in my lent rotation project report). I thus 
concluded that such differentiation protocol was suboptimal and did not yield ATM-like 
cells. 
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Overall, existing co-culturing protocols suffer from the lack of knowledge regarding the 
molecular intercellular communication occurring within the culture, leading to poor 
reproducibility and control over the experiments. While the factors that shape the 
phenotype of macrophages in the adipocyte co-cultures can be investigated in order 
to improve the co-culturing protocols, it is arguably better to direct that effort into 
understanding the developmental niche of ATMs. As ATMs can be repopulated by 
bone marrow-derived progenitors in vivo, there exists a defined physiological 
sequence of environmental stimuli that transform monocyte progenitors into 
ATMs. Large scale -omics approaches can now enable us to investigate protein, lipid 
and small molecule factors present within the adipose tissues during ATM 
development, as well as to monitor the changes in the progenitor transcriptomes during 
their transition to ATMs. A thorough bioinformatics analysis linking the temporal 
presence of tissue factors to the activation of macrophage intracellular signalling 
pathways and transcriptional regulators could be used to formulate a protocol to 
differentiate bone marrow progenitor cells into ATMs in vitro. In my opinion, such 
protocol would be superior to existing macrophage-adipocyte co-culture methods 
because of its reproducibility, flexibility and relative simplicity. 
 
Such approach could also be extended to obtain an in vitro model of SAMs. Like ATMs, 
SAMs can be repopulated by monocyte progenitors424, suggesting that their in vivo 
differentiation conditions could be mimicked on bone marrow cells in vitro. SAMs and 
ATMs within WAT have similar developmental niches, with SAMs having one additional 
factor present – a neighbouring sympathetic nerve axon. Therefore, the paracrine 
factors released by sympathetic nerve axons in WAT could be identified and matched 
to the transcriptional changes of developing SAMs. As I have already suggested in this 
thesis, one of the factors mediating SAM development might be NE acting on surface 
β2ARs of the progenitor cells. However, it is likely that there are numerous other SNS-
derived protein, lipid and small molecule mediators that influence SAM phenotype. The 
identity and molecular targets of these mediators could be investigated in future in 
order to increase our understanding of tissue macrophage biology, but also to aid the 
formulation of an in vitro SAM differentiation protocol. 
 
Finally, the knowledge of environmental stimuli, leading to changes in transcription 
factor activity involved in shaping ATM phenotype will be crucial for the development 
of a successful platform of human induced pluripotent stem cell (iPSC) differentiation 
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into ATMs or SAMs. Human iPSC-derived ATMs and SAMs could be useful tools for 
studying human mutations associated with obesity, insulin resistance and 
dyslipidaemia, as well as to assess the effect of potential drugs targeting and adipose 
tissue inflammation and immune system-mediated BAT activation. 
 
6.2.2 Modelling lipid-induced inflammation in vitro 
The prevailing view within the scientific community is that saturated fatty acids drive 
the inflammatory activation of ATMs. This view was greatly influenced by numerous in 
vitro studies (many of which were summarised in the introduction of this thesis) 
showing that palmitate and other saturated FFAs induce ER stress and inflammation 
in cultured macrophages. The main problem in interpreting these studies is that under 
no physiological or pathophysiological conditions, the quantity of palmitate (or any 
other saturated fatty acid) is vastly overrepresented compared to other FFAs in any 
animal tissue. As the lipotoxic and inflammatory effects of saturated FFAs on virtually 
all cell types are abolished in the presence of unsaturated FFAs, it is difficult to envision 
how saturated FFAs alone could cause WAT inflammation during obesity. 
 
The hypothesis that fatty acids induce inflammatory activation of macrophages has 
already been challenged by a recent study, which showed that fatty acids released 
from adipocyte lipolysis do not modulate inflammation in cultured macrophages136. 
During my PhD, I have also stimulated BMDMs with FFA mixtures that had been mixed 
according to their measured relative abundances in healthy WAT, as well as in WAT 
from HFD-fed and ob/ob mice. While the stimulations promoted intracellular TG 
accumulation, none of the FFA mixtures induced ER stress or inflammatory activation 
of BMDMs (data not shown). It is important to emphasise that like the mentioned study, 
the concentration of FFA mixtures that I used was approximately 250 M136. However, 
the concentration of circulating FFAs in mice and humans is approximately 1 mM, and 
the intra-WAT concentration of FFAs might even exceed 1 mM during on-demand 
lipolysis or obesity. I have not attempted myself, or found any published studies that 
treated macrophages with individual FFAs or their mixtures in the millimolar 
concentration range. It is therefore plausible that ‘overloading’ macrophages with 
millimolar concentrations of FFA mixtures could induce ER stress and inflammation in 
a manner that is more similar to obesity-induced WAT inflammation, and could be 
tested in future. 
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6.3 Targeting ATMs to alleviate WAT inflammation during 
obesity 
6.3.1 Targeting ATM lipid metabolism 
There have been numerous attempts to target inflammatory pathways in order to 
alleviate insulin resistance in humans, and several clinical trials are currently ongoing 
(the main studies have been summarised in the introduction). However, with the 
aberrant ATM lipid metabolism emerging as the major initiator of WAT inflammation 
during obesity, insulin-sensitising interventions directed at normalising ATM lipid 
metabolism might be superior to existing generic anti-inflammatory drugs. For 
example, systemic administration of monoclonal antibody against lipid chaperone 
FABP4, which is highly expressed in macrophages, successfully alleviated diabetic 
symptoms in obese mouse models and could be a feasible approach for the treatment 
of metabolic disorders632. 
 
However, systemically inhibiting major intracellular metabolic pathways can have 
detrimental consequences for the patient health. Therefore, the major challenge in the 
development of macrophage metabolism-based therapeutics is to deliver them 
specifically to ATMs. Currently, multiple delivery systems, including liposomes, 
nanoparticles, carbon nanotubes and dendrimers, have been used to successfully 
deliver bioactives to the macrophages in mouse models in vivo633. With the rapid 
improvement of particle engineering technologies, as well as identification of new 
tissue macrophage-specific surface receptors that can be targeted for delivery, 
macrophage-aimed therapeutics should become widely applicable in the near future. 
 
Paradoxically, lipid-centric view of ATM inflammatory activation and the development 
of WAT inflammation is a good argument against the primary targeting of ATM lipid 
metabolism in order to improve WAT function. As the accumulation of inflammatory 
lipid species in ATMs is a secondary event to the adipocyte lipid overload, 
pharmacologically manipulating macrophage lipid metabolism without normalising 
caloric intake or WAT storage capacity would still lead to the ectopic lipid accumulation 
and the development of metabolic complications. Therefore, once the ATM-specific 
targeting of lipid metabolism pathways is achieved, it should ideally be only used in 
conjunction with therapies aimed to enhance adipocyte lipid storage capacity. Such 
combined therapies would likely be faster and more effective at improving the 
  293 
metabolic profile of obese individuals compared to adipocyte-targeting interventions 
alone. 
 
6.3.2 Targeting ATM GPCRs 
This thesis has illustrated how lipid metabolism in macrophages is regulated by β2AR 
signalling. Another example of GPCR signalling-mediated regulation of macrophage 
lipid metabolism is a recent report showing that melanocortin-1 receptor agonism 
promotes cholesterol efflux from macrophages both in vitro and in vivo634.   It is likely 
that there are other GPCRs modulating lipid metabolism in macrophages, that could 
be exploited pharmaceutically. 
 
The main advantage of pharmaceutical GPCR manipulation is their ease of targeting. 
As GPCRs are located extracellularly, cell-impermeable molecules can be utilised to 
alter their activity with relatively few off-target effects, which is not the case for the 
majority of drugs that act inside the cell. Furthermore, multiple GPCRs can be 
manipulated simultaneously, and a cocktail of GPCR-targeting drugs could be 
administered to elicit a desired effect on a phenotype of cells that express a specific 
set of GPCRs. 
 
With the increasing number of studies analysing the ATM transcriptomes under 
different conditions, it should be possible to obtain a profile of Gs-linked GPCRs that 
are over-represented in the ATM population. Pharmacologically activating a subset of 
such ATM-specific GPCRs should increase intracellular cAMP concentration and 
promote a resolution phenotype in the ATM population during obesity, leading to 
reduced WAT inflammation. Finally, while macrophage-specific β2AR knockout mice 
did not exhibit increased WAT inflammation on chow or HFD compared to controls, it 
only indicated that the intrinsic SNS output to ATMs did not modulate their 
inflammatory status. A timed exogenous β2AR activation in ATMs could potentially 
alleviate WAT inflammation, and could be tested in vivo in future. 
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6.4 Summary and conclusions 
Overall, our understanding of ATM biology and the development of WAT inflammation 
has greatly improved in the last several years. In particular, lipids and their intracellular 
metabolism are now considered as some of the main factors that drive the 
inflammatory activation of ATMs during obesity, leading to the development of WAT 
dysfunction and insulin resistance.  
 
This thesis has described a link between the de novo PC biosynthesis capacity in 
macrophages and their inflammatory response to saturated fatty acids. In particular, 
macrophages with a reduced rate of de novo PC biosynthesis were protected against 
palmitate-induced inflammatory activation compared to control cells, likely because of 
increased expression of fatty acid remodelling enzymes. An inverse relationship 
between measured PC:PE ratio and the expression of fatty acid remodelling genes 
was also observed in ATMs in vivo – macrophages isolated from WAT of obese mice 
had higher PC:PE molar ratio and lower mRNA levels of fatty acid remodelling and 
anti-inflammatory genes than ATMs obtain from lean animals. While mice with a 
macrophage-specific deletion of Pcyt1a, a gene encoding the rate-limiting enzyme of 
de novo PC biosynthesis pathway, did not exhibit differences in WAT inflammation on 
a chow or HFD, they showed a minor improvement in the transcriptional profile of 
hepatic genes involved in nutrient metabolism compared to controls on HFD. More 
experiments are still required to understand the molecular mechanisms mediating the 
phenotype of mice lacking Pcyt1a in macrophages. 
 
Furthermore, this thesis have identified a novel physiological regulator of TG 
metabolism in macrophages. In particular, I found that NE, acting on surface 2ARs, 
rapidly increases macrophage TG storage capacity by simultaneously supressing 
lipolysis and enhancing TG esterification. Such finding suggests that lipid accumulation 
in macrophages is not only a consequence of pathophysiological challenges, such as 
bacterial infection, WAT inflammation or atherosclerosis, but can also occur in a 
regulated manner. Future experiments designed to identify the biological purpose for 
such regulation will also improve our understanding of the mechanisms that drive lipid 
accumulation in ATMs during obesity.  
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